data_1e4q_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1e4q _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.456 ' O ' ' HB2' ' A' ' 31' ' ' CYS . 98.5 m . . . . . 0 N--CA 1.493 1.711 0 CA-C-O 121.095 0.474 . . . . 50.0 110.566 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . 0.456 ' HB2' ' O ' ' A' ' 30' ' ' THR . 93.3 m 56.22 22.44 6.14 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.215 -0.928 . . . . 50.0 110.311 -179.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.481 ' CD1' ' C ' ' A' ' 32' ' ' LEU . 3.4 tm? -75.35 -38.51 60.06 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.137 -0.977 . . . . 50.0 110.283 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 96.0 mttt -68.69 -41.64 78.88 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.303 -0.873 . . . . 50.0 110.209 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 94.9 p -69.77 -20.46 63.48 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.303 -0.873 . . . . 50.0 110.32 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 79.25 6.73 88.82 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.662 -1.375 . . . . 50.0 109.662 179.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . 0.441 ' HB2' ' HB2' ' A' ' 62' ' ' LYS . . . -68.93 147.65 51.33 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.119 -1.224 . . . . 50.0 110.151 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.475 HD12 ' CE2' ' A' ' 47' ' ' TYR . 2.1 pt -93.45 151.77 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.148 -0.97 . . . . 50.0 110.063 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 86.3 m -91.27 142.57 27.57 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.244 -0.91 . . . . 50.0 110.372 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.514 ' CB ' ' SG ' ' A' ' 61' ' ' CYS . 54.4 t-80 -119.98 142.2 32.9 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.282 -0.886 . . . . 50.0 109.981 179.755 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.505 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 44.9 Cg_endo -71.52 155.85 58.87 Favored 'Trans proline' 0 C--N 1.305 -1.762 0 O-C-N 123.907 1.477 . . . . 50.0 110.857 -179.575 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.474 ' HB ' ' O ' ' A' ' 40' ' ' PRO . 47.8 t 59.27 -93.87 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.449 -0.782 . . . . 50.0 110.679 179.658 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.458 ' CD1' ' C ' ' A' ' 42' ' ' PHE . 21.4 p90 -139.14 161.43 37.42 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.84 -1.163 . . . . 50.0 110.62 -179.74 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.508 ' CB ' ' HB2' ' A' ' 49' ' ' GLN . 0.8 OUTLIER -80.45 127.56 75.51 Favored Pre-proline 0 N--CA 1.492 1.663 0 O-C-N 121.398 -0.814 . . . . 50.0 109.958 179.822 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -72.43 -162.4 0.12 Allowed 'Trans proline' 0 C--N 1.306 -1.699 0 O-C-N 123.742 1.39 . . . . 50.0 110.445 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 6.5 mtt180 -81.25 -36.59 29.76 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.475 -0.766 . . . . 50.0 109.698 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 60.0 mtp180 -58.71 -27.59 65.0 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.554 -0.716 . . . . 50.0 109.942 179.674 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' TYR . . . . . 0.525 ' HB3' ' HB3' ' A' ' 61' ' ' CYS . 37.0 m-85 -120.84 138.72 53.91 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.337 -0.852 . . . . 50.0 110.294 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 88.5 mttt -95.14 124.3 39.1 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.202 -0.936 . . . . 50.0 109.837 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.508 ' HB2' ' CB ' ' A' ' 43' ' ' CYS . 41.8 tt0 -74.8 105.64 5.95 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.494 -0.754 . . . . 50.0 110.94 -179.162 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.5 mt -75.16 -28.52 20.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.198 -0.939 . . . . 50.0 109.628 179.361 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.466 ' O ' ' CG2' ' A' ' 52' ' ' THR . . . 176.76 -94.56 0.1 OUTLIER Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.368 -1.493 . . . . 50.0 109.368 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.466 ' CG2' ' O ' ' A' ' 51' ' ' GLY . 60.5 p -155.24 137.99 15.26 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.192 -1.181 . . . . 50.0 110.222 179.781 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' CYS . . . . . . . . . . . . . 18.5 t -54.12 -50.44 66.87 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.24 -0.913 . . . . 50.0 110.131 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 176.78 -45.26 0.11 Allowed Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.266 -1.534 . . . . 50.0 109.266 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.468 ' HB3' ' HD2' ' A' ' 56' ' ' PRO . 87.0 mt -110.82 164.9 13.78 Favored Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.288 -1.125 . . . . 50.0 109.973 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . 0.468 ' HD2' ' HB3' ' A' ' 55' ' ' LEU . 45.6 Cg_endo -72.75 -3.03 12.8 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 O-C-N 123.88 1.463 . . . . 50.0 110.395 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -77.49 -43.5 15.37 Favored Glycine 0 N--CA 1.487 2.096 0 N-CA-C 109.491 -1.444 . . . . 50.0 109.491 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' THR . . . . . 0.416 HG21 ' C ' ' A' ' 39' ' ' HIS . 10.9 m -125.31 166.38 16.65 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.336 -1.097 . . . . 50.0 110.508 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 74.6 mmtt -123.21 148.6 45.66 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.336 -0.853 . . . . 50.0 109.902 179.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 13.2 t -73.52 127.93 34.08 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.145 -0.972 . . . . 50.0 110.376 -179.672 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' CYS . . . . . 0.525 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 28.3 m -128.02 154.17 45.94 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.29 -0.882 . . . . 50.0 109.994 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.441 ' HB2' ' HB2' ' A' ' 36' ' ' ALA . 87.9 tttt -132.99 138.68 46.93 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.157 -0.965 . . . . 50.0 110.249 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . 0.514 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 93.8 mttt . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.311 -0.868 . . . . 50.0 110.274 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.467 HG23 ' HB2' ' A' ' 32' ' ' LEU . 58.7 m . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 121.246 0.546 . . . . 50.0 109.919 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 52.8 m -75.73 -6.24 49.61 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.35 -0.843 . . . . 50.0 110.691 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.467 ' HB2' HG23 ' A' ' 30' ' ' THR . 95.3 mt -57.35 -34.73 69.09 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.032 -1.043 . . . . 50.0 110.205 -179.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 24.8 mttp -68.03 -37.33 81.23 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.389 -0.819 . . . . 50.0 110.153 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 95.0 p -77.49 -18.25 57.26 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.474 -0.766 . . . . 50.0 110.252 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 89.81 5.71 70.86 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.503 -1.439 . . . . 50.0 109.503 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -77.37 147.97 35.81 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.217 -1.167 . . . . 50.0 110.284 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.519 HD12 ' CE2' ' A' ' 47' ' ' TYR . 4.0 pt -95.44 152.72 3.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.225 -0.922 . . . . 50.0 109.858 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . 0.413 ' HA ' ' O ' ' A' ' 59' ' ' LYS . 79.0 m -100.16 139.77 35.36 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.205 -0.934 . . . . 50.0 110.143 -179.766 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.486 ' N ' ' O ' ' A' ' 59' ' ' LYS . 59.2 t-80 -117.82 136.26 23.66 Favored Pre-proline 0 N--CA 1.492 1.663 0 O-C-N 121.345 -0.847 . . . . 50.0 110.007 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.471 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 47.7 Cg_endo -72.23 164.58 35.2 Favored 'Trans proline' 0 C--N 1.303 -1.827 0 O-C-N 123.929 1.489 . . . . 50.0 110.503 -179.792 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.471 ' HB ' ' O ' ' A' ' 40' ' ' PRO . 44.2 t 60.73 -82.78 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.524 -0.735 . . . . 50.0 111.171 179.538 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.536 ' CD1' ' C ' ' A' ' 42' ' ' PHE . 9.7 p90 -155.7 154.29 31.28 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.957 -1.09 . . . . 50.0 110.662 -179.43 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 1.7 t -77.43 130.92 72.92 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.257 -0.902 . . . . 50.0 109.784 179.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -70.96 -162.29 0.1 Allowed 'Trans proline' 0 C--N 1.304 -1.803 0 O-C-N 123.88 1.463 . . . . 50.0 110.549 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 18.3 mtm180 -84.83 -40.13 17.51 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 121.475 -0.766 . . . . 50.0 109.818 -179.856 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 57.9 ttm-85 -61.73 -15.95 45.17 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.457 -0.777 . . . . 50.0 109.965 179.67 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' TYR . . . . . 0.531 ' HB3' ' HB3' ' A' ' 61' ' ' CYS . 58.4 m-85 -123.99 134.33 53.49 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.316 -0.865 . . . . 50.0 110.507 -179.789 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -97.71 137.95 35.82 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.287 -0.883 . . . . 50.0 109.595 179.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.4 ' HA ' ' O ' ' A' ' 60' ' ' CYS . 36.3 tt0 -87.2 103.98 15.93 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.156 -0.965 . . . . 50.0 110.917 -179.308 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.459 HD13 ' HD2' ' A' ' 62' ' ' LYS . 96.5 mt -62.8 -29.07 46.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.301 -0.874 . . . . 50.0 109.733 179.472 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.441 ' C ' HG22 ' A' ' 52' ' ' THR . . . 171.19 -91.23 0.09 OUTLIER Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.476 -1.45 . . . . 50.0 109.476 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.441 HG22 ' C ' ' A' ' 51' ' ' GLY . 71.9 p -151.58 127.92 10.61 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.259 -1.142 . . . . 50.0 110.292 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' CYS . . . . . . . . . . . . . 15.6 t -49.82 -47.41 51.42 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.297 -0.877 . . . . 50.0 110.081 179.694 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.415 ' C ' HD13 ' A' ' 55' ' ' LEU . . . 168.77 -38.33 0.21 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 108.683 -1.767 . . . . 50.0 108.683 -179.77 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.553 ' N ' ' CD1' ' A' ' 55' ' ' LEU . 6.1 mp -119.79 158.1 50.64 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.475 -1.015 . . . . 50.0 109.752 179.604 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -70.8 -10.29 27.43 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 O-C-N 123.904 1.476 . . . . 50.0 110.286 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -67.87 -41.96 87.12 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.312 -1.515 . . . . 50.0 109.312 179.704 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' THR . . . . . 0.441 ' HA ' ' HA ' ' A' ' 40' ' ' PRO . 5.2 m -127.6 164.06 22.85 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.342 -1.093 . . . . 50.0 110.28 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.486 ' O ' ' N ' ' A' ' 39' ' ' HIS . 33.4 mmtp -118.75 152.6 35.88 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.318 -0.864 . . . . 50.0 109.741 179.654 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.4 ' O ' ' HA ' ' A' ' 49' ' ' GLN . 34.5 t -80.32 127.57 32.53 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.029 -1.045 . . . . 50.0 110.333 -179.793 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' CYS . . . . . 0.531 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 52.5 m -125.61 151.53 46.35 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.33 -0.856 . . . . 50.0 109.879 179.74 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.459 ' HD2' HD13 ' A' ' 50' ' ' ILE . 87.0 tttt -136.75 144.97 44.08 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.081 -1.012 . . . . 50.0 110.597 -179.775 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 50.8 mtmt . . . . . 0 N--CA 1.493 1.685 0 O-C-N 121.289 -0.882 . . . . 50.0 110.272 179.879 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.474 ' O ' ' HB2' ' A' ' 31' ' ' CYS . 74.5 m . . . . . 0 N--CA 1.492 1.644 0 CA-C-O 121.213 0.53 . . . . 50.0 110.392 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . 0.474 ' HB2' ' O ' ' A' ' 30' ' ' THR . 90.4 m 56.23 27.86 12.34 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.231 -0.918 . . . . 50.0 110.586 179.773 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.466 ' HB2' HG23 ' A' ' 30' ' ' THR . 67.2 tp -76.95 -43.26 35.88 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.208 -0.933 . . . . 50.0 110.08 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -67.43 -34.58 77.52 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.277 -0.889 . . . . 50.0 110.117 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 81.0 p -71.98 -24.45 61.59 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.422 -0.799 . . . . 50.0 110.259 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 75.87 10.99 84.96 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.626 -1.389 . . . . 50.0 109.626 179.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . 0.438 ' HB2' ' HG3' ' A' ' 62' ' ' LYS . . . -77.04 156.11 32.03 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.186 -1.185 . . . . 50.0 110.257 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.518 HD12 ' CE2' ' A' ' 47' ' ' TYR . 13.8 pt -93.96 167.22 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.285 -0.885 . . . . 50.0 110.147 179.864 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 96.6 m -108.2 148.35 30.06 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.293 -0.879 . . . . 50.0 109.951 179.749 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.585 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 60.9 t-80 -138.68 145.66 47.13 Favored Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.297 -0.877 . . . . 50.0 110.435 -179.649 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.585 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 43.5 Cg_endo -69.1 160.39 50.07 Favored 'Trans proline' 0 C--N 1.305 -1.727 0 O-C-N 124.012 1.532 . . . . 50.0 110.42 179.486 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.524 HG13 ' CD2' ' A' ' 42' ' ' PHE . 15.9 t 62.3 -97.27 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.437 -0.789 . . . . 50.0 110.312 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.524 ' CD2' HG13 ' A' ' 41' ' ' VAL . 35.4 p90 -150.18 154.4 37.94 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 120.728 -1.233 . . . . 50.0 110.07 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.458 ' SG ' ' HA ' ' A' ' 49' ' ' GLN . 64.6 m -61.96 133.62 93.98 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.196 -0.94 . . . . 50.0 110.581 -179.63 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.412 ' HD2' ' HB2' ' A' ' 47' ' ' TYR . 43.4 Cg_endo -68.49 -161.33 0.06 OUTLIER 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 123.959 1.505 . . . . 50.0 110.474 179.709 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 62.5 ttt180 -77.25 -44.08 31.16 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.558 -0.713 . . . . 50.0 110.664 -179.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 51.5 mmm-85 -61.23 -31.42 71.21 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.233 -0.917 . . . . 50.0 110.422 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' TYR . . . . . 0.518 ' CE2' HD12 ' A' ' 37' ' ' ILE . 48.4 m-85 -105.73 149.38 26.47 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.273 -0.892 . . . . 50.0 110.491 -179.788 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -108.56 131.79 54.5 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.337 -0.852 . . . . 50.0 109.688 179.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.458 ' HA ' ' SG ' ' A' ' 43' ' ' CYS . 59.6 tt0 -82.81 101.43 10.94 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.327 -0.858 . . . . 50.0 110.702 -179.36 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.478 HD13 ' HB2' ' A' ' 62' ' ' LYS . 85.1 mt -70.36 -30.93 45.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.245 -0.909 . . . . 50.0 109.677 179.452 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.43 ' C ' HG21 ' A' ' 52' ' ' THR . . . 178.14 -99.05 0.12 Allowed Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.294 -1.522 . . . . 50.0 109.294 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.43 HG21 ' C ' ' A' ' 51' ' ' GLY . 61.7 p -146.12 137.28 24.57 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.305 -1.115 . . . . 50.0 110.403 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' CYS . . . . . 0.474 ' HA ' ' HB2' ' A' ' 60' ' ' CYS . 17.2 t -51.95 -48.1 64.44 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.334 -0.854 . . . . 50.0 109.565 179.467 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 172.87 -30.4 0.1 Allowed Glycine 0 N--CA 1.489 2.193 0 N-CA-C 108.95 -1.66 . . . . 50.0 108.95 179.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 98.1 mt -124.44 159.63 56.7 Favored Pre-proline 0 N--CA 1.488 1.471 0 O-C-N 121.41 -1.053 . . . . 50.0 109.802 179.668 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -71.29 -9.81 26.03 Favored 'Trans proline' 0 C--N 1.304 -1.809 0 O-C-N 124.013 1.533 . . . . 50.0 110.537 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -73.57 -34.56 56.8 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.296 -1.521 . . . . 50.0 109.296 179.714 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' THR . . . . . 0.404 HG23 ' N ' ' A' ' 59' ' ' LYS . 25.6 m -131.6 168.42 17.73 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.302 -1.117 . . . . 50.0 109.976 179.789 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.418 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 33.6 mmtp -126.82 149.74 49.54 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.279 -0.888 . . . . 50.0 110.091 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.474 ' HB2' ' HA ' ' A' ' 53' ' ' CYS . 15.9 t -76.6 129.58 36.62 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.243 -0.911 . . . . 50.0 110.295 -179.633 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' CYS . . . . . 0.477 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 83.7 m -127.56 145.27 50.92 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.425 -0.797 . . . . 50.0 110.001 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.478 ' HB2' HD13 ' A' ' 50' ' ' ILE . 85.5 tttt -124.55 144.66 50.01 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.254 -0.904 . . . . 50.0 110.345 -179.814 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . 0.502 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 97.0 mttt . . . . . 0 N--CA 1.49 1.529 0 O-C-N 121.343 -0.848 . . . . 50.0 110.066 179.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 51.6 m . . . . . 0 N--CA 1.49 1.528 0 CA-C-O 121.258 0.552 . . . . 50.0 109.815 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 63.2 m -90.83 4.97 50.32 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.21 -0.931 . . . . 50.0 110.443 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 46.7 tp -66.68 -44.41 81.87 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.147 -0.97 . . . . 50.0 110.263 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -61.69 -39.03 90.02 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.382 -0.824 . . . . 50.0 110.384 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 87.7 p -71.32 -24.25 62.09 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.34 -0.85 . . . . 50.0 110.14 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 89.73 3.64 73.89 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.626 -1.389 . . . . 50.0 109.626 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . 0.457 ' HB2' ' HB3' ' A' ' 62' ' ' LYS . . . -73.87 154.57 39.39 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.211 -1.17 . . . . 50.0 110.142 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.436 ' O ' HG13 ' A' ' 37' ' ' ILE . 3.9 pt -102.24 154.27 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.13 -0.981 . . . . 50.0 110.081 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 93.0 m -98.1 138.48 35.33 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.235 -0.916 . . . . 50.0 110.208 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.49 ' N ' ' O ' ' A' ' 59' ' ' LYS . 58.6 t-80 -114.63 140.41 25.26 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.268 -0.895 . . . . 50.0 110.235 -179.8 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.489 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 44.1 Cg_endo -70.44 162.4 42.54 Favored 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 123.995 1.524 . . . . 50.0 110.272 179.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.489 ' HB ' ' O ' ' A' ' 40' ' ' PRO . 18.3 t 62.96 -108.36 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.461 -0.775 . . . . 50.0 110.285 179.885 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 35.7 p90 -135.31 148.87 49.63 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.796 -1.19 . . . . 50.0 110.24 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -68.5 131.03 91.73 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.265 -0.897 . . . . 50.0 110.204 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.435 ' HD2' ' HB2' ' A' ' 47' ' ' TYR . 46.6 Cg_endo -71.22 -163.03 0.12 Allowed 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 123.859 1.452 . . . . 50.0 110.415 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 32.3 mtt85 -80.57 -44.75 18.5 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.512 -0.743 . . . . 50.0 109.887 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 28.6 tpt180 -58.74 -24.46 61.62 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.53 -0.731 . . . . 50.0 110.152 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' TYR . . . . . 0.526 ' HB3' ' HB3' ' A' ' 61' ' ' CYS . 42.0 m-85 -114.98 135.8 53.83 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.255 -0.903 . . . . 50.0 110.266 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 88.3 mttt -105.01 147.97 27.25 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.204 -0.935 . . . . 50.0 109.945 179.751 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.482 ' HA ' ' O ' ' A' ' 60' ' ' CYS . 52.7 tt0 -87.31 106.78 18.16 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.215 -0.928 . . . . 50.0 110.788 -179.432 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 67.8 mt -63.39 -24.12 35.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.289 -0.882 . . . . 50.0 109.731 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.483 ' O ' ' CB ' ' A' ' 52' ' ' THR . . . 152.5 40.18 0.03 OUTLIER Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.284 -1.527 . . . . 50.0 109.284 -179.868 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.483 ' CB ' ' O ' ' A' ' 51' ' ' GLY . 0.2 OUTLIER 69.76 151.17 0.09 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.404 -1.056 . . . . 50.0 110.435 -179.925 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' CYS . . . . . 0.44 ' HA ' ' HB2' ' A' ' 60' ' ' CYS . 7.3 t -71.19 -41.99 69.59 Favored 'General case' 0 N--CA 1.492 1.629 0 CA-C-O 121.763 0.792 . . . . 50.0 109.964 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.435 ' C ' HD13 ' A' ' 55' ' ' LEU . . . 154.63 -26.03 0.66 Allowed Glycine 0 N--CA 1.49 2.244 0 N-CA-C 108.438 -1.865 . . . . 50.0 108.438 -179.746 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.584 ' N ' ' CD1' ' A' ' 55' ' ' LEU . 5.8 mp -124.72 158.1 63.54 Favored Pre-proline 0 N--CA 1.489 1.495 0 O-C-N 121.55 -0.97 . . . . 50.0 109.465 179.611 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -71.79 -8.46 23.1 Favored 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.886 1.466 . . . . 50.0 110.432 -179.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -71.33 -45.83 45.5 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.545 -1.422 . . . . 50.0 109.545 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' THR . . . . . 0.415 HG21 ' C ' ' A' ' 39' ' ' HIS . 7.2 m -128.89 166.01 19.94 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.136 -1.214 . . . . 50.0 110.434 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.49 ' O ' ' N ' ' A' ' 39' ' ' HIS . 33.5 mmtp -121.16 148.49 44.16 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.415 -0.803 . . . . 50.0 109.558 179.62 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.482 ' O ' ' HA ' ' A' ' 49' ' ' GLN . 35.1 t -74.82 130.54 39.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.991 -1.068 . . . . 50.0 110.117 -179.741 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' CYS . . . . . 0.526 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 59.9 m -135.32 155.11 51.15 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.274 -0.891 . . . . 50.0 110.102 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.457 ' HB3' ' HB2' ' A' ' 36' ' ' ALA . 34.9 pttt -146.57 166.83 25.3 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.103 -0.998 . . . . 50.0 110.299 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 52.7 mtmt . . . . . 0 N--CA 1.492 1.643 0 O-C-N 121.278 -0.889 . . . . 50.0 110.255 -179.971 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 95.9 m . . . . . 0 N--CA 1.491 1.581 0 CA-C-O 121.23 0.538 . . . . 50.0 110.348 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 72.0 m -77.44 -12.05 59.91 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.907 . . . . 50.0 110.225 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.493 ' CD1' ' C ' ' A' ' 32' ' ' LEU . 3.4 tm? -57.68 -44.52 85.85 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.26 -0.9 . . . . 50.0 110.294 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -61.74 -38.01 86.36 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.312 -0.868 . . . . 50.0 110.149 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 69.5 m -72.53 -21.31 61.19 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.288 -0.882 . . . . 50.0 110.152 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 85.44 -3.18 87.57 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.633 -1.387 . . . . 50.0 109.633 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . 0.524 ' HB2' ' CB ' ' A' ' 62' ' ' LYS . . . -77.47 159.49 29.35 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.14 -1.212 . . . . 50.0 110.19 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.471 HG13 ' O ' ' A' ' 37' ' ' ILE . 3.6 pt -108.22 151.15 10.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.288 -0.883 . . . . 50.0 110.118 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 85.4 m -88.78 141.29 28.63 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.198 -0.939 . . . . 50.0 109.964 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 50.5 t-80 -120.5 134.43 24.18 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.243 -0.911 . . . . 50.0 110.247 -179.77 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.484 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 44.0 Cg_endo -71.55 168.13 24.48 Favored 'Trans proline' 0 C--N 1.305 -1.724 0 O-C-N 124.001 1.527 . . . . 50.0 110.458 179.873 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.484 ' HB ' ' O ' ' A' ' 40' ' ' PRO . 38.9 t 61.26 -92.51 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.383 -0.823 . . . . 50.0 110.69 179.806 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.508 ' CD1' ' C ' ' A' ' 42' ' ' PHE . 16.2 p90 -148.58 148.69 30.45 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.967 -1.083 . . . . 50.0 110.379 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 1.8 t -73.47 128.74 86.76 Favored Pre-proline 0 N--CA 1.493 1.706 0 O-C-N 121.238 -0.914 . . . . 50.0 109.883 179.573 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -71.79 -162.6 0.12 Allowed 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.835 1.44 . . . . 50.0 110.568 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 6.7 ptp180 -90.51 -15.25 31.09 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.525 -0.734 . . . . 50.0 110.123 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 89.6 mtm180 -73.18 -31.23 64.09 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.186 -0.946 . . . . 50.0 110.166 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' TYR . . . . . 0.551 ' CD1' ' N ' ' A' ' 47' ' ' TYR . 6.9 m-85 -113.23 147.87 36.65 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.223 -0.923 . . . . 50.0 110.333 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 61.6 mttm -93.43 152.6 19.0 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.255 -0.903 . . . . 50.0 109.799 179.272 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 58.7 tt0 -91.59 97.47 11.06 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.068 -1.02 . . . . 50.0 110.615 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 86.7 mt -63.88 -32.65 57.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.312 -0.868 . . . . 50.0 109.701 179.512 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.431 ' C ' HG21 ' A' ' 52' ' ' THR . . . 166.17 -95.99 0.12 Allowed Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.408 -1.477 . . . . 50.0 109.408 179.811 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.431 HG21 ' C ' ' A' ' 51' ' ' GLY . 21.7 p -145.24 129.07 17.32 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.329 -1.101 . . . . 50.0 110.193 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' CYS . . . . . 0.454 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 30.7 t -61.41 -47.9 83.65 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.15 -0.969 . . . . 50.0 109.654 179.577 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 129.68 1.89 5.41 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.491 -1.443 . . . . 50.0 109.491 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 92.0 mt -105.27 143.42 26.73 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.278 -1.13 . . . . 50.0 110.174 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -73.38 79.59 2.1 Favored 'Trans proline' 0 C--N 1.303 -1.821 0 O-C-N 124.062 1.559 . . . . 50.0 110.688 -179.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 139.17 -3.03 2.69 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.696 -1.24 . . . . 50.0 110.378 179.55 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' THR . . . . . 0.432 ' HA ' ' HA ' ' A' ' 40' ' ' PRO . 1.2 m -121.86 159.69 26.29 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.974 -1.309 . . . . 50.0 110.476 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 16.2 tppt? -129.59 123.81 32.25 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.355 -0.841 . . . . 50.0 109.895 179.584 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.454 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 34.2 t -53.92 128.99 32.4 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.177 -0.952 . . . . 50.0 110.375 -179.692 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' CYS . . . . . 0.497 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 62.3 m -128.84 146.41 50.94 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.222 -0.924 . . . . 50.0 110.076 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.524 ' CB ' ' HB2' ' A' ' 36' ' ' ALA . 79.6 tttt -125.08 143.75 50.76 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.2 -0.937 . . . . 50.0 110.477 -179.678 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . 0.421 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 86.9 mttt . . . . . 0 N--CA 1.491 1.608 0 O-C-N 121.345 -0.847 . . . . 50.0 110.361 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.485 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 23.7 m . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 121.074 0.464 . . . . 50.0 110.372 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . 0.48 ' HB2' ' O ' ' A' ' 30' ' ' THR . 98.7 m 58.86 19.66 7.25 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.314 -0.866 . . . . 50.0 110.538 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.485 ' HG ' ' O ' ' A' ' 30' ' ' THR . 93.5 mt -111.27 -15.83 13.53 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.258 -0.901 . . . . 50.0 109.896 179.605 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 63.8 mmtt -69.26 -39.71 78.26 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.309 -0.869 . . . . 50.0 110.18 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' SER . . . . . 0.462 ' HB3' ' NZ ' ' A' ' 62' ' ' LYS . 66.7 m -90.27 -9.88 46.3 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.357 -0.84 . . . . 50.0 110.031 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 87.13 7.8 76.46 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.509 -1.436 . . . . 50.0 109.509 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . 0.468 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -69.21 140.1 54.56 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.326 -1.102 . . . . 50.0 110.265 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.572 ' CD1' ' NE2' ' A' ' 39' ' ' HIS . 3.8 pt -100.54 155.92 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.227 -0.92 . . . . 50.0 109.871 179.821 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 83.5 m -95.46 141.0 29.52 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.152 -0.967 . . . . 50.0 110.043 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.572 ' NE2' ' CD1' ' A' ' 37' ' ' ILE . 38.4 m-70 -117.9 161.93 31.86 Favored Pre-proline 0 N--CA 1.497 1.889 0 O-C-N 121.33 -0.856 . . . . 50.0 110.55 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.47 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 44.0 Cg_endo -72.22 156.22 55.48 Favored 'Trans proline' 0 C--N 1.304 -1.766 0 O-C-N 124.024 1.539 . . . . 50.0 110.224 179.754 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.485 HG13 ' CD2' ' A' ' 42' ' ' PHE . 15.4 t 61.5 -108.53 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.246 -0.909 . . . . 50.0 110.064 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.485 ' CD2' HG13 ' A' ' 41' ' ' VAL . 44.0 p90 -135.16 164.79 26.88 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.685 -1.26 . . . . 50.0 110.225 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.47 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 70.9 m -70.72 130.88 88.22 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.172 -0.955 . . . . 50.0 110.668 -179.547 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -71.42 -161.44 0.09 OUTLIER 'Trans proline' 0 C--N 1.305 -1.742 0 O-C-N 123.851 1.448 . . . . 50.0 110.391 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 15.3 ptm180 -81.88 -24.54 35.68 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.492 -0.755 . . . . 50.0 110.786 -179.483 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 79.5 mtp180 -71.7 -16.29 62.23 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.046 -1.034 . . . . 50.0 110.594 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' TYR . . . . . 0.602 ' CE2' ' CG ' ' A' ' 63' ' ' LYS . 36.2 m-85 -129.81 153.06 48.63 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.088 -1.008 . . . . 50.0 110.878 -179.698 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -99.92 141.86 32.18 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.37 -0.831 . . . . 50.0 109.263 179.11 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.463 ' NE2' ' CE ' ' A' ' 59' ' ' LYS . 37.5 tt0 -84.44 98.82 10.29 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.162 -0.962 . . . . 50.0 110.955 -179.169 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.523 ' CD1' ' HB2' ' A' ' 62' ' ' LYS . 95.3 mt -62.98 -32.06 54.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.166 -0.958 . . . . 50.0 109.627 179.303 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.496 ' C ' ' CG2' ' A' ' 52' ' ' THR . . . 165.83 -92.09 0.1 Allowed Glycine 0 N--CA 1.487 2.044 0 N-CA-C 109.426 -1.47 . . . . 50.0 109.426 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.496 ' CG2' ' C ' ' A' ' 51' ' ' GLY . 20.9 p -152.02 134.19 15.09 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.319 -1.107 . . . . 50.0 110.152 -179.914 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' CYS . . . . . 0.523 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 5.0 t -59.14 -45.64 90.43 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.277 -0.889 . . . . 50.0 110.207 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 163.97 -41.53 0.32 Allowed Glycine 0 N--CA 1.489 2.233 0 N-CA-C 108.993 -1.643 . . . . 50.0 108.993 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 76.5 mt -118.43 158.03 47.92 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.511 -0.993 . . . . 50.0 109.928 179.747 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -71.82 -4.92 16.02 Favored 'Trans proline' 0 C--N 1.304 -1.807 0 O-C-N 123.922 1.486 . . . . 50.0 110.35 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -70.89 -30.28 68.25 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.371 -1.492 . . . . 50.0 109.371 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' THR . . . . . 0.402 HG21 ' C ' ' A' ' 39' ' ' HIS . 5.8 m -139.11 163.56 32.08 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.284 -1.127 . . . . 50.0 110.393 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.463 ' CE ' ' NE2' ' A' ' 49' ' ' GLN . 54.8 tptt -119.31 128.18 53.88 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.405 -0.809 . . . . 50.0 109.42 179.528 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.523 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 41.1 t -63.71 131.54 48.23 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.181 -0.949 . . . . 50.0 110.431 -179.282 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' CYS . . . . . 0.48 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 74.8 m -126.2 156.81 39.61 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.467 -0.771 . . . . 50.0 110.181 -179.675 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.523 ' HB2' ' CD1' ' A' ' 50' ' ' ILE . 57.3 tttp -137.51 138.07 39.29 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.146 -0.971 . . . . 50.0 110.343 -179.801 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . 0.602 ' CG ' ' CE2' ' A' ' 47' ' ' TYR . 56.0 mtpt . . . . . 0 N--CA 1.491 1.625 0 O-C-N 121.122 -0.987 . . . . 50.0 110.043 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 72.9 m . . . . . 0 N--CA 1.492 1.65 0 CA-C-O 121.203 0.525 . . . . 50.0 109.899 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 52.1 m -79.4 -3.43 46.39 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.158 -0.963 . . . . 50.0 110.425 -179.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 70.4 mt -56.91 -41.56 78.37 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.129 -0.982 . . . . 50.0 110.063 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 30.3 mmtp -67.52 -38.34 84.09 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.393 -0.817 . . . . 50.0 110.359 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 41.4 t -68.36 -32.64 72.87 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.29 -0.881 . . . . 50.0 110.047 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.78 -5.68 56.76 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.711 -1.356 . . . . 50.0 109.711 179.714 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -74.29 130.39 39.62 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.181 -1.188 . . . . 50.0 110.206 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.522 HD12 ' CE2' ' A' ' 47' ' ' TYR . 7.0 pt -73.34 162.73 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.209 -0.932 . . . . 50.0 110.22 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 71.9 m -106.44 152.29 23.82 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.273 -0.892 . . . . 50.0 110.093 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.576 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 60.4 t-80 -138.39 145.23 46.04 Favored Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.315 -0.865 . . . . 50.0 109.892 -179.734 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.576 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 41.8 Cg_endo -67.7 161.01 45.61 Favored 'Trans proline' 0 C--N 1.302 -1.912 0 O-C-N 123.898 1.473 . . . . 50.0 110.189 179.728 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.485 ' HB ' ' O ' ' A' ' 40' ' ' PRO . 17.5 t 62.43 -104.59 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.42 -0.8 . . . . 50.0 110.035 -179.716 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.402 ' CD2' HG13 ' A' ' 41' ' ' VAL . 36.7 p90 -142.72 155.93 44.95 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.642 -1.286 . . . . 50.0 110.126 179.834 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.448 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 75.6 m -65.06 132.45 95.44 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.286 -0.883 . . . . 50.0 110.262 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -69.1 -161.64 0.07 OUTLIER 'Trans proline' 0 C--N 1.304 -1.783 0 O-C-N 123.927 1.488 . . . . 50.0 110.802 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 14.3 mtt180 -78.46 -39.49 38.4 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.461 -0.775 . . . . 50.0 109.907 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 95.4 mtt180 -60.02 -34.27 73.14 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.44 -0.787 . . . . 50.0 110.346 -179.727 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' TYR . . . . . 0.541 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 18.7 m-85 -110.71 144.01 40.31 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.295 -0.878 . . . . 50.0 110.899 -179.558 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 64.6 mttm -98.06 138.26 35.63 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.39 -0.819 . . . . 50.0 109.183 178.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 39.9 tt0 -80.68 101.88 9.53 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.053 -1.029 . . . . 50.0 110.686 -179.402 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.477 HD13 ' HB2' ' A' ' 62' ' ' LYS . 74.4 mt -65.46 -31.26 53.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.222 -0.924 . . . . 50.0 109.618 179.366 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.423 ' C ' HG21 ' A' ' 52' ' ' THR . . . 165.09 -94.13 0.11 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.291 -1.523 . . . . 50.0 109.291 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.423 HG21 ' C ' ' A' ' 51' ' ' GLY . 65.3 p -143.3 136.21 27.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.311 -1.111 . . . . 50.0 110.284 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' CYS . . . . . 0.509 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 17.5 t -58.07 -49.4 77.05 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.256 -0.903 . . . . 50.0 109.793 179.67 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 176.45 -32.17 0.08 OUTLIER Glycine 0 N--CA 1.49 2.265 0 N-CA-C 108.791 -1.723 . . . . 50.0 108.791 -179.854 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 80.6 mt -127.71 160.03 63.05 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.504 -0.997 . . . . 50.0 109.545 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -72.19 -2.14 11.17 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 123.88 1.463 . . . . 50.0 110.36 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -74.75 -38.88 41.38 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.545 -1.422 . . . . 50.0 109.545 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 21.2 m -126.7 168.58 14.17 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.199 -1.177 . . . . 50.0 110.367 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 14.5 tppt? -119.43 136.29 54.37 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.322 -0.861 . . . . 50.0 109.982 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.509 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 20.4 t -69.01 128.69 37.59 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.262 -0.899 . . . . 50.0 110.484 -179.739 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' CYS . . . . . 0.471 ' SG ' ' HB3' ' A' ' 39' ' ' HIS . 74.2 m -125.42 153.13 43.92 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.241 -0.912 . . . . 50.0 109.748 179.687 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.477 ' HB2' HD13 ' A' ' 50' ' ' ILE . 83.6 tttt -130.08 144.33 51.28 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.172 -0.955 . . . . 50.0 110.487 -179.616 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . 0.541 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 97.7 mttt . . . . . 0 N--CA 1.49 1.527 0 O-C-N 121.301 -0.875 . . . . 50.0 110.047 179.718 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 88.7 m . . . . . 0 N--CA 1.491 1.609 0 CA-C-O 121.167 0.508 . . . . 50.0 110.137 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . 0.422 ' SG ' ' HA ' ' A' ' 53' ' ' CYS . 79.3 m -77.15 -13.12 60.0 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.255 -0.903 . . . . 50.0 110.214 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 46.1 tp -57.32 -40.79 78.67 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.263 -0.898 . . . . 50.0 110.488 -179.717 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 60.3 mmtt -68.34 -41.25 81.03 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.265 -0.897 . . . . 50.0 110.297 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 56.9 m -70.86 -29.59 65.75 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.224 -0.923 . . . . 50.0 110.19 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 87.07 8.16 76.0 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.552 -1.419 . . . . 50.0 109.552 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -72.35 176.84 4.96 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.235 -1.156 . . . . 50.0 110.287 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.551 HD13 ' CD2' ' A' ' 39' ' ' HIS . 2.9 pt -115.83 153.53 17.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.316 -0.865 . . . . 50.0 109.984 179.663 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 83.0 m -112.52 153.31 27.67 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.167 -0.958 . . . . 50.0 109.969 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.551 ' CD2' HD13 ' A' ' 37' ' ' ILE . 31.6 m-70 -140.33 162.58 48.92 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 121.315 -0.865 . . . . 50.0 110.282 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -70.81 166.5 28.69 Favored 'Trans proline' 0 C--N 1.305 -1.759 0 O-C-N 124.037 1.546 . . . . 50.0 110.847 -179.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.465 ' O ' ' HG3' ' A' ' 59' ' ' LYS . 14.4 t 54.07 -108.43 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.393 -0.817 . . . . 50.0 110.167 179.811 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.456 ' CD1' ' O ' ' A' ' 43' ' ' CYS . 29.3 p90 -141.36 151.37 43.47 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.817 -1.177 . . . . 50.0 110.129 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.475 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 72.5 m -50.65 130.36 27.33 Favored Pre-proline 0 N--CA 1.489 1.517 0 O-C-N 121.155 -0.965 . . . . 50.0 109.813 179.771 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.452 ' HD2' ' HB2' ' A' ' 47' ' ' TYR . 43.6 Cg_endo -70.16 -162.78 0.1 OUTLIER 'Trans proline' 0 C--N 1.304 -1.783 0 O-C-N 123.954 1.502 . . . . 50.0 110.304 179.792 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 28.8 mtp180 -74.68 -42.79 57.77 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.417 -0.802 . . . . 50.0 110.04 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 79.0 mtp180 -61.96 -14.87 39.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.486 -0.759 . . . . 50.0 110.37 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' TYR . . . . . 0.5 ' HB3' ' HB3' ' A' ' 61' ' ' CYS . 72.6 m-85 -128.28 164.19 23.13 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.232 -0.918 . . . . 50.0 110.683 -179.68 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -127.79 154.79 45.0 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.349 -0.845 . . . . 50.0 109.958 179.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -87.93 115.46 25.41 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.181 -0.95 . . . . 50.0 110.06 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 22.6 pt -110.41 15.91 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.282 -0.886 . . . . 50.0 110.459 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.479 ' O ' ' HB3' ' A' ' 60' ' ' CYS . . . 133.24 114.89 1.57 Allowed Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.403 -1.479 . . . . 50.0 109.403 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.47 ' C ' ' O ' ' A' ' 51' ' ' GLY . 75.9 p -34.65 134.05 0.24 Allowed 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.771 -0.841 . . . . 50.0 110.965 -179.841 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' CYS . . . . . 0.515 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 4.4 t -51.67 -42.03 61.84 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.452 -0.78 . . . . 50.0 110.34 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 163.36 -27.52 0.23 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.062 -1.615 . . . . 50.0 109.062 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 97.0 mt -122.45 152.9 62.0 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.358 -1.084 . . . . 50.0 109.856 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.44 -16.25 27.6 Favored 'Trans proline' 0 C--N 1.303 -1.824 0 O-C-N 123.886 1.466 . . . . 50.0 110.416 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -69.02 -32.71 73.37 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.389 -1.484 . . . . 50.0 109.389 179.83 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' THR . . . . . 0.411 HG21 ' C ' ' A' ' 39' ' ' HIS . 8.6 m -128.74 168.12 16.29 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.287 -1.125 . . . . 50.0 110.198 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.465 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 75.1 mmtt -130.91 141.96 50.33 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.365 -0.835 . . . . 50.0 109.767 179.688 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.515 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 7.4 t -73.35 139.51 46.04 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.127 -0.983 . . . . 50.0 109.98 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' CYS . . . . . 0.5 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 97.8 m -131.89 144.47 50.89 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.378 -0.826 . . . . 50.0 109.94 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 54.7 tttm -127.81 140.36 52.08 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.089 -1.007 . . . . 50.0 110.31 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . 0.424 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 93.3 mttt . . . . . 0 N--CA 1.49 1.538 0 O-C-N 121.219 -0.926 . . . . 50.0 110.09 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 36.4 m . . . . . 0 N--CA 1.491 1.6 0 CA-C-O 121.211 0.529 . . . . 50.0 110.098 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 65.9 m -84.71 0.35 50.78 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.188 -0.945 . . . . 50.0 110.317 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.439 ' N ' HD23 ' A' ' 32' ' ' LEU . 4.2 mm? -65.82 -45.25 82.99 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.209 -0.932 . . . . 50.0 110.179 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -64.53 -36.16 83.3 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.409 -0.807 . . . . 50.0 110.181 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 95.2 p -69.48 -20.26 63.74 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.374 -0.829 . . . . 50.0 110.299 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 89.7 0.35 78.86 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.492 -1.443 . . . . 50.0 109.492 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -77.98 154.45 31.53 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.148 -1.207 . . . . 50.0 110.128 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.487 ' O ' ' O ' ' A' ' 61' ' ' CYS . 1.1 pt -99.72 157.22 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.285 -0.884 . . . . 50.0 109.875 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 70.9 m -107.06 143.7 34.79 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.012 -1.055 . . . . 50.0 110.121 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.599 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 14.8 t-80 -108.2 145.92 32.49 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.269 -0.894 . . . . 50.0 109.851 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.599 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 42.4 Cg_endo -68.03 -23.92 39.71 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 O-C-N 123.847 1.446 . . . . 50.0 110.878 -179.674 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.444 ' O ' ' HG3' ' A' ' 59' ' ' LYS . 66.3 t -117.91 -88.77 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.087 -1.008 . . . . 50.0 110.527 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.521 ' CD1' ' C ' ' A' ' 42' ' ' PHE . 13.4 p90 -140.02 151.31 45.35 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.111 -0.993 . . . . 50.0 110.148 -179.765 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.464 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 75.8 m -61.95 123.81 79.19 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.127 -0.983 . . . . 50.0 109.937 179.782 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.477 ' HD2' ' HB2' ' A' ' 47' ' ' TYR . 45.1 Cg_endo -69.95 -163.04 0.1 Allowed 'Trans proline' 0 C--N 1.304 -1.769 0 O-C-N 123.975 1.513 . . . . 50.0 110.732 179.812 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 65.2 ttt180 -75.02 -42.29 57.66 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.475 -0.766 . . . . 50.0 110.419 -179.74 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 86.4 mmt-85 -62.19 -29.07 70.11 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.366 -0.834 . . . . 50.0 110.221 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' TYR . . . . . 0.579 ' CE2' ' CG ' ' A' ' 63' ' ' LYS . 16.6 m-85 -113.35 159.26 19.6 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.178 -0.952 . . . . 50.0 110.717 -179.732 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 13.5 ptmm? -120.5 145.61 47.11 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.36 -0.838 . . . . 50.0 109.462 179.116 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.449 ' HA ' ' SG ' ' A' ' 43' ' ' CYS . 63.3 tt0 -90.09 103.49 16.15 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.124 -0.985 . . . . 50.0 110.714 -179.53 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.449 HD13 ' HB2' ' A' ' 62' ' ' LYS . 90.7 mt -68.17 -29.45 44.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.207 -0.933 . . . . 50.0 109.623 179.438 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.412 ' C ' HG21 ' A' ' 52' ' ' THR . . . 172.31 -95.31 0.11 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.217 -1.553 . . . . 50.0 109.217 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.412 HG21 ' C ' ' A' ' 51' ' ' GLY . 70.7 p -144.17 134.19 24.07 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.209 -1.171 . . . . 50.0 110.309 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' CYS . . . . . 0.514 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 16.5 t -54.26 -43.79 71.28 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.134 -0.979 . . . . 50.0 109.669 179.571 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 152.65 -24.64 0.84 Allowed Glycine 0 N--CA 1.49 2.253 0 N-CA-C 108.637 -1.785 . . . . 50.0 108.637 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.473 ' HG ' ' HD2' ' A' ' 56' ' ' PRO . 16.7 tp -121.74 142.58 36.3 Favored Pre-proline 0 C--N 1.303 -1.449 0 O-C-N 121.505 -0.997 . . . . 50.0 109.374 179.594 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . 0.473 ' HD2' ' HG ' ' A' ' 55' ' ' LEU . 41.3 Cg_endo -67.37 -5.27 13.52 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 123.794 1.418 . . . . 50.0 110.465 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -80.14 -27.63 52.01 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.333 -1.507 . . . . 50.0 109.333 179.483 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' THR . . . . . 0.479 ' CG2' ' O ' ' A' ' 39' ' ' HIS . 3.4 m -137.33 160.68 38.37 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.247 -1.149 . . . . 50.0 110.433 179.908 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.464 ' O ' ' N ' ' A' ' 39' ' ' HIS . 73.4 mmtt -113.31 155.41 25.2 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.527 -0.733 . . . . 50.0 109.538 179.425 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.514 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 37.3 t -85.8 130.88 34.43 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.185 -0.947 . . . . 50.0 110.897 -179.24 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' CYS . . . . . 0.487 ' O ' ' O ' ' A' ' 37' ' ' ILE . 71.3 m -134.06 128.95 35.31 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.425 -0.797 . . . . 50.0 109.301 179.542 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.449 ' HB2' HD13 ' A' ' 50' ' ' ILE . 84.8 tttt -109.48 147.74 32.38 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.003 -1.06 . . . . 50.0 111.148 -179.154 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . 0.579 ' CG ' ' CE2' ' A' ' 47' ' ' TYR . 51.3 mtmt . . . . . 0 N--CA 1.49 1.532 0 O-C-N 121.365 -0.834 . . . . 50.0 109.663 179.317 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 99.8 m . . . . . 0 N--CA 1.492 1.653 0 CA-C-O 121.171 0.51 . . . . 50.0 110.345 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 65.1 m -82.1 -6.42 59.16 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.19 -0.944 . . . . 50.0 109.995 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 60.1 tp -57.99 -46.48 85.15 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.329 -0.857 . . . . 50.0 110.189 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -64.83 -34.52 78.55 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.393 -0.817 . . . . 50.0 110.21 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 65.1 m -69.67 -31.94 70.29 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.277 -0.889 . . . . 50.0 110.3 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.15 5.21 62.43 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.698 -1.361 . . . . 50.0 109.698 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . 0.439 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -78.41 173.05 12.75 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.189 -1.183 . . . . 50.0 110.326 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.574 HD13 ' CD2' ' A' ' 39' ' ' HIS . 7.1 pt -114.73 152.25 16.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.305 -0.872 . . . . 50.0 109.925 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 77.1 m -107.18 142.76 36.38 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.326 -0.859 . . . . 50.0 110.156 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.574 ' CD2' HD13 ' A' ' 37' ' ' ILE . 23.6 m-70 -134.04 157.4 77.76 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.258 -0.901 . . . . 50.0 110.12 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.469 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 45.8 Cg_endo -72.18 165.03 33.82 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 O-C-N 124.096 1.577 . . . . 50.0 110.931 -179.42 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.469 ' HB ' ' O ' ' A' ' 40' ' ' PRO . 18.6 t 61.02 -100.73 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.453 -0.78 . . . . 50.0 110.26 179.689 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.41 ' CD2' HG13 ' A' ' 41' ' ' VAL . 35.4 p90 -145.64 157.55 43.95 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.757 -1.214 . . . . 50.0 110.467 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.426 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 76.5 m -68.98 131.24 90.97 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.324 -0.86 . . . . 50.0 110.089 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -69.45 -160.05 0.06 OUTLIER 'Trans proline' 0 C--N 1.305 -1.75 0 O-C-N 123.908 1.478 . . . . 50.0 110.945 -179.709 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 31.7 mtt180 -80.85 -41.22 23.54 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.537 -0.727 . . . . 50.0 109.884 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 82.7 mmt-85 -55.82 -25.46 41.75 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.466 -0.771 . . . . 50.0 109.97 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' TYR . . . . . 0.531 ' CD1' ' N ' ' A' ' 47' ' ' TYR . 18.3 m-85 -125.82 161.61 27.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.285 -0.884 . . . . 50.0 110.399 179.722 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.421 ' N ' ' O ' ' A' ' 62' ' ' LYS . 88.8 mttt -116.43 146.12 42.76 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.443 -0.785 . . . . 50.0 109.021 178.801 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.407 ' HA ' ' O ' ' A' ' 60' ' ' CYS . 45.4 tt0 -90.23 104.02 16.64 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.96 -1.087 . . . . 50.0 111.215 -178.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.481 HD13 ' HB2' ' A' ' 62' ' ' LYS . 80.2 mt -64.81 -32.54 58.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.276 -0.89 . . . . 50.0 109.136 178.857 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.404 ' C ' HG21 ' A' ' 52' ' ' THR . . . 168.63 -96.07 0.12 Allowed Glycine 0 N--CA 1.488 2.108 0 N-CA-C 109.469 -1.452 . . . . 50.0 109.469 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.404 HG21 ' C ' ' A' ' 51' ' ' GLY . 74.3 p -143.22 127.77 17.99 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.25 -1.147 . . . . 50.0 110.29 -179.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' CYS . . . . . . . . . . . . . 4.4 t -50.44 -44.76 55.55 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.225 -0.922 . . . . 50.0 109.848 179.721 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 176.71 -33.23 0.08 OUTLIER Glycine 0 N--CA 1.49 2.288 0 N-CA-C 108.994 -1.642 . . . . 50.0 108.994 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 97.5 mt -127.21 161.36 54.72 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.455 -1.027 . . . . 50.0 109.77 179.651 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -72.61 -5.31 16.94 Favored 'Trans proline' 0 C--N 1.304 -1.774 0 O-C-N 123.912 1.48 . . . . 50.0 110.462 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -71.45 -34.68 63.46 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.596 -1.402 . . . . 50.0 109.596 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' THR . . . . . 0.411 HG22 ' C ' ' A' ' 39' ' ' HIS . 11.5 m -132.88 165.64 24.17 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.312 -1.111 . . . . 50.0 110.149 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.456 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 75.3 mmtt -122.31 135.46 54.73 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.38 -0.825 . . . . 50.0 109.675 179.563 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.426 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 39.4 t -68.98 133.73 48.55 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.261 -0.9 . . . . 50.0 110.426 -179.432 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' CYS . . . . . 0.487 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 71.2 m -123.13 153.58 39.79 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.355 -0.841 . . . . 50.0 110.023 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.481 ' HB2' HD13 ' A' ' 50' ' ' ILE . 65.4 tttm -139.78 147.68 41.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.068 -1.02 . . . . 50.0 110.51 -179.721 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 97.4 mttt . . . . . 0 N--CA 1.491 1.618 0 O-C-N 121.259 -0.9 . . . . 50.0 110.207 179.844 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 95.8 m . . . . . 0 N--CA 1.491 1.581 0 CA-C-O 121.259 0.552 . . . . 50.0 110.229 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . 0.452 ' SG ' ' HA ' ' A' ' 53' ' ' CYS . 72.1 m -65.67 -16.83 64.12 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.265 -0.897 . . . . 50.0 110.184 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 9.9 tp -61.21 -45.98 92.33 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.282 -0.886 . . . . 50.0 110.082 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 67.5 mttm -63.12 -35.04 78.94 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.393 -0.817 . . . . 50.0 110.065 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 31.6 t -70.05 -24.3 63.24 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.361 -0.837 . . . . 50.0 110.204 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.03 9.9 47.33 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.604 -1.398 . . . . 50.0 109.604 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . 0.494 ' HB3' ' CG ' ' A' ' 62' ' ' LYS . . . -106.78 151.45 25.15 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.196 -1.179 . . . . 50.0 110.172 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.502 HG12 ' CE2' ' A' ' 47' ' ' TYR . 6.6 pt -100.7 151.86 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.347 -0.845 . . . . 50.0 110.26 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 87.0 m -92.75 148.15 22.28 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.301 -0.874 . . . . 50.0 109.964 179.781 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.608 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 53.0 t-80 -135.42 147.05 60.29 Favored Pre-proline 0 N--CA 1.495 1.783 0 O-C-N 121.247 -0.908 . . . . 50.0 110.045 -179.488 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.608 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 43.5 Cg_endo -69.89 160.47 49.53 Favored 'Trans proline' 0 C--N 1.308 -1.597 0 O-C-N 123.773 1.407 . . . . 50.0 110.59 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.573 HG13 ' CD2' ' A' ' 42' ' ' PHE . 21.6 t 61.57 -87.54 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.427 -0.796 . . . . 50.0 110.655 179.749 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.573 ' CD2' HG13 ' A' ' 41' ' ' VAL . 25.8 p90 -155.42 164.89 38.11 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 120.845 -1.159 . . . . 50.0 110.333 179.872 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.451 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 85.3 m -73.87 131.7 81.27 Favored Pre-proline 0 N--CA 1.496 1.834 0 O-C-N 121.239 -0.913 . . . . 50.0 110.601 -179.566 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -71.02 -162.18 0.1 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 O-C-N 123.9 1.474 . . . . 50.0 110.787 -179.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 19.4 ptp180 -80.11 -20.96 43.83 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.536 -0.727 . . . . 50.0 110.413 -179.758 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -76.73 -26.13 54.29 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.261 -0.899 . . . . 50.0 110.013 179.821 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' TYR . . . . . 0.513 ' CD1' ' N ' ' A' ' 47' ' ' TYR . 15.5 m-85 -124.21 158.76 31.67 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.308 -0.87 . . . . 50.0 110.6 -179.813 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 54.0 tptt -111.89 156.03 22.71 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.438 -0.788 . . . . 50.0 109.151 178.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.443 ' HG3' ' HG3' ' A' ' 59' ' ' LYS . 32.7 tt0 -95.25 100.75 12.49 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.923 -1.11 . . . . 50.0 110.65 -179.546 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.544 HD12 ' CD ' ' A' ' 62' ' ' LYS . 66.3 mt -66.92 -31.02 51.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.284 -0.885 . . . . 50.0 109.783 179.443 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.41 ' C ' HG21 ' A' ' 52' ' ' THR . . . 172.67 -97.77 0.12 Allowed Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.55 -1.42 . . . . 50.0 109.55 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.41 HG21 ' C ' ' A' ' 51' ' ' GLY . 64.9 p -143.36 133.15 23.91 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.205 -1.173 . . . . 50.0 110.44 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' CYS . . . . . 0.523 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 13.8 t -55.01 -45.05 75.09 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.315 -0.865 . . . . 50.0 109.67 179.57 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 167.66 -35.73 0.21 Allowed Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.383 -1.887 . . . . 50.0 108.383 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 66.4 mt -122.38 157.02 59.97 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.542 -0.975 . . . . 50.0 109.491 179.488 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -72.48 -6.5 19.17 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 123.852 1.448 . . . . 50.0 110.641 -179.79 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -71.52 -35.9 62.77 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.495 -1.442 . . . . 50.0 109.495 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 6.2 m -128.59 167.92 16.46 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.323 -1.104 . . . . 50.0 110.183 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.443 ' HG3' ' HG3' ' A' ' 49' ' ' GLN . 16.3 tppt? -124.41 133.68 53.32 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.266 -0.896 . . . . 50.0 110.173 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.523 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 35.3 t -63.06 133.83 55.13 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.29 -0.881 . . . . 50.0 110.527 -179.823 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' CYS . . . . . 0.476 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 74.7 m -133.15 138.65 46.7 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.281 -0.887 . . . . 50.0 110.084 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.544 ' CD ' HD12 ' A' ' 50' ' ' ILE . 87.5 tttt -135.65 144.45 46.05 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.199 -0.938 . . . . 50.0 110.136 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 97.6 mttt . . . . . 0 N--CA 1.491 1.617 0 O-C-N 121.124 -0.985 . . . . 50.0 109.933 179.965 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 26.1 m . . . . . 0 N--CA 1.493 1.679 0 CA-C-O 121.265 0.555 . . . . 50.0 110.054 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 93.3 m -76.79 -4.54 44.02 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.264 -0.898 . . . . 50.0 110.437 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 18.9 mt -58.91 -45.19 90.92 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.139 -0.975 . . . . 50.0 110.07 179.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -66.71 -34.98 79.05 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.368 -0.833 . . . . 50.0 110.223 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 46.6 t -67.58 -25.08 65.61 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.365 -0.834 . . . . 50.0 110.192 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.77 -14.22 60.46 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.707 -1.357 . . . . 50.0 109.707 179.71 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . 0.497 ' HB2' ' CB ' ' A' ' 62' ' ' LYS . . . -70.31 170.58 11.5 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.143 -1.21 . . . . 50.0 110.255 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.565 HD13 ' CD2' ' A' ' 39' ' ' HIS . 14.7 pt -115.38 163.05 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.346 -0.846 . . . . 50.0 109.748 179.464 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 74.8 m -109.74 140.7 43.33 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.156 -0.965 . . . . 50.0 110.046 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.565 ' CD2' HD13 ' A' ' 37' ' ' ILE . 17.2 m-70 -134.34 153.92 79.6 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.198 -0.939 . . . . 50.0 110.115 179.892 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.471 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 45.1 Cg_endo -70.54 162.79 41.19 Favored 'Trans proline' 0 C--N 1.305 -1.743 0 O-C-N 124.029 1.541 . . . . 50.0 111.262 -179.178 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.474 ' O ' ' HG3' ' A' ' 59' ' ' LYS . 18.9 t 62.11 -105.18 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.578 -0.701 . . . . 50.0 110.607 179.546 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 25.8 p90 -140.01 157.27 45.94 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.863 -1.148 . . . . 50.0 110.359 -179.688 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.465 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 83.8 m -67.83 129.46 93.26 Favored Pre-proline 0 N--CA 1.492 1.626 0 O-C-N 121.181 -0.95 . . . . 50.0 109.829 179.599 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -67.6 -162.94 0.08 OUTLIER 'Trans proline' 0 C--N 1.303 -1.848 0 O-C-N 123.881 1.464 . . . . 50.0 110.846 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 16.2 ptm180 -78.33 -32.26 49.12 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.467 -0.77 . . . . 50.0 110.274 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.453 ' HG2' ' CE1' ' A' ' 47' ' ' TYR . 55.6 ttm-85 -68.3 -25.73 65.29 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.265 -0.897 . . . . 50.0 109.902 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' TYR . . . . . 0.542 ' CZ ' ' HE2' ' A' ' 63' ' ' LYS . 29.3 m-85 -119.84 157.4 28.75 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.258 -0.901 . . . . 50.0 110.035 179.623 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 76.6 tttt -109.54 152.22 25.76 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.262 -0.899 . . . . 50.0 109.323 178.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.409 ' HA ' ' SG ' ' A' ' 43' ' ' CYS . 56.8 tp60 -95.18 101.51 13.26 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.171 -0.955 . . . . 50.0 110.24 -179.777 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 98.2 mt -72.17 -28.98 30.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.289 -0.882 . . . . 50.0 109.775 179.788 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 165.88 -91.87 0.1 Allowed Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.75 -1.34 . . . . 50.0 109.75 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 76.4 p -150.52 130.91 13.75 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.188 -1.184 . . . . 50.0 110.563 -179.573 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' CYS . . . . . . . . . . . . . 8.6 t -51.2 -43.17 61.31 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.221 -0.924 . . . . 50.0 110.083 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.451 ' C ' ' CD2' ' A' ' 55' ' ' LEU . . . 162.91 -31.63 0.29 Allowed Glycine 0 N--CA 1.488 2.151 0 N-CA-C 109.001 -1.64 . . . . 50.0 109.001 -179.687 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.527 ' N ' ' CD2' ' A' ' 55' ' ' LEU . 3.2 mm? -126.43 160.9 55.6 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.442 -1.034 . . . . 50.0 109.743 179.758 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -71.45 -10.49 26.99 Favored 'Trans proline' 0 C--N 1.304 -1.799 0 O-C-N 123.801 1.421 . . . . 50.0 110.44 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -64.99 -45.03 93.59 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.595 -1.402 . . . . 50.0 109.595 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' THR . . . . . 0.409 HG21 ' C ' ' A' ' 39' ' ' HIS . 20.1 m -131.36 167.1 19.83 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.327 -1.102 . . . . 50.0 110.423 -179.873 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.474 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 47.0 mmtm -118.93 149.48 41.52 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.439 -0.788 . . . . 50.0 109.533 179.387 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.465 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 36.9 t -76.74 132.55 39.36 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.146 -0.971 . . . . 50.0 110.797 -179.093 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' CYS . . . . . 0.496 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 92.5 m -133.17 133.9 43.42 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.465 -0.772 . . . . 50.0 109.858 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.497 ' CB ' ' HB2' ' A' ' 36' ' ' ALA . 81.3 tttt -127.95 141.97 51.38 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.148 -0.97 . . . . 50.0 110.689 -179.539 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . 0.542 ' HE2' ' CZ ' ' A' ' 47' ' ' TYR . 99.4 mttt . . . . . 0 N--CA 1.491 1.595 0 O-C-N 121.36 -0.837 . . . . 50.0 110.023 179.592 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.459 ' O ' ' HB2' ' A' ' 31' ' ' CYS . 85.0 m . . . . . 0 N--CA 1.492 1.645 0 CA-C-O 121.251 0.548 . . . . 50.0 110.314 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . 0.459 ' HB2' ' O ' ' A' ' 30' ' ' THR . 64.1 m 57.28 19.29 4.87 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.161 -0.962 . . . . 50.0 110.399 179.813 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 33.2 tp -72.69 -32.17 65.58 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.165 -0.959 . . . . 50.0 110.633 -179.727 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -71.85 -40.18 69.2 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.103 -0.998 . . . . 50.0 110.226 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 72.3 m -71.82 -24.58 61.74 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.415 -0.803 . . . . 50.0 110.175 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 75.63 16.1 80.85 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.483 -1.447 . . . . 50.0 109.483 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . 0.425 ' HB2' ' HA ' ' A' ' 62' ' ' LYS . . . -83.12 176.74 8.98 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.281 -1.129 . . . . 50.0 110.024 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.473 HG13 ' O ' ' A' ' 37' ' ' ILE . 3.7 pt -116.91 150.77 18.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.134 -0.979 . . . . 50.0 110.42 -179.901 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . 0.426 ' HA ' ' HA ' ' A' ' 60' ' ' CYS . 61.0 m -91.26 137.3 32.47 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.173 -0.954 . . . . 50.0 109.333 179.484 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.52 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 58.3 t-80 -109.49 143.03 26.95 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.054 -1.028 . . . . 50.0 110.76 -179.157 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.52 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 47.5 Cg_endo -73.33 164.78 34.3 Favored 'Trans proline' 0 C--N 1.305 -1.713 0 O-C-N 124.19 1.626 . . . . 50.0 110.316 179.694 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.549 HG13 ' CD2' ' A' ' 42' ' ' PHE . 27.7 t 59.71 -84.02 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.298 -0.876 . . . . 50.0 110.558 179.667 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.549 ' CD2' HG13 ' A' ' 41' ' ' VAL . 16.5 p90 -158.64 161.89 37.21 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.854 -1.154 . . . . 50.0 110.389 -179.916 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.41 ' SG ' ' HB3' ' A' ' 47' ' ' TYR . 0.6 OUTLIER -80.92 121.62 81.06 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.216 -0.928 . . . . 50.0 110.059 179.911 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -70.39 -162.52 0.1 OUTLIER 'Trans proline' 0 C--N 1.306 -1.677 0 O-C-N 123.908 1.478 . . . . 50.0 110.592 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 11.2 ptm180 -81.8 -29.76 32.54 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.546 -0.721 . . . . 50.0 110.369 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 45.4 mmm-85 -69.06 -16.1 63.61 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.274 -0.891 . . . . 50.0 110.163 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' TYR . . . . . 0.547 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 72.4 m-85 -122.93 150.14 43.34 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.29 -0.881 . . . . 50.0 110.337 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 54.0 tptt -110.9 154.11 24.53 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.35 -0.844 . . . . 50.0 110.224 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.521 ' HG3' ' CE ' ' A' ' 59' ' ' LYS . 46.2 tt0 -88.48 108.91 19.63 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.23 -0.919 . . . . 50.0 110.01 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 39.4 pt -104.32 10.76 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.22 -0.925 . . . . 50.0 110.966 -179.51 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.536 ' O ' ' CB ' ' A' ' 60' ' ' CYS . . . 130.62 113.01 1.55 Allowed Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.431 -1.468 . . . . 50.0 109.431 179.927 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.493 ' C ' ' O ' ' A' ' 51' ' ' GLY . 81.9 p -29.52 140.09 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.991 -0.711 . . . . 50.0 111.633 -179.612 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' CYS . . . . . . . . . . . . . 8.3 t -59.52 -50.24 74.69 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.385 -0.822 . . . . 50.0 110.219 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -179.06 -39.85 0.07 OUTLIER Glycine 0 N--CA 1.491 2.323 0 N-CA-C 108.945 -1.662 . . . . 50.0 108.945 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.451 ' HB3' ' HD2' ' A' ' 56' ' ' PRO . 70.2 mt -126.59 164.12 36.44 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.437 -1.037 . . . . 50.0 109.836 179.664 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . 0.451 ' HD2' ' HB3' ' A' ' 55' ' ' LEU . 45.2 Cg_endo -71.21 -7.29 21.04 Favored 'Trans proline' 0 C--N 1.305 -1.762 0 O-C-N 123.971 1.511 . . . . 50.0 110.555 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -68.98 -37.64 83.56 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.16 -1.576 . . . . 50.0 109.16 179.765 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' THR . . . . . 0.45 HG21 ' O ' ' A' ' 39' ' ' HIS . 1.4 m -129.42 159.97 34.57 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.316 -1.108 . . . . 50.0 110.005 179.773 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.521 ' CE ' ' HG3' ' A' ' 49' ' ' GLN . 37.7 tptt -121.84 127.27 50.35 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.197 -0.94 . . . . 50.0 109.984 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.536 ' CB ' ' O ' ' A' ' 51' ' ' GLY . 49.8 t -57.03 134.26 55.66 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.196 -0.94 . . . . 50.0 110.073 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' CYS . . . . . 0.521 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 54.5 m -136.76 148.26 47.15 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.3 -0.875 . . . . 50.0 109.981 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.425 ' HA ' ' HB2' ' A' ' 36' ' ' ALA . 81.0 tttt -128.4 132.26 48.5 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.207 -0.933 . . . . 50.0 110.418 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . 0.547 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 49.2 mtpt . . . . . 0 N--CA 1.491 1.58 0 O-C-N 121.299 -0.875 . . . . 50.0 110.202 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 57.7 m . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 121.376 0.608 . . . . 50.0 109.927 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 92.6 m -80.01 -8.3 59.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.252 -0.905 . . . . 50.0 110.594 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.0 mt -58.29 -33.14 69.12 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.147 -0.971 . . . . 50.0 110.38 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 95.0 mttt -67.39 -39.09 85.59 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.266 -0.896 . . . . 50.0 110.229 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 14.4 m -65.4 -31.71 72.95 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.292 -0.88 . . . . 50.0 110.154 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 106.73 15.44 16.83 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.696 -1.362 . . . . 50.0 109.696 179.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -120.31 126.38 50.41 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.17 -1.194 . . . . 50.0 110.152 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.561 ' CD1' ' NE2' ' A' ' 39' ' ' HIS . 1.1 pt -84.02 144.54 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.281 -0.887 . . . . 50.0 109.995 179.855 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . 0.468 ' HA ' ' HA ' ' A' ' 60' ' ' CYS . 22.6 p -87.95 159.69 18.23 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.196 -0.94 . . . . 50.0 110.411 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.561 ' NE2' ' CD1' ' A' ' 37' ' ' ILE . 41.8 m-70 -131.02 167.88 19.66 Favored Pre-proline 0 N--CA 1.496 1.839 0 O-C-N 121.408 -0.808 . . . . 50.0 110.168 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.47 ' HD2' ' HB3' ' A' ' 39' ' ' HIS . 43.5 Cg_endo -70.16 161.17 46.97 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 O-C-N 123.711 1.374 . . . . 50.0 110.742 -179.601 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.527 HG13 ' CD2' ' A' ' 42' ' ' PHE . 9.8 t 55.82 -112.15 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.297 -0.877 . . . . 50.0 109.883 -179.682 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.527 ' CD2' HG13 ' A' ' 41' ' ' VAL . 50.2 p90 -135.2 156.27 49.27 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.676 -1.265 . . . . 50.0 109.96 179.749 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.476 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 83.6 m -59.14 130.47 86.87 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.137 -0.977 . . . . 50.0 110.043 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -70.71 -162.54 0.1 Allowed 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 123.979 1.515 . . . . 50.0 110.603 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 41.5 ptt180 -78.6 -29.35 46.02 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.493 -0.754 . . . . 50.0 110.413 -179.623 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 86.5 mtm180 -72.39 -12.43 61.11 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.237 -0.914 . . . . 50.0 110.16 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' TYR . . . . . 0.585 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 38.1 m-85 -131.36 165.66 22.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.267 -0.896 . . . . 50.0 111.084 -179.611 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.455 ' O ' ' HA ' ' A' ' 61' ' ' CYS . 33.2 mttm -117.31 142.68 46.78 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.514 -0.741 . . . . 50.0 109.295 178.865 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.47 ' HA ' ' O ' ' A' ' 60' ' ' CYS . 32.7 tt0 -88.19 110.04 20.38 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.981 -1.075 . . . . 50.0 111.188 -179.131 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.527 ' CG1' ' HD2' ' A' ' 62' ' ' LYS . 80.7 mt -77.21 -28.89 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.314 -0.866 . . . . 50.0 109.326 178.909 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.531 ' O ' ' CG2' ' A' ' 52' ' ' THR . . . 174.3 -99.54 0.14 Allowed Glycine 0 N--CA 1.488 2.166 0 N-CA-C 108.819 -1.712 . . . . 50.0 108.819 -179.836 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.531 ' CG2' ' O ' ' A' ' 51' ' ' GLY . 70.9 p -157.65 143.74 17.55 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.284 -1.127 . . . . 50.0 110.191 179.571 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' CYS . . . . . 0.465 ' HA ' ' SG ' ' A' ' 60' ' ' CYS . 1.8 t -58.1 -39.06 77.67 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.217 -0.927 . . . . 50.0 109.882 179.606 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.428 ' O ' HD22 ' A' ' 55' ' ' LEU . . . 165.85 -27.68 0.18 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 108.818 -1.713 . . . . 50.0 108.818 -179.936 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.49 ' HB3' ' HD2' ' A' ' 56' ' ' PRO . 30.2 mt -127.36 166.46 22.86 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.409 -1.054 . . . . 50.0 109.816 179.748 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . 0.49 ' HD2' ' HB3' ' A' ' 55' ' ' LEU . 45.6 Cg_endo -73.52 -4.85 16.12 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.884 1.465 . . . . 50.0 110.447 179.889 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -78.61 -32.81 40.39 Favored Glycine 0 N--CA 1.489 2.167 0 N-CA-C 109.421 -1.472 . . . . 50.0 109.421 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' THR . . . . . 0.466 HG21 ' O ' ' A' ' 39' ' ' HIS . 2.5 m -128.37 162.58 26.77 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.273 -1.134 . . . . 50.0 110.587 -179.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.524 ' CG ' ' O ' ' A' ' 41' ' ' VAL . 72.1 mmtt -133.38 142.96 48.63 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.536 -0.728 . . . . 50.0 109.511 179.615 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.476 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 45.1 m -68.98 131.09 44.51 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.083 -1.01 . . . . 50.0 110.255 -179.861 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' CYS . . . . . 0.521 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 98.3 m -124.29 162.07 24.51 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.399 -0.813 . . . . 50.0 110.247 -179.812 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.584 ' O ' ' CD2' ' A' ' 47' ' ' TYR . 46.0 mtpt -122.31 164.31 18.14 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.233 -0.917 . . . . 50.0 110.672 -179.748 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . 0.585 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 52.1 mtpt . . . . . 0 N--CA 1.492 1.638 0 O-C-N 121.364 -0.835 . . . . 50.0 110.334 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 25.0 m . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 121.262 0.554 . . . . 50.0 110.097 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . 0.44 ' HB3' ' HB3' ' A' ' 36' ' ' ALA . 87.2 m -77.39 -1.6 30.94 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.193 -0.942 . . . . 50.0 110.411 -179.834 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 32.9 mt -63.35 -39.64 95.08 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.222 -0.924 . . . . 50.0 110.261 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 43.0 mmtm -66.75 -42.58 85.95 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.29 -0.882 . . . . 50.0 110.362 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 86.3 p -70.46 -14.77 62.67 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.347 -0.846 . . . . 50.0 110.143 -179.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 87.12 4.79 81.19 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.543 -1.423 . . . . 50.0 109.543 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . 0.44 ' HB3' ' HB3' ' A' ' 31' ' ' CYS . . . -71.8 155.64 40.21 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.159 -1.201 . . . . 50.0 110.009 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.581 HD12 ' CE2' ' A' ' 47' ' ' TYR . 26.7 pt -103.89 145.0 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.185 -0.947 . . . . 50.0 110.015 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 8.7 m -101.22 125.39 47.84 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.258 -0.901 . . . . 50.0 109.936 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.545 ' NE2' ' CD1' ' A' ' 37' ' ' ILE . 12.5 m-70 -119.48 153.06 53.77 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.232 -0.917 . . . . 50.0 110.345 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.422 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 45.7 Cg_endo -71.16 169.88 19.55 Favored 'Trans proline' 0 C--N 1.305 -1.727 0 O-C-N 124.04 1.547 . . . . 50.0 110.852 -179.604 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.422 ' HB ' ' O ' ' A' ' 40' ' ' PRO . 17.4 t 59.15 -109.35 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.362 -0.836 . . . . 50.0 110.186 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 36.8 p90 -136.24 153.64 51.15 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.827 -1.171 . . . . 50.0 110.017 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.407 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 76.4 m -69.88 132.26 88.8 Favored Pre-proline 0 N--CA 1.487 1.415 0 O-C-N 121.11 -0.994 . . . . 50.0 109.911 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -68.41 -162.76 0.08 OUTLIER 'Trans proline' 0 C--N 1.305 -1.732 0 O-C-N 123.996 1.524 . . . . 50.0 111.004 -179.564 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 16.2 ptm180 -81.58 -26.37 35.01 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.558 -0.714 . . . . 50.0 110.453 -179.617 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 13.3 mmm180 -66.71 -22.22 66.07 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.148 -0.97 . . . . 50.0 110.1 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' TYR . . . . . 0.598 ' CB ' ' HB3' ' A' ' 61' ' ' CYS . 70.8 m-85 -128.1 144.01 51.09 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.217 -0.927 . . . . 50.0 110.589 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 85.0 tttt -88.67 152.88 21.53 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.267 -0.896 . . . . 50.0 109.221 178.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 56.4 tt0 -93.4 96.44 9.93 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.093 -1.005 . . . . 50.0 110.562 -179.702 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.468 HD13 ' CB ' ' A' ' 62' ' ' LYS . 93.6 mt -69.42 -30.11 44.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.309 -0.87 . . . . 50.0 109.904 179.575 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.456 ' O ' ' CG2' ' A' ' 52' ' ' THR . . . 159.12 -91.86 0.12 Allowed Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.263 -1.535 . . . . 50.0 109.263 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.456 ' CG2' ' O ' ' A' ' 51' ' ' GLY . 63.3 p -153.92 150.58 28.5 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.26 -1.141 . . . . 50.0 109.992 179.695 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' CYS . . . . . 0.435 ' SG ' ' HB2' ' A' ' 60' ' ' CYS . 1.6 m -84.89 -27.33 26.72 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.189 -0.944 . . . . 50.0 110.694 -179.599 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 179.03 -49.5 0.09 OUTLIER Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.764 -1.334 . . . . 50.0 109.764 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 56.2 mt -119.74 161.92 35.47 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.16 -1.2 . . . . 50.0 110.419 -179.851 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -71.93 -11.4 27.42 Favored 'Trans proline' 0 C--N 1.305 -1.74 0 O-C-N 124.08 1.569 . . . . 50.0 110.292 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -68.94 -30.47 72.32 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.448 -1.461 . . . . 50.0 109.448 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -125.25 155.28 40.37 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.275 -1.132 . . . . 50.0 110.298 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.445 ' O ' ' SG ' ' A' ' 61' ' ' CYS . 14.1 tppt? -120.56 127.16 51.89 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.396 -0.815 . . . . 50.0 109.839 179.686 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.435 ' HB2' ' SG ' ' A' ' 53' ' ' CYS . 34.3 t -63.51 130.9 46.29 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.252 -0.905 . . . . 50.0 110.663 -179.604 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' CYS . . . . . 0.598 ' HB3' ' CB ' ' A' ' 47' ' ' TYR . 7.4 m -128.58 130.3 47.16 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.371 -0.831 . . . . 50.0 109.635 179.765 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.468 ' CB ' HD13 ' A' ' 50' ' ' ILE . 83.4 tttt -131.62 148.69 52.62 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.157 -0.964 . . . . 50.0 110.507 -179.638 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 86.0 mttt . . . . . 0 N--CA 1.49 1.575 0 O-C-N 121.281 -0.887 . . . . 50.0 110.021 179.887 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.484 ' O ' ' HB2' ' A' ' 31' ' ' CYS . 85.8 m . . . . . 0 N--CA 1.492 1.666 0 CA-C-O 121.098 0.475 . . . . 50.0 110.54 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . 0.484 ' HB2' ' O ' ' A' ' 30' ' ' THR . 97.9 m 56.61 18.38 3.6 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.232 -0.918 . . . . 50.0 110.223 179.836 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.48 ' CD1' ' C ' ' A' ' 32' ' ' LEU . 3.4 tm? -76.62 -39.47 52.36 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.223 -0.923 . . . . 50.0 110.477 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 74.4 mmtt -75.13 -35.24 61.7 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.324 -0.86 . . . . 50.0 109.985 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 73.9 m -71.18 -26.72 63.09 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.374 -0.829 . . . . 50.0 110.191 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 84.98 9.0 81.54 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.493 -1.443 . . . . 50.0 109.493 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . 0.441 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -76.66 134.37 39.29 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.232 -1.158 . . . . 50.0 110.262 -179.914 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.515 ' CD1' ' CE2' ' A' ' 47' ' ' TYR . 9.1 pt -83.02 148.13 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.239 -0.913 . . . . 50.0 110.028 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 96.5 m -91.79 148.79 21.98 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.075 -1.016 . . . . 50.0 109.882 179.862 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.584 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 62.6 t-80 -139.71 145.9 45.17 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 121.312 -0.868 . . . . 50.0 109.89 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.584 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 41.6 Cg_endo -66.89 159.63 50.79 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.868 1.457 . . . . 50.0 110.075 179.723 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.496 HG13 ' CD2' ' A' ' 42' ' ' PHE . 13.5 t 62.99 -105.94 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.224 -0.922 . . . . 50.0 109.913 -179.673 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.496 ' CD2' HG13 ' A' ' 41' ' ' VAL . 42.1 p90 -142.26 157.9 44.32 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.626 -1.296 . . . . 50.0 110.148 179.814 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.455 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 84.4 m -65.02 132.54 95.5 Favored Pre-proline 0 N--CA 1.493 1.699 0 O-C-N 121.241 -0.912 . . . . 50.0 110.371 -179.792 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -68.71 -162.16 0.08 OUTLIER 'Trans proline' 0 C--N 1.305 -1.75 0 O-C-N 123.995 1.524 . . . . 50.0 110.839 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 27.3 tpt180 -75.61 -43.13 49.63 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.519 -0.738 . . . . 50.0 110.537 -179.681 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 45.8 ttt85 -61.45 -30.77 70.8 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.333 -0.854 . . . . 50.0 110.372 -179.723 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' TYR . . . . . 0.515 ' CE2' ' CD1' ' A' ' 37' ' ' ILE . 32.2 m-85 -111.1 136.36 50.26 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.193 -0.942 . . . . 50.0 110.747 -179.85 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 24.6 tptp -87.37 157.14 19.32 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.261 -0.899 . . . . 50.0 109.387 179.034 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.442 ' HA ' ' SG ' ' A' ' 43' ' ' CYS . 53.7 tt0 -89.5 102.7 15.38 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.099 -1.001 . . . . 50.0 110.356 -179.777 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.411 ' HB ' ' SG ' ' A' ' 60' ' ' CYS . 30.6 mm -67.08 -30.66 50.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.227 -0.921 . . . . 50.0 109.555 179.552 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.475 ' O ' HG21 ' A' ' 52' ' ' THR . . . 153.77 -91.16 0.13 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.035 -1.626 . . . . 50.0 109.035 179.866 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.475 HG21 ' O ' ' A' ' 51' ' ' GLY . 50.1 p -146.2 125.9 13.42 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.363 -1.081 . . . . 50.0 109.976 179.603 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' CYS . . . . . . . . . . . . . 19.1 t -49.85 -49.22 49.98 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.252 -0.905 . . . . 50.0 109.669 179.635 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 173.47 -30.15 0.1 OUTLIER Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.211 -1.556 . . . . 50.0 109.211 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 55.6 mt -124.87 160.3 54.72 Favored Pre-proline 0 N--CA 1.489 1.512 0 O-C-N 121.384 -1.068 . . . . 50.0 109.917 179.866 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -71.97 -5.8 17.83 Favored 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.928 1.488 . . . . 50.0 110.198 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -78.32 -37.12 28.83 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.469 -1.452 . . . . 50.0 109.469 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' THR . . . . . 0.421 HG21 ' C ' ' A' ' 39' ' ' HIS . 5.1 m -130.59 162.23 29.79 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.269 -1.136 . . . . 50.0 110.268 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 66.7 mmtt -117.56 164.59 14.69 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.408 -0.808 . . . . 50.0 109.778 179.718 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.455 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 42.2 t -91.32 129.7 37.27 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.139 -0.975 . . . . 50.0 110.468 -179.78 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' CYS . . . . . 0.487 ' O ' ' N ' ' A' ' 37' ' ' ILE . 72.4 m -126.42 147.71 49.75 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.342 -0.849 . . . . 50.0 109.832 179.808 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 89.1 tttt -126.58 138.35 53.45 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.15 -0.969 . . . . 50.0 110.323 -179.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . 0.413 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 30.3 mtmm . . . . . 0 N--CA 1.491 1.598 0 O-C-N 121.333 -0.855 . . . . 50.0 110.325 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.48 ' CG2' ' O ' ' A' ' 30' ' ' THR . 95.3 m . . . . . 0 N--CA 1.494 1.754 0 CA-C-O 121.237 0.542 . . . . 50.0 110.587 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 65.4 m -48.5 -22.5 0.74 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.13 -0.981 . . . . 50.0 109.721 179.682 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.7 mt -57.98 -42.76 85.76 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.249 -0.907 . . . . 50.0 110.08 179.568 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 64.8 mmtt -68.24 -33.3 74.13 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.444 -0.785 . . . . 50.0 110.185 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 69.3 m -76.37 -17.53 59.34 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.228 -0.92 . . . . 50.0 109.942 179.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 91.93 -2.87 76.67 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.858 -1.297 . . . . 50.0 109.858 179.586 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . 0.426 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -79.59 153.94 29.09 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.124 -1.221 . . . . 50.0 110.226 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.514 ' O ' ' N ' ' A' ' 61' ' ' CYS . 4.8 pt -107.79 152.88 9.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.288 -0.882 . . . . 50.0 110.052 179.826 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 71.8 m -93.32 148.98 21.57 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.202 -0.937 . . . . 50.0 110.045 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.594 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 42.0 t-80 -136.49 145.96 53.73 Favored Pre-proline 0 N--CA 1.491 1.614 0 O-C-N 121.275 -0.891 . . . . 50.0 110.16 -179.685 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.594 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 42.5 Cg_endo -68.59 153.02 74.38 Favored 'Trans proline' 0 C--N 1.307 -1.612 0 O-C-N 123.844 1.444 . . . . 50.0 110.544 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.503 HG13 ' CD2' ' A' ' 42' ' ' PHE . 18.0 t 64.24 -84.62 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.577 -0.702 . . . . 50.0 110.559 -179.784 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.503 ' CD2' HG13 ' A' ' 41' ' ' VAL . 21.6 p90 -156.56 161.96 39.94 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.714 -1.241 . . . . 50.0 110.214 179.963 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.435 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 58.4 m -73.25 134.12 80.48 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.249 -0.907 . . . . 50.0 110.526 -179.665 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.454 ' O ' ' O ' ' A' ' 47' ' ' TYR . 44.3 Cg_endo -70.18 -160.63 0.07 OUTLIER 'Trans proline' 0 C--N 1.305 -1.718 0 O-C-N 123.874 1.46 . . . . 50.0 110.522 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 17.4 mmt180 -78.45 -46.58 19.41 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.493 -0.754 . . . . 50.0 109.68 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 82.1 mtm180 -54.39 -23.97 17.82 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.56 -0.713 . . . . 50.0 109.674 179.783 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' TYR . . . . . 0.521 ' CZ ' ' HE2' ' A' ' 63' ' ' LYS . 39.4 m-85 -122.95 154.04 38.93 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.411 -0.805 . . . . 50.0 110.259 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 82.1 tttt -117.84 149.74 40.33 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.4 -0.813 . . . . 50.0 109.679 179.594 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 58.8 tt0 -88.71 94.92 10.07 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.184 -0.948 . . . . 50.0 109.892 179.638 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.457 HG13 ' N ' ' A' ' 51' ' ' GLY . 21.6 pt -71.4 -30.08 38.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.402 -0.811 . . . . 50.0 110.326 -179.821 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.464 ' O ' HG21 ' A' ' 52' ' ' THR . . . -171.52 -105.63 0.18 Allowed Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.483 -1.447 . . . . 50.0 109.483 179.76 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.464 HG21 ' O ' ' A' ' 51' ' ' GLY . 41.2 p -151.17 141.02 21.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.285 -1.127 . . . . 50.0 110.218 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' CYS . . . . . 0.558 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 10.0 t -58.49 -44.39 89.38 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.273 -0.892 . . . . 50.0 109.873 179.879 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 160.08 -36.9 0.46 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.033 -1.627 . . . . 50.0 109.033 -179.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 74.8 mt -113.45 155.29 44.94 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.428 -1.042 . . . . 50.0 109.924 179.669 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -71.32 -11.8 29.04 Favored 'Trans proline' 0 C--N 1.303 -1.853 0 O-C-N 123.922 1.485 . . . . 50.0 110.69 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -70.92 -41.92 61.07 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.57 -1.412 . . . . 50.0 109.57 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 14.6 m -122.79 166.86 14.27 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.337 -1.096 . . . . 50.0 110.248 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -124.7 145.66 49.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.406 -0.809 . . . . 50.0 109.87 179.806 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.558 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 45.2 t -73.47 139.36 45.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.151 -0.968 . . . . 50.0 110.431 -179.803 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' CYS . . . . . 0.514 ' N ' ' O ' ' A' ' 37' ' ' ILE . 74.8 m -131.49 141.65 49.81 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.389 -0.82 . . . . 50.0 109.61 179.748 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 81.8 tttt -138.65 143.52 39.26 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.205 -0.934 . . . . 50.0 110.658 -179.341 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . 0.521 ' HE2' ' CZ ' ' A' ' 47' ' ' TYR . 98.9 mttt . . . . . 0 N--CA 1.491 1.59 0 O-C-N 121.294 -0.879 . . . . 50.0 110.158 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.481 ' O ' ' HB2' ' A' ' 31' ' ' CYS . 85.6 m . . . . . 0 N--CA 1.491 1.61 0 CA-C-O 121.121 0.486 . . . . 50.0 110.571 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . 0.481 ' HB2' ' O ' ' A' ' 30' ' ' THR . 47.9 m 56.87 21.97 6.63 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.14 -0.975 . . . . 50.0 110.312 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.481 ' HG ' ' O ' ' A' ' 30' ' ' THR . 79.2 mt -105.12 -21.05 13.33 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.193 -0.942 . . . . 50.0 110.176 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 95.2 mttt -72.58 -37.52 68.15 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.345 -0.847 . . . . 50.0 110.324 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 87.9 p -88.76 -4.04 58.61 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.292 -0.88 . . . . 50.0 110.25 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 69.42 21.38 76.01 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.195 -1.562 . . . . 50.0 109.195 -179.84 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -70.22 155.16 41.03 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.35 -1.088 . . . . 50.0 110.211 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.563 HD13 ' CD2' ' A' ' 39' ' ' HIS . 12.8 pt -104.73 151.05 7.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.21 -0.931 . . . . 50.0 110.253 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 76.2 m -105.38 139.54 39.85 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.299 -0.875 . . . . 50.0 110.031 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.563 ' CD2' HD13 ' A' ' 37' ' ' ILE . 17.3 m-70 -133.52 157.9 76.9 Favored Pre-proline 0 N--CA 1.494 1.74 0 O-C-N 121.346 -0.846 . . . . 50.0 110.192 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.465 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 45.2 Cg_endo -71.58 168.42 23.68 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 O-C-N 124.059 1.557 . . . . 50.0 110.415 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.528 HG13 ' CD2' ' A' ' 42' ' ' PHE . 10.8 t 61.84 -108.37 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.237 -0.914 . . . . 50.0 109.804 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.528 ' CD2' HG13 ' A' ' 41' ' ' VAL . 48.6 p90 -143.63 161.78 37.63 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.747 -1.221 . . . . 50.0 110.108 179.704 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.462 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 70.8 m -67.33 132.43 93.24 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.222 -0.924 . . . . 50.0 110.356 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -71.29 -162.56 0.11 Allowed 'Trans proline' 0 C--N 1.306 -1.707 0 O-C-N 123.933 1.491 . . . . 50.0 110.346 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 30.2 mtt180 -78.21 -41.47 34.32 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.424 -0.798 . . . . 50.0 110.015 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 26.0 mmm180 -57.95 -27.94 63.87 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.483 -0.761 . . . . 50.0 110.21 -179.777 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' TYR . . . . . 0.535 ' CE2' ' CG ' ' A' ' 63' ' ' LYS . 21.7 m-85 -119.12 158.9 24.98 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.345 -0.847 . . . . 50.0 110.534 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -117.08 131.0 57.02 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.467 -0.77 . . . . 50.0 109.634 179.307 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.454 ' HA ' ' SG ' ' A' ' 43' ' ' CYS . 54.4 tt0 -78.14 104.14 8.53 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.276 -0.89 . . . . 50.0 111.024 -179.082 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.461 HD13 ' HB2' ' A' ' 62' ' ' LYS . 79.5 mt -68.71 -31.21 49.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.335 -0.853 . . . . 50.0 109.387 179.111 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 172.95 -96.67 0.11 Allowed Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.662 -1.375 . . . . 50.0 109.662 179.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 68.6 p -146.7 137.2 23.8 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.207 -1.172 . . . . 50.0 110.327 -179.9 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' CYS . . . . . . . . . . . . . 4.1 t -62.35 -41.43 98.58 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.263 -0.898 . . . . 50.0 110.137 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 158.93 -25.68 0.36 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 108.994 -1.642 . . . . 50.0 108.994 -179.897 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.505 ' CD1' ' HD2' ' A' ' 56' ' ' PRO . 17.4 tp -120.8 142.44 34.45 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.401 -1.059 . . . . 50.0 109.712 179.777 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . 0.505 ' HD2' ' CD1' ' A' ' 55' ' ' LEU . 42.0 Cg_endo -67.92 -8.17 21.82 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 O-C-N 123.872 1.459 . . . . 50.0 110.442 -179.841 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -75.99 -32.09 53.88 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.062 -1.615 . . . . 50.0 109.062 179.511 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' THR . . . . . 0.462 ' HA ' ' HA ' ' A' ' 40' ' ' PRO . 4.0 m -131.28 162.12 30.75 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.262 -1.14 . . . . 50.0 110.4 179.896 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.468 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 46.5 mmtm -120.76 146.63 46.3 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.285 -0.884 . . . . 50.0 109.829 179.741 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.462 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 42.7 t -75.82 133.4 40.64 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.264 -0.898 . . . . 50.0 110.749 -179.376 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' CYS . . . . . 0.479 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 73.6 m -130.45 135.08 47.62 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.365 -0.834 . . . . 50.0 109.791 179.807 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.461 ' HB2' HD13 ' A' ' 50' ' ' ILE . 39.8 ttpt -126.51 135.15 50.95 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.09 -1.006 . . . . 50.0 110.287 -179.862 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . 0.535 ' CG ' ' CE2' ' A' ' 47' ' ' TYR . 49.5 mtmt . . . . . 0 N--CA 1.491 1.602 0 O-C-N 121.319 -0.863 . . . . 50.0 110.128 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 97.0 m . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 121.305 0.574 . . . . 50.0 110.034 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . 0.862 ' SG ' ' SG ' ' A' ' 53' ' ' CYS . 76.9 m -76.56 -7.15 54.62 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.274 -0.891 . . . . 50.0 110.399 -179.856 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 50.7 tp -65.35 -40.98 94.3 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.189 -0.945 . . . . 50.0 110.28 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -62.55 -44.19 96.94 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.321 -0.862 . . . . 50.0 110.271 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 58.1 m -66.13 -33.32 75.51 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.357 -0.839 . . . . 50.0 110.139 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 104.56 8.52 37.5 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.397 -1.481 . . . . 50.0 109.397 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -96.13 123.38 39.72 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.263 -1.14 . . . . 50.0 109.95 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.461 ' O ' HG13 ' A' ' 37' ' ' ILE . 2.2 pt -71.61 151.5 8.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.155 -0.965 . . . . 50.0 110.495 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 24.5 m -91.28 154.73 19.05 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.182 -0.949 . . . . 50.0 109.871 179.645 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.545 ' O ' ' N ' ' A' ' 59' ' ' LYS . 64.7 t-80 -129.78 140.79 39.69 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.123 -0.986 . . . . 50.0 110.571 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.484 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 43.7 Cg_endo -70.4 161.83 44.6 Favored 'Trans proline' 0 C--N 1.304 -1.806 0 O-C-N 123.967 1.509 . . . . 50.0 111.091 -179.78 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.567 HG13 ' CD2' ' A' ' 42' ' ' PHE . 33.1 t 57.18 -84.23 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.536 -0.727 . . . . 50.0 110.955 179.846 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.567 ' CD2' HG13 ' A' ' 41' ' ' VAL . 14.0 p90 -155.26 157.65 37.59 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.873 -1.142 . . . . 50.0 110.457 -179.653 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.408 ' SG ' ' CB ' ' A' ' 47' ' ' TYR . 0.7 OUTLIER -71.82 133.9 84.01 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 121.327 -0.858 . . . . 50.0 110.293 179.896 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.435 ' HD2' ' HB2' ' A' ' 47' ' ' TYR . 45.1 Cg_endo -70.55 -162.23 0.1 OUTLIER 'Trans proline' 0 C--N 1.306 -1.665 0 O-C-N 123.883 1.465 . . . . 50.0 110.543 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 28.7 tpt180 -81.93 -37.05 27.35 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.534 -0.729 . . . . 50.0 110.365 -179.813 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -66.39 -29.71 69.93 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.381 -0.824 . . . . 50.0 110.172 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' TYR . . . . . 0.516 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 45.8 m-85 -110.37 138.48 46.7 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.267 -0.896 . . . . 50.0 110.842 -179.597 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.428 ' O ' ' HA ' ' A' ' 61' ' ' CYS . 67.0 tttt -90.6 153.05 20.61 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.242 -0.912 . . . . 50.0 109.219 178.915 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 36.0 tt0 -102.07 98.9 9.02 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.041 -1.037 . . . . 50.0 110.302 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 97.0 mt -64.38 -28.6 45.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.46 -0.775 . . . . 50.0 109.984 179.888 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 160.5 -91.3 0.11 Allowed Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.551 -1.419 . . . . 50.0 109.551 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 67.6 p -145.29 159.28 43.27 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.283 -1.128 . . . . 50.0 110.313 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' CYS . . . . . 0.862 ' SG ' ' SG ' ' A' ' 31' ' ' CYS . 0.5 OUTLIER -104.53 -15.76 15.25 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.279 -0.888 . . . . 50.0 110.329 -179.923 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 162.34 -43.6 0.36 Allowed Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.45 -1.46 . . . . 50.0 109.45 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 87.2 mt -123.34 159.39 55.01 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.277 -1.131 . . . . 50.0 109.955 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.72 -16.99 26.37 Favored 'Trans proline' 0 C--N 1.304 -1.787 0 O-C-N 123.896 1.472 . . . . 50.0 110.383 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -68.08 -33.97 80.18 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.457 -1.457 . . . . 50.0 109.457 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' THR . . . . . 0.427 ' HA ' ' HA ' ' A' ' 40' ' ' PRO . 34.3 m -117.24 170.14 8.92 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.262 -1.14 . . . . 50.0 110.388 179.861 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.545 ' N ' ' O ' ' A' ' 39' ' ' HIS . 73.7 mmtt -133.75 155.93 48.89 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.437 -0.789 . . . . 50.0 109.56 179.787 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 13.1 t -83.09 127.86 33.96 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.075 -1.016 . . . . 50.0 110.308 -179.586 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' CYS . . . . . 0.514 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 51.0 m -127.05 146.4 50.37 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.272 -0.892 . . . . 50.0 110.266 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 76.9 tttt -129.38 136.11 49.56 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.211 -0.931 . . . . 50.0 110.319 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . 0.516 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 97.6 mttt . . . . . 0 N--CA 1.492 1.637 0 O-C-N 121.251 -0.906 . . . . 50.0 109.968 179.805 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 86.1 m . . . . . 0 N--CA 1.491 1.613 0 CA-C-O 121.235 0.54 . . . . 50.0 110.012 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 95.8 m -75.86 -4.55 41.41 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.35 -0.844 . . . . 50.0 110.35 -179.793 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 49.8 tp -55.67 -49.57 72.56 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.192 -0.943 . . . . 50.0 109.996 179.764 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -59.89 -36.18 76.41 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.481 -0.762 . . . . 50.0 110.153 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 70.6 m -73.06 -27.46 61.75 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.34 -0.85 . . . . 50.0 110.235 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 95.01 -6.32 69.22 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.509 -1.436 . . . . 50.0 109.509 -179.861 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -66.46 141.6 57.85 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.209 -1.171 . . . . 50.0 110.074 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.573 HD13 ' CD2' ' A' ' 39' ' ' HIS . 7.2 pt -86.98 150.16 3.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.203 -0.935 . . . . 50.0 110.253 -179.841 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 76.6 m -105.99 144.64 32.43 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.261 -0.9 . . . . 50.0 110.1 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.573 ' CD2' HD13 ' A' ' 37' ' ' ILE . 27.6 m-70 -135.48 158.99 73.27 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.259 -0.901 . . . . 50.0 110.315 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -70.15 172.59 12.74 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 O-C-N 124.002 1.527 . . . . 50.0 110.274 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.455 ' O ' ' HG3' ' A' ' 59' ' ' LYS . 7.5 t 54.74 -115.35 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.297 -0.877 . . . . 50.0 109.788 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . 0.441 ' CD1' HG13 ' A' ' 41' ' ' VAL . 39.4 p90 -137.88 156.31 48.04 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.774 -1.204 . . . . 50.0 109.94 179.641 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' CYS . . . . . 0.459 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 82.6 m -57.46 130.87 81.38 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.242 -0.911 . . . . 50.0 110.372 -179.737 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -71.72 -161.88 0.1 Allowed 'Trans proline' 0 C--N 1.305 -1.718 0 O-C-N 124.062 1.559 . . . . 50.0 110.73 179.777 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 19.1 ptp180 -76.35 -29.43 57.23 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.562 -0.711 . . . . 50.0 110.557 -179.584 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 62.7 mtp180 -69.88 -25.94 63.95 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.245 -0.91 . . . . 50.0 110.623 -179.544 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' TYR . . . . . 0.561 ' CD1' ' N ' ' A' ' 47' ' ' TYR . 11.6 m-85 -124.81 151.39 45.27 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.164 -0.96 . . . . 50.0 110.635 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 45.8 tttm -97.91 150.86 20.86 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.355 -0.841 . . . . 50.0 109.225 178.768 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.444 ' HA ' ' SG ' ' A' ' 43' ' ' CYS . 50.8 tt0 -93.54 95.38 9.21 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.983 -1.073 . . . . 50.0 110.42 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . 0.499 HD12 ' CD ' ' A' ' 62' ' ' LYS . 97.3 mt -65.36 -31.24 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.297 -0.877 . . . . 50.0 110.068 179.807 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.433 ' C ' HG22 ' A' ' 52' ' ' THR . . . 168.77 -95.44 0.11 Allowed Glycine 0 N--CA 1.487 2.074 0 N-CA-C 109.534 -1.426 . . . . 50.0 109.534 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.433 HG22 ' C ' ' A' ' 51' ' ' GLY . 62.5 p -150.32 143.26 24.78 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.217 -1.166 . . . . 50.0 110.386 -179.824 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' CYS . . . . . . . . . . . . . 4.4 t -63.87 -40.95 97.76 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.237 -0.914 . . . . 50.0 109.844 179.74 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 157.84 -24.98 0.42 Allowed Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.07 -1.612 . . . . 50.0 109.07 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.501 ' CD1' ' HD2' ' A' ' 56' ' ' PRO . 16.9 tp -123.96 143.64 42.85 Favored Pre-proline 0 N--CA 1.489 1.517 0 O-C-N 121.5 -1.0 . . . . 50.0 109.596 179.773 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . 0.501 ' HD2' ' CD1' ' A' ' 55' ' ' LEU . 39.9 Cg_endo -66.48 -5.3 12.5 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 O-C-N 123.773 1.407 . . . . 50.0 110.827 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -74.65 -33.88 54.85 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.158 -1.577 . . . . 50.0 109.158 179.378 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' THR . . . . . 0.466 ' CG2' ' C ' ' A' ' 39' ' ' HIS . 4.8 m -135.53 162.74 31.82 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.231 -1.158 . . . . 50.0 110.211 179.692 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.455 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 43.5 mmtm -115.49 151.82 34.1 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.346 -0.846 . . . . 50.0 109.937 179.662 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.459 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 26.6 t -81.39 133.5 35.42 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.251 -0.905 . . . . 50.0 110.656 -179.525 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' CYS . . . . . 0.484 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 72.0 m -131.12 141.22 50.1 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.371 -0.831 . . . . 50.0 109.961 179.73 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . 0.499 ' CD ' HD12 ' A' ' 50' ' ' ILE . 81.1 tttt -131.93 144.35 50.78 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.174 -0.954 . . . . 50.0 110.309 -179.737 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . 0.466 ' HE2' ' OH ' ' A' ' 47' ' ' TYR . 96.2 mttt . . . . . 0 N--CA 1.491 1.603 0 O-C-N 121.411 -0.806 . . . . 50.0 110.31 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo . . . . . 0 N--CA 1.487 1.146 0 N-CA-C 110.406 -0.652 . . . . 50.0 110.406 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.483 ' O ' HG21 ' A' ' 29' ' ' VAL . 34.1 m -114.99 129.16 71.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.283 -0.886 . . . . 50.0 109.897 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.456 ' O ' ' HB2' ' A' ' 31' ' ' CYS . 98.5 m -69.04 -19.29 64.1 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.129 -0.982 . . . . 50.0 110.566 -179.639 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . 0.456 ' HB2' ' O ' ' A' ' 30' ' ' THR . 93.3 m 56.22 22.44 6.14 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.215 -0.928 . . . . 50.0 110.311 -179.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.481 ' CD1' ' C ' ' A' ' 32' ' ' LEU . 3.4 tm? -75.35 -38.51 60.06 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.137 -0.977 . . . . 50.0 110.283 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 96.0 mttt -68.69 -41.64 78.88 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.303 -0.873 . . . . 50.0 110.209 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 94.9 p -69.77 -20.46 63.48 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.303 -0.873 . . . . 50.0 110.32 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 79.25 6.73 88.82 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.662 -1.375 . . . . 50.0 109.662 179.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . 0.441 ' HB2' ' HB2' ' A' ' 62' ' ' LYS . . . -68.93 147.65 51.33 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.119 -1.224 . . . . 50.0 110.151 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.475 HD12 ' CE2' ' A' ' 47' ' ' TYR . 2.1 pt -93.45 151.77 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.148 -0.97 . . . . 50.0 110.063 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 86.3 m -91.27 142.57 27.57 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.244 -0.91 . . . . 50.0 110.372 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.514 ' CB ' ' SG ' ' A' ' 61' ' ' CYS . 54.4 t-80 -119.98 142.2 32.9 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.282 -0.886 . . . . 50.0 109.981 179.755 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.505 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 44.9 Cg_endo -71.52 155.85 58.87 Favored 'Trans proline' 0 C--N 1.305 -1.762 0 O-C-N 123.907 1.477 . . . . 50.0 110.857 -179.575 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.474 ' HB ' ' O ' ' A' ' 40' ' ' PRO . 47.8 t 59.27 -93.87 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.449 -0.782 . . . . 50.0 110.679 179.658 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.458 ' CD1' ' C ' ' A' ' 42' ' ' PHE . 21.4 p90 -139.14 161.43 37.42 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.84 -1.163 . . . . 50.0 110.62 -179.74 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.508 ' CB ' ' HB2' ' A' ' 49' ' ' GLN . 0.8 OUTLIER -80.45 127.56 75.51 Favored Pre-proline 0 N--CA 1.492 1.663 0 O-C-N 121.398 -0.814 . . . . 50.0 109.958 179.822 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -72.43 -162.4 0.12 Allowed 'Trans proline' 0 C--N 1.306 -1.699 0 O-C-N 123.742 1.39 . . . . 50.0 110.445 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 6.5 mtt180 -81.25 -36.59 29.76 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.475 -0.766 . . . . 50.0 109.698 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.446 ' O ' ' HD3' ' A' ' 64' ' ' PRO . 60.0 mtp180 -58.71 -27.59 65.0 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.554 -0.716 . . . . 50.0 109.942 179.674 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.525 ' HB3' ' HB3' ' A' ' 61' ' ' CYS . 37.0 m-85 -120.84 138.72 53.91 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.337 -0.852 . . . . 50.0 110.294 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 88.5 mttt -95.14 124.3 39.1 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.202 -0.936 . . . . 50.0 109.837 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.508 ' HB2' ' CB ' ' A' ' 43' ' ' CYS . 41.8 tt0 -74.8 105.64 5.95 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.494 -0.754 . . . . 50.0 110.94 -179.162 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.5 mt -75.16 -28.52 20.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.198 -0.939 . . . . 50.0 109.628 179.361 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.466 ' O ' ' CG2' ' A' ' 52' ' ' THR . . . 176.76 -94.56 0.1 OUTLIER Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.368 -1.493 . . . . 50.0 109.368 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.466 ' CG2' ' O ' ' A' ' 51' ' ' GLY . 60.5 p -155.24 137.99 15.26 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.192 -1.181 . . . . 50.0 110.222 179.781 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' CYS . . . . . 0.459 ' O ' ' O ' ' A' ' 29' ' ' VAL . 18.5 t -54.12 -50.44 66.87 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.24 -0.913 . . . . 50.0 110.131 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 176.78 -45.26 0.11 Allowed Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.266 -1.534 . . . . 50.0 109.266 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.468 ' HB3' ' HD2' ' A' ' 56' ' ' PRO . 87.0 mt -110.82 164.9 13.78 Favored Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.288 -1.125 . . . . 50.0 109.973 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . 0.468 ' HD2' ' HB3' ' A' ' 55' ' ' LEU . 45.6 Cg_endo -72.75 -3.03 12.8 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 O-C-N 123.88 1.463 . . . . 50.0 110.395 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -77.49 -43.5 15.37 Favored Glycine 0 N--CA 1.487 2.096 0 N-CA-C 109.491 -1.444 . . . . 50.0 109.491 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.416 HG21 ' C ' ' A' ' 39' ' ' HIS . 10.9 m -125.31 166.38 16.65 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.336 -1.097 . . . . 50.0 110.508 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 74.6 mmtt -123.21 148.6 45.66 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.336 -0.853 . . . . 50.0 109.902 179.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 13.2 t -73.52 127.93 34.08 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.145 -0.972 . . . . 50.0 110.376 -179.672 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' CYS . . . . . 0.525 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 28.3 m -128.02 154.17 45.94 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.29 -0.882 . . . . 50.0 109.994 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.441 ' HB2' ' HB2' ' A' ' 36' ' ' ALA . 87.9 tttt -132.99 138.68 46.93 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.157 -0.965 . . . . 50.0 110.249 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . 0.514 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 93.8 mttt -77.77 143.54 67.23 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.311 -0.868 . . . . 50.0 110.274 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . 0.446 ' HD3' ' O ' ' A' ' 46' ' ' ARG . 46.3 Cg_endo . . . . . 0 C--N 1.304 -1.765 0 O-C-N 124.044 1.549 . . . . 99.99 110.498 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo . . . . . 0 N--CA 1.489 1.22 0 N-CA-C 110.283 -0.699 . . . . 50.0 110.283 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.474 ' O ' ' O ' ' A' ' 53' ' ' CYS . 19.5 t -143.35 176.0 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.129 -0.982 . . . . 50.0 110.373 -179.881 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.467 HG23 ' HB2' ' A' ' 32' ' ' LEU . 58.7 m -114.77 113.55 24.41 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.233 -0.917 . . . . 50.0 109.919 179.739 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 52.8 m -75.73 -6.24 49.61 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.35 -0.843 . . . . 50.0 110.691 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.467 ' HB2' HG23 ' A' ' 30' ' ' THR . 95.3 mt -57.35 -34.73 69.09 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.032 -1.043 . . . . 50.0 110.205 -179.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 24.8 mttp -68.03 -37.33 81.23 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.389 -0.819 . . . . 50.0 110.153 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 95.0 p -77.49 -18.25 57.26 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.474 -0.766 . . . . 50.0 110.252 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 89.81 5.71 70.86 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.503 -1.439 . . . . 50.0 109.503 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -77.37 147.97 35.81 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.217 -1.167 . . . . 50.0 110.284 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.519 HD12 ' CE2' ' A' ' 47' ' ' TYR . 4.0 pt -95.44 152.72 3.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.225 -0.922 . . . . 50.0 109.858 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . 0.413 ' HA ' ' O ' ' A' ' 59' ' ' LYS . 79.0 m -100.16 139.77 35.36 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.205 -0.934 . . . . 50.0 110.143 -179.766 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.486 ' N ' ' O ' ' A' ' 59' ' ' LYS . 59.2 t-80 -117.82 136.26 23.66 Favored Pre-proline 0 N--CA 1.492 1.663 0 O-C-N 121.345 -0.847 . . . . 50.0 110.007 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.471 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 47.7 Cg_endo -72.23 164.58 35.2 Favored 'Trans proline' 0 C--N 1.303 -1.827 0 O-C-N 123.929 1.489 . . . . 50.0 110.503 -179.792 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.471 ' HB ' ' O ' ' A' ' 40' ' ' PRO . 44.2 t 60.73 -82.78 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.524 -0.735 . . . . 50.0 111.171 179.538 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.536 ' CD1' ' C ' ' A' ' 42' ' ' PHE . 9.7 p90 -155.7 154.29 31.28 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.957 -1.09 . . . . 50.0 110.662 -179.43 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 1.7 t -77.43 130.92 72.92 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.257 -0.902 . . . . 50.0 109.784 179.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -70.96 -162.29 0.1 Allowed 'Trans proline' 0 C--N 1.304 -1.803 0 O-C-N 123.88 1.463 . . . . 50.0 110.549 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 18.3 mtm180 -84.83 -40.13 17.51 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 121.475 -0.766 . . . . 50.0 109.818 -179.856 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 57.9 ttm-85 -61.73 -15.95 45.17 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.457 -0.777 . . . . 50.0 109.965 179.67 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.531 ' HB3' ' HB3' ' A' ' 61' ' ' CYS . 58.4 m-85 -123.99 134.33 53.49 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.316 -0.865 . . . . 50.0 110.507 -179.789 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -97.71 137.95 35.82 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.287 -0.883 . . . . 50.0 109.595 179.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.4 ' HA ' ' O ' ' A' ' 60' ' ' CYS . 36.3 tt0 -87.2 103.98 15.93 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.156 -0.965 . . . . 50.0 110.917 -179.308 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.459 HD13 ' HD2' ' A' ' 62' ' ' LYS . 96.5 mt -62.8 -29.07 46.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.301 -0.874 . . . . 50.0 109.733 179.472 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.441 ' C ' HG22 ' A' ' 52' ' ' THR . . . 171.19 -91.23 0.09 OUTLIER Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.476 -1.45 . . . . 50.0 109.476 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.441 HG22 ' C ' ' A' ' 51' ' ' GLY . 71.9 p -151.58 127.92 10.61 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.259 -1.142 . . . . 50.0 110.292 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' CYS . . . . . 0.474 ' O ' ' O ' ' A' ' 29' ' ' VAL . 15.6 t -49.82 -47.41 51.42 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.297 -0.877 . . . . 50.0 110.081 179.694 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.415 ' C ' HD13 ' A' ' 55' ' ' LEU . . . 168.77 -38.33 0.21 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 108.683 -1.767 . . . . 50.0 108.683 -179.77 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.553 ' N ' ' CD1' ' A' ' 55' ' ' LEU . 6.1 mp -119.79 158.1 50.64 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.475 -1.015 . . . . 50.0 109.752 179.604 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -70.8 -10.29 27.43 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 O-C-N 123.904 1.476 . . . . 50.0 110.286 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -67.87 -41.96 87.12 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.312 -1.515 . . . . 50.0 109.312 179.704 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.441 ' HA ' ' HA ' ' A' ' 40' ' ' PRO . 5.2 m -127.6 164.06 22.85 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.342 -1.093 . . . . 50.0 110.28 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.486 ' O ' ' N ' ' A' ' 39' ' ' HIS . 33.4 mmtp -118.75 152.6 35.88 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.318 -0.864 . . . . 50.0 109.741 179.654 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.4 ' O ' ' HA ' ' A' ' 49' ' ' GLN . 34.5 t -80.32 127.57 32.53 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.029 -1.045 . . . . 50.0 110.333 -179.793 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' CYS . . . . . 0.531 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 52.5 m -125.61 151.53 46.35 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.33 -0.856 . . . . 50.0 109.879 179.74 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.459 ' HD2' HD13 ' A' ' 50' ' ' ILE . 87.0 tttt -136.75 144.97 44.08 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.081 -1.012 . . . . 50.0 110.597 -179.775 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 50.8 mtmt -80.58 146.88 61.96 Favored Pre-proline 0 N--CA 1.493 1.685 0 O-C-N 121.289 -0.882 . . . . 50.0 110.272 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo . . . . . 0 C--N 1.307 -1.652 0 O-C-N 123.939 1.494 . . . . 99.99 110.49 179.871 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo . . . . . 0 N--CA 1.489 1.26 0 N-CA-C 110.431 -0.642 . . . . 50.0 110.431 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.449 HG22 ' SG ' ' A' ' 31' ' ' CYS . 35.7 m -126.35 133.19 69.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.3 -0.875 . . . . 50.0 109.918 179.721 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.474 ' O ' ' HB2' ' A' ' 31' ' ' CYS . 74.5 m -69.97 -15.97 63.12 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.223 -0.923 . . . . 50.0 110.392 -179.74 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . 0.474 ' HB2' ' O ' ' A' ' 30' ' ' THR . 90.4 m 56.23 27.86 12.34 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.231 -0.918 . . . . 50.0 110.586 179.773 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.466 ' HB2' HG23 ' A' ' 30' ' ' THR . 67.2 tp -76.95 -43.26 35.88 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.208 -0.933 . . . . 50.0 110.08 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -67.43 -34.58 77.52 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.277 -0.889 . . . . 50.0 110.117 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 81.0 p -71.98 -24.45 61.59 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.422 -0.799 . . . . 50.0 110.259 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 75.87 10.99 84.96 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.626 -1.389 . . . . 50.0 109.626 179.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . 0.438 ' HB2' ' HG3' ' A' ' 62' ' ' LYS . . . -77.04 156.11 32.03 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.186 -1.185 . . . . 50.0 110.257 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.518 HD12 ' CE2' ' A' ' 47' ' ' TYR . 13.8 pt -93.96 167.22 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.285 -0.885 . . . . 50.0 110.147 179.864 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 96.6 m -108.2 148.35 30.06 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.293 -0.879 . . . . 50.0 109.951 179.749 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.585 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 60.9 t-80 -138.68 145.66 47.13 Favored Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.297 -0.877 . . . . 50.0 110.435 -179.649 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.585 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 43.5 Cg_endo -69.1 160.39 50.07 Favored 'Trans proline' 0 C--N 1.305 -1.727 0 O-C-N 124.012 1.532 . . . . 50.0 110.42 179.486 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.524 HG13 ' CD2' ' A' ' 42' ' ' PHE . 15.9 t 62.3 -97.27 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.437 -0.789 . . . . 50.0 110.312 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.524 ' CD2' HG13 ' A' ' 41' ' ' VAL . 35.4 p90 -150.18 154.4 37.94 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 120.728 -1.233 . . . . 50.0 110.07 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.458 ' SG ' ' HA ' ' A' ' 49' ' ' GLN . 64.6 m -61.96 133.62 93.98 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.196 -0.94 . . . . 50.0 110.581 -179.63 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.412 ' HD2' ' HB2' ' A' ' 47' ' ' TYR . 43.4 Cg_endo -68.49 -161.33 0.06 OUTLIER 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 123.959 1.505 . . . . 50.0 110.474 179.709 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 62.5 ttt180 -77.25 -44.08 31.16 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.558 -0.713 . . . . 50.0 110.664 -179.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.46 ' O ' ' HD3' ' A' ' 64' ' ' PRO . 51.5 mmm-85 -61.23 -31.42 71.21 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.233 -0.917 . . . . 50.0 110.422 -179.707 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.518 ' CE2' HD12 ' A' ' 37' ' ' ILE . 48.4 m-85 -105.73 149.38 26.47 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.273 -0.892 . . . . 50.0 110.491 -179.788 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -108.56 131.79 54.5 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.337 -0.852 . . . . 50.0 109.688 179.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.458 ' HA ' ' SG ' ' A' ' 43' ' ' CYS . 59.6 tt0 -82.81 101.43 10.94 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.327 -0.858 . . . . 50.0 110.702 -179.36 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.478 HD13 ' HB2' ' A' ' 62' ' ' LYS . 85.1 mt -70.36 -30.93 45.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.245 -0.909 . . . . 50.0 109.677 179.452 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.43 ' C ' HG21 ' A' ' 52' ' ' THR . . . 178.14 -99.05 0.12 Allowed Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.294 -1.522 . . . . 50.0 109.294 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.43 HG21 ' C ' ' A' ' 51' ' ' GLY . 61.7 p -146.12 137.28 24.57 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.305 -1.115 . . . . 50.0 110.403 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' CYS . . . . . 0.474 ' HA ' ' HB2' ' A' ' 60' ' ' CYS . 17.2 t -51.95 -48.1 64.44 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.334 -0.854 . . . . 50.0 109.565 179.467 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 172.87 -30.4 0.1 Allowed Glycine 0 N--CA 1.489 2.193 0 N-CA-C 108.95 -1.66 . . . . 50.0 108.95 179.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 98.1 mt -124.44 159.63 56.7 Favored Pre-proline 0 N--CA 1.488 1.471 0 O-C-N 121.41 -1.053 . . . . 50.0 109.802 179.668 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -71.29 -9.81 26.03 Favored 'Trans proline' 0 C--N 1.304 -1.809 0 O-C-N 124.013 1.533 . . . . 50.0 110.537 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -73.57 -34.56 56.8 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.296 -1.521 . . . . 50.0 109.296 179.714 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.404 HG23 ' N ' ' A' ' 59' ' ' LYS . 25.6 m -131.6 168.42 17.73 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.302 -1.117 . . . . 50.0 109.976 179.789 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.418 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 33.6 mmtp -126.82 149.74 49.54 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.279 -0.888 . . . . 50.0 110.091 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.474 ' HB2' ' HA ' ' A' ' 53' ' ' CYS . 15.9 t -76.6 129.58 36.62 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.243 -0.911 . . . . 50.0 110.295 -179.633 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' CYS . . . . . 0.477 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 83.7 m -127.56 145.27 50.92 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.425 -0.797 . . . . 50.0 110.001 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.478 ' HB2' HD13 ' A' ' 50' ' ' ILE . 85.5 tttt -124.55 144.66 50.01 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.254 -0.904 . . . . 50.0 110.345 -179.814 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . 0.502 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 97.0 mttt -75.56 163.12 69.47 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.343 -0.848 . . . . 50.0 110.066 179.814 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . 0.46 ' HD3' ' O ' ' A' ' 46' ' ' ARG . 46.4 Cg_endo . . . . . 0 C--N 1.303 -1.832 0 O-C-N 124.031 1.543 . . . . 99.99 110.373 -179.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.404 ' C ' HG21 ' A' ' 29' ' ' VAL . 47.4 Cg_endo . . . . . 0 N--CA 1.489 1.221 0 N-CA-C 110.323 -0.683 . . . . 50.0 110.323 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.404 HG21 ' C ' ' A' ' 28' ' ' PRO . 27.5 t -137.17 172.32 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.172 -0.955 . . . . 50.0 110.452 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 51.6 m -102.77 110.95 23.05 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.24 -0.912 . . . . 50.0 109.815 179.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 63.2 m -90.83 4.97 50.32 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.21 -0.931 . . . . 50.0 110.443 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 46.7 tp -66.68 -44.41 81.87 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.147 -0.97 . . . . 50.0 110.263 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -61.69 -39.03 90.02 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.382 -0.824 . . . . 50.0 110.384 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 87.7 p -71.32 -24.25 62.09 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.34 -0.85 . . . . 50.0 110.14 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 89.73 3.64 73.89 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.626 -1.389 . . . . 50.0 109.626 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . 0.457 ' HB2' ' HB3' ' A' ' 62' ' ' LYS . . . -73.87 154.57 39.39 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.211 -1.17 . . . . 50.0 110.142 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.436 ' O ' HG13 ' A' ' 37' ' ' ILE . 3.9 pt -102.24 154.27 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.13 -0.981 . . . . 50.0 110.081 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 93.0 m -98.1 138.48 35.33 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.235 -0.916 . . . . 50.0 110.208 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.49 ' N ' ' O ' ' A' ' 59' ' ' LYS . 58.6 t-80 -114.63 140.41 25.26 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.268 -0.895 . . . . 50.0 110.235 -179.8 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.489 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 44.1 Cg_endo -70.44 162.4 42.54 Favored 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 123.995 1.524 . . . . 50.0 110.272 179.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.489 ' HB ' ' O ' ' A' ' 40' ' ' PRO . 18.3 t 62.96 -108.36 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.461 -0.775 . . . . 50.0 110.285 179.885 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 35.7 p90 -135.31 148.87 49.63 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.796 -1.19 . . . . 50.0 110.24 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -68.5 131.03 91.73 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.265 -0.897 . . . . 50.0 110.204 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.435 ' HD2' ' HB2' ' A' ' 47' ' ' TYR . 46.6 Cg_endo -71.22 -163.03 0.12 Allowed 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 123.859 1.452 . . . . 50.0 110.415 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 32.3 mtt85 -80.57 -44.75 18.5 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.512 -0.743 . . . . 50.0 109.887 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 28.6 tpt180 -58.74 -24.46 61.62 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.53 -0.731 . . . . 50.0 110.152 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.526 ' HB3' ' HB3' ' A' ' 61' ' ' CYS . 42.0 m-85 -114.98 135.8 53.83 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.255 -0.903 . . . . 50.0 110.266 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 88.3 mttt -105.01 147.97 27.25 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.204 -0.935 . . . . 50.0 109.945 179.751 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.482 ' HA ' ' O ' ' A' ' 60' ' ' CYS . 52.7 tt0 -87.31 106.78 18.16 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.215 -0.928 . . . . 50.0 110.788 -179.432 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 67.8 mt -63.39 -24.12 35.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.289 -0.882 . . . . 50.0 109.731 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.483 ' O ' ' CB ' ' A' ' 52' ' ' THR . . . 152.5 40.18 0.03 OUTLIER Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.284 -1.527 . . . . 50.0 109.284 -179.868 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.483 ' CB ' ' O ' ' A' ' 51' ' ' GLY . 0.2 OUTLIER 69.76 151.17 0.09 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.404 -1.056 . . . . 50.0 110.435 -179.925 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' CYS . . . . . 0.44 ' HA ' ' HB2' ' A' ' 60' ' ' CYS . 7.3 t -71.19 -41.99 69.59 Favored 'General case' 0 N--CA 1.492 1.629 0 CA-C-O 121.763 0.792 . . . . 50.0 109.964 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.435 ' C ' HD13 ' A' ' 55' ' ' LEU . . . 154.63 -26.03 0.66 Allowed Glycine 0 N--CA 1.49 2.244 0 N-CA-C 108.438 -1.865 . . . . 50.0 108.438 -179.746 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.584 ' N ' ' CD1' ' A' ' 55' ' ' LEU . 5.8 mp -124.72 158.1 63.54 Favored Pre-proline 0 N--CA 1.489 1.495 0 O-C-N 121.55 -0.97 . . . . 50.0 109.465 179.611 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -71.79 -8.46 23.1 Favored 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.886 1.466 . . . . 50.0 110.432 -179.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -71.33 -45.83 45.5 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.545 -1.422 . . . . 50.0 109.545 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.415 HG21 ' C ' ' A' ' 39' ' ' HIS . 7.2 m -128.89 166.01 19.94 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.136 -1.214 . . . . 50.0 110.434 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.49 ' O ' ' N ' ' A' ' 39' ' ' HIS . 33.5 mmtp -121.16 148.49 44.16 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.415 -0.803 . . . . 50.0 109.558 179.62 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.482 ' O ' ' HA ' ' A' ' 49' ' ' GLN . 35.1 t -74.82 130.54 39.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.991 -1.068 . . . . 50.0 110.117 -179.741 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' CYS . . . . . 0.526 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 59.9 m -135.32 155.11 51.15 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.274 -0.891 . . . . 50.0 110.102 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.457 ' HB3' ' HB2' ' A' ' 36' ' ' ALA . 34.9 pttt -146.57 166.83 25.3 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.103 -0.998 . . . . 50.0 110.299 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 52.7 mtmt -100.68 136.75 19.81 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 121.278 -0.889 . . . . 50.0 110.255 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo . . . . . 0 C--N 1.304 -1.765 0 O-C-N 124.039 1.547 . . . . 99.99 110.504 -179.981 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo . . . . . 0 N--CA 1.49 1.292 0 N-CA-C 110.551 -0.596 . . . . 50.0 110.551 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.9 t -141.83 170.34 12.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.209 -0.932 . . . . 50.0 110.356 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 95.9 m -106.64 108.72 20.37 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.21 -0.931 . . . . 50.0 110.348 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 72.0 m -77.44 -12.05 59.91 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.907 . . . . 50.0 110.225 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.493 ' CD1' ' C ' ' A' ' 32' ' ' LEU . 3.4 tm? -57.68 -44.52 85.85 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.26 -0.9 . . . . 50.0 110.294 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -61.74 -38.01 86.36 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.312 -0.868 . . . . 50.0 110.149 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 69.5 m -72.53 -21.31 61.19 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.288 -0.882 . . . . 50.0 110.152 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 85.44 -3.18 87.57 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.633 -1.387 . . . . 50.0 109.633 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . 0.524 ' HB2' ' CB ' ' A' ' 62' ' ' LYS . . . -77.47 159.49 29.35 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.14 -1.212 . . . . 50.0 110.19 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.471 HG13 ' O ' ' A' ' 37' ' ' ILE . 3.6 pt -108.22 151.15 10.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.288 -0.883 . . . . 50.0 110.118 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 85.4 m -88.78 141.29 28.63 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.198 -0.939 . . . . 50.0 109.964 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 50.5 t-80 -120.5 134.43 24.18 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.243 -0.911 . . . . 50.0 110.247 -179.77 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.484 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 44.0 Cg_endo -71.55 168.13 24.48 Favored 'Trans proline' 0 C--N 1.305 -1.724 0 O-C-N 124.001 1.527 . . . . 50.0 110.458 179.873 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.484 ' HB ' ' O ' ' A' ' 40' ' ' PRO . 38.9 t 61.26 -92.51 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.383 -0.823 . . . . 50.0 110.69 179.806 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.508 ' CD1' ' C ' ' A' ' 42' ' ' PHE . 16.2 p90 -148.58 148.69 30.45 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.967 -1.083 . . . . 50.0 110.379 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 1.8 t -73.47 128.74 86.76 Favored Pre-proline 0 N--CA 1.493 1.706 0 O-C-N 121.238 -0.914 . . . . 50.0 109.883 179.573 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -71.79 -162.6 0.12 Allowed 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.835 1.44 . . . . 50.0 110.568 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 6.7 ptp180 -90.51 -15.25 31.09 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.525 -0.734 . . . . 50.0 110.123 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.466 ' O ' ' HD3' ' A' ' 64' ' ' PRO . 89.6 mtm180 -73.18 -31.23 64.09 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.186 -0.946 . . . . 50.0 110.166 179.844 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.551 ' CD1' ' N ' ' A' ' 47' ' ' TYR . 6.9 m-85 -113.23 147.87 36.65 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.223 -0.923 . . . . 50.0 110.333 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 61.6 mttm -93.43 152.6 19.0 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.255 -0.903 . . . . 50.0 109.799 179.272 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 58.7 tt0 -91.59 97.47 11.06 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.068 -1.02 . . . . 50.0 110.615 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 86.7 mt -63.88 -32.65 57.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.312 -0.868 . . . . 50.0 109.701 179.512 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.431 ' C ' HG21 ' A' ' 52' ' ' THR . . . 166.17 -95.99 0.12 Allowed Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.408 -1.477 . . . . 50.0 109.408 179.811 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.431 HG21 ' C ' ' A' ' 51' ' ' GLY . 21.7 p -145.24 129.07 17.32 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.329 -1.101 . . . . 50.0 110.193 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' CYS . . . . . 0.454 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 30.7 t -61.41 -47.9 83.65 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.15 -0.969 . . . . 50.0 109.654 179.577 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 129.68 1.89 5.41 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.491 -1.443 . . . . 50.0 109.491 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 92.0 mt -105.27 143.42 26.73 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.278 -1.13 . . . . 50.0 110.174 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -73.38 79.59 2.1 Favored 'Trans proline' 0 C--N 1.303 -1.821 0 O-C-N 124.062 1.559 . . . . 50.0 110.688 -179.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 139.17 -3.03 2.69 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.696 -1.24 . . . . 50.0 110.378 179.55 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.432 ' HA ' ' HA ' ' A' ' 40' ' ' PRO . 1.2 m -121.86 159.69 26.29 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.974 -1.309 . . . . 50.0 110.476 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 16.2 tppt? -129.59 123.81 32.25 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.355 -0.841 . . . . 50.0 109.895 179.584 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.454 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 34.2 t -53.92 128.99 32.4 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.177 -0.952 . . . . 50.0 110.375 -179.692 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' CYS . . . . . 0.497 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 62.3 m -128.84 146.41 50.94 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.222 -0.924 . . . . 50.0 110.076 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.524 ' CB ' ' HB2' ' A' ' 36' ' ' ALA . 79.6 tttt -125.08 143.75 50.76 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.2 -0.937 . . . . 50.0 110.477 -179.678 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . 0.421 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 86.9 mttt -74.95 152.72 86.69 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.345 -0.847 . . . . 50.0 110.361 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . 0.466 ' HD3' ' O ' ' A' ' 46' ' ' ARG . 47.2 Cg_endo . . . . . 0 C--N 1.304 -1.771 0 O-C-N 124.047 1.551 . . . . 99.99 110.446 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.506 ' N ' ' OG1' ' A' ' 52' ' ' THR . 45.1 Cg_endo . . . . . 0 N--CA 1.489 1.227 0 N-CA-C 110.465 -0.629 . . . . 50.0 110.465 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 24.0 t -132.66 174.47 13.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.276 -0.89 . . . . 50.0 110.183 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.485 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 23.7 m -75.05 -31.39 61.28 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.215 -0.928 . . . . 50.0 110.372 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . 0.48 ' HB2' ' O ' ' A' ' 30' ' ' THR . 98.7 m 58.86 19.66 7.25 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.314 -0.866 . . . . 50.0 110.538 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.485 ' HG ' ' O ' ' A' ' 30' ' ' THR . 93.5 mt -111.27 -15.83 13.53 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.258 -0.901 . . . . 50.0 109.896 179.605 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 63.8 mmtt -69.26 -39.71 78.26 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.309 -0.869 . . . . 50.0 110.18 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' SER . . . . . 0.462 ' HB3' ' NZ ' ' A' ' 62' ' ' LYS . 66.7 m -90.27 -9.88 46.3 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.357 -0.84 . . . . 50.0 110.031 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 87.13 7.8 76.46 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.509 -1.436 . . . . 50.0 109.509 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . 0.468 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -69.21 140.1 54.56 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.326 -1.102 . . . . 50.0 110.265 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.572 ' CD1' ' NE2' ' A' ' 39' ' ' HIS . 3.8 pt -100.54 155.92 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.227 -0.92 . . . . 50.0 109.871 179.821 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 83.5 m -95.46 141.0 29.52 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.152 -0.967 . . . . 50.0 110.043 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.572 ' NE2' ' CD1' ' A' ' 37' ' ' ILE . 38.4 m-70 -117.9 161.93 31.86 Favored Pre-proline 0 N--CA 1.497 1.889 0 O-C-N 121.33 -0.856 . . . . 50.0 110.55 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.47 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 44.0 Cg_endo -72.22 156.22 55.48 Favored 'Trans proline' 0 C--N 1.304 -1.766 0 O-C-N 124.024 1.539 . . . . 50.0 110.224 179.754 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.485 HG13 ' CD2' ' A' ' 42' ' ' PHE . 15.4 t 61.5 -108.53 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.246 -0.909 . . . . 50.0 110.064 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.485 ' CD2' HG13 ' A' ' 41' ' ' VAL . 44.0 p90 -135.16 164.79 26.88 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.685 -1.26 . . . . 50.0 110.225 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.47 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 70.9 m -70.72 130.88 88.22 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.172 -0.955 . . . . 50.0 110.668 -179.547 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -71.42 -161.44 0.09 OUTLIER 'Trans proline' 0 C--N 1.305 -1.742 0 O-C-N 123.851 1.448 . . . . 50.0 110.391 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 15.3 ptm180 -81.88 -24.54 35.68 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.492 -0.755 . . . . 50.0 110.786 -179.483 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 79.5 mtp180 -71.7 -16.29 62.23 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.046 -1.034 . . . . 50.0 110.594 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.602 ' CE2' ' CG ' ' A' ' 63' ' ' LYS . 36.2 m-85 -129.81 153.06 48.63 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.088 -1.008 . . . . 50.0 110.878 -179.698 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -99.92 141.86 32.18 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.37 -0.831 . . . . 50.0 109.263 179.11 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.463 ' NE2' ' CE ' ' A' ' 59' ' ' LYS . 37.5 tt0 -84.44 98.82 10.29 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.162 -0.962 . . . . 50.0 110.955 -179.169 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.523 ' CD1' ' HB2' ' A' ' 62' ' ' LYS . 95.3 mt -62.98 -32.06 54.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.166 -0.958 . . . . 50.0 109.627 179.303 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.496 ' C ' ' CG2' ' A' ' 52' ' ' THR . . . 165.83 -92.09 0.1 Allowed Glycine 0 N--CA 1.487 2.044 0 N-CA-C 109.426 -1.47 . . . . 50.0 109.426 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.506 ' OG1' ' N ' ' A' ' 28' ' ' PRO . 20.9 p -152.02 134.19 15.09 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.319 -1.107 . . . . 50.0 110.152 -179.914 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' CYS . . . . . 0.523 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 5.0 t -59.14 -45.64 90.43 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.277 -0.889 . . . . 50.0 110.207 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 163.97 -41.53 0.32 Allowed Glycine 0 N--CA 1.489 2.233 0 N-CA-C 108.993 -1.643 . . . . 50.0 108.993 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 76.5 mt -118.43 158.03 47.92 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.511 -0.993 . . . . 50.0 109.928 179.747 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -71.82 -4.92 16.02 Favored 'Trans proline' 0 C--N 1.304 -1.807 0 O-C-N 123.922 1.486 . . . . 50.0 110.35 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -70.89 -30.28 68.25 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.371 -1.492 . . . . 50.0 109.371 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.402 HG21 ' C ' ' A' ' 39' ' ' HIS . 5.8 m -139.11 163.56 32.08 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.284 -1.127 . . . . 50.0 110.393 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.463 ' CE ' ' NE2' ' A' ' 49' ' ' GLN . 54.8 tptt -119.31 128.18 53.88 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.405 -0.809 . . . . 50.0 109.42 179.528 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.523 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 41.1 t -63.71 131.54 48.23 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.181 -0.949 . . . . 50.0 110.431 -179.282 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' CYS . . . . . 0.48 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 74.8 m -126.2 156.81 39.61 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.467 -0.771 . . . . 50.0 110.181 -179.675 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.523 ' HB2' ' CD1' ' A' ' 50' ' ' ILE . 57.3 tttp -137.51 138.07 39.29 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.146 -0.971 . . . . 50.0 110.343 -179.801 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . 0.602 ' CG ' ' CE2' ' A' ' 47' ' ' TYR . 56.0 mtpt -82.26 146.15 53.9 Favored Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.122 -0.987 . . . . 50.0 110.043 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo . . . . . 0 C--N 1.306 -1.687 0 O-C-N 123.959 1.505 . . . . 99.99 110.354 179.921 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo . . . . . 0 N--CA 1.489 1.232 0 N-CA-C 110.324 -0.683 . . . . 50.0 110.324 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.464 ' O ' ' O ' ' A' ' 53' ' ' CYS . 14.0 m -128.31 141.25 47.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.118 -0.989 . . . . 50.0 110.438 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 72.9 m -107.66 110.94 22.92 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.262 -0.898 . . . . 50.0 109.899 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 52.1 m -79.4 -3.43 46.39 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.158 -0.963 . . . . 50.0 110.425 -179.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 70.4 mt -56.91 -41.56 78.37 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.129 -0.982 . . . . 50.0 110.063 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 30.3 mmtp -67.52 -38.34 84.09 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.393 -0.817 . . . . 50.0 110.359 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 41.4 t -68.36 -32.64 72.87 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.29 -0.881 . . . . 50.0 110.047 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.78 -5.68 56.76 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.711 -1.356 . . . . 50.0 109.711 179.714 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -74.29 130.39 39.62 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.181 -1.188 . . . . 50.0 110.206 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.522 HD12 ' CE2' ' A' ' 47' ' ' TYR . 7.0 pt -73.34 162.73 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.209 -0.932 . . . . 50.0 110.22 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 71.9 m -106.44 152.29 23.82 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.273 -0.892 . . . . 50.0 110.093 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.576 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 60.4 t-80 -138.39 145.23 46.04 Favored Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.315 -0.865 . . . . 50.0 109.892 -179.734 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.576 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 41.8 Cg_endo -67.7 161.01 45.61 Favored 'Trans proline' 0 C--N 1.302 -1.912 0 O-C-N 123.898 1.473 . . . . 50.0 110.189 179.728 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.485 ' HB ' ' O ' ' A' ' 40' ' ' PRO . 17.5 t 62.43 -104.59 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.42 -0.8 . . . . 50.0 110.035 -179.716 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.402 ' CD2' HG13 ' A' ' 41' ' ' VAL . 36.7 p90 -142.72 155.93 44.95 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.642 -1.286 . . . . 50.0 110.126 179.834 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.448 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 75.6 m -65.06 132.45 95.44 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.286 -0.883 . . . . 50.0 110.262 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -69.1 -161.64 0.07 OUTLIER 'Trans proline' 0 C--N 1.304 -1.783 0 O-C-N 123.927 1.488 . . . . 50.0 110.802 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 14.3 mtt180 -78.46 -39.49 38.4 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.461 -0.775 . . . . 50.0 109.907 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.477 ' O ' ' HD3' ' A' ' 64' ' ' PRO . 95.4 mtt180 -60.02 -34.27 73.14 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.44 -0.787 . . . . 50.0 110.346 -179.727 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.541 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 18.7 m-85 -110.71 144.01 40.31 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.295 -0.878 . . . . 50.0 110.899 -179.558 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 64.6 mttm -98.06 138.26 35.63 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.39 -0.819 . . . . 50.0 109.183 178.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 39.9 tt0 -80.68 101.88 9.53 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.053 -1.029 . . . . 50.0 110.686 -179.402 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.477 HD13 ' HB2' ' A' ' 62' ' ' LYS . 74.4 mt -65.46 -31.26 53.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.222 -0.924 . . . . 50.0 109.618 179.366 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.423 ' C ' HG21 ' A' ' 52' ' ' THR . . . 165.09 -94.13 0.11 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.291 -1.523 . . . . 50.0 109.291 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.423 HG21 ' C ' ' A' ' 51' ' ' GLY . 65.3 p -143.3 136.21 27.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.311 -1.111 . . . . 50.0 110.284 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' CYS . . . . . 0.509 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 17.5 t -58.07 -49.4 77.05 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.256 -0.903 . . . . 50.0 109.793 179.67 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 176.45 -32.17 0.08 OUTLIER Glycine 0 N--CA 1.49 2.265 0 N-CA-C 108.791 -1.723 . . . . 50.0 108.791 -179.854 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 80.6 mt -127.71 160.03 63.05 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.504 -0.997 . . . . 50.0 109.545 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -72.19 -2.14 11.17 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 123.88 1.463 . . . . 50.0 110.36 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -74.75 -38.88 41.38 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.545 -1.422 . . . . 50.0 109.545 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 21.2 m -126.7 168.58 14.17 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.199 -1.177 . . . . 50.0 110.367 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 14.5 tppt? -119.43 136.29 54.37 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.322 -0.861 . . . . 50.0 109.982 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.509 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 20.4 t -69.01 128.69 37.59 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.262 -0.899 . . . . 50.0 110.484 -179.739 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' CYS . . . . . 0.471 ' SG ' ' HB3' ' A' ' 39' ' ' HIS . 74.2 m -125.42 153.13 43.92 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.241 -0.912 . . . . 50.0 109.748 179.687 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.477 ' HB2' HD13 ' A' ' 50' ' ' ILE . 83.6 tttt -130.08 144.33 51.28 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.172 -0.955 . . . . 50.0 110.487 -179.616 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . 0.541 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 97.7 mttt -79.73 154.15 75.79 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.301 -0.875 . . . . 50.0 110.047 179.718 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . 0.477 ' HD3' ' O ' ' A' ' 46' ' ' ARG . 46.6 Cg_endo . . . . . 0 C--N 1.303 -1.85 0 O-C-N 124.008 1.53 . . . . 99.99 110.388 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.484 ' HG2' ' HA3' ' A' ' 54' ' ' GLY . 46.6 Cg_endo . . . . . 0 N--CA 1.489 1.233 0 N-CA-C 110.478 -0.624 . . . . 50.0 110.478 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.0 t -139.11 174.18 10.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.045 -1.034 . . . . 50.0 110.336 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 88.7 m -114.24 109.7 18.78 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.35 -0.844 . . . . 50.0 110.137 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . 0.422 ' SG ' ' HA ' ' A' ' 53' ' ' CYS . 79.3 m -77.15 -13.12 60.0 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.255 -0.903 . . . . 50.0 110.214 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 46.1 tp -57.32 -40.79 78.67 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.263 -0.898 . . . . 50.0 110.488 -179.717 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 60.3 mmtt -68.34 -41.25 81.03 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.265 -0.897 . . . . 50.0 110.297 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 56.9 m -70.86 -29.59 65.75 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.224 -0.923 . . . . 50.0 110.19 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 87.07 8.16 76.0 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.552 -1.419 . . . . 50.0 109.552 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -72.35 176.84 4.96 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.235 -1.156 . . . . 50.0 110.287 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.551 HD13 ' CD2' ' A' ' 39' ' ' HIS . 2.9 pt -115.83 153.53 17.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.316 -0.865 . . . . 50.0 109.984 179.663 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 83.0 m -112.52 153.31 27.67 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.167 -0.958 . . . . 50.0 109.969 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.551 ' CD2' HD13 ' A' ' 37' ' ' ILE . 31.6 m-70 -140.33 162.58 48.92 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 121.315 -0.865 . . . . 50.0 110.282 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -70.81 166.5 28.69 Favored 'Trans proline' 0 C--N 1.305 -1.759 0 O-C-N 124.037 1.546 . . . . 50.0 110.847 -179.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.465 ' O ' ' HG3' ' A' ' 59' ' ' LYS . 14.4 t 54.07 -108.43 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.393 -0.817 . . . . 50.0 110.167 179.811 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.456 ' CD1' ' O ' ' A' ' 43' ' ' CYS . 29.3 p90 -141.36 151.37 43.47 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.817 -1.177 . . . . 50.0 110.129 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.475 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 72.5 m -50.65 130.36 27.33 Favored Pre-proline 0 N--CA 1.489 1.517 0 O-C-N 121.155 -0.965 . . . . 50.0 109.813 179.771 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.452 ' HD2' ' HB2' ' A' ' 47' ' ' TYR . 43.6 Cg_endo -70.16 -162.78 0.1 OUTLIER 'Trans proline' 0 C--N 1.304 -1.783 0 O-C-N 123.954 1.502 . . . . 50.0 110.304 179.792 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 28.8 mtp180 -74.68 -42.79 57.77 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.417 -0.802 . . . . 50.0 110.04 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 79.0 mtp180 -61.96 -14.87 39.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.486 -0.759 . . . . 50.0 110.37 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.5 ' HB3' ' HB3' ' A' ' 61' ' ' CYS . 72.6 m-85 -128.28 164.19 23.13 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.232 -0.918 . . . . 50.0 110.683 -179.68 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -127.79 154.79 45.0 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.349 -0.845 . . . . 50.0 109.958 179.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -87.93 115.46 25.41 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.181 -0.95 . . . . 50.0 110.06 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 22.6 pt -110.41 15.91 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.282 -0.886 . . . . 50.0 110.459 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.479 ' O ' ' HB3' ' A' ' 60' ' ' CYS . . . 133.24 114.89 1.57 Allowed Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.403 -1.479 . . . . 50.0 109.403 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.476 ' OG1' ' CB ' ' A' ' 28' ' ' PRO . 75.9 p -34.65 134.05 0.24 Allowed 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.771 -0.841 . . . . 50.0 110.965 -179.841 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' CYS . . . . . 0.515 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 4.4 t -51.67 -42.03 61.84 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.452 -0.78 . . . . 50.0 110.34 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.484 ' HA3' ' HG2' ' A' ' 28' ' ' PRO . . . 163.36 -27.52 0.23 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.062 -1.615 . . . . 50.0 109.062 -179.787 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 97.0 mt -122.45 152.9 62.0 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.358 -1.084 . . . . 50.0 109.856 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.44 -16.25 27.6 Favored 'Trans proline' 0 C--N 1.303 -1.824 0 O-C-N 123.886 1.466 . . . . 50.0 110.416 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -69.02 -32.71 73.37 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.389 -1.484 . . . . 50.0 109.389 179.83 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.411 HG21 ' C ' ' A' ' 39' ' ' HIS . 8.6 m -128.74 168.12 16.29 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.287 -1.125 . . . . 50.0 110.198 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.465 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 75.1 mmtt -130.91 141.96 50.33 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.365 -0.835 . . . . 50.0 109.767 179.688 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.515 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 7.4 t -73.35 139.51 46.04 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.127 -0.983 . . . . 50.0 109.98 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' CYS . . . . . 0.5 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 97.8 m -131.89 144.47 50.89 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.378 -0.826 . . . . 50.0 109.94 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 54.7 tttm -127.81 140.36 52.08 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.089 -1.007 . . . . 50.0 110.31 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . 0.424 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 93.3 mttt -73.0 149.19 89.68 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.219 -0.926 . . . . 50.0 110.09 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo . . . . . 0 C--N 1.305 -1.758 0 O-C-N 124.012 1.532 . . . . 99.99 110.446 -179.963 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo . . . . . 0 N--CA 1.488 1.197 0 N-CA-C 110.313 -0.687 . . . . 50.0 110.313 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.481 ' O ' ' O ' ' A' ' 53' ' ' CYS . 16.8 t -136.3 172.65 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.176 -0.953 . . . . 50.0 110.249 -179.877 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 36.4 m -116.0 112.41 21.78 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.31 -0.869 . . . . 50.0 110.098 179.78 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 65.9 m -84.71 0.35 50.78 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.188 -0.945 . . . . 50.0 110.317 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.439 ' N ' HD23 ' A' ' 32' ' ' LEU . 4.2 mm? -65.82 -45.25 82.99 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.209 -0.932 . . . . 50.0 110.179 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -64.53 -36.16 83.3 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.409 -0.807 . . . . 50.0 110.181 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 95.2 p -69.48 -20.26 63.74 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.374 -0.829 . . . . 50.0 110.299 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 89.7 0.35 78.86 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.492 -1.443 . . . . 50.0 109.492 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -77.98 154.45 31.53 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.148 -1.207 . . . . 50.0 110.128 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.487 ' O ' ' O ' ' A' ' 61' ' ' CYS . 1.1 pt -99.72 157.22 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.285 -0.884 . . . . 50.0 109.875 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 70.9 m -107.06 143.7 34.79 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.012 -1.055 . . . . 50.0 110.121 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.599 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 14.8 t-80 -108.2 145.92 32.49 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.269 -0.894 . . . . 50.0 109.851 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.599 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 42.4 Cg_endo -68.03 -23.92 39.71 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 O-C-N 123.847 1.446 . . . . 50.0 110.878 -179.674 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.444 ' O ' ' HG3' ' A' ' 59' ' ' LYS . 66.3 t -117.91 -88.77 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.087 -1.008 . . . . 50.0 110.527 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.521 ' CD1' ' C ' ' A' ' 42' ' ' PHE . 13.4 p90 -140.02 151.31 45.35 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.111 -0.993 . . . . 50.0 110.148 -179.765 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.464 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 75.8 m -61.95 123.81 79.19 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.127 -0.983 . . . . 50.0 109.937 179.782 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.477 ' HD2' ' HB2' ' A' ' 47' ' ' TYR . 45.1 Cg_endo -69.95 -163.04 0.1 Allowed 'Trans proline' 0 C--N 1.304 -1.769 0 O-C-N 123.975 1.513 . . . . 50.0 110.732 179.812 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 65.2 ttt180 -75.02 -42.29 57.66 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.475 -0.766 . . . . 50.0 110.419 -179.74 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.465 ' O ' ' HD3' ' A' ' 64' ' ' PRO . 86.4 mmt-85 -62.19 -29.07 70.11 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.366 -0.834 . . . . 50.0 110.221 -179.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.579 ' CE2' ' CG ' ' A' ' 63' ' ' LYS . 16.6 m-85 -113.35 159.26 19.6 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.178 -0.952 . . . . 50.0 110.717 -179.732 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 13.5 ptmm? -120.5 145.61 47.11 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.36 -0.838 . . . . 50.0 109.462 179.116 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.449 ' HA ' ' SG ' ' A' ' 43' ' ' CYS . 63.3 tt0 -90.09 103.49 16.15 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.124 -0.985 . . . . 50.0 110.714 -179.53 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.449 HD13 ' HB2' ' A' ' 62' ' ' LYS . 90.7 mt -68.17 -29.45 44.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.207 -0.933 . . . . 50.0 109.623 179.438 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.412 ' C ' HG21 ' A' ' 52' ' ' THR . . . 172.31 -95.31 0.11 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.217 -1.553 . . . . 50.0 109.217 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.412 HG21 ' C ' ' A' ' 51' ' ' GLY . 70.7 p -144.17 134.19 24.07 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.209 -1.171 . . . . 50.0 110.309 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' CYS . . . . . 0.514 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 16.5 t -54.26 -43.79 71.28 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.134 -0.979 . . . . 50.0 109.669 179.571 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 152.65 -24.64 0.84 Allowed Glycine 0 N--CA 1.49 2.253 0 N-CA-C 108.637 -1.785 . . . . 50.0 108.637 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.473 ' HG ' ' HD2' ' A' ' 56' ' ' PRO . 16.7 tp -121.74 142.58 36.3 Favored Pre-proline 0 C--N 1.303 -1.449 0 O-C-N 121.505 -0.997 . . . . 50.0 109.374 179.594 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . 0.473 ' HD2' ' HG ' ' A' ' 55' ' ' LEU . 41.3 Cg_endo -67.37 -5.27 13.52 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 123.794 1.418 . . . . 50.0 110.465 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -80.14 -27.63 52.01 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.333 -1.507 . . . . 50.0 109.333 179.483 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.479 ' CG2' ' O ' ' A' ' 39' ' ' HIS . 3.4 m -137.33 160.68 38.37 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.247 -1.149 . . . . 50.0 110.433 179.908 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.464 ' O ' ' N ' ' A' ' 39' ' ' HIS . 73.4 mmtt -113.31 155.41 25.2 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.527 -0.733 . . . . 50.0 109.538 179.425 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.514 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 37.3 t -85.8 130.88 34.43 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.185 -0.947 . . . . 50.0 110.897 -179.24 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' CYS . . . . . 0.487 ' O ' ' O ' ' A' ' 37' ' ' ILE . 71.3 m -134.06 128.95 35.31 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.425 -0.797 . . . . 50.0 109.301 179.542 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.449 ' HB2' HD13 ' A' ' 50' ' ' ILE . 84.8 tttt -109.48 147.74 32.38 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.003 -1.06 . . . . 50.0 111.148 -179.154 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . 0.579 ' CG ' ' CE2' ' A' ' 47' ' ' TYR . 51.3 mtmt -84.69 154.16 61.57 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.365 -0.834 . . . . 50.0 109.663 179.317 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . 0.465 ' HD3' ' O ' ' A' ' 46' ' ' ARG . 48.2 Cg_endo . . . . . 0 C--N 1.304 -1.793 0 O-C-N 123.849 1.447 . . . . 99.99 110.487 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo . . . . . 0 N--CA 1.49 1.309 0 N-CA-C 110.378 -0.662 . . . . 50.0 110.378 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 49.1 t -133.0 174.21 13.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.258 -0.901 . . . . 50.0 110.277 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 99.8 m -115.92 104.97 12.14 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.277 -0.89 . . . . 50.0 110.345 -179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 65.1 m -82.1 -6.42 59.16 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.19 -0.944 . . . . 50.0 109.995 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 60.1 tp -57.99 -46.48 85.15 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.329 -0.857 . . . . 50.0 110.189 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -64.83 -34.52 78.55 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.393 -0.817 . . . . 50.0 110.21 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 65.1 m -69.67 -31.94 70.29 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.277 -0.889 . . . . 50.0 110.3 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.15 5.21 62.43 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.698 -1.361 . . . . 50.0 109.698 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . 0.439 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -78.41 173.05 12.75 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.189 -1.183 . . . . 50.0 110.326 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.574 HD13 ' CD2' ' A' ' 39' ' ' HIS . 7.1 pt -114.73 152.25 16.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.305 -0.872 . . . . 50.0 109.925 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 77.1 m -107.18 142.76 36.38 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.326 -0.859 . . . . 50.0 110.156 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.574 ' CD2' HD13 ' A' ' 37' ' ' ILE . 23.6 m-70 -134.04 157.4 77.76 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.258 -0.901 . . . . 50.0 110.12 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.469 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 45.8 Cg_endo -72.18 165.03 33.82 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 O-C-N 124.096 1.577 . . . . 50.0 110.931 -179.42 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.469 ' HB ' ' O ' ' A' ' 40' ' ' PRO . 18.6 t 61.02 -100.73 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.453 -0.78 . . . . 50.0 110.26 179.689 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.41 ' CD2' HG13 ' A' ' 41' ' ' VAL . 35.4 p90 -145.64 157.55 43.95 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.757 -1.214 . . . . 50.0 110.467 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.426 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 76.5 m -68.98 131.24 90.97 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.324 -0.86 . . . . 50.0 110.089 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -69.45 -160.05 0.06 OUTLIER 'Trans proline' 0 C--N 1.305 -1.75 0 O-C-N 123.908 1.478 . . . . 50.0 110.945 -179.709 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 31.7 mtt180 -80.85 -41.22 23.54 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.537 -0.727 . . . . 50.0 109.884 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 82.7 mmt-85 -55.82 -25.46 41.75 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.466 -0.771 . . . . 50.0 109.97 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.531 ' CD1' ' N ' ' A' ' 47' ' ' TYR . 18.3 m-85 -125.82 161.61 27.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.285 -0.884 . . . . 50.0 110.399 179.722 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.421 ' N ' ' O ' ' A' ' 62' ' ' LYS . 88.8 mttt -116.43 146.12 42.76 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.443 -0.785 . . . . 50.0 109.021 178.801 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.407 ' HA ' ' O ' ' A' ' 60' ' ' CYS . 45.4 tt0 -90.23 104.02 16.64 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.96 -1.087 . . . . 50.0 111.215 -178.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.481 HD13 ' HB2' ' A' ' 62' ' ' LYS . 80.2 mt -64.81 -32.54 58.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.276 -0.89 . . . . 50.0 109.136 178.857 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.404 ' C ' HG21 ' A' ' 52' ' ' THR . . . 168.63 -96.07 0.12 Allowed Glycine 0 N--CA 1.488 2.108 0 N-CA-C 109.469 -1.452 . . . . 50.0 109.469 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.404 HG21 ' C ' ' A' ' 51' ' ' GLY . 74.3 p -143.22 127.77 17.99 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.25 -1.147 . . . . 50.0 110.29 -179.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' CYS . . . . . . . . . . . . . 4.4 t -50.44 -44.76 55.55 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.225 -0.922 . . . . 50.0 109.848 179.721 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 176.71 -33.23 0.08 OUTLIER Glycine 0 N--CA 1.49 2.288 0 N-CA-C 108.994 -1.642 . . . . 50.0 108.994 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 97.5 mt -127.21 161.36 54.72 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.455 -1.027 . . . . 50.0 109.77 179.651 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -72.61 -5.31 16.94 Favored 'Trans proline' 0 C--N 1.304 -1.774 0 O-C-N 123.912 1.48 . . . . 50.0 110.462 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -71.45 -34.68 63.46 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.596 -1.402 . . . . 50.0 109.596 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.411 HG22 ' C ' ' A' ' 39' ' ' HIS . 11.5 m -132.88 165.64 24.17 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.312 -1.111 . . . . 50.0 110.149 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.456 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 75.3 mmtt -122.31 135.46 54.73 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.38 -0.825 . . . . 50.0 109.675 179.563 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.426 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 39.4 t -68.98 133.73 48.55 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.261 -0.9 . . . . 50.0 110.426 -179.432 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' CYS . . . . . 0.487 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 71.2 m -123.13 153.58 39.79 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.355 -0.841 . . . . 50.0 110.023 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.481 ' HB2' HD13 ' A' ' 50' ' ' ILE . 65.4 tttm -139.78 147.68 41.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.068 -1.02 . . . . 50.0 110.51 -179.721 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -84.08 154.88 64.06 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.259 -0.9 . . . . 50.0 110.207 179.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo . . . . . 0 C--N 1.305 -1.716 0 O-C-N 124.008 1.53 . . . . 99.99 110.38 179.835 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo . . . . . 0 N--CA 1.488 1.194 0 N-CA-C 110.289 -0.696 . . . . 50.0 110.289 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.8 m -129.6 157.63 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.191 -0.943 . . . . 50.0 110.31 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 95.8 m -109.99 104.03 12.87 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.353 -0.842 . . . . 50.0 110.229 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . 0.452 ' SG ' ' HA ' ' A' ' 53' ' ' CYS . 72.1 m -65.67 -16.83 64.12 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.265 -0.897 . . . . 50.0 110.184 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 9.9 tp -61.21 -45.98 92.33 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.282 -0.886 . . . . 50.0 110.082 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 67.5 mttm -63.12 -35.04 78.94 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.393 -0.817 . . . . 50.0 110.065 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 31.6 t -70.05 -24.3 63.24 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.361 -0.837 . . . . 50.0 110.204 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.03 9.9 47.33 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.604 -1.398 . . . . 50.0 109.604 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . 0.494 ' HB3' ' CG ' ' A' ' 62' ' ' LYS . . . -106.78 151.45 25.15 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.196 -1.179 . . . . 50.0 110.172 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.502 HG12 ' CE2' ' A' ' 47' ' ' TYR . 6.6 pt -100.7 151.86 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.347 -0.845 . . . . 50.0 110.26 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 87.0 m -92.75 148.15 22.28 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.301 -0.874 . . . . 50.0 109.964 179.781 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.608 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 53.0 t-80 -135.42 147.05 60.29 Favored Pre-proline 0 N--CA 1.495 1.783 0 O-C-N 121.247 -0.908 . . . . 50.0 110.045 -179.488 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.608 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 43.5 Cg_endo -69.89 160.47 49.53 Favored 'Trans proline' 0 C--N 1.308 -1.597 0 O-C-N 123.773 1.407 . . . . 50.0 110.59 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.573 HG13 ' CD2' ' A' ' 42' ' ' PHE . 21.6 t 61.57 -87.54 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.427 -0.796 . . . . 50.0 110.655 179.749 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.573 ' CD2' HG13 ' A' ' 41' ' ' VAL . 25.8 p90 -155.42 164.89 38.11 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 120.845 -1.159 . . . . 50.0 110.333 179.872 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.451 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 85.3 m -73.87 131.7 81.27 Favored Pre-proline 0 N--CA 1.496 1.834 0 O-C-N 121.239 -0.913 . . . . 50.0 110.601 -179.566 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -71.02 -162.18 0.1 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 O-C-N 123.9 1.474 . . . . 50.0 110.787 -179.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 19.4 ptp180 -80.11 -20.96 43.83 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.536 -0.727 . . . . 50.0 110.413 -179.758 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.434 ' O ' ' HD3' ' A' ' 64' ' ' PRO . 99.3 mtt180 -76.73 -26.13 54.29 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.261 -0.899 . . . . 50.0 110.013 179.821 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.513 ' CD1' ' N ' ' A' ' 47' ' ' TYR . 15.5 m-85 -124.21 158.76 31.67 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.308 -0.87 . . . . 50.0 110.6 -179.813 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 54.0 tptt -111.89 156.03 22.71 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.438 -0.788 . . . . 50.0 109.151 178.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.443 ' HG3' ' HG3' ' A' ' 59' ' ' LYS . 32.7 tt0 -95.25 100.75 12.49 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.923 -1.11 . . . . 50.0 110.65 -179.546 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.544 HD12 ' CD ' ' A' ' 62' ' ' LYS . 66.3 mt -66.92 -31.02 51.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.284 -0.885 . . . . 50.0 109.783 179.443 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.41 ' C ' HG21 ' A' ' 52' ' ' THR . . . 172.67 -97.77 0.12 Allowed Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.55 -1.42 . . . . 50.0 109.55 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.41 HG21 ' C ' ' A' ' 51' ' ' GLY . 64.9 p -143.36 133.15 23.91 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.205 -1.173 . . . . 50.0 110.44 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' CYS . . . . . 0.523 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 13.8 t -55.01 -45.05 75.09 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.315 -0.865 . . . . 50.0 109.67 179.57 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 167.66 -35.73 0.21 Allowed Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.383 -1.887 . . . . 50.0 108.383 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 66.4 mt -122.38 157.02 59.97 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.542 -0.975 . . . . 50.0 109.491 179.488 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -72.48 -6.5 19.17 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 123.852 1.448 . . . . 50.0 110.641 -179.79 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -71.52 -35.9 62.77 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.495 -1.442 . . . . 50.0 109.495 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 6.2 m -128.59 167.92 16.46 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.323 -1.104 . . . . 50.0 110.183 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.443 ' HG3' ' HG3' ' A' ' 49' ' ' GLN . 16.3 tppt? -124.41 133.68 53.32 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.266 -0.896 . . . . 50.0 110.173 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.523 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 35.3 t -63.06 133.83 55.13 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.29 -0.881 . . . . 50.0 110.527 -179.823 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' CYS . . . . . 0.476 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 74.7 m -133.15 138.65 46.7 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.281 -0.887 . . . . 50.0 110.084 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.544 ' CD ' HD12 ' A' ' 50' ' ' ILE . 87.5 tttt -135.65 144.45 46.05 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.199 -0.938 . . . . 50.0 110.136 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -65.63 150.04 96.6 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.124 -0.985 . . . . 50.0 109.933 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . 0.434 ' HD3' ' O ' ' A' ' 46' ' ' ARG . 45.9 Cg_endo . . . . . 0 C--N 1.305 -1.756 0 O-C-N 123.964 1.507 . . . . 99.99 110.359 -179.676 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.456 ' HB2' ' HA3' ' A' ' 54' ' ' GLY . 48.9 Cg_endo . . . . . 0 N--CA 1.489 1.246 0 N-CA-C 110.441 -0.638 . . . . 50.0 110.441 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.475 ' O ' ' O ' ' A' ' 53' ' ' CYS . 17.9 t -134.17 172.0 16.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.215 -0.928 . . . . 50.0 110.303 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 26.1 m -117.12 111.63 19.75 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.299 -0.876 . . . . 50.0 110.054 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 93.3 m -76.79 -4.54 44.02 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.264 -0.898 . . . . 50.0 110.437 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 18.9 mt -58.91 -45.19 90.92 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.139 -0.975 . . . . 50.0 110.07 179.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -66.71 -34.98 79.05 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.368 -0.833 . . . . 50.0 110.223 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 46.6 t -67.58 -25.08 65.61 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.365 -0.834 . . . . 50.0 110.192 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.77 -14.22 60.46 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.707 -1.357 . . . . 50.0 109.707 179.71 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . 0.497 ' HB2' ' CB ' ' A' ' 62' ' ' LYS . . . -70.31 170.58 11.5 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.143 -1.21 . . . . 50.0 110.255 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.565 HD13 ' CD2' ' A' ' 39' ' ' HIS . 14.7 pt -115.38 163.05 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.346 -0.846 . . . . 50.0 109.748 179.464 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 74.8 m -109.74 140.7 43.33 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.156 -0.965 . . . . 50.0 110.046 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.565 ' CD2' HD13 ' A' ' 37' ' ' ILE . 17.2 m-70 -134.34 153.92 79.6 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.198 -0.939 . . . . 50.0 110.115 179.892 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.471 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 45.1 Cg_endo -70.54 162.79 41.19 Favored 'Trans proline' 0 C--N 1.305 -1.743 0 O-C-N 124.029 1.541 . . . . 50.0 111.262 -179.178 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.474 ' O ' ' HG3' ' A' ' 59' ' ' LYS . 18.9 t 62.11 -105.18 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.578 -0.701 . . . . 50.0 110.607 179.546 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 25.8 p90 -140.01 157.27 45.94 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.863 -1.148 . . . . 50.0 110.359 -179.688 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.465 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 83.8 m -67.83 129.46 93.26 Favored Pre-proline 0 N--CA 1.492 1.626 0 O-C-N 121.181 -0.95 . . . . 50.0 109.829 179.599 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -67.6 -162.94 0.08 OUTLIER 'Trans proline' 0 C--N 1.303 -1.848 0 O-C-N 123.881 1.464 . . . . 50.0 110.846 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 16.2 ptm180 -78.33 -32.26 49.12 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.467 -0.77 . . . . 50.0 110.274 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.453 ' HG2' ' CE1' ' A' ' 47' ' ' TYR . 55.6 ttm-85 -68.3 -25.73 65.29 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.265 -0.897 . . . . 50.0 109.902 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.542 ' CZ ' ' HE2' ' A' ' 63' ' ' LYS . 29.3 m-85 -119.84 157.4 28.75 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.258 -0.901 . . . . 50.0 110.035 179.623 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 76.6 tttt -109.54 152.22 25.76 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.262 -0.899 . . . . 50.0 109.323 178.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.409 ' HA ' ' SG ' ' A' ' 43' ' ' CYS . 56.8 tp60 -95.18 101.51 13.26 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.171 -0.955 . . . . 50.0 110.24 -179.777 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 98.2 mt -72.17 -28.98 30.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.289 -0.882 . . . . 50.0 109.775 179.788 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 165.88 -91.87 0.1 Allowed Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.75 -1.34 . . . . 50.0 109.75 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 76.4 p -150.52 130.91 13.75 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.188 -1.184 . . . . 50.0 110.563 -179.573 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' CYS . . . . . 0.475 ' O ' ' O ' ' A' ' 29' ' ' VAL . 8.6 t -51.2 -43.17 61.31 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.221 -0.924 . . . . 50.0 110.083 179.87 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.456 ' HA3' ' HB2' ' A' ' 28' ' ' PRO . . . 162.91 -31.63 0.29 Allowed Glycine 0 N--CA 1.488 2.151 0 N-CA-C 109.001 -1.64 . . . . 50.0 109.001 -179.687 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.527 ' N ' ' CD2' ' A' ' 55' ' ' LEU . 3.2 mm? -126.43 160.9 55.6 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.442 -1.034 . . . . 50.0 109.743 179.758 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -71.45 -10.49 26.99 Favored 'Trans proline' 0 C--N 1.304 -1.799 0 O-C-N 123.801 1.421 . . . . 50.0 110.44 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -64.99 -45.03 93.59 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.595 -1.402 . . . . 50.0 109.595 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.409 HG21 ' C ' ' A' ' 39' ' ' HIS . 20.1 m -131.36 167.1 19.83 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.327 -1.102 . . . . 50.0 110.423 -179.873 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.474 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 47.0 mmtm -118.93 149.48 41.52 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.439 -0.788 . . . . 50.0 109.533 179.387 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.465 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 36.9 t -76.74 132.55 39.36 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.146 -0.971 . . . . 50.0 110.797 -179.093 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' CYS . . . . . 0.496 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 92.5 m -133.17 133.9 43.42 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.465 -0.772 . . . . 50.0 109.858 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.497 ' CB ' ' HB2' ' A' ' 36' ' ' ALA . 81.3 tttt -127.95 141.97 51.38 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.148 -0.97 . . . . 50.0 110.689 -179.539 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . 0.542 ' HE2' ' CZ ' ' A' ' 47' ' ' TYR . 99.4 mttt -75.94 156.69 84.21 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.36 -0.837 . . . . 50.0 110.023 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo . . . . . 0 C--N 1.304 -1.768 0 O-C-N 123.948 1.499 . . . . 99.99 110.508 179.86 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo . . . . . 0 N--CA 1.487 1.133 0 N-CA-C 110.34 -0.677 . . . . 50.0 110.34 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.463 ' O ' ' O ' ' A' ' 53' ' ' CYS . 15.5 m -107.68 134.19 50.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.305 -0.872 . . . . 50.0 110.206 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.459 ' O ' ' HB2' ' A' ' 31' ' ' CYS . 85.0 m -67.39 -11.89 58.87 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.274 -0.891 . . . . 50.0 110.314 -179.914 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . 0.459 ' HB2' ' O ' ' A' ' 30' ' ' THR . 64.1 m 57.28 19.29 4.87 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.161 -0.962 . . . . 50.0 110.399 179.813 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 33.2 tp -72.69 -32.17 65.58 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.165 -0.959 . . . . 50.0 110.633 -179.727 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -71.85 -40.18 69.2 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.103 -0.998 . . . . 50.0 110.226 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 72.3 m -71.82 -24.58 61.74 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.415 -0.803 . . . . 50.0 110.175 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 75.63 16.1 80.85 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.483 -1.447 . . . . 50.0 109.483 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . 0.425 ' HB2' ' HA ' ' A' ' 62' ' ' LYS . . . -83.12 176.74 8.98 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.281 -1.129 . . . . 50.0 110.024 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.473 HG13 ' O ' ' A' ' 37' ' ' ILE . 3.7 pt -116.91 150.77 18.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.134 -0.979 . . . . 50.0 110.42 -179.901 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . 0.426 ' HA ' ' HA ' ' A' ' 60' ' ' CYS . 61.0 m -91.26 137.3 32.47 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.173 -0.954 . . . . 50.0 109.333 179.484 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.52 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 58.3 t-80 -109.49 143.03 26.95 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.054 -1.028 . . . . 50.0 110.76 -179.157 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.52 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 47.5 Cg_endo -73.33 164.78 34.3 Favored 'Trans proline' 0 C--N 1.305 -1.713 0 O-C-N 124.19 1.626 . . . . 50.0 110.316 179.694 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.549 HG13 ' CD2' ' A' ' 42' ' ' PHE . 27.7 t 59.71 -84.02 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.298 -0.876 . . . . 50.0 110.558 179.667 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.549 ' CD2' HG13 ' A' ' 41' ' ' VAL . 16.5 p90 -158.64 161.89 37.21 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.854 -1.154 . . . . 50.0 110.389 -179.916 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.41 ' SG ' ' HB3' ' A' ' 47' ' ' TYR . 0.6 OUTLIER -80.92 121.62 81.06 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.216 -0.928 . . . . 50.0 110.059 179.911 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -70.39 -162.52 0.1 OUTLIER 'Trans proline' 0 C--N 1.306 -1.677 0 O-C-N 123.908 1.478 . . . . 50.0 110.592 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 11.2 ptm180 -81.8 -29.76 32.54 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.546 -0.721 . . . . 50.0 110.369 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 45.4 mmm-85 -69.06 -16.1 63.61 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.274 -0.891 . . . . 50.0 110.163 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.547 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 72.4 m-85 -122.93 150.14 43.34 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.29 -0.881 . . . . 50.0 110.337 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 54.0 tptt -110.9 154.11 24.53 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.35 -0.844 . . . . 50.0 110.224 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.521 ' HG3' ' CE ' ' A' ' 59' ' ' LYS . 46.2 tt0 -88.48 108.91 19.63 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.23 -0.919 . . . . 50.0 110.01 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 39.4 pt -104.32 10.76 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.22 -0.925 . . . . 50.0 110.966 -179.51 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.536 ' O ' ' CB ' ' A' ' 60' ' ' CYS . . . 130.62 113.01 1.55 Allowed Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.431 -1.468 . . . . 50.0 109.431 179.927 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.493 ' C ' ' O ' ' A' ' 51' ' ' GLY . 81.9 p -29.52 140.09 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.991 -0.711 . . . . 50.0 111.633 -179.612 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' CYS . . . . . 0.463 ' O ' ' O ' ' A' ' 29' ' ' VAL . 8.3 t -59.52 -50.24 74.69 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.385 -0.822 . . . . 50.0 110.219 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -179.06 -39.85 0.07 OUTLIER Glycine 0 N--CA 1.491 2.323 0 N-CA-C 108.945 -1.662 . . . . 50.0 108.945 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.451 ' HB3' ' HD2' ' A' ' 56' ' ' PRO . 70.2 mt -126.59 164.12 36.44 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.437 -1.037 . . . . 50.0 109.836 179.664 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . 0.451 ' HD2' ' HB3' ' A' ' 55' ' ' LEU . 45.2 Cg_endo -71.21 -7.29 21.04 Favored 'Trans proline' 0 C--N 1.305 -1.762 0 O-C-N 123.971 1.511 . . . . 50.0 110.555 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -68.98 -37.64 83.56 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.16 -1.576 . . . . 50.0 109.16 179.765 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.45 HG21 ' O ' ' A' ' 39' ' ' HIS . 1.4 m -129.42 159.97 34.57 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.316 -1.108 . . . . 50.0 110.005 179.773 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.521 ' CE ' ' HG3' ' A' ' 49' ' ' GLN . 37.7 tptt -121.84 127.27 50.35 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.197 -0.94 . . . . 50.0 109.984 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.536 ' CB ' ' O ' ' A' ' 51' ' ' GLY . 49.8 t -57.03 134.26 55.66 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.196 -0.94 . . . . 50.0 110.073 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' CYS . . . . . 0.521 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 54.5 m -136.76 148.26 47.15 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.3 -0.875 . . . . 50.0 109.981 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.425 ' HA ' ' HB2' ' A' ' 36' ' ' ALA . 81.0 tttt -128.4 132.26 48.5 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.207 -0.933 . . . . 50.0 110.418 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . 0.547 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 49.2 mtpt -72.81 152.74 91.25 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.299 -0.875 . . . . 50.0 110.202 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo . . . . . 0 C--N 1.305 -1.758 0 O-C-N 123.983 1.517 . . . . 99.99 110.497 -179.811 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.458 ' O ' HG21 ' A' ' 29' ' ' VAL . 47.1 Cg_endo . . . . . 0 N--CA 1.49 1.312 0 N-CA-C 110.384 -0.66 . . . . 50.0 110.384 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.458 HG21 ' O ' ' A' ' 28' ' ' PRO . 38.6 t -143.29 171.37 8.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.186 -0.946 . . . . 50.0 110.53 -179.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 57.7 m -109.45 111.26 22.7 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.337 -0.852 . . . . 50.0 109.927 179.619 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 92.6 m -80.01 -8.3 59.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.252 -0.905 . . . . 50.0 110.594 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.0 mt -58.29 -33.14 69.12 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.147 -0.971 . . . . 50.0 110.38 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 95.0 mttt -67.39 -39.09 85.59 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.266 -0.896 . . . . 50.0 110.229 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 14.4 m -65.4 -31.71 72.95 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.292 -0.88 . . . . 50.0 110.154 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 106.73 15.44 16.83 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.696 -1.362 . . . . 50.0 109.696 179.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -120.31 126.38 50.41 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.17 -1.194 . . . . 50.0 110.152 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.561 ' CD1' ' NE2' ' A' ' 39' ' ' HIS . 1.1 pt -84.02 144.54 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.281 -0.887 . . . . 50.0 109.995 179.855 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . 0.468 ' HA ' ' HA ' ' A' ' 60' ' ' CYS . 22.6 p -87.95 159.69 18.23 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.196 -0.94 . . . . 50.0 110.411 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.561 ' NE2' ' CD1' ' A' ' 37' ' ' ILE . 41.8 m-70 -131.02 167.88 19.66 Favored Pre-proline 0 N--CA 1.496 1.839 0 O-C-N 121.408 -0.808 . . . . 50.0 110.168 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.47 ' HD2' ' HB3' ' A' ' 39' ' ' HIS . 43.5 Cg_endo -70.16 161.17 46.97 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 O-C-N 123.711 1.374 . . . . 50.0 110.742 -179.601 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.527 HG13 ' CD2' ' A' ' 42' ' ' PHE . 9.8 t 55.82 -112.15 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.297 -0.877 . . . . 50.0 109.883 -179.682 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.527 ' CD2' HG13 ' A' ' 41' ' ' VAL . 50.2 p90 -135.2 156.27 49.27 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.676 -1.265 . . . . 50.0 109.96 179.749 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.476 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 83.6 m -59.14 130.47 86.87 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.137 -0.977 . . . . 50.0 110.043 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -70.71 -162.54 0.1 Allowed 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 123.979 1.515 . . . . 50.0 110.603 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 41.5 ptt180 -78.6 -29.35 46.02 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.493 -0.754 . . . . 50.0 110.413 -179.623 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 86.5 mtm180 -72.39 -12.43 61.11 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.237 -0.914 . . . . 50.0 110.16 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.585 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 38.1 m-85 -131.36 165.66 22.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.267 -0.896 . . . . 50.0 111.084 -179.611 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.455 ' O ' ' HA ' ' A' ' 61' ' ' CYS . 33.2 mttm -117.31 142.68 46.78 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.514 -0.741 . . . . 50.0 109.295 178.865 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.47 ' HA ' ' O ' ' A' ' 60' ' ' CYS . 32.7 tt0 -88.19 110.04 20.38 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.981 -1.075 . . . . 50.0 111.188 -179.131 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.527 ' CG1' ' HD2' ' A' ' 62' ' ' LYS . 80.7 mt -77.21 -28.89 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.314 -0.866 . . . . 50.0 109.326 178.909 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.531 ' O ' ' CG2' ' A' ' 52' ' ' THR . . . 174.3 -99.54 0.14 Allowed Glycine 0 N--CA 1.488 2.166 0 N-CA-C 108.819 -1.712 . . . . 50.0 108.819 -179.836 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.531 ' CG2' ' O ' ' A' ' 51' ' ' GLY . 70.9 p -157.65 143.74 17.55 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.284 -1.127 . . . . 50.0 110.191 179.571 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' CYS . . . . . 0.465 ' HA ' ' SG ' ' A' ' 60' ' ' CYS . 1.8 t -58.1 -39.06 77.67 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.217 -0.927 . . . . 50.0 109.882 179.606 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.428 ' O ' HD22 ' A' ' 55' ' ' LEU . . . 165.85 -27.68 0.18 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 108.818 -1.713 . . . . 50.0 108.818 -179.936 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.49 ' HB3' ' HD2' ' A' ' 56' ' ' PRO . 30.2 mt -127.36 166.46 22.86 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.409 -1.054 . . . . 50.0 109.816 179.748 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . 0.49 ' HD2' ' HB3' ' A' ' 55' ' ' LEU . 45.6 Cg_endo -73.52 -4.85 16.12 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.884 1.465 . . . . 50.0 110.447 179.889 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -78.61 -32.81 40.39 Favored Glycine 0 N--CA 1.489 2.167 0 N-CA-C 109.421 -1.472 . . . . 50.0 109.421 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.466 HG21 ' O ' ' A' ' 39' ' ' HIS . 2.5 m -128.37 162.58 26.77 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.273 -1.134 . . . . 50.0 110.587 -179.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.524 ' CG ' ' O ' ' A' ' 41' ' ' VAL . 72.1 mmtt -133.38 142.96 48.63 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.536 -0.728 . . . . 50.0 109.511 179.615 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.476 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 45.1 m -68.98 131.09 44.51 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.083 -1.01 . . . . 50.0 110.255 -179.861 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' CYS . . . . . 0.521 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 98.3 m -124.29 162.07 24.51 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.399 -0.813 . . . . 50.0 110.247 -179.812 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.584 ' O ' ' CD2' ' A' ' 47' ' ' TYR . 46.0 mtpt -122.31 164.31 18.14 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.233 -0.917 . . . . 50.0 110.672 -179.748 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . 0.585 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 52.1 mtpt -115.19 133.87 22.63 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.364 -0.835 . . . . 50.0 110.334 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo . . . . . 0 C--N 1.307 -1.63 0 O-C-N 123.927 1.488 . . . . 99.99 110.579 179.729 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo . . . . . 0 N--CA 1.49 1.284 0 N-CA-C 110.351 -0.673 . . . . 50.0 110.351 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.447 HG21 ' O ' ' A' ' 52' ' ' THR . 27.3 m -135.12 145.56 31.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.208 -0.932 . . . . 50.0 110.489 -179.787 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 25.0 m -100.48 105.99 17.5 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.297 -0.877 . . . . 50.0 110.097 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . 0.44 ' HB3' ' HB3' ' A' ' 36' ' ' ALA . 87.2 m -77.39 -1.6 30.94 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.193 -0.942 . . . . 50.0 110.411 -179.834 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 32.9 mt -63.35 -39.64 95.08 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.222 -0.924 . . . . 50.0 110.261 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 43.0 mmtm -66.75 -42.58 85.95 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.29 -0.882 . . . . 50.0 110.362 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 86.3 p -70.46 -14.77 62.67 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.347 -0.846 . . . . 50.0 110.143 -179.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 87.12 4.79 81.19 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.543 -1.423 . . . . 50.0 109.543 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . 0.44 ' HB3' ' HB3' ' A' ' 31' ' ' CYS . . . -71.8 155.64 40.21 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.159 -1.201 . . . . 50.0 110.009 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.581 HD12 ' CE2' ' A' ' 47' ' ' TYR . 26.7 pt -103.89 145.0 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.185 -0.947 . . . . 50.0 110.015 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 8.7 m -101.22 125.39 47.84 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.258 -0.901 . . . . 50.0 109.936 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.545 ' NE2' ' CD1' ' A' ' 37' ' ' ILE . 12.5 m-70 -119.48 153.06 53.77 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.232 -0.917 . . . . 50.0 110.345 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.422 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 45.7 Cg_endo -71.16 169.88 19.55 Favored 'Trans proline' 0 C--N 1.305 -1.727 0 O-C-N 124.04 1.547 . . . . 50.0 110.852 -179.604 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.422 ' HB ' ' O ' ' A' ' 40' ' ' PRO . 17.4 t 59.15 -109.35 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.362 -0.836 . . . . 50.0 110.186 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 36.8 p90 -136.24 153.64 51.15 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.827 -1.171 . . . . 50.0 110.017 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.407 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 76.4 m -69.88 132.26 88.8 Favored Pre-proline 0 N--CA 1.487 1.415 0 O-C-N 121.11 -0.994 . . . . 50.0 109.911 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -68.41 -162.76 0.08 OUTLIER 'Trans proline' 0 C--N 1.305 -1.732 0 O-C-N 123.996 1.524 . . . . 50.0 111.004 -179.564 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 16.2 ptm180 -81.58 -26.37 35.01 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.558 -0.714 . . . . 50.0 110.453 -179.617 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 13.3 mmm180 -66.71 -22.22 66.07 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.148 -0.97 . . . . 50.0 110.1 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.598 ' CB ' ' HB3' ' A' ' 61' ' ' CYS . 70.8 m-85 -128.1 144.01 51.09 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.217 -0.927 . . . . 50.0 110.589 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 85.0 tttt -88.67 152.88 21.53 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.267 -0.896 . . . . 50.0 109.221 178.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 56.4 tt0 -93.4 96.44 9.93 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.093 -1.005 . . . . 50.0 110.562 -179.702 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.468 HD13 ' CB ' ' A' ' 62' ' ' LYS . 93.6 mt -69.42 -30.11 44.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.309 -0.87 . . . . 50.0 109.904 179.575 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.456 ' O ' ' CG2' ' A' ' 52' ' ' THR . . . 159.12 -91.86 0.12 Allowed Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.263 -1.535 . . . . 50.0 109.263 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.456 ' CG2' ' O ' ' A' ' 51' ' ' GLY . 63.3 p -153.92 150.58 28.5 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.26 -1.141 . . . . 50.0 109.992 179.695 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' CYS . . . . . 0.435 ' SG ' ' HB2' ' A' ' 60' ' ' CYS . 1.6 m -84.89 -27.33 26.72 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.189 -0.944 . . . . 50.0 110.694 -179.599 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 179.03 -49.5 0.09 OUTLIER Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.764 -1.334 . . . . 50.0 109.764 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 56.2 mt -119.74 161.92 35.47 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.16 -1.2 . . . . 50.0 110.419 -179.851 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -71.93 -11.4 27.42 Favored 'Trans proline' 0 C--N 1.305 -1.74 0 O-C-N 124.08 1.569 . . . . 50.0 110.292 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -68.94 -30.47 72.32 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.448 -1.461 . . . . 50.0 109.448 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -125.25 155.28 40.37 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.275 -1.132 . . . . 50.0 110.298 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.445 ' O ' ' SG ' ' A' ' 61' ' ' CYS . 14.1 tppt? -120.56 127.16 51.89 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.396 -0.815 . . . . 50.0 109.839 179.686 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.435 ' HB2' ' SG ' ' A' ' 53' ' ' CYS . 34.3 t -63.51 130.9 46.29 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.252 -0.905 . . . . 50.0 110.663 -179.604 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' CYS . . . . . 0.598 ' HB3' ' CB ' ' A' ' 47' ' ' TYR . 7.4 m -128.58 130.3 47.16 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.371 -0.831 . . . . 50.0 109.635 179.765 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.468 ' CB ' HD13 ' A' ' 50' ' ' ILE . 83.4 tttt -131.62 148.69 52.62 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.157 -0.964 . . . . 50.0 110.507 -179.638 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 86.0 mttt -72.76 150.36 90.77 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.281 -0.887 . . . . 50.0 110.021 179.887 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo . . . . . 0 C--N 1.306 -1.685 0 O-C-N 123.955 1.502 . . . . 99.99 110.401 179.977 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo . . . . . 0 N--CA 1.489 1.25 0 N-CA-C 110.553 -0.595 . . . . 50.0 110.553 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.47 ' O ' ' O ' ' A' ' 53' ' ' CYS . 18.2 m -125.21 125.45 69.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.311 -0.868 . . . . 50.0 110.084 179.879 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.484 ' O ' ' HB2' ' A' ' 31' ' ' CYS . 85.8 m -64.7 -15.59 61.64 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.323 -0.861 . . . . 50.0 110.54 -179.789 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . 0.484 ' HB2' ' O ' ' A' ' 30' ' ' THR . 97.9 m 56.61 18.38 3.6 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.232 -0.918 . . . . 50.0 110.223 179.836 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.48 ' CD1' ' C ' ' A' ' 32' ' ' LEU . 3.4 tm? -76.62 -39.47 52.36 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.223 -0.923 . . . . 50.0 110.477 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 74.4 mmtt -75.13 -35.24 61.7 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.324 -0.86 . . . . 50.0 109.985 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 73.9 m -71.18 -26.72 63.09 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.374 -0.829 . . . . 50.0 110.191 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 84.98 9.0 81.54 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.493 -1.443 . . . . 50.0 109.493 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . 0.441 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -76.66 134.37 39.29 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.232 -1.158 . . . . 50.0 110.262 -179.914 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.515 ' CD1' ' CE2' ' A' ' 47' ' ' TYR . 9.1 pt -83.02 148.13 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.239 -0.913 . . . . 50.0 110.028 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 96.5 m -91.79 148.79 21.98 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.075 -1.016 . . . . 50.0 109.882 179.862 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.584 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 62.6 t-80 -139.71 145.9 45.17 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 121.312 -0.868 . . . . 50.0 109.89 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.584 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 41.6 Cg_endo -66.89 159.63 50.79 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.868 1.457 . . . . 50.0 110.075 179.723 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.496 HG13 ' CD2' ' A' ' 42' ' ' PHE . 13.5 t 62.99 -105.94 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.224 -0.922 . . . . 50.0 109.913 -179.673 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.496 ' CD2' HG13 ' A' ' 41' ' ' VAL . 42.1 p90 -142.26 157.9 44.32 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.626 -1.296 . . . . 50.0 110.148 179.814 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.455 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 84.4 m -65.02 132.54 95.5 Favored Pre-proline 0 N--CA 1.493 1.699 0 O-C-N 121.241 -0.912 . . . . 50.0 110.371 -179.792 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -68.71 -162.16 0.08 OUTLIER 'Trans proline' 0 C--N 1.305 -1.75 0 O-C-N 123.995 1.524 . . . . 50.0 110.839 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 27.3 tpt180 -75.61 -43.13 49.63 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.519 -0.738 . . . . 50.0 110.537 -179.681 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.467 ' O ' ' HD3' ' A' ' 64' ' ' PRO . 45.8 ttt85 -61.45 -30.77 70.8 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.333 -0.854 . . . . 50.0 110.372 -179.723 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.515 ' CE2' ' CD1' ' A' ' 37' ' ' ILE . 32.2 m-85 -111.1 136.36 50.26 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.193 -0.942 . . . . 50.0 110.747 -179.85 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 24.6 tptp -87.37 157.14 19.32 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.261 -0.899 . . . . 50.0 109.387 179.034 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.442 ' HA ' ' SG ' ' A' ' 43' ' ' CYS . 53.7 tt0 -89.5 102.7 15.38 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.099 -1.001 . . . . 50.0 110.356 -179.777 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.411 ' HB ' ' SG ' ' A' ' 60' ' ' CYS . 30.6 mm -67.08 -30.66 50.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.227 -0.921 . . . . 50.0 109.555 179.552 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.475 ' O ' HG21 ' A' ' 52' ' ' THR . . . 153.77 -91.16 0.13 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.035 -1.626 . . . . 50.0 109.035 179.866 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.475 HG21 ' O ' ' A' ' 51' ' ' GLY . 50.1 p -146.2 125.9 13.42 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.363 -1.081 . . . . 50.0 109.976 179.603 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' CYS . . . . . 0.47 ' O ' ' O ' ' A' ' 29' ' ' VAL . 19.1 t -49.85 -49.22 49.98 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.252 -0.905 . . . . 50.0 109.669 179.635 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 173.47 -30.15 0.1 OUTLIER Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.211 -1.556 . . . . 50.0 109.211 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 55.6 mt -124.87 160.3 54.72 Favored Pre-proline 0 N--CA 1.489 1.512 0 O-C-N 121.384 -1.068 . . . . 50.0 109.917 179.866 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -71.97 -5.8 17.83 Favored 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.928 1.488 . . . . 50.0 110.198 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -78.32 -37.12 28.83 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.469 -1.452 . . . . 50.0 109.469 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.421 HG21 ' C ' ' A' ' 39' ' ' HIS . 5.1 m -130.59 162.23 29.79 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.269 -1.136 . . . . 50.0 110.268 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 66.7 mmtt -117.56 164.59 14.69 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.408 -0.808 . . . . 50.0 109.778 179.718 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.455 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 42.2 t -91.32 129.7 37.27 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.139 -0.975 . . . . 50.0 110.468 -179.78 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' CYS . . . . . 0.487 ' O ' ' N ' ' A' ' 37' ' ' ILE . 72.4 m -126.42 147.71 49.75 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.342 -0.849 . . . . 50.0 109.832 179.808 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 89.1 tttt -126.58 138.35 53.45 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.15 -0.969 . . . . 50.0 110.323 -179.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . 0.413 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 30.3 mtmm -63.07 154.69 76.43 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.333 -0.855 . . . . 50.0 110.325 179.88 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . 0.467 ' HD3' ' O ' ' A' ' 46' ' ' ARG . 47.5 Cg_endo . . . . . 0 C--N 1.306 -1.71 0 O-C-N 124.01 1.532 . . . . 99.99 110.38 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.436 ' O ' ' HB ' ' A' ' 29' ' ' VAL . 47.1 Cg_endo . . . . . 0 N--CA 1.489 1.246 0 N-CA-C 110.399 -0.654 . . . . 50.0 110.399 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.48 ' O ' ' N ' ' A' ' 31' ' ' CYS . 46.9 t 56.8 172.52 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.16 -0.962 . . . . 50.0 110.102 -179.914 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.48 ' CG2' ' O ' ' A' ' 30' ' ' THR . 95.3 m 39.16 28.21 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.491 -0.755 . . . . 50.0 110.587 -179.812 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . 0.48 ' N ' ' O ' ' A' ' 29' ' ' VAL . 65.4 m -48.5 -22.5 0.74 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.13 -0.981 . . . . 50.0 109.721 179.682 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.7 mt -57.98 -42.76 85.76 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.249 -0.907 . . . . 50.0 110.08 179.568 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 64.8 mmtt -68.24 -33.3 74.13 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.444 -0.785 . . . . 50.0 110.185 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 69.3 m -76.37 -17.53 59.34 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.228 -0.92 . . . . 50.0 109.942 179.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 91.93 -2.87 76.67 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.858 -1.297 . . . . 50.0 109.858 179.586 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . 0.426 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -79.59 153.94 29.09 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.124 -1.221 . . . . 50.0 110.226 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.514 ' O ' ' N ' ' A' ' 61' ' ' CYS . 4.8 pt -107.79 152.88 9.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.288 -0.882 . . . . 50.0 110.052 179.826 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 71.8 m -93.32 148.98 21.57 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.202 -0.937 . . . . 50.0 110.045 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.594 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 42.0 t-80 -136.49 145.96 53.73 Favored Pre-proline 0 N--CA 1.491 1.614 0 O-C-N 121.275 -0.891 . . . . 50.0 110.16 -179.685 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.594 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 42.5 Cg_endo -68.59 153.02 74.38 Favored 'Trans proline' 0 C--N 1.307 -1.612 0 O-C-N 123.844 1.444 . . . . 50.0 110.544 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.503 HG13 ' CD2' ' A' ' 42' ' ' PHE . 18.0 t 64.24 -84.62 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.577 -0.702 . . . . 50.0 110.559 -179.784 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.503 ' CD2' HG13 ' A' ' 41' ' ' VAL . 21.6 p90 -156.56 161.96 39.94 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.714 -1.241 . . . . 50.0 110.214 179.963 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.435 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 58.4 m -73.25 134.12 80.48 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.249 -0.907 . . . . 50.0 110.526 -179.665 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.454 ' O ' ' O ' ' A' ' 47' ' ' TYR . 44.3 Cg_endo -70.18 -160.63 0.07 OUTLIER 'Trans proline' 0 C--N 1.305 -1.718 0 O-C-N 123.874 1.46 . . . . 50.0 110.522 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 17.4 mmt180 -78.45 -46.58 19.41 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.493 -0.754 . . . . 50.0 109.68 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 82.1 mtm180 -54.39 -23.97 17.82 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.56 -0.713 . . . . 50.0 109.674 179.783 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.521 ' CZ ' ' HE2' ' A' ' 63' ' ' LYS . 39.4 m-85 -122.95 154.04 38.93 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.411 -0.805 . . . . 50.0 110.259 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 82.1 tttt -117.84 149.74 40.33 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.4 -0.813 . . . . 50.0 109.679 179.594 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 58.8 tt0 -88.71 94.92 10.07 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.184 -0.948 . . . . 50.0 109.892 179.638 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.457 HG13 ' N ' ' A' ' 51' ' ' GLY . 21.6 pt -71.4 -30.08 38.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.402 -0.811 . . . . 50.0 110.326 -179.821 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.464 ' O ' HG21 ' A' ' 52' ' ' THR . . . -171.52 -105.63 0.18 Allowed Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.483 -1.447 . . . . 50.0 109.483 179.76 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.464 HG21 ' O ' ' A' ' 51' ' ' GLY . 41.2 p -151.17 141.02 21.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.285 -1.127 . . . . 50.0 110.218 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' CYS . . . . . 0.558 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 10.0 t -58.49 -44.39 89.38 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.273 -0.892 . . . . 50.0 109.873 179.879 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 160.08 -36.9 0.46 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.033 -1.627 . . . . 50.0 109.033 -179.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 74.8 mt -113.45 155.29 44.94 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.428 -1.042 . . . . 50.0 109.924 179.669 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -71.32 -11.8 29.04 Favored 'Trans proline' 0 C--N 1.303 -1.853 0 O-C-N 123.922 1.485 . . . . 50.0 110.69 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -70.92 -41.92 61.07 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.57 -1.412 . . . . 50.0 109.57 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 14.6 m -122.79 166.86 14.27 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.337 -1.096 . . . . 50.0 110.248 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -124.7 145.66 49.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.406 -0.809 . . . . 50.0 109.87 179.806 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.558 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 45.2 t -73.47 139.36 45.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.151 -0.968 . . . . 50.0 110.431 -179.803 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' CYS . . . . . 0.514 ' N ' ' O ' ' A' ' 37' ' ' ILE . 74.8 m -131.49 141.65 49.81 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.389 -0.82 . . . . 50.0 109.61 179.748 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 81.8 tttt -138.65 143.52 39.26 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.205 -0.934 . . . . 50.0 110.658 -179.341 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . 0.521 ' HE2' ' CZ ' ' A' ' 47' ' ' TYR . 98.9 mttt -77.28 142.0 67.19 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.294 -0.879 . . . . 50.0 110.158 179.81 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo . . . . . 0 C--N 1.305 -1.741 0 O-C-N 123.957 1.504 . . . . 99.99 110.412 179.975 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo . . . . . 0 N--CA 1.491 1.332 0 N-CA-C 110.445 -0.637 . . . . 50.0 110.445 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.492 ' CG2' ' SG ' ' A' ' 31' ' ' CYS . 31.0 m -90.46 147.25 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.259 -0.901 . . . . 50.0 110.293 179.891 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.481 ' O ' ' HB2' ' A' ' 31' ' ' CYS . 85.6 m -64.22 -40.14 95.44 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.254 -0.904 . . . . 50.0 110.571 -179.768 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . 0.492 ' SG ' ' CG2' ' A' ' 29' ' ' VAL . 47.9 m 56.87 21.97 6.63 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.14 -0.975 . . . . 50.0 110.312 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.481 ' HG ' ' O ' ' A' ' 30' ' ' THR . 79.2 mt -105.12 -21.05 13.33 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.193 -0.942 . . . . 50.0 110.176 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 95.2 mttt -72.58 -37.52 68.15 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.345 -0.847 . . . . 50.0 110.324 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 87.9 p -88.76 -4.04 58.61 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.292 -0.88 . . . . 50.0 110.25 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 69.42 21.38 76.01 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.195 -1.562 . . . . 50.0 109.195 -179.84 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -70.22 155.16 41.03 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.35 -1.088 . . . . 50.0 110.211 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.563 HD13 ' CD2' ' A' ' 39' ' ' HIS . 12.8 pt -104.73 151.05 7.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.21 -0.931 . . . . 50.0 110.253 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 76.2 m -105.38 139.54 39.85 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.299 -0.875 . . . . 50.0 110.031 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.563 ' CD2' HD13 ' A' ' 37' ' ' ILE . 17.3 m-70 -133.52 157.9 76.9 Favored Pre-proline 0 N--CA 1.494 1.74 0 O-C-N 121.346 -0.846 . . . . 50.0 110.192 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.465 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 45.2 Cg_endo -71.58 168.42 23.68 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 O-C-N 124.059 1.557 . . . . 50.0 110.415 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.528 HG13 ' CD2' ' A' ' 42' ' ' PHE . 10.8 t 61.84 -108.37 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.237 -0.914 . . . . 50.0 109.804 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.528 ' CD2' HG13 ' A' ' 41' ' ' VAL . 48.6 p90 -143.63 161.78 37.63 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.747 -1.221 . . . . 50.0 110.108 179.704 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.462 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 70.8 m -67.33 132.43 93.24 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.222 -0.924 . . . . 50.0 110.356 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -71.29 -162.56 0.11 Allowed 'Trans proline' 0 C--N 1.306 -1.707 0 O-C-N 123.933 1.491 . . . . 50.0 110.346 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 30.2 mtt180 -78.21 -41.47 34.32 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.424 -0.798 . . . . 50.0 110.015 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.43 ' O ' ' HD3' ' A' ' 64' ' ' PRO . 26.0 mmm180 -57.95 -27.94 63.87 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.483 -0.761 . . . . 50.0 110.21 -179.777 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.535 ' CE2' ' CG ' ' A' ' 63' ' ' LYS . 21.7 m-85 -119.12 158.9 24.98 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.345 -0.847 . . . . 50.0 110.534 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -117.08 131.0 57.02 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.467 -0.77 . . . . 50.0 109.634 179.307 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.454 ' HA ' ' SG ' ' A' ' 43' ' ' CYS . 54.4 tt0 -78.14 104.14 8.53 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.276 -0.89 . . . . 50.0 111.024 -179.082 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.461 HD13 ' HB2' ' A' ' 62' ' ' LYS . 79.5 mt -68.71 -31.21 49.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.335 -0.853 . . . . 50.0 109.387 179.111 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 172.95 -96.67 0.11 Allowed Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.662 -1.375 . . . . 50.0 109.662 179.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.487 ' O ' ' CG2' ' A' ' 29' ' ' VAL . 68.6 p -146.7 137.2 23.8 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.207 -1.172 . . . . 50.0 110.327 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' CYS . . . . . . . . . . . . . 4.1 t -62.35 -41.43 98.58 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.263 -0.898 . . . . 50.0 110.137 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 158.93 -25.68 0.36 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 108.994 -1.642 . . . . 50.0 108.994 -179.897 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.505 ' CD1' ' HD2' ' A' ' 56' ' ' PRO . 17.4 tp -120.8 142.44 34.45 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.401 -1.059 . . . . 50.0 109.712 179.777 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . 0.505 ' HD2' ' CD1' ' A' ' 55' ' ' LEU . 42.0 Cg_endo -67.92 -8.17 21.82 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 O-C-N 123.872 1.459 . . . . 50.0 110.442 -179.841 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -75.99 -32.09 53.88 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.062 -1.615 . . . . 50.0 109.062 179.511 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.462 ' HA ' ' HA ' ' A' ' 40' ' ' PRO . 4.0 m -131.28 162.12 30.75 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.262 -1.14 . . . . 50.0 110.4 179.896 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.468 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 46.5 mmtm -120.76 146.63 46.3 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.285 -0.884 . . . . 50.0 109.829 179.741 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.462 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 42.7 t -75.82 133.4 40.64 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.264 -0.898 . . . . 50.0 110.749 -179.376 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' CYS . . . . . 0.479 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 73.6 m -130.45 135.08 47.62 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.365 -0.834 . . . . 50.0 109.791 179.807 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.461 ' HB2' HD13 ' A' ' 50' ' ' ILE . 39.8 ttpt -126.51 135.15 50.95 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.09 -1.006 . . . . 50.0 110.287 -179.862 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . 0.535 ' CG ' ' CE2' ' A' ' 47' ' ' TYR . 49.5 mtmt -70.97 151.83 95.01 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.319 -0.863 . . . . 50.0 110.128 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . 0.43 ' HD3' ' O ' ' A' ' 46' ' ' ARG . 45.6 Cg_endo . . . . . 0 C--N 1.304 -1.781 0 O-C-N 124.022 1.538 . . . . 99.99 110.494 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo . . . . . 0 N--CA 1.489 1.228 0 N-CA-C 110.225 -0.721 . . . . 50.0 110.225 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 5.3 m -133.44 144.36 36.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.247 -0.908 . . . . 50.0 110.373 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 97.0 m -115.72 114.24 24.56 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.337 -0.852 . . . . 50.0 110.034 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . 0.862 ' SG ' ' SG ' ' A' ' 53' ' ' CYS . 76.9 m -76.56 -7.15 54.62 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.274 -0.891 . . . . 50.0 110.399 -179.856 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 50.7 tp -65.35 -40.98 94.3 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.189 -0.945 . . . . 50.0 110.28 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -62.55 -44.19 96.94 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.321 -0.862 . . . . 50.0 110.271 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 58.1 m -66.13 -33.32 75.51 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.357 -0.839 . . . . 50.0 110.139 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 104.56 8.52 37.5 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.397 -1.481 . . . . 50.0 109.397 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -96.13 123.38 39.72 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.263 -1.14 . . . . 50.0 109.95 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.461 ' O ' HG13 ' A' ' 37' ' ' ILE . 2.2 pt -71.61 151.5 8.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.155 -0.965 . . . . 50.0 110.495 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 24.5 m -91.28 154.73 19.05 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.182 -0.949 . . . . 50.0 109.871 179.645 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.545 ' O ' ' N ' ' A' ' 59' ' ' LYS . 64.7 t-80 -129.78 140.79 39.69 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.123 -0.986 . . . . 50.0 110.571 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.484 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 43.7 Cg_endo -70.4 161.83 44.6 Favored 'Trans proline' 0 C--N 1.304 -1.806 0 O-C-N 123.967 1.509 . . . . 50.0 111.091 -179.78 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.567 HG13 ' CD2' ' A' ' 42' ' ' PHE . 33.1 t 57.18 -84.23 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.536 -0.727 . . . . 50.0 110.955 179.846 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.567 ' CD2' HG13 ' A' ' 41' ' ' VAL . 14.0 p90 -155.26 157.65 37.59 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.873 -1.142 . . . . 50.0 110.457 -179.653 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.408 ' SG ' ' CB ' ' A' ' 47' ' ' TYR . 0.7 OUTLIER -71.82 133.9 84.01 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 121.327 -0.858 . . . . 50.0 110.293 179.896 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.435 ' HD2' ' HB2' ' A' ' 47' ' ' TYR . 45.1 Cg_endo -70.55 -162.23 0.1 OUTLIER 'Trans proline' 0 C--N 1.306 -1.665 0 O-C-N 123.883 1.465 . . . . 50.0 110.543 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 28.7 tpt180 -81.93 -37.05 27.35 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.534 -0.729 . . . . 50.0 110.365 -179.813 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -66.39 -29.71 69.93 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.381 -0.824 . . . . 50.0 110.172 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.516 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 45.8 m-85 -110.37 138.48 46.7 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.267 -0.896 . . . . 50.0 110.842 -179.597 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.428 ' O ' ' HA ' ' A' ' 61' ' ' CYS . 67.0 tttt -90.6 153.05 20.61 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.242 -0.912 . . . . 50.0 109.219 178.915 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 36.0 tt0 -102.07 98.9 9.02 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.041 -1.037 . . . . 50.0 110.302 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 97.0 mt -64.38 -28.6 45.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.46 -0.775 . . . . 50.0 109.984 179.888 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 160.5 -91.3 0.11 Allowed Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.551 -1.419 . . . . 50.0 109.551 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 67.6 p -145.29 159.28 43.27 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.283 -1.128 . . . . 50.0 110.313 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' CYS . . . . . 0.862 ' SG ' ' SG ' ' A' ' 31' ' ' CYS . 0.5 OUTLIER -104.53 -15.76 15.25 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.279 -0.888 . . . . 50.0 110.329 -179.923 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 162.34 -43.6 0.36 Allowed Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.45 -1.46 . . . . 50.0 109.45 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 87.2 mt -123.34 159.39 55.01 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.277 -1.131 . . . . 50.0 109.955 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.72 -16.99 26.37 Favored 'Trans proline' 0 C--N 1.304 -1.787 0 O-C-N 123.896 1.472 . . . . 50.0 110.383 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -68.08 -33.97 80.18 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.457 -1.457 . . . . 50.0 109.457 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.427 ' HA ' ' HA ' ' A' ' 40' ' ' PRO . 34.3 m -117.24 170.14 8.92 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.262 -1.14 . . . . 50.0 110.388 179.861 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.545 ' N ' ' O ' ' A' ' 39' ' ' HIS . 73.7 mmtt -133.75 155.93 48.89 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.437 -0.789 . . . . 50.0 109.56 179.787 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 13.1 t -83.09 127.86 33.96 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.075 -1.016 . . . . 50.0 110.308 -179.586 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' CYS . . . . . 0.514 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 51.0 m -127.05 146.4 50.37 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.272 -0.892 . . . . 50.0 110.266 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 76.9 tttt -129.38 136.11 49.56 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.211 -0.931 . . . . 50.0 110.319 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . 0.516 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 97.6 mttt -79.57 143.42 59.12 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.251 -0.906 . . . . 50.0 109.968 179.805 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo . . . . . 0 C--N 1.305 -1.733 0 O-C-N 123.897 1.472 . . . . 99.99 110.394 -179.805 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo . . . . . 0 N--CA 1.49 1.309 0 N-CA-C 110.478 -0.624 . . . . 50.0 110.478 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' A' ' 53' ' ' CYS . 27.6 m -150.19 145.42 17.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.171 -0.956 . . . . 50.0 110.263 179.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 86.1 m -105.71 107.7 18.83 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.272 -0.892 . . . . 50.0 110.012 179.802 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 95.8 m -75.86 -4.55 41.41 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.35 -0.844 . . . . 50.0 110.35 -179.793 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 49.8 tp -55.67 -49.57 72.56 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.192 -0.943 . . . . 50.0 109.996 179.764 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -59.89 -36.18 76.41 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.481 -0.762 . . . . 50.0 110.153 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 70.6 m -73.06 -27.46 61.75 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.34 -0.85 . . . . 50.0 110.235 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 95.01 -6.32 69.22 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.509 -1.436 . . . . 50.0 109.509 -179.861 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -66.46 141.6 57.85 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.209 -1.171 . . . . 50.0 110.074 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.573 HD13 ' CD2' ' A' ' 39' ' ' HIS . 7.2 pt -86.98 150.16 3.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.203 -0.935 . . . . 50.0 110.253 -179.841 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 76.6 m -105.99 144.64 32.43 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.261 -0.9 . . . . 50.0 110.1 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.573 ' CD2' HD13 ' A' ' 37' ' ' ILE . 27.6 m-70 -135.48 158.99 73.27 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.259 -0.901 . . . . 50.0 110.315 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -70.15 172.59 12.74 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 O-C-N 124.002 1.527 . . . . 50.0 110.274 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.455 ' O ' ' HG3' ' A' ' 59' ' ' LYS . 7.5 t 54.74 -115.35 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.297 -0.877 . . . . 50.0 109.788 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . 0.441 ' CD1' HG13 ' A' ' 41' ' ' VAL . 39.4 p90 -137.88 156.31 48.04 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.774 -1.204 . . . . 50.0 109.94 179.641 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' CYS . . . . . 0.459 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 82.6 m -57.46 130.87 81.38 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.242 -0.911 . . . . 50.0 110.372 -179.737 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -71.72 -161.88 0.1 Allowed 'Trans proline' 0 C--N 1.305 -1.718 0 O-C-N 124.062 1.559 . . . . 50.0 110.73 179.777 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 19.1 ptp180 -76.35 -29.43 57.23 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.562 -0.711 . . . . 50.0 110.557 -179.584 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 62.7 mtp180 -69.88 -25.94 63.95 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.245 -0.91 . . . . 50.0 110.623 -179.544 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' TYR . . . . . 0.561 ' CD1' ' N ' ' A' ' 47' ' ' TYR . 11.6 m-85 -124.81 151.39 45.27 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.164 -0.96 . . . . 50.0 110.635 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 45.8 tttm -97.91 150.86 20.86 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.355 -0.841 . . . . 50.0 109.225 178.768 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.444 ' HA ' ' SG ' ' A' ' 43' ' ' CYS . 50.8 tt0 -93.54 95.38 9.21 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.983 -1.073 . . . . 50.0 110.42 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.499 HD12 ' CD ' ' A' ' 62' ' ' LYS . 97.3 mt -65.36 -31.24 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.297 -0.877 . . . . 50.0 110.068 179.807 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.433 ' C ' HG22 ' A' ' 52' ' ' THR . . . 168.77 -95.44 0.11 Allowed Glycine 0 N--CA 1.487 2.074 0 N-CA-C 109.534 -1.426 . . . . 50.0 109.534 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.433 HG22 ' C ' ' A' ' 51' ' ' GLY . 62.5 p -150.32 143.26 24.78 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.217 -1.166 . . . . 50.0 110.386 -179.824 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' CYS . . . . . 0.455 ' O ' ' O ' ' A' ' 29' ' ' VAL . 4.4 t -63.87 -40.95 97.76 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.237 -0.914 . . . . 50.0 109.844 179.74 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 157.84 -24.98 0.42 Allowed Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.07 -1.612 . . . . 50.0 109.07 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.501 ' CD1' ' HD2' ' A' ' 56' ' ' PRO . 16.9 tp -123.96 143.64 42.85 Favored Pre-proline 0 N--CA 1.489 1.517 0 O-C-N 121.5 -1.0 . . . . 50.0 109.596 179.773 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . 0.501 ' HD2' ' CD1' ' A' ' 55' ' ' LEU . 39.9 Cg_endo -66.48 -5.3 12.5 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 O-C-N 123.773 1.407 . . . . 50.0 110.827 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -74.65 -33.88 54.85 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.158 -1.577 . . . . 50.0 109.158 179.378 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.466 ' CG2' ' C ' ' A' ' 39' ' ' HIS . 4.8 m -135.53 162.74 31.82 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.231 -1.158 . . . . 50.0 110.211 179.692 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.455 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 43.5 mmtm -115.49 151.82 34.1 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.346 -0.846 . . . . 50.0 109.937 179.662 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.459 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 26.6 t -81.39 133.5 35.42 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.251 -0.905 . . . . 50.0 110.656 -179.525 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' CYS . . . . . 0.484 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 72.0 m -131.12 141.22 50.1 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.371 -0.831 . . . . 50.0 109.961 179.73 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . 0.499 ' CD ' HD12 ' A' ' 50' ' ' ILE . 81.1 tttt -131.93 144.35 50.78 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.174 -0.954 . . . . 50.0 110.309 -179.737 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . 0.466 ' HE2' ' OH ' ' A' ' 47' ' ' TYR . 96.2 mttt -77.0 151.17 81.75 Favored Pre-proline 0 N--CA 1.491 1.603 0 O-C-N 121.411 -0.806 . . . . 50.0 110.31 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo . . . . . 0 C--N 1.304 -1.766 0 O-C-N 123.94 1.495 . . . . 99.99 110.435 179.967 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.553 HG22 ' HB2' ' A' ' 32' ' ' LEU . 98.5 m . . . . . 0 N--CA 1.493 1.711 0 CA-C-O 121.095 0.474 . . . . 50.0 110.566 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' CYS . . . . . 0.447 ' HB2' ' O ' ' A' ' 30' ' ' THR . 93.3 m 56.22 22.44 6.14 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.215 -0.928 . . . . 50.0 110.311 -179.851 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.747 HD13 ' C ' ' A' ' 32' ' ' LEU . 3.4 tm? -75.35 -38.51 60.06 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.137 -0.977 . . . . 50.0 110.283 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 96.0 mttt -68.69 -41.64 78.88 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.303 -0.873 . . . . 50.0 110.209 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 94.9 p -69.77 -20.46 63.48 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.303 -0.873 . . . . 50.0 110.32 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 79.25 6.73 88.82 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.662 -1.375 . . . . 50.0 109.662 179.791 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ALA . . . . . 0.679 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -68.93 147.65 51.33 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.119 -1.224 . . . . 50.0 110.151 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.645 HD11 ' CE2' ' A' ' 47' ' ' TYR . 2.1 pt -93.45 151.77 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.148 -0.97 . . . . 50.0 110.063 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 86.3 m -91.27 142.57 27.57 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.244 -0.91 . . . . 50.0 110.372 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.514 ' CB ' ' SG ' ' A' ' 61' ' ' CYS . 54.4 t-80 -119.98 142.2 32.9 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.282 -0.886 . . . . 50.0 109.981 179.755 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.505 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 44.9 Cg_endo -71.52 155.85 58.87 Favored 'Trans proline' 0 C--N 1.305 -1.762 0 O-C-N 123.907 1.477 . . . . 50.0 110.857 -179.575 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.661 HG12 ' HD2' ' A' ' 42' ' ' PHE . 47.8 t 59.27 -93.87 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.449 -0.782 . . . . 50.0 110.679 179.658 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.661 ' HD2' HG12 ' A' ' 41' ' ' VAL . 21.4 p90 -139.14 161.43 37.42 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.84 -1.163 . . . . 50.0 110.62 -179.74 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' CYS . . . . . 0.51 ' CB ' ' HB2' ' A' ' 49' ' ' GLN . 0.8 OUTLIER -80.45 127.56 75.51 Favored Pre-proline 0 N--CA 1.492 1.663 0 O-C-N 121.398 -0.814 . . . . 50.0 109.958 179.822 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -72.43 -162.4 0.12 Allowed 'Trans proline' 0 C--N 1.306 -1.699 0 O-C-N 123.742 1.39 . . . . 50.0 110.445 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 6.5 mtt180 -81.25 -36.59 29.76 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.475 -0.766 . . . . 50.0 109.698 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 60.0 mtp180 -58.71 -27.59 65.0 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.554 -0.716 . . . . 50.0 109.942 179.674 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' TYR . . . . . 0.645 ' CE2' HD11 ' A' ' 37' ' ' ILE . 37.0 m-85 -120.84 138.72 53.91 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.337 -0.852 . . . . 50.0 110.294 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 88.5 mttt -95.14 124.3 39.1 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.202 -0.936 . . . . 50.0 109.837 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.51 ' HB2' ' CB ' ' A' ' 43' ' ' CYS . 41.8 tt0 -74.8 105.64 5.95 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.494 -0.754 . . . . 50.0 110.94 -179.162 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.5 mt -75.16 -28.52 20.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.198 -0.939 . . . . 50.0 109.628 179.361 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.545 ' C ' HG23 ' A' ' 52' ' ' THR . . . 176.76 -94.56 0.1 OUTLIER Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.368 -1.493 . . . . 50.0 109.368 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.545 HG23 ' C ' ' A' ' 51' ' ' GLY . 60.5 p -155.24 137.99 15.26 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.192 -1.181 . . . . 50.0 110.222 179.781 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' CYS . . . . . . . . . . . . . 18.5 t -54.12 -50.44 66.87 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.24 -0.913 . . . . 50.0 110.131 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 176.78 -45.26 0.11 Allowed Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.266 -1.534 . . . . 50.0 109.266 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.465 ' HB3' ' HD2' ' A' ' 56' ' ' PRO . 87.0 mt -110.82 164.9 13.78 Favored Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.288 -1.125 . . . . 50.0 109.973 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.465 ' HD2' ' HB3' ' A' ' 55' ' ' LEU . 45.6 Cg_endo -72.75 -3.03 12.8 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 O-C-N 123.88 1.463 . . . . 50.0 110.395 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -77.49 -43.5 15.37 Favored Glycine 0 N--CA 1.487 2.096 0 N-CA-C 109.491 -1.444 . . . . 50.0 109.491 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' THR . . . . . 0.407 HG23 ' C ' ' A' ' 39' ' ' HIS . 10.9 m -125.31 166.38 16.65 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.336 -1.097 . . . . 50.0 110.508 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.471 ' O ' ' N ' ' A' ' 39' ' ' HIS . 74.6 mmtt -123.21 148.6 45.66 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.336 -0.853 . . . . 50.0 109.902 179.857 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 13.2 t -73.52 127.93 34.08 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.145 -0.972 . . . . 50.0 110.376 -179.672 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' CYS . . . . . 0.679 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 28.3 m -128.02 154.17 45.94 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.29 -0.882 . . . . 50.0 109.994 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -132.99 138.68 46.93 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.157 -0.965 . . . . 50.0 110.249 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' LYS . . . . . 0.537 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 93.8 mttt . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.311 -0.868 . . . . 50.0 110.274 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 58.7 m . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 121.246 0.546 . . . . 50.0 109.919 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 31' ' ' CYS . . . . . 0.588 ' HB3' ' HB3' ' A' ' 36' ' ' ALA . 52.8 m -75.73 -6.24 49.61 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.35 -0.843 . . . . 50.0 110.691 -179.641 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 95.3 mt -57.35 -34.73 69.09 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.032 -1.043 . . . . 50.0 110.205 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 24.8 mttp -68.03 -37.33 81.23 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.389 -0.819 . . . . 50.0 110.153 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 95.0 p -77.49 -18.25 57.26 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.474 -0.766 . . . . 50.0 110.252 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 89.81 5.71 70.86 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.503 -1.439 . . . . 50.0 109.503 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ALA . . . . . 0.588 ' HB3' ' HB3' ' A' ' 31' ' ' CYS . . . -77.37 147.97 35.81 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.217 -1.167 . . . . 50.0 110.284 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.472 ' O ' ' N ' ' A' ' 61' ' ' CYS . 4.0 pt -95.44 152.72 3.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.225 -0.922 . . . . 50.0 109.858 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.458 ' HA ' ' O ' ' A' ' 59' ' ' LYS . 79.0 m -100.16 139.77 35.36 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.205 -0.934 . . . . 50.0 110.143 -179.766 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.53 ' N ' ' O ' ' A' ' 59' ' ' LYS . 59.2 t-80 -117.82 136.26 23.66 Favored Pre-proline 0 N--CA 1.492 1.663 0 O-C-N 121.345 -0.847 . . . . 50.0 110.007 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.478 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 47.7 Cg_endo -72.23 164.58 35.2 Favored 'Trans proline' 0 C--N 1.303 -1.827 0 O-C-N 123.929 1.489 . . . . 50.0 110.503 -179.792 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.724 HG12 ' HD2' ' A' ' 42' ' ' PHE . 44.2 t 60.73 -82.78 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.524 -0.735 . . . . 50.0 111.171 179.538 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.724 ' HD2' HG12 ' A' ' 41' ' ' VAL . 9.7 p90 -155.7 154.29 31.28 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.957 -1.09 . . . . 50.0 110.662 -179.43 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 1.7 t -77.43 130.92 72.92 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.257 -0.902 . . . . 50.0 109.784 179.534 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -70.96 -162.29 0.1 Allowed 'Trans proline' 0 C--N 1.304 -1.803 0 O-C-N 123.88 1.463 . . . . 50.0 110.549 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 18.3 mtm180 -84.83 -40.13 17.51 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 121.475 -0.766 . . . . 50.0 109.818 -179.856 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 57.9 ttm-85 -61.73 -15.95 45.17 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.457 -0.777 . . . . 50.0 109.965 179.67 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' TYR . . . . . 0.535 ' HB3' ' HB3' ' A' ' 61' ' ' CYS . 58.4 m-85 -123.99 134.33 53.49 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.316 -0.865 . . . . 50.0 110.507 -179.789 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -97.71 137.95 35.82 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.287 -0.883 . . . . 50.0 109.595 179.351 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.426 ' HA ' ' O ' ' A' ' 60' ' ' CYS . 36.3 tt0 -87.2 103.98 15.93 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.156 -0.965 . . . . 50.0 110.917 -179.308 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.654 HD11 ' HD2' ' A' ' 62' ' ' LYS . 96.5 mt -62.8 -29.07 46.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.301 -0.874 . . . . 50.0 109.733 179.472 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.508 ' C ' HG23 ' A' ' 52' ' ' THR . . . 171.19 -91.23 0.09 OUTLIER Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.476 -1.45 . . . . 50.0 109.476 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.508 HG23 ' C ' ' A' ' 51' ' ' GLY . 71.9 p -151.58 127.92 10.61 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.259 -1.142 . . . . 50.0 110.292 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' CYS . . . . . . . . . . . . . 15.6 t -49.82 -47.41 51.42 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.297 -0.877 . . . . 50.0 110.081 179.694 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.765 ' C ' HD12 ' A' ' 55' ' ' LEU . . . 168.77 -38.33 0.21 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 108.683 -1.767 . . . . 50.0 108.683 -179.77 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.784 HD12 ' N ' ' A' ' 55' ' ' LEU . 6.1 mp -119.79 158.1 50.64 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.475 -1.015 . . . . 50.0 109.752 179.604 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -70.8 -10.29 27.43 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 O-C-N 123.904 1.476 . . . . 50.0 110.286 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -67.87 -41.96 87.12 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.312 -1.515 . . . . 50.0 109.312 179.704 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' THR . . . . . 0.461 ' HA ' ' HA ' ' A' ' 40' ' ' PRO . 5.2 m -127.6 164.06 22.85 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.342 -1.093 . . . . 50.0 110.28 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.53 ' O ' ' N ' ' A' ' 39' ' ' HIS . 33.4 mmtp -118.75 152.6 35.88 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.318 -0.864 . . . . 50.0 109.741 179.654 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.426 ' O ' ' HA ' ' A' ' 49' ' ' GLN . 34.5 t -80.32 127.57 32.53 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.029 -1.045 . . . . 50.0 110.333 -179.793 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' CYS . . . . . 0.535 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 52.5 m -125.61 151.53 46.35 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.33 -0.856 . . . . 50.0 109.879 179.74 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.654 ' HD2' HD11 ' A' ' 50' ' ' ILE . 87.0 tttt -136.75 144.97 44.08 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.081 -1.012 . . . . 50.0 110.597 -179.775 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 50.8 mtmt . . . . . 0 N--CA 1.493 1.685 0 O-C-N 121.289 -0.882 . . . . 50.0 110.272 179.879 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.469 ' O ' ' HB2' ' A' ' 31' ' ' CYS . 74.5 m . . . . . 0 N--CA 1.492 1.644 0 CA-C-O 121.213 0.53 . . . . 50.0 110.392 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' CYS . . . . . 0.469 ' HB2' ' O ' ' A' ' 30' ' ' THR . 90.4 m 56.23 27.86 12.34 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.231 -0.918 . . . . 50.0 110.586 179.773 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 67.2 tp -76.95 -43.26 35.88 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.208 -0.933 . . . . 50.0 110.08 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -67.43 -34.58 77.52 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.277 -0.889 . . . . 50.0 110.117 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 81.0 p -71.98 -24.45 61.59 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.422 -0.799 . . . . 50.0 110.259 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 75.87 10.99 84.96 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.626 -1.389 . . . . 50.0 109.626 179.829 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ALA . . . . . 0.597 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -77.04 156.11 32.03 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.186 -1.185 . . . . 50.0 110.257 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.494 HD11 ' CE2' ' A' ' 47' ' ' TYR . 13.8 pt -93.96 167.22 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.285 -0.885 . . . . 50.0 110.147 179.864 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 96.6 m -108.2 148.35 30.06 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.293 -0.879 . . . . 50.0 109.951 179.749 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.589 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 60.9 t-80 -138.68 145.66 47.13 Favored Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.297 -0.877 . . . . 50.0 110.435 -179.649 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.589 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 43.5 Cg_endo -69.1 160.39 50.07 Favored 'Trans proline' 0 C--N 1.305 -1.727 0 O-C-N 124.012 1.532 . . . . 50.0 110.42 179.486 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.829 HG12 ' HD2' ' A' ' 42' ' ' PHE . 15.9 t 62.3 -97.27 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.437 -0.789 . . . . 50.0 110.312 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.829 ' HD2' HG12 ' A' ' 41' ' ' VAL . 35.4 p90 -150.18 154.4 37.94 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 120.728 -1.233 . . . . 50.0 110.07 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' CYS . . . . . 0.414 ' HB2' ' HB2' ' A' ' 49' ' ' GLN . 64.6 m -61.96 133.62 93.98 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.196 -0.94 . . . . 50.0 110.581 -179.63 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.414 ' HD2' ' HB2' ' A' ' 47' ' ' TYR . 43.4 Cg_endo -68.49 -161.33 0.06 OUTLIER 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 123.959 1.505 . . . . 50.0 110.474 179.709 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 62.5 ttt180 -77.25 -44.08 31.16 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.558 -0.713 . . . . 50.0 110.664 -179.527 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 51.5 mmm-85 -61.23 -31.42 71.21 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.233 -0.917 . . . . 50.0 110.422 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' TYR . . . . . 0.527 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 48.4 m-85 -105.73 149.38 26.47 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.273 -0.892 . . . . 50.0 110.491 -179.788 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -108.56 131.79 54.5 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.337 -0.852 . . . . 50.0 109.688 179.512 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.414 ' HB2' ' HB2' ' A' ' 43' ' ' CYS . 59.6 tt0 -82.81 101.43 10.94 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.327 -0.858 . . . . 50.0 110.702 -179.36 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.509 HD11 ' HD2' ' A' ' 62' ' ' LYS . 85.1 mt -70.36 -30.93 45.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.245 -0.909 . . . . 50.0 109.677 179.452 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 178.14 -99.05 0.12 Allowed Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.294 -1.522 . . . . 50.0 109.294 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 61.7 p -146.12 137.28 24.57 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.305 -1.115 . . . . 50.0 110.403 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' CYS . . . . . 0.446 ' HA ' ' HB2' ' A' ' 60' ' ' CYS . 17.2 t -51.95 -48.1 64.44 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.334 -0.854 . . . . 50.0 109.565 179.467 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 172.87 -30.4 0.1 Allowed Glycine 0 N--CA 1.489 2.193 0 N-CA-C 108.95 -1.66 . . . . 50.0 108.95 179.826 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 98.1 mt -124.44 159.63 56.7 Favored Pre-proline 0 N--CA 1.488 1.471 0 O-C-N 121.41 -1.053 . . . . 50.0 109.802 179.668 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -71.29 -9.81 26.03 Favored 'Trans proline' 0 C--N 1.304 -1.809 0 O-C-N 124.013 1.533 . . . . 50.0 110.537 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -73.57 -34.56 56.8 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.296 -1.521 . . . . 50.0 109.296 179.714 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' THR . . . . . 0.446 HG22 ' N ' ' A' ' 59' ' ' LYS . 25.6 m -131.6 168.42 17.73 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.302 -1.117 . . . . 50.0 109.976 179.789 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.446 ' N ' HG22 ' A' ' 58' ' ' THR . 33.6 mmtp -126.82 149.74 49.54 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.279 -0.888 . . . . 50.0 110.091 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.446 ' HB2' ' HA ' ' A' ' 53' ' ' CYS . 15.9 t -76.6 129.58 36.62 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.243 -0.911 . . . . 50.0 110.295 -179.633 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' CYS . . . . . 0.597 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 83.7 m -127.56 145.27 50.92 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.425 -0.797 . . . . 50.0 110.001 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.509 ' HD2' HD11 ' A' ' 50' ' ' ILE . 85.5 tttt -124.55 144.66 50.01 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.254 -0.904 . . . . 50.0 110.345 -179.814 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' LYS . . . . . 0.527 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 97.0 mttt . . . . . 0 N--CA 1.49 1.529 0 O-C-N 121.343 -0.848 . . . . 50.0 110.066 179.814 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 51.6 m . . . . . 0 N--CA 1.49 1.528 0 CA-C-O 121.258 0.552 . . . . 50.0 109.815 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 63.2 m -90.83 4.97 50.32 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.21 -0.931 . . . . 50.0 110.443 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 46.7 tp -66.68 -44.41 81.87 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.147 -0.97 . . . . 50.0 110.263 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -61.69 -39.03 90.02 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.382 -0.824 . . . . 50.0 110.384 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 87.7 p -71.32 -24.25 62.09 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.34 -0.85 . . . . 50.0 110.14 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 89.73 3.64 73.89 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.626 -1.389 . . . . 50.0 109.626 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -73.87 154.57 39.39 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.211 -1.17 . . . . 50.0 110.142 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.441 ' O ' HG13 ' A' ' 37' ' ' ILE . 3.9 pt -102.24 154.27 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.13 -0.981 . . . . 50.0 110.081 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.443 ' HA ' ' O ' ' A' ' 59' ' ' LYS . 93.0 m -98.1 138.48 35.33 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.235 -0.916 . . . . 50.0 110.208 179.873 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.49 ' N ' ' O ' ' A' ' 59' ' ' LYS . 58.6 t-80 -114.63 140.41 25.26 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.268 -0.895 . . . . 50.0 110.235 -179.8 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.5 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 44.1 Cg_endo -70.44 162.4 42.54 Favored 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 123.995 1.524 . . . . 50.0 110.272 179.84 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.779 HG12 ' HD2' ' A' ' 42' ' ' PHE . 18.3 t 62.96 -108.36 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.461 -0.775 . . . . 50.0 110.285 179.885 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.779 ' HD2' HG12 ' A' ' 41' ' ' VAL . 35.7 p90 -135.31 148.87 49.63 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.796 -1.19 . . . . 50.0 110.24 -179.842 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -68.5 131.03 91.73 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.265 -0.897 . . . . 50.0 110.204 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.432 ' HD2' ' HB2' ' A' ' 47' ' ' TYR . 46.6 Cg_endo -71.22 -163.03 0.12 Allowed 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 123.859 1.452 . . . . 50.0 110.415 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 32.3 mtt85 -80.57 -44.75 18.5 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.512 -0.743 . . . . 50.0 109.887 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 28.6 tpt180 -58.74 -24.46 61.62 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.53 -0.731 . . . . 50.0 110.152 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' TYR . . . . . 0.533 ' HB3' ' HB3' ' A' ' 61' ' ' CYS . 42.0 m-85 -114.98 135.8 53.83 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.255 -0.903 . . . . 50.0 110.266 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 88.3 mttt -105.01 147.97 27.25 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.204 -0.935 . . . . 50.0 109.945 179.751 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.506 ' HA ' ' O ' ' A' ' 60' ' ' CYS . 15.7 tt0 -87.31 106.78 18.16 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.215 -0.928 . . . . 50.0 110.788 -179.432 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.767 HD12 ' SG ' ' A' ' 60' ' ' CYS . 67.8 mt -63.39 -24.12 35.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.289 -0.882 . . . . 50.0 109.731 179.438 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.483 ' O ' ' CB ' ' A' ' 52' ' ' THR . . . 152.5 40.18 0.03 OUTLIER Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.284 -1.527 . . . . 50.0 109.284 -179.868 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.483 ' CB ' ' O ' ' A' ' 51' ' ' GLY . 0.2 OUTLIER 69.76 151.17 0.09 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.404 -1.056 . . . . 50.0 110.435 -179.925 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 53' ' ' CYS . . . . . 0.409 ' HA ' ' HB2' ' A' ' 60' ' ' CYS . 7.3 t -71.19 -41.99 69.59 Favored 'General case' 0 N--CA 1.492 1.629 0 CA-C-O 121.763 0.792 . . . . 50.0 109.964 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.877 ' C ' HD12 ' A' ' 55' ' ' LEU . . . 154.63 -26.03 0.66 Allowed Glycine 0 N--CA 1.49 2.244 0 N-CA-C 108.438 -1.865 . . . . 50.0 108.438 -179.746 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.877 HD12 ' C ' ' A' ' 54' ' ' GLY . 5.8 mp -124.72 158.1 63.54 Favored Pre-proline 0 N--CA 1.489 1.495 0 O-C-N 121.55 -0.97 . . . . 50.0 109.465 179.611 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -71.79 -8.46 23.1 Favored 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.886 1.466 . . . . 50.0 110.432 -179.765 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -71.33 -45.83 45.5 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.545 -1.422 . . . . 50.0 109.545 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' THR . . . . . 0.407 HG23 ' C ' ' A' ' 39' ' ' HIS . 7.2 m -128.89 166.01 19.94 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.136 -1.214 . . . . 50.0 110.434 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.49 ' O ' ' N ' ' A' ' 39' ' ' HIS . 33.5 mmtp -121.16 148.49 44.16 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.415 -0.803 . . . . 50.0 109.558 179.62 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.767 ' SG ' HD12 ' A' ' 50' ' ' ILE . 35.1 t -74.82 130.54 39.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.991 -1.068 . . . . 50.0 110.117 -179.741 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' CYS . . . . . 0.533 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 59.9 m -135.32 155.11 51.15 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.274 -0.891 . . . . 50.0 110.102 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.474 ' HB3' HD11 ' A' ' 50' ' ' ILE . 34.9 pttt -146.57 166.83 25.3 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.103 -0.998 . . . . 50.0 110.299 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 52.7 mtmt . . . . . 0 N--CA 1.492 1.643 0 O-C-N 121.278 -0.889 . . . . 50.0 110.255 -179.971 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 95.9 m . . . . . 0 N--CA 1.491 1.581 0 CA-C-O 121.23 0.538 . . . . 50.0 110.348 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 72.0 m -77.44 -12.05 59.91 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.907 . . . . 50.0 110.225 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.757 HD13 ' C ' ' A' ' 32' ' ' LEU . 3.4 tm? -57.68 -44.52 85.85 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.26 -0.9 . . . . 50.0 110.294 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -61.74 -38.01 86.36 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.312 -0.868 . . . . 50.0 110.149 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 69.5 m -72.53 -21.31 61.19 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.288 -0.882 . . . . 50.0 110.152 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 85.44 -3.18 87.57 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.633 -1.387 . . . . 50.0 109.633 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ALA . . . . . 0.736 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -77.47 159.49 29.35 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.14 -1.212 . . . . 50.0 110.19 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.475 ' O ' HG13 ' A' ' 37' ' ' ILE . 3.6 pt -108.22 151.15 10.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.288 -0.883 . . . . 50.0 110.118 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 85.4 m -88.78 141.29 28.63 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.198 -0.939 . . . . 50.0 109.964 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 50.5 t-80 -120.5 134.43 24.18 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.243 -0.911 . . . . 50.0 110.247 -179.77 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.494 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 44.0 Cg_endo -71.55 168.13 24.48 Favored 'Trans proline' 0 C--N 1.305 -1.724 0 O-C-N 124.001 1.527 . . . . 50.0 110.458 179.873 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.732 HG12 ' HD2' ' A' ' 42' ' ' PHE . 38.9 t 61.26 -92.51 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.383 -0.823 . . . . 50.0 110.69 179.806 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.732 ' HD2' HG12 ' A' ' 41' ' ' VAL . 16.2 p90 -148.58 148.69 30.45 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.967 -1.083 . . . . 50.0 110.379 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 1.8 t -73.47 128.74 86.76 Favored Pre-proline 0 N--CA 1.493 1.706 0 O-C-N 121.238 -0.914 . . . . 50.0 109.883 179.573 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -71.79 -162.6 0.12 Allowed 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.835 1.44 . . . . 50.0 110.568 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 6.7 ptp180 -90.51 -15.25 31.09 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.525 -0.734 . . . . 50.0 110.123 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 89.6 mtm180 -73.18 -31.23 64.09 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.186 -0.946 . . . . 50.0 110.166 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' TYR . . . . . 0.551 ' N ' ' CD1' ' A' ' 47' ' ' TYR . 6.9 m-85 -113.23 147.87 36.65 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.223 -0.923 . . . . 50.0 110.333 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 61.6 mttm -93.43 152.6 19.0 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.255 -0.903 . . . . 50.0 109.799 179.272 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 58.7 tt0 -91.59 97.47 11.06 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.068 -1.02 . . . . 50.0 110.615 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.443 HD11 ' HB2' ' A' ' 62' ' ' LYS . 86.7 mt -63.88 -32.65 57.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.312 -0.868 . . . . 50.0 109.701 179.512 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 166.17 -95.99 0.12 Allowed Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.408 -1.477 . . . . 50.0 109.408 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 21.7 p -145.24 129.07 17.32 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.329 -1.101 . . . . 50.0 110.193 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' CYS . . . . . 0.467 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 30.7 t -61.41 -47.9 83.65 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.15 -0.969 . . . . 50.0 109.654 179.577 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 129.68 1.89 5.41 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.491 -1.443 . . . . 50.0 109.491 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 92.0 mt -105.27 143.42 26.73 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.278 -1.13 . . . . 50.0 110.174 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -73.38 79.59 2.1 Favored 'Trans proline' 0 C--N 1.303 -1.821 0 O-C-N 124.062 1.559 . . . . 50.0 110.688 -179.82 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 139.17 -3.03 2.69 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.696 -1.24 . . . . 50.0 110.378 179.55 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' THR . . . . . 0.442 ' HA ' ' HA ' ' A' ' 40' ' ' PRO . 1.2 m -121.86 159.69 26.29 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.974 -1.309 . . . . 50.0 110.476 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 16.2 tppt? -129.59 123.81 32.25 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.355 -0.841 . . . . 50.0 109.895 179.584 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.467 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 34.2 t -53.92 128.99 32.4 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.177 -0.952 . . . . 50.0 110.375 -179.692 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' CYS . . . . . 0.736 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 62.3 m -128.84 146.41 50.94 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.222 -0.924 . . . . 50.0 110.076 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.482 ' O ' ' HA ' ' A' ' 47' ' ' TYR . 79.6 tttt -125.08 143.75 50.76 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.2 -0.937 . . . . 50.0 110.477 -179.678 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' LYS . . . . . 0.441 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 86.9 mttt . . . . . 0 N--CA 1.491 1.608 0 O-C-N 121.345 -0.847 . . . . 50.0 110.361 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.516 ' CG2' HD12 ' A' ' 32' ' ' LEU . 23.7 m . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 121.074 0.464 . . . . 50.0 110.372 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' CYS . . . . . 0.478 ' HB2' ' O ' ' A' ' 30' ' ' THR . 98.7 m 58.86 19.66 7.25 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.314 -0.866 . . . . 50.0 110.538 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.516 HD12 ' CG2' ' A' ' 30' ' ' THR . 93.5 mt -111.27 -15.83 13.53 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.258 -0.901 . . . . 50.0 109.896 179.605 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 63.8 mmtt -69.26 -39.71 78.26 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.309 -0.869 . . . . 50.0 110.18 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' SER . . . . . 0.474 ' HB3' ' NZ ' ' A' ' 62' ' ' LYS . 66.7 m -90.27 -9.88 46.3 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.357 -0.84 . . . . 50.0 110.031 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 87.13 7.8 76.46 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.509 -1.436 . . . . 50.0 109.509 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ALA . . . . . 0.912 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -69.21 140.1 54.56 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.326 -1.102 . . . . 50.0 110.265 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.906 HD11 ' NE2' ' A' ' 39' ' ' HIS . 3.8 pt -100.54 155.92 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.227 -0.92 . . . . 50.0 109.871 179.821 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 83.5 m -95.46 141.0 29.52 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.152 -0.967 . . . . 50.0 110.043 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.906 ' NE2' HD11 ' A' ' 37' ' ' ILE . 38.4 m-70 -117.9 161.93 31.86 Favored Pre-proline 0 N--CA 1.497 1.889 0 O-C-N 121.33 -0.856 . . . . 50.0 110.55 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.475 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 44.0 Cg_endo -72.22 156.22 55.48 Favored 'Trans proline' 0 C--N 1.304 -1.766 0 O-C-N 124.024 1.539 . . . . 50.0 110.224 179.754 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.786 HG12 ' HD2' ' A' ' 42' ' ' PHE . 15.4 t 61.5 -108.53 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.246 -0.909 . . . . 50.0 110.064 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.786 ' HD2' HG12 ' A' ' 41' ' ' VAL . 44.0 p90 -135.16 164.79 26.88 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.685 -1.26 . . . . 50.0 110.225 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' CYS . . . . . 0.47 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 70.9 m -70.72 130.88 88.22 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.172 -0.955 . . . . 50.0 110.668 -179.547 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -71.42 -161.44 0.09 OUTLIER 'Trans proline' 0 C--N 1.305 -1.742 0 O-C-N 123.851 1.448 . . . . 50.0 110.391 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 15.3 ptm180 -81.88 -24.54 35.68 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.492 -0.755 . . . . 50.0 110.786 -179.483 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 79.5 mtp180 -71.7 -16.29 62.23 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.046 -1.034 . . . . 50.0 110.594 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' TYR . . . . . 0.607 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 36.2 m-85 -129.81 153.06 48.63 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.088 -1.008 . . . . 50.0 110.878 -179.698 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.418 ' N ' ' O ' ' A' ' 62' ' ' LYS . 98.5 mttt -99.92 141.86 32.18 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.37 -0.831 . . . . 50.0 109.263 179.11 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 8.0 tt0 -84.44 98.82 10.29 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.162 -0.962 . . . . 50.0 110.955 -179.169 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.583 HD11 ' HB2' ' A' ' 62' ' ' LYS . 95.3 mt -62.98 -32.06 54.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.166 -0.958 . . . . 50.0 109.627 179.303 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.508 ' C ' HG23 ' A' ' 52' ' ' THR . . . 165.83 -92.09 0.1 Allowed Glycine 0 N--CA 1.487 2.044 0 N-CA-C 109.426 -1.47 . . . . 50.0 109.426 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.508 HG23 ' C ' ' A' ' 51' ' ' GLY . 20.9 p -152.02 134.19 15.09 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.319 -1.107 . . . . 50.0 110.152 -179.914 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' CYS . . . . . 0.546 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 5.0 t -59.14 -45.64 90.43 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.277 -0.889 . . . . 50.0 110.207 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 163.97 -41.53 0.32 Allowed Glycine 0 N--CA 1.489 2.233 0 N-CA-C 108.993 -1.643 . . . . 50.0 108.993 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 76.5 mt -118.43 158.03 47.92 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.511 -0.993 . . . . 50.0 109.928 179.747 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -71.82 -4.92 16.02 Favored 'Trans proline' 0 C--N 1.304 -1.807 0 O-C-N 123.922 1.486 . . . . 50.0 110.35 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -70.89 -30.28 68.25 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.371 -1.492 . . . . 50.0 109.371 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 5.8 m -139.11 163.56 32.08 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.284 -1.127 . . . . 50.0 110.393 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 54.8 tptt -119.31 128.18 53.88 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.405 -0.809 . . . . 50.0 109.42 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.546 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 41.1 t -63.71 131.54 48.23 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.181 -0.949 . . . . 50.0 110.431 -179.282 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' CYS . . . . . 0.912 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 74.8 m -126.2 156.81 39.61 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.467 -0.771 . . . . 50.0 110.181 -179.675 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.583 ' HB2' HD11 ' A' ' 50' ' ' ILE . 57.3 tttp -137.51 138.07 39.29 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.146 -0.971 . . . . 50.0 110.343 -179.801 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' LYS . . . . . 0.607 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 56.0 mtpt . . . . . 0 N--CA 1.491 1.625 0 O-C-N 121.122 -0.987 . . . . 50.0 110.043 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.459 HG22 ' HB2' ' A' ' 32' ' ' LEU . 72.9 m . . . . . 0 N--CA 1.492 1.65 0 CA-C-O 121.203 0.525 . . . . 50.0 109.899 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 52.1 m -79.4 -3.43 46.39 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.158 -0.963 . . . . 50.0 110.425 -179.856 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.459 ' HB2' HG22 ' A' ' 30' ' ' THR . 70.4 mt -56.91 -41.56 78.37 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.129 -0.982 . . . . 50.0 110.063 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 30.3 mmtp -67.52 -38.34 84.09 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.393 -0.817 . . . . 50.0 110.359 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 41.4 t -68.36 -32.64 72.87 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.29 -0.881 . . . . 50.0 110.047 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.78 -5.68 56.76 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.711 -1.356 . . . . 50.0 109.711 179.714 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ALA . . . . . 0.647 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -74.29 130.39 39.62 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.181 -1.188 . . . . 50.0 110.206 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 7.0 pt -73.34 162.73 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.209 -0.932 . . . . 50.0 110.22 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 71.9 m -106.44 152.29 23.82 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.273 -0.892 . . . . 50.0 110.093 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.572 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 60.4 t-80 -138.39 145.23 46.04 Favored Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.315 -0.865 . . . . 50.0 109.892 -179.734 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.572 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 41.8 Cg_endo -67.7 161.01 45.61 Favored 'Trans proline' 0 C--N 1.302 -1.912 0 O-C-N 123.898 1.473 . . . . 50.0 110.189 179.728 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.821 HG12 ' HD2' ' A' ' 42' ' ' PHE . 17.5 t 62.43 -104.59 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.42 -0.8 . . . . 50.0 110.035 -179.716 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.821 ' HD2' HG12 ' A' ' 41' ' ' VAL . 36.7 p90 -142.72 155.93 44.95 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.642 -1.286 . . . . 50.0 110.126 179.834 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' CYS . . . . . 0.448 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 75.6 m -65.06 132.45 95.44 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.286 -0.883 . . . . 50.0 110.262 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -69.1 -161.64 0.07 OUTLIER 'Trans proline' 0 C--N 1.304 -1.783 0 O-C-N 123.927 1.488 . . . . 50.0 110.802 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 14.3 mtt180 -78.46 -39.49 38.4 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.461 -0.775 . . . . 50.0 109.907 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 95.4 mtt180 -60.02 -34.27 73.14 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.44 -0.787 . . . . 50.0 110.346 -179.727 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' TYR . . . . . 0.566 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 18.7 m-85 -110.71 144.01 40.31 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.295 -0.878 . . . . 50.0 110.899 -179.558 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 64.6 mttm -98.06 138.26 35.63 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.39 -0.819 . . . . 50.0 109.183 178.899 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 39.9 tt0 -80.68 101.88 9.53 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.053 -1.029 . . . . 50.0 110.686 -179.402 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 74.4 mt -65.46 -31.26 53.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.222 -0.924 . . . . 50.0 109.618 179.366 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 165.09 -94.13 0.11 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.291 -1.523 . . . . 50.0 109.291 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 65.3 p -143.3 136.21 27.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.311 -1.111 . . . . 50.0 110.284 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' CYS . . . . . 0.525 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 17.5 t -58.07 -49.4 77.05 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.256 -0.903 . . . . 50.0 109.793 179.67 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 176.45 -32.17 0.08 OUTLIER Glycine 0 N--CA 1.49 2.265 0 N-CA-C 108.791 -1.723 . . . . 50.0 108.791 -179.854 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 80.6 mt -127.71 160.03 63.05 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.504 -0.997 . . . . 50.0 109.545 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -72.19 -2.14 11.17 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 123.88 1.463 . . . . 50.0 110.36 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -74.75 -38.88 41.38 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.545 -1.422 . . . . 50.0 109.545 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' THR . . . . . 0.439 HG22 ' N ' ' A' ' 59' ' ' LYS . 21.2 m -126.7 168.58 14.17 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.199 -1.177 . . . . 50.0 110.367 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.439 ' N ' HG22 ' A' ' 58' ' ' THR . 14.5 tppt? -119.43 136.29 54.37 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.322 -0.861 . . . . 50.0 109.982 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.525 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 20.4 t -69.01 128.69 37.59 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.262 -0.899 . . . . 50.0 110.484 -179.739 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' CYS . . . . . 0.647 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 74.2 m -125.42 153.13 43.92 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.241 -0.912 . . . . 50.0 109.748 179.687 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.474 ' O ' ' HA ' ' A' ' 47' ' ' TYR . 83.6 tttt -130.08 144.33 51.28 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.172 -0.955 . . . . 50.0 110.487 -179.616 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' LYS . . . . . 0.566 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 97.7 mttt . . . . . 0 N--CA 1.49 1.527 0 O-C-N 121.301 -0.875 . . . . 50.0 110.047 179.718 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 88.7 m . . . . . 0 N--CA 1.491 1.609 0 CA-C-O 121.167 0.508 . . . . 50.0 110.137 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 31' ' ' CYS . . . . . 0.432 ' SG ' ' HA ' ' A' ' 53' ' ' CYS . 79.3 m -77.15 -13.12 60.0 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.255 -0.903 . . . . 50.0 110.214 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 46.1 tp -57.32 -40.79 78.67 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.263 -0.898 . . . . 50.0 110.488 -179.717 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 60.3 mmtt -68.34 -41.25 81.03 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.265 -0.897 . . . . 50.0 110.297 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 56.9 m -70.86 -29.59 65.75 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.224 -0.923 . . . . 50.0 110.19 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 87.07 8.16 76.0 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.552 -1.419 . . . . 50.0 109.552 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -72.35 176.84 4.96 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.235 -1.156 . . . . 50.0 110.287 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.703 HD12 ' NE2' ' A' ' 39' ' ' HIS . 2.9 pt -115.83 153.53 17.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.316 -0.865 . . . . 50.0 109.984 179.663 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 83.0 m -112.52 153.31 27.67 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.167 -0.958 . . . . 50.0 109.969 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.703 ' NE2' HD12 ' A' ' 37' ' ' ILE . 31.6 m-70 -140.33 162.58 48.92 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 121.315 -0.865 . . . . 50.0 110.282 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -70.81 166.5 28.69 Favored 'Trans proline' 0 C--N 1.305 -1.759 0 O-C-N 124.037 1.546 . . . . 50.0 110.847 -179.659 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.793 HG12 ' HD2' ' A' ' 42' ' ' PHE . 14.4 t 54.07 -108.43 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.393 -0.817 . . . . 50.0 110.167 179.811 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.793 ' HD2' HG12 ' A' ' 41' ' ' VAL . 29.3 p90 -141.36 151.37 43.47 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.817 -1.177 . . . . 50.0 110.129 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' CYS . . . . . 0.475 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 72.5 m -50.65 130.36 27.33 Favored Pre-proline 0 N--CA 1.489 1.517 0 O-C-N 121.155 -0.965 . . . . 50.0 109.813 179.771 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.449 ' HD2' ' HB2' ' A' ' 47' ' ' TYR . 43.6 Cg_endo -70.16 -162.78 0.1 OUTLIER 'Trans proline' 0 C--N 1.304 -1.783 0 O-C-N 123.954 1.502 . . . . 50.0 110.304 179.792 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 28.8 mtp180 -74.68 -42.79 57.77 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.417 -0.802 . . . . 50.0 110.04 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 79.0 mtp180 -61.96 -14.87 39.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.486 -0.759 . . . . 50.0 110.37 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' TYR . . . . . 0.517 ' HB3' ' HB3' ' A' ' 61' ' ' CYS . 72.6 m-85 -128.28 164.19 23.13 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.232 -0.918 . . . . 50.0 110.683 -179.68 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -127.79 154.79 45.0 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.349 -0.845 . . . . 50.0 109.958 179.787 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -87.93 115.46 25.41 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.181 -0.95 . . . . 50.0 110.06 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.436 HD13 ' HB2' ' A' ' 62' ' ' LYS . 22.6 pt -110.41 15.91 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.282 -0.886 . . . . 50.0 110.459 -179.826 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.508 ' O ' ' HB3' ' A' ' 60' ' ' CYS . . . 133.24 114.89 1.57 Allowed Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.403 -1.479 . . . . 50.0 109.403 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.47 ' C ' ' O ' ' A' ' 51' ' ' GLY . 75.9 p -34.65 134.05 0.24 Allowed 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.771 -0.841 . . . . 50.0 110.965 -179.841 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' CYS . . . . . 0.526 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 4.4 t -51.67 -42.03 61.84 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.452 -0.78 . . . . 50.0 110.34 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 163.36 -27.52 0.23 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.062 -1.615 . . . . 50.0 109.062 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 97.0 mt -122.45 152.9 62.0 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.358 -1.084 . . . . 50.0 109.856 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.44 -16.25 27.6 Favored 'Trans proline' 0 C--N 1.303 -1.824 0 O-C-N 123.886 1.466 . . . . 50.0 110.416 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -69.02 -32.71 73.37 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.389 -1.484 . . . . 50.0 109.389 179.83 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 8.6 m -128.74 168.12 16.29 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.287 -1.125 . . . . 50.0 110.198 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.49 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 75.1 mmtt -130.91 141.96 50.33 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.365 -0.835 . . . . 50.0 109.767 179.688 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.526 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 7.4 t -73.35 139.51 46.04 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.127 -0.983 . . . . 50.0 109.98 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' CYS . . . . . 0.517 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 97.8 m -131.89 144.47 50.89 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.378 -0.826 . . . . 50.0 109.94 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.436 ' HB2' HD13 ' A' ' 50' ' ' ILE . 54.7 tttm -127.81 140.36 52.08 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.089 -1.007 . . . . 50.0 110.31 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' LYS . . . . . 0.445 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 93.3 mttt . . . . . 0 N--CA 1.49 1.538 0 O-C-N 121.219 -0.926 . . . . 50.0 110.09 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.444 HG22 ' HB2' ' A' ' 32' ' ' LEU . 36.4 m . . . . . 0 N--CA 1.491 1.6 0 CA-C-O 121.211 0.529 . . . . 50.0 110.098 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 65.9 m -84.71 0.35 50.78 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.188 -0.945 . . . . 50.0 110.317 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.519 HD22 ' N ' ' A' ' 32' ' ' LEU . 4.2 mm? -65.82 -45.25 82.99 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.209 -0.932 . . . . 50.0 110.179 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -64.53 -36.16 83.3 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.409 -0.807 . . . . 50.0 110.181 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 95.2 p -69.48 -20.26 63.74 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.374 -0.829 . . . . 50.0 110.299 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 89.7 0.35 78.86 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.492 -1.443 . . . . 50.0 109.492 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -77.98 154.45 31.53 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.148 -1.207 . . . . 50.0 110.128 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.487 ' O ' ' O ' ' A' ' 61' ' ' CYS . 1.1 pt -99.72 157.22 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.285 -0.884 . . . . 50.0 109.875 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 70.9 m -107.06 143.7 34.79 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.012 -1.055 . . . . 50.0 110.121 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.601 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 14.8 t-80 -108.2 145.92 32.49 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.269 -0.894 . . . . 50.0 109.851 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.601 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 42.4 Cg_endo -68.03 -23.92 39.71 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 O-C-N 123.847 1.446 . . . . 50.0 110.878 -179.674 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.646 HG12 ' HD2' ' A' ' 42' ' ' PHE . 66.3 t -117.91 -88.77 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.087 -1.008 . . . . 50.0 110.527 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.646 ' HD2' HG12 ' A' ' 41' ' ' VAL . 13.4 p90 -140.02 151.31 45.35 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.111 -0.993 . . . . 50.0 110.148 -179.765 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' CYS . . . . . 0.464 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 75.8 m -61.95 123.81 79.19 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.127 -0.983 . . . . 50.0 109.937 179.782 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.479 ' HD2' ' HB2' ' A' ' 47' ' ' TYR . 45.1 Cg_endo -69.95 -163.04 0.1 Allowed 'Trans proline' 0 C--N 1.304 -1.769 0 O-C-N 123.975 1.513 . . . . 50.0 110.732 179.812 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 65.2 ttt180 -75.02 -42.29 57.66 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.475 -0.766 . . . . 50.0 110.419 -179.74 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 86.4 mmt-85 -62.19 -29.07 70.11 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.366 -0.834 . . . . 50.0 110.221 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' TYR . . . . . 0.592 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 16.6 m-85 -113.35 159.26 19.6 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.178 -0.952 . . . . 50.0 110.717 -179.732 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 13.5 ptmm? -120.5 145.61 47.11 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.36 -0.838 . . . . 50.0 109.462 179.116 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 63.3 tt0 -90.09 103.49 16.15 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.124 -0.985 . . . . 50.0 110.714 -179.53 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.607 HD11 ' HD2' ' A' ' 62' ' ' LYS . 90.7 mt -68.17 -29.45 44.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.207 -0.933 . . . . 50.0 109.623 179.438 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 172.31 -95.31 0.11 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.217 -1.553 . . . . 50.0 109.217 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 70.7 p -144.17 134.19 24.07 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.209 -1.171 . . . . 50.0 110.309 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' CYS . . . . . 0.53 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 16.5 t -54.26 -43.79 71.28 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.134 -0.979 . . . . 50.0 109.669 179.571 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 152.65 -24.64 0.84 Allowed Glycine 0 N--CA 1.49 2.253 0 N-CA-C 108.637 -1.785 . . . . 50.0 108.637 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.465 ' CD1' ' HD2' ' A' ' 56' ' ' PRO . 16.7 tp -121.74 142.58 36.3 Favored Pre-proline 0 C--N 1.303 -1.449 0 O-C-N 121.505 -0.997 . . . . 50.0 109.374 179.594 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.465 ' HD2' ' CD1' ' A' ' 55' ' ' LEU . 41.3 Cg_endo -67.37 -5.27 13.52 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 123.794 1.418 . . . . 50.0 110.465 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -80.14 -27.63 52.01 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.333 -1.507 . . . . 50.0 109.333 179.483 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' THR . . . . . 0.479 ' CG2' ' O ' ' A' ' 39' ' ' HIS . 3.4 m -137.33 160.68 38.37 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.247 -1.149 . . . . 50.0 110.433 179.908 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.464 ' O ' ' N ' ' A' ' 39' ' ' HIS . 73.4 mmtt -113.31 155.41 25.2 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.527 -0.733 . . . . 50.0 109.538 179.425 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.53 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 37.3 t -85.8 130.88 34.43 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.185 -0.947 . . . . 50.0 110.897 -179.24 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' CYS . . . . . 0.495 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 71.3 m -134.06 128.95 35.31 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.425 -0.797 . . . . 50.0 109.301 179.542 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.607 ' HD2' HD11 ' A' ' 50' ' ' ILE . 84.8 tttt -109.48 147.74 32.38 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.003 -1.06 . . . . 50.0 111.148 -179.154 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' LYS . . . . . 0.592 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 51.3 mtmt . . . . . 0 N--CA 1.49 1.532 0 O-C-N 121.365 -0.834 . . . . 50.0 109.663 179.317 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 99.8 m . . . . . 0 N--CA 1.492 1.653 0 CA-C-O 121.171 0.51 . . . . 50.0 110.345 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 65.1 m -82.1 -6.42 59.16 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.19 -0.944 . . . . 50.0 109.995 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 60.1 tp -57.99 -46.48 85.15 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.329 -0.857 . . . . 50.0 110.189 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -64.83 -34.52 78.55 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.393 -0.817 . . . . 50.0 110.21 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 65.1 m -69.67 -31.94 70.29 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.277 -0.889 . . . . 50.0 110.3 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.15 5.21 62.43 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.698 -1.361 . . . . 50.0 109.698 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ALA . . . . . 0.706 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -78.41 173.05 12.75 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.189 -1.183 . . . . 50.0 110.326 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.873 HD12 ' NE2' ' A' ' 39' ' ' HIS . 7.1 pt -114.73 152.25 16.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.305 -0.872 . . . . 50.0 109.925 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 77.1 m -107.18 142.76 36.38 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.326 -0.859 . . . . 50.0 110.156 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.873 ' NE2' HD12 ' A' ' 37' ' ' ILE . 23.6 m-70 -134.04 157.4 77.76 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.258 -0.901 . . . . 50.0 110.12 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.476 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 45.8 Cg_endo -72.18 165.03 33.82 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 O-C-N 124.096 1.577 . . . . 50.0 110.931 -179.42 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.835 HG12 ' HD2' ' A' ' 42' ' ' PHE . 18.6 t 61.02 -100.73 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.453 -0.78 . . . . 50.0 110.26 179.689 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.835 ' HD2' HG12 ' A' ' 41' ' ' VAL . 35.4 p90 -145.64 157.55 43.95 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.757 -1.214 . . . . 50.0 110.467 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' CYS . . . . . 0.426 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 76.5 m -68.98 131.24 90.97 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.324 -0.86 . . . . 50.0 110.089 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -69.45 -160.05 0.06 OUTLIER 'Trans proline' 0 C--N 1.305 -1.75 0 O-C-N 123.908 1.478 . . . . 50.0 110.945 -179.709 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 31.7 mtt180 -80.85 -41.22 23.54 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.537 -0.727 . . . . 50.0 109.884 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 82.7 mmt-85 -55.82 -25.46 41.75 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.466 -0.771 . . . . 50.0 109.97 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' TYR . . . . . 0.531 ' N ' ' CD1' ' A' ' 47' ' ' TYR . 18.3 m-85 -125.82 161.61 27.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.285 -0.884 . . . . 50.0 110.399 179.722 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.421 ' N ' ' O ' ' A' ' 62' ' ' LYS . 88.8 mttt -116.43 146.12 42.76 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.443 -0.785 . . . . 50.0 109.021 178.801 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.425 ' HA ' ' O ' ' A' ' 60' ' ' CYS . 45.4 tt0 -90.23 104.02 16.64 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.96 -1.087 . . . . 50.0 111.215 -178.938 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.673 HD11 ' HD2' ' A' ' 62' ' ' LYS . 80.2 mt -64.81 -32.54 58.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.276 -0.89 . . . . 50.0 109.136 178.857 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 168.63 -96.07 0.12 Allowed Glycine 0 N--CA 1.488 2.108 0 N-CA-C 109.469 -1.452 . . . . 50.0 109.469 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 74.3 p -143.22 127.77 17.99 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.25 -1.147 . . . . 50.0 110.29 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' CYS . . . . . . . . . . . . . 4.4 t -50.44 -44.76 55.55 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.225 -0.922 . . . . 50.0 109.848 179.721 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 176.71 -33.23 0.08 OUTLIER Glycine 0 N--CA 1.49 2.288 0 N-CA-C 108.994 -1.642 . . . . 50.0 108.994 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 97.5 mt -127.21 161.36 54.72 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.455 -1.027 . . . . 50.0 109.77 179.651 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -72.61 -5.31 16.94 Favored 'Trans proline' 0 C--N 1.304 -1.774 0 O-C-N 123.912 1.48 . . . . 50.0 110.462 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -71.45 -34.68 63.46 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.596 -1.402 . . . . 50.0 109.596 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' THR . . . . . 0.427 HG23 ' C ' ' A' ' 39' ' ' HIS . 11.5 m -132.88 165.64 24.17 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.312 -1.111 . . . . 50.0 110.149 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.479 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 75.3 mmtt -122.31 135.46 54.73 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.38 -0.825 . . . . 50.0 109.675 179.563 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.426 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 39.4 t -68.98 133.73 48.55 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.261 -0.9 . . . . 50.0 110.426 -179.432 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' CYS . . . . . 0.706 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 71.2 m -123.13 153.58 39.79 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.355 -0.841 . . . . 50.0 110.023 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.673 ' HD2' HD11 ' A' ' 50' ' ' ILE . 65.4 tttm -139.78 147.68 41.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.068 -1.02 . . . . 50.0 110.51 -179.721 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 97.4 mttt . . . . . 0 N--CA 1.491 1.618 0 O-C-N 121.259 -0.9 . . . . 50.0 110.207 179.844 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.411 HG22 ' HB3' ' A' ' 32' ' ' LEU . 95.8 m . . . . . 0 N--CA 1.491 1.581 0 CA-C-O 121.259 0.552 . . . . 50.0 110.229 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' CYS . . . . . 0.463 ' SG ' ' HA ' ' A' ' 53' ' ' CYS . 72.1 m -65.67 -16.83 64.12 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.265 -0.897 . . . . 50.0 110.184 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.411 ' HB3' HG22 ' A' ' 30' ' ' THR . 9.9 tp -61.21 -45.98 92.33 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.282 -0.886 . . . . 50.0 110.082 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 67.5 mttm -63.12 -35.04 78.94 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.393 -0.817 . . . . 50.0 110.065 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 31.6 t -70.05 -24.3 63.24 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.361 -0.837 . . . . 50.0 110.204 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.03 9.9 47.33 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.604 -1.398 . . . . 50.0 109.604 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ALA . . . . . 0.474 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -106.78 151.45 25.15 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.196 -1.179 . . . . 50.0 110.172 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.509 HG12 ' CE2' ' A' ' 47' ' ' TYR . 6.6 pt -100.7 151.86 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.347 -0.845 . . . . 50.0 110.26 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 87.0 m -92.75 148.15 22.28 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.301 -0.874 . . . . 50.0 109.964 179.781 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.612 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 53.0 t-80 -135.42 147.05 60.29 Favored Pre-proline 0 N--CA 1.495 1.783 0 O-C-N 121.247 -0.908 . . . . 50.0 110.045 -179.488 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.612 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 43.5 Cg_endo -69.89 160.47 49.53 Favored 'Trans proline' 0 C--N 1.308 -1.597 0 O-C-N 123.773 1.407 . . . . 50.0 110.59 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.835 HG12 ' HD2' ' A' ' 42' ' ' PHE . 21.6 t 61.57 -87.54 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.427 -0.796 . . . . 50.0 110.655 179.749 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.835 ' HD2' HG12 ' A' ' 41' ' ' VAL . 25.8 p90 -155.42 164.89 38.11 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 120.845 -1.159 . . . . 50.0 110.333 179.872 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' CYS . . . . . 0.451 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 85.3 m -73.87 131.7 81.27 Favored Pre-proline 0 N--CA 1.496 1.834 0 O-C-N 121.239 -0.913 . . . . 50.0 110.601 -179.566 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -71.02 -162.18 0.1 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 O-C-N 123.9 1.474 . . . . 50.0 110.787 -179.812 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 19.4 ptp180 -80.11 -20.96 43.83 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.536 -0.727 . . . . 50.0 110.413 -179.758 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -76.73 -26.13 54.29 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.261 -0.899 . . . . 50.0 110.013 179.821 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' TYR . . . . . 0.513 ' N ' ' CD1' ' A' ' 47' ' ' TYR . 15.5 m-85 -124.21 158.76 31.67 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.308 -0.87 . . . . 50.0 110.6 -179.813 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.416 ' O ' ' HA ' ' A' ' 61' ' ' CYS . 54.0 tptt -111.89 156.03 22.71 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.438 -0.788 . . . . 50.0 109.151 178.849 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.472 ' HG3' ' HG3' ' A' ' 59' ' ' LYS . 32.7 tt0 -95.25 100.75 12.49 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.923 -1.11 . . . . 50.0 110.65 -179.546 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.537 HD11 ' CD ' ' A' ' 62' ' ' LYS . 66.3 mt -66.92 -31.02 51.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.284 -0.885 . . . . 50.0 109.783 179.443 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 172.67 -97.77 0.12 Allowed Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.55 -1.42 . . . . 50.0 109.55 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 64.9 p -143.36 133.15 23.91 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.205 -1.173 . . . . 50.0 110.44 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' CYS . . . . . 0.535 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 13.8 t -55.01 -45.05 75.09 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.315 -0.865 . . . . 50.0 109.67 179.57 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 167.66 -35.73 0.21 Allowed Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.383 -1.887 . . . . 50.0 108.383 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 66.4 mt -122.38 157.02 59.97 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.542 -0.975 . . . . 50.0 109.491 179.488 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -72.48 -6.5 19.17 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 123.852 1.448 . . . . 50.0 110.641 -179.79 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -71.52 -35.9 62.77 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.495 -1.442 . . . . 50.0 109.495 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 6.2 m -128.59 167.92 16.46 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.323 -1.104 . . . . 50.0 110.183 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.472 ' HG3' ' HG3' ' A' ' 49' ' ' GLN . 16.3 tppt? -124.41 133.68 53.32 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.266 -0.896 . . . . 50.0 110.173 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.535 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 35.3 t -63.06 133.83 55.13 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.29 -0.881 . . . . 50.0 110.527 -179.823 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' CYS . . . . . 0.504 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 74.7 m -133.15 138.65 46.7 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.281 -0.887 . . . . 50.0 110.084 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.537 ' CD ' HD11 ' A' ' 50' ' ' ILE . 87.5 tttt -135.65 144.45 46.05 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.199 -0.938 . . . . 50.0 110.136 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 97.6 mttt . . . . . 0 N--CA 1.491 1.617 0 O-C-N 121.124 -0.985 . . . . 50.0 109.933 179.965 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.49 HG22 ' HB2' ' A' ' 32' ' ' LEU . 26.1 m . . . . . 0 N--CA 1.493 1.679 0 CA-C-O 121.265 0.555 . . . . 50.0 110.054 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 93.3 m -76.79 -4.54 44.02 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.264 -0.898 . . . . 50.0 110.437 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.49 ' HB2' HG22 ' A' ' 30' ' ' THR . 18.9 mt -58.91 -45.19 90.92 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.139 -0.975 . . . . 50.0 110.07 179.858 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -66.71 -34.98 79.05 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.368 -0.833 . . . . 50.0 110.223 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 46.6 t -67.58 -25.08 65.61 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.365 -0.834 . . . . 50.0 110.192 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.77 -14.22 60.46 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.707 -1.357 . . . . 50.0 109.707 179.71 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ALA . . . . . 0.469 ' HB2' ' HG3' ' A' ' 62' ' ' LYS . . . -70.31 170.58 11.5 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.143 -1.21 . . . . 50.0 110.255 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.787 HD12 ' NE2' ' A' ' 39' ' ' HIS . 14.7 pt -115.38 163.05 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.346 -0.846 . . . . 50.0 109.748 179.464 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 74.8 m -109.74 140.7 43.33 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.156 -0.965 . . . . 50.0 110.046 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.787 ' NE2' HD12 ' A' ' 37' ' ' ILE . 17.2 m-70 -134.34 153.92 79.6 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.198 -0.939 . . . . 50.0 110.115 179.892 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.475 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 45.1 Cg_endo -70.54 162.79 41.19 Favored 'Trans proline' 0 C--N 1.305 -1.743 0 O-C-N 124.029 1.541 . . . . 50.0 111.262 -179.178 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.764 HG12 ' HD2' ' A' ' 42' ' ' PHE . 18.9 t 62.11 -105.18 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.578 -0.701 . . . . 50.0 110.607 179.546 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.764 ' HD2' HG12 ' A' ' 41' ' ' VAL . 25.8 p90 -140.01 157.27 45.94 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.863 -1.148 . . . . 50.0 110.359 -179.688 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' CYS . . . . . 0.465 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 83.8 m -67.83 129.46 93.26 Favored Pre-proline 0 N--CA 1.492 1.626 0 O-C-N 121.181 -0.95 . . . . 50.0 109.829 179.599 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -67.6 -162.94 0.08 OUTLIER 'Trans proline' 0 C--N 1.303 -1.848 0 O-C-N 123.881 1.464 . . . . 50.0 110.846 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 16.2 ptm180 -78.33 -32.26 49.12 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.467 -0.77 . . . . 50.0 110.274 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.439 ' HG2' ' CE1' ' A' ' 47' ' ' TYR . 55.6 ttm-85 -68.3 -25.73 65.29 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.265 -0.897 . . . . 50.0 109.902 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' TYR . . . . . 0.579 ' CE2' HD11 ' A' ' 37' ' ' ILE . 29.3 m-85 -119.84 157.4 28.75 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.258 -0.901 . . . . 50.0 110.035 179.623 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.405 ' O ' ' HA ' ' A' ' 61' ' ' CYS . 76.6 tttt -109.54 152.22 25.76 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.262 -0.899 . . . . 50.0 109.323 178.986 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 56.8 tp60 -95.18 101.51 13.26 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.171 -0.955 . . . . 50.0 110.24 -179.777 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 98.2 mt -72.17 -28.98 30.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.289 -0.882 . . . . 50.0 109.775 179.788 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.53 ' C ' HG23 ' A' ' 52' ' ' THR . . . 165.88 -91.87 0.1 Allowed Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.75 -1.34 . . . . 50.0 109.75 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.53 HG23 ' C ' ' A' ' 51' ' ' GLY . 76.4 p -150.52 130.91 13.75 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.188 -1.184 . . . . 50.0 110.563 -179.573 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' CYS . . . . . . . . . . . . . 8.6 t -51.2 -43.17 61.31 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.221 -0.924 . . . . 50.0 110.083 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.96 ' C ' HD22 ' A' ' 55' ' ' LEU . . . 162.91 -31.63 0.29 Allowed Glycine 0 N--CA 1.488 2.151 0 N-CA-C 109.001 -1.64 . . . . 50.0 109.001 -179.687 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.96 HD22 ' C ' ' A' ' 54' ' ' GLY . 3.2 mm? -126.43 160.9 55.6 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.442 -1.034 . . . . 50.0 109.743 179.758 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -71.45 -10.49 26.99 Favored 'Trans proline' 0 C--N 1.304 -1.799 0 O-C-N 123.801 1.421 . . . . 50.0 110.44 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -64.99 -45.03 93.59 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.595 -1.402 . . . . 50.0 109.595 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' THR . . . . . 0.41 HG22 ' N ' ' A' ' 59' ' ' LYS . 20.1 m -131.36 167.1 19.83 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.327 -1.102 . . . . 50.0 110.423 -179.873 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.492 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 47.0 mmtm -118.93 149.48 41.52 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.439 -0.788 . . . . 50.0 109.533 179.387 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.465 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 36.9 t -76.74 132.55 39.36 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.146 -0.971 . . . . 50.0 110.797 -179.093 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' CYS . . . . . 0.531 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 92.5 m -133.17 133.9 43.42 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.465 -0.772 . . . . 50.0 109.858 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.469 ' HG3' ' HB2' ' A' ' 36' ' ' ALA . 81.3 tttt -127.95 141.97 51.38 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.148 -0.97 . . . . 50.0 110.689 -179.539 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' LYS . . . . . 0.574 ' HE2' ' CZ ' ' A' ' 47' ' ' TYR . 99.4 mttt . . . . . 0 N--CA 1.491 1.595 0 O-C-N 121.36 -0.837 . . . . 50.0 110.023 179.592 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.451 ' O ' ' HB2' ' A' ' 31' ' ' CYS . 85.0 m . . . . . 0 N--CA 1.492 1.645 0 CA-C-O 121.251 0.548 . . . . 50.0 110.314 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' CYS . . . . . 0.451 ' HB2' ' O ' ' A' ' 30' ' ' THR . 64.1 m 57.28 19.29 4.87 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.161 -0.962 . . . . 50.0 110.399 179.813 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 33.2 tp -72.69 -32.17 65.58 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.165 -0.959 . . . . 50.0 110.633 -179.727 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -71.85 -40.18 69.2 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.103 -0.998 . . . . 50.0 110.226 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 72.3 m -71.82 -24.58 61.74 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.415 -0.803 . . . . 50.0 110.175 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 75.63 16.1 80.85 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.483 -1.447 . . . . 50.0 109.483 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ALA . . . . . 0.668 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -83.12 176.74 8.98 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.281 -1.129 . . . . 50.0 110.024 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.472 ' O ' HG13 ' A' ' 37' ' ' ILE . 3.7 pt -116.91 150.77 18.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.134 -0.979 . . . . 50.0 110.42 -179.901 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.446 ' HA ' ' HA ' ' A' ' 60' ' ' CYS . 61.0 m -91.26 137.3 32.47 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.173 -0.954 . . . . 50.0 109.333 179.484 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.517 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 58.3 t-80 -109.49 143.03 26.95 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.054 -1.028 . . . . 50.0 110.76 -179.157 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.517 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 47.5 Cg_endo -73.33 164.78 34.3 Favored 'Trans proline' 0 C--N 1.305 -1.713 0 O-C-N 124.19 1.626 . . . . 50.0 110.316 179.694 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.827 HG12 ' HD2' ' A' ' 42' ' ' PHE . 27.7 t 59.71 -84.02 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.298 -0.876 . . . . 50.0 110.558 179.667 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.827 ' HD2' HG12 ' A' ' 41' ' ' VAL . 16.5 p90 -158.64 161.89 37.21 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.854 -1.154 . . . . 50.0 110.389 -179.916 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' CYS . . . . . 0.434 ' SG ' ' HB3' ' A' ' 47' ' ' TYR . 0.6 OUTLIER -80.92 121.62 81.06 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.216 -0.928 . . . . 50.0 110.059 179.911 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -70.39 -162.52 0.1 OUTLIER 'Trans proline' 0 C--N 1.306 -1.677 0 O-C-N 123.908 1.478 . . . . 50.0 110.592 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 11.2 ptm180 -81.8 -29.76 32.54 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.546 -0.721 . . . . 50.0 110.369 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 45.4 mmm-85 -69.06 -16.1 63.61 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.274 -0.891 . . . . 50.0 110.163 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' TYR . . . . . 0.568 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 72.4 m-85 -122.93 150.14 43.34 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.29 -0.881 . . . . 50.0 110.337 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 54.0 tptt -110.9 154.11 24.53 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.35 -0.844 . . . . 50.0 110.224 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.517 ' HG3' ' CE ' ' A' ' 59' ' ' LYS . 46.2 tt0 -88.48 108.91 19.63 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.23 -0.919 . . . . 50.0 110.01 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 39.4 pt -104.32 10.76 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.22 -0.925 . . . . 50.0 110.966 -179.51 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.536 ' O ' ' CB ' ' A' ' 60' ' ' CYS . . . 130.62 113.01 1.55 Allowed Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.431 -1.468 . . . . 50.0 109.431 179.927 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.493 ' C ' ' O ' ' A' ' 51' ' ' GLY . 81.9 p -29.52 140.09 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.991 -0.711 . . . . 50.0 111.633 -179.612 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' CYS . . . . . 0.403 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 8.3 t -59.52 -50.24 74.69 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.385 -0.822 . . . . 50.0 110.219 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -179.06 -39.85 0.07 OUTLIER Glycine 0 N--CA 1.491 2.323 0 N-CA-C 108.945 -1.662 . . . . 50.0 108.945 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.453 ' HB3' ' HD2' ' A' ' 56' ' ' PRO . 70.2 mt -126.59 164.12 36.44 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.437 -1.037 . . . . 50.0 109.836 179.664 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.453 ' HD2' ' HB3' ' A' ' 55' ' ' LEU . 45.2 Cg_endo -71.21 -7.29 21.04 Favored 'Trans proline' 0 C--N 1.305 -1.762 0 O-C-N 123.971 1.511 . . . . 50.0 110.555 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -68.98 -37.64 83.56 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.16 -1.576 . . . . 50.0 109.16 179.765 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.4 m -129.42 159.97 34.57 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.316 -1.108 . . . . 50.0 110.005 179.773 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.517 ' CE ' ' HG3' ' A' ' 49' ' ' GLN . 37.7 tptt -121.84 127.27 50.35 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.197 -0.94 . . . . 50.0 109.984 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.536 ' CB ' ' O ' ' A' ' 51' ' ' GLY . 49.8 t -57.03 134.26 55.66 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.196 -0.94 . . . . 50.0 110.073 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' CYS . . . . . 0.668 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 54.5 m -136.76 148.26 47.15 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.3 -0.875 . . . . 50.0 109.981 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 81.0 tttt -128.4 132.26 48.5 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.207 -0.933 . . . . 50.0 110.418 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' LYS . . . . . 0.568 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 49.2 mtpt . . . . . 0 N--CA 1.491 1.58 0 O-C-N 121.299 -0.875 . . . . 50.0 110.202 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 57.7 m . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 121.376 0.608 . . . . 50.0 109.927 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 92.6 m -80.01 -8.3 59.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.252 -0.905 . . . . 50.0 110.594 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.0 mt -58.29 -33.14 69.12 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.147 -0.971 . . . . 50.0 110.38 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 95.0 mttt -67.39 -39.09 85.59 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.266 -0.896 . . . . 50.0 110.229 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 14.4 m -65.4 -31.71 72.95 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.292 -0.88 . . . . 50.0 110.154 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 106.73 15.44 16.83 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.696 -1.362 . . . . 50.0 109.696 179.865 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ALA . . . . . 0.875 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -120.31 126.38 50.41 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.17 -1.194 . . . . 50.0 110.152 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.74 HD11 ' NE2' ' A' ' 39' ' ' HIS . 1.1 pt -84.02 144.54 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.281 -0.887 . . . . 50.0 109.995 179.855 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.46 ' HA ' ' HA ' ' A' ' 60' ' ' CYS . 22.6 p -87.95 159.69 18.23 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.196 -0.94 . . . . 50.0 110.411 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.74 ' NE2' HD11 ' A' ' 37' ' ' ILE . 41.8 m-70 -131.02 167.88 19.66 Favored Pre-proline 0 N--CA 1.496 1.839 0 O-C-N 121.408 -0.808 . . . . 50.0 110.168 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.453 ' HD2' ' HB3' ' A' ' 39' ' ' HIS . 43.5 Cg_endo -70.16 161.17 46.97 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 O-C-N 123.711 1.374 . . . . 50.0 110.742 -179.601 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.857 HG12 ' HD2' ' A' ' 42' ' ' PHE . 9.8 t 55.82 -112.15 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.297 -0.877 . . . . 50.0 109.883 -179.682 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.857 ' HD2' HG12 ' A' ' 41' ' ' VAL . 50.2 p90 -135.2 156.27 49.27 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.676 -1.265 . . . . 50.0 109.96 179.749 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' CYS . . . . . 0.476 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 83.6 m -59.14 130.47 86.87 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.137 -0.977 . . . . 50.0 110.043 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -70.71 -162.54 0.1 Allowed 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 123.979 1.515 . . . . 50.0 110.603 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 41.5 ptt180 -78.6 -29.35 46.02 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.493 -0.754 . . . . 50.0 110.413 -179.623 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 86.5 mtm180 -72.39 -12.43 61.11 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.237 -0.914 . . . . 50.0 110.16 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' TYR . . . . . 0.609 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 38.1 m-85 -131.36 165.66 22.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.267 -0.896 . . . . 50.0 111.084 -179.611 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.501 ' O ' ' HA ' ' A' ' 61' ' ' CYS . 33.2 mttm -117.31 142.68 46.78 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.514 -0.741 . . . . 50.0 109.295 178.865 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.497 ' HA ' ' O ' ' A' ' 60' ' ' CYS . 32.7 tt0 -88.19 110.04 20.38 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.981 -1.075 . . . . 50.0 111.188 -179.131 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.646 HD11 ' CG ' ' A' ' 62' ' ' LYS . 80.7 mt -77.21 -28.89 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.314 -0.866 . . . . 50.0 109.326 178.909 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.579 ' C ' HG23 ' A' ' 52' ' ' THR . . . 174.3 -99.54 0.14 Allowed Glycine 0 N--CA 1.488 2.166 0 N-CA-C 108.819 -1.712 . . . . 50.0 108.819 -179.836 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.579 HG23 ' C ' ' A' ' 51' ' ' GLY . 70.9 p -157.65 143.74 17.55 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.284 -1.127 . . . . 50.0 110.191 179.571 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' CYS . . . . . 0.441 ' HA ' ' SG ' ' A' ' 60' ' ' CYS . 1.8 t -58.1 -39.06 77.67 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.217 -0.927 . . . . 50.0 109.882 179.606 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.546 ' O ' HD23 ' A' ' 55' ' ' LEU . . . 165.85 -27.68 0.18 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 108.818 -1.713 . . . . 50.0 108.818 -179.936 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.546 HD23 ' O ' ' A' ' 54' ' ' GLY . 30.2 mt -127.36 166.46 22.86 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.409 -1.054 . . . . 50.0 109.816 179.748 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.488 ' HD2' ' HB3' ' A' ' 55' ' ' LEU . 45.6 Cg_endo -73.52 -4.85 16.12 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.884 1.465 . . . . 50.0 110.447 179.889 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -78.61 -32.81 40.39 Favored Glycine 0 N--CA 1.489 2.167 0 N-CA-C 109.421 -1.472 . . . . 50.0 109.421 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' THR . . . . . 0.536 HG23 ' C ' ' A' ' 39' ' ' HIS . 2.5 m -128.37 162.58 26.77 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.273 -1.134 . . . . 50.0 110.587 -179.897 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.524 ' CG ' ' O ' ' A' ' 41' ' ' VAL . 72.1 mmtt -133.38 142.96 48.63 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.536 -0.728 . . . . 50.0 109.511 179.615 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.497 ' O ' ' HA ' ' A' ' 49' ' ' GLN . 45.1 m -68.98 131.09 44.51 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.083 -1.01 . . . . 50.0 110.255 -179.861 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' CYS . . . . . 0.875 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 98.3 m -124.29 162.07 24.51 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.399 -0.813 . . . . 50.0 110.247 -179.812 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.646 ' CG ' HD11 ' A' ' 50' ' ' ILE . 46.0 mtpt -122.31 164.31 18.14 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.233 -0.917 . . . . 50.0 110.672 -179.748 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' LYS . . . . . 0.609 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 52.1 mtpt . . . . . 0 N--CA 1.492 1.638 0 O-C-N 121.364 -0.835 . . . . 50.0 110.334 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.494 HG22 ' HB2' ' A' ' 32' ' ' LEU . 25.0 m . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 121.262 0.554 . . . . 50.0 110.097 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' CYS . . . . . 0.848 ' HB3' ' HB3' ' A' ' 36' ' ' ALA . 87.2 m -77.39 -1.6 30.94 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.193 -0.942 . . . . 50.0 110.411 -179.834 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.494 ' HB2' HG22 ' A' ' 30' ' ' THR . 32.9 mt -63.35 -39.64 95.08 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.222 -0.924 . . . . 50.0 110.261 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 43.0 mmtm -66.75 -42.58 85.95 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.29 -0.882 . . . . 50.0 110.362 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 86.3 p -70.46 -14.77 62.67 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.347 -0.846 . . . . 50.0 110.143 -179.892 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 87.12 4.79 81.19 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.543 -1.423 . . . . 50.0 109.543 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ALA . . . . . 0.848 ' HB3' ' HB3' ' A' ' 31' ' ' CYS . . . -71.8 155.64 40.21 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.159 -1.201 . . . . 50.0 110.009 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 1.008 HD12 ' NE2' ' A' ' 39' ' ' HIS . 26.7 pt -103.89 145.0 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.185 -0.947 . . . . 50.0 110.015 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 8.7 m -101.22 125.39 47.84 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.258 -0.901 . . . . 50.0 109.936 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 1.008 ' NE2' HD12 ' A' ' 37' ' ' ILE . 12.5 m-70 -119.48 153.06 53.77 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.232 -0.917 . . . . 50.0 110.345 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.427 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 45.7 Cg_endo -71.16 169.88 19.55 Favored 'Trans proline' 0 C--N 1.305 -1.727 0 O-C-N 124.04 1.547 . . . . 50.0 110.852 -179.604 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.795 HG12 ' HD2' ' A' ' 42' ' ' PHE . 17.4 t 59.15 -109.35 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.362 -0.836 . . . . 50.0 110.186 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.795 ' HD2' HG12 ' A' ' 41' ' ' VAL . 36.8 p90 -136.24 153.64 51.15 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.827 -1.171 . . . . 50.0 110.017 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' CYS . . . . . 0.407 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 76.4 m -69.88 132.26 88.8 Favored Pre-proline 0 N--CA 1.487 1.415 0 O-C-N 121.11 -0.994 . . . . 50.0 109.911 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -68.41 -162.76 0.08 OUTLIER 'Trans proline' 0 C--N 1.305 -1.732 0 O-C-N 123.996 1.524 . . . . 50.0 111.004 -179.564 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 16.2 ptm180 -81.58 -26.37 35.01 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.558 -0.714 . . . . 50.0 110.453 -179.617 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 13.3 mmm180 -66.71 -22.22 66.07 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.148 -0.97 . . . . 50.0 110.1 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' TYR . . . . . 0.626 ' CB ' ' HB3' ' A' ' 61' ' ' CYS . 70.8 m-85 -128.1 144.01 51.09 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.217 -0.927 . . . . 50.0 110.589 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 85.0 tttt -88.67 152.88 21.53 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.267 -0.896 . . . . 50.0 109.221 178.872 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 56.4 tt0 -93.4 96.44 9.93 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.093 -1.005 . . . . 50.0 110.562 -179.702 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 93.6 mt -69.42 -30.11 44.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.309 -0.87 . . . . 50.0 109.904 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.576 ' C ' HG23 ' A' ' 52' ' ' THR . . . 159.12 -91.86 0.12 Allowed Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.263 -1.535 . . . . 50.0 109.263 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.576 HG23 ' C ' ' A' ' 51' ' ' GLY . 63.3 p -153.92 150.58 28.5 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.26 -1.141 . . . . 50.0 109.992 179.695 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' CYS . . . . . 0.42 ' SG ' ' HB2' ' A' ' 60' ' ' CYS . 1.6 m -84.89 -27.33 26.72 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.189 -0.944 . . . . 50.0 110.694 -179.599 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 179.03 -49.5 0.09 OUTLIER Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.764 -1.334 . . . . 50.0 109.764 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 56.2 mt -119.74 161.92 35.47 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.16 -1.2 . . . . 50.0 110.419 -179.851 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -71.93 -11.4 27.42 Favored 'Trans proline' 0 C--N 1.305 -1.74 0 O-C-N 124.08 1.569 . . . . 50.0 110.292 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -68.94 -30.47 72.32 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.448 -1.461 . . . . 50.0 109.448 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -125.25 155.28 40.37 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.275 -1.132 . . . . 50.0 110.298 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.445 ' O ' ' SG ' ' A' ' 61' ' ' CYS . 14.1 tppt? -120.56 127.16 51.89 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.396 -0.815 . . . . 50.0 109.839 179.686 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.42 ' HB2' ' SG ' ' A' ' 53' ' ' CYS . 34.3 t -63.51 130.9 46.29 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.252 -0.905 . . . . 50.0 110.663 -179.604 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' CYS . . . . . 0.626 ' HB3' ' CB ' ' A' ' 47' ' ' TYR . 7.4 m -128.58 130.3 47.16 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.371 -0.831 . . . . 50.0 109.635 179.765 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 83.4 tttt -131.62 148.69 52.62 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.157 -0.964 . . . . 50.0 110.507 -179.638 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 86.0 mttt . . . . . 0 N--CA 1.49 1.575 0 O-C-N 121.281 -0.887 . . . . 50.0 110.021 179.887 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.507 HG22 ' HB2' ' A' ' 32' ' ' LEU . 85.8 m . . . . . 0 N--CA 1.492 1.666 0 CA-C-O 121.098 0.475 . . . . 50.0 110.54 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' CYS . . . . . 0.479 ' HB2' ' O ' ' A' ' 30' ' ' THR . 97.9 m 56.61 18.38 3.6 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.232 -0.918 . . . . 50.0 110.223 179.836 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.753 HD13 ' C ' ' A' ' 32' ' ' LEU . 3.4 tm? -76.62 -39.47 52.36 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.223 -0.923 . . . . 50.0 110.477 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 74.4 mmtt -75.13 -35.24 61.7 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.324 -0.86 . . . . 50.0 109.985 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 73.9 m -71.18 -26.72 63.09 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.374 -0.829 . . . . 50.0 110.191 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 84.98 9.0 81.54 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.493 -1.443 . . . . 50.0 109.493 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' ALA . . . . . 0.455 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -76.66 134.37 39.29 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.232 -1.158 . . . . 50.0 110.262 -179.914 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.684 HD11 ' CE2' ' A' ' 47' ' ' TYR . 9.1 pt -83.02 148.13 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.239 -0.913 . . . . 50.0 110.028 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 96.5 m -91.79 148.79 21.98 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.075 -1.016 . . . . 50.0 109.882 179.862 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.583 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 62.6 t-80 -139.71 145.9 45.17 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 121.312 -0.868 . . . . 50.0 109.89 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.583 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 41.6 Cg_endo -66.89 159.63 50.79 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.868 1.457 . . . . 50.0 110.075 179.723 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.827 HG12 ' HD2' ' A' ' 42' ' ' PHE . 13.5 t 62.99 -105.94 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.224 -0.922 . . . . 50.0 109.913 -179.673 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.827 ' HD2' HG12 ' A' ' 41' ' ' VAL . 42.1 p90 -142.26 157.9 44.32 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.626 -1.296 . . . . 50.0 110.148 179.814 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' CYS . . . . . 0.455 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 84.4 m -65.02 132.54 95.5 Favored Pre-proline 0 N--CA 1.493 1.699 0 O-C-N 121.241 -0.912 . . . . 50.0 110.371 -179.792 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -68.71 -162.16 0.08 OUTLIER 'Trans proline' 0 C--N 1.305 -1.75 0 O-C-N 123.995 1.524 . . . . 50.0 110.839 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 27.3 tpt180 -75.61 -43.13 49.63 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.519 -0.738 . . . . 50.0 110.537 -179.681 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 45.8 ttt85 -61.45 -30.77 70.8 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.333 -0.854 . . . . 50.0 110.372 -179.723 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' TYR . . . . . 0.684 ' CE2' HD11 ' A' ' 37' ' ' ILE . 32.2 m-85 -111.1 136.36 50.26 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.193 -0.942 . . . . 50.0 110.747 -179.85 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 24.6 tptp -87.37 157.14 19.32 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.261 -0.899 . . . . 50.0 109.387 179.034 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.416 ' HA ' ' SG ' ' A' ' 43' ' ' CYS . 53.7 tt0 -89.5 102.7 15.38 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.099 -1.001 . . . . 50.0 110.356 -179.777 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.419 ' HB ' ' SG ' ' A' ' 60' ' ' CYS . 30.6 mm -67.08 -30.66 50.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.227 -0.921 . . . . 50.0 109.555 179.552 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 153.77 -91.16 0.13 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.035 -1.626 . . . . 50.0 109.035 179.866 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 50.1 p -146.2 125.9 13.42 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.363 -1.081 . . . . 50.0 109.976 179.603 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' CYS . . . . . . . . . . . . . 19.1 t -49.85 -49.22 49.98 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.252 -0.905 . . . . 50.0 109.669 179.635 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 173.47 -30.15 0.1 OUTLIER Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.211 -1.556 . . . . 50.0 109.211 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.407 ' HA ' HD23 ' A' ' 55' ' ' LEU . 55.6 mt -124.87 160.3 54.72 Favored Pre-proline 0 N--CA 1.489 1.512 0 O-C-N 121.384 -1.068 . . . . 50.0 109.917 179.866 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -71.97 -5.8 17.83 Favored 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.928 1.488 . . . . 50.0 110.198 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -78.32 -37.12 28.83 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.469 -1.452 . . . . 50.0 109.469 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 5.1 m -130.59 162.23 29.79 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.269 -1.136 . . . . 50.0 110.268 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 66.7 mmtt -117.56 164.59 14.69 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.408 -0.808 . . . . 50.0 109.778 179.718 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.455 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 42.2 t -91.32 129.7 37.27 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.139 -0.975 . . . . 50.0 110.468 -179.78 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' CYS . . . . . 0.505 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 72.4 m -126.42 147.71 49.75 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.342 -0.849 . . . . 50.0 109.832 179.808 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 89.1 tttt -126.58 138.35 53.45 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.15 -0.969 . . . . 50.0 110.323 -179.857 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' LYS . . . . . 0.433 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 30.3 mtmm . . . . . 0 N--CA 1.491 1.598 0 O-C-N 121.333 -0.855 . . . . 50.0 110.325 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.737 ' O ' HG22 ' A' ' 30' ' ' THR . 95.3 m . . . . . 0 N--CA 1.494 1.754 0 CA-C-O 121.237 0.542 . . . . 50.0 110.587 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 65.4 m -48.5 -22.5 0.74 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.13 -0.981 . . . . 50.0 109.721 179.682 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.7 mt -57.98 -42.76 85.76 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.249 -0.907 . . . . 50.0 110.08 179.568 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.638 ' HB2' HG22 ' A' ' 30' ' ' THR . 64.8 mmtt -68.24 -33.3 74.13 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.444 -0.785 . . . . 50.0 110.185 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 69.3 m -76.37 -17.53 59.34 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.228 -0.92 . . . . 50.0 109.942 179.837 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 91.93 -2.87 76.67 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.858 -1.297 . . . . 50.0 109.858 179.586 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' ALA . . . . . 0.435 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -79.59 153.94 29.09 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.124 -1.221 . . . . 50.0 110.226 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.471 ' O ' ' N ' ' A' ' 61' ' ' CYS . 4.8 pt -107.79 152.88 9.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.288 -0.882 . . . . 50.0 110.052 179.826 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 71.8 m -93.32 148.98 21.57 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.202 -0.937 . . . . 50.0 110.045 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.596 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 42.0 t-80 -136.49 145.96 53.73 Favored Pre-proline 0 N--CA 1.491 1.614 0 O-C-N 121.275 -0.891 . . . . 50.0 110.16 -179.685 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.596 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 42.5 Cg_endo -68.59 153.02 74.38 Favored 'Trans proline' 0 C--N 1.307 -1.612 0 O-C-N 123.844 1.444 . . . . 50.0 110.544 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.835 HG12 ' HD2' ' A' ' 42' ' ' PHE . 18.0 t 64.24 -84.62 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.577 -0.702 . . . . 50.0 110.559 -179.784 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.835 ' HD2' HG12 ' A' ' 41' ' ' VAL . 21.6 p90 -156.56 161.96 39.94 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.714 -1.241 . . . . 50.0 110.214 179.963 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' CYS . . . . . 0.435 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 58.4 m -73.25 134.12 80.48 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.249 -0.907 . . . . 50.0 110.526 -179.665 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.454 ' O ' ' O ' ' A' ' 47' ' ' TYR . 44.3 Cg_endo -70.18 -160.63 0.07 OUTLIER 'Trans proline' 0 C--N 1.305 -1.718 0 O-C-N 123.874 1.46 . . . . 50.0 110.522 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 17.4 mmt180 -78.45 -46.58 19.41 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.493 -0.754 . . . . 50.0 109.68 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 82.1 mtm180 -54.39 -23.97 17.82 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.56 -0.713 . . . . 50.0 109.674 179.783 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' TYR . . . . . 0.555 ' CZ ' ' HE2' ' A' ' 63' ' ' LYS . 39.4 m-85 -122.95 154.04 38.93 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.411 -0.805 . . . . 50.0 110.259 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 82.1 tttt -117.84 149.74 40.33 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.4 -0.813 . . . . 50.0 109.679 179.594 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 58.8 tt0 -88.71 94.92 10.07 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.184 -0.948 . . . . 50.0 109.892 179.638 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.463 HG13 ' N ' ' A' ' 51' ' ' GLY . 21.6 pt -71.4 -30.08 38.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.402 -0.811 . . . . 50.0 110.326 -179.821 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.504 ' C ' HG23 ' A' ' 52' ' ' THR . . . -171.52 -105.63 0.18 Allowed Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.483 -1.447 . . . . 50.0 109.483 179.76 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.504 HG23 ' C ' ' A' ' 51' ' ' GLY . 41.2 p -151.17 141.02 21.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.285 -1.127 . . . . 50.0 110.218 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' CYS . . . . . 0.577 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 10.0 t -58.49 -44.39 89.38 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.273 -0.892 . . . . 50.0 109.873 179.879 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 160.08 -36.9 0.46 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.033 -1.627 . . . . 50.0 109.033 -179.83 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 74.8 mt -113.45 155.29 44.94 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.428 -1.042 . . . . 50.0 109.924 179.669 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -71.32 -11.8 29.04 Favored 'Trans proline' 0 C--N 1.303 -1.853 0 O-C-N 123.922 1.485 . . . . 50.0 110.69 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -70.92 -41.92 61.07 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.57 -1.412 . . . . 50.0 109.57 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 14.6 m -122.79 166.86 14.27 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.337 -1.096 . . . . 50.0 110.248 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -124.7 145.66 49.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.406 -0.809 . . . . 50.0 109.87 179.806 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.577 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 45.2 t -73.47 139.36 45.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.151 -0.968 . . . . 50.0 110.431 -179.803 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' CYS . . . . . 0.494 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 74.8 m -131.49 141.65 49.81 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.389 -0.82 . . . . 50.0 109.61 179.748 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 81.8 tttt -138.65 143.52 39.26 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.205 -0.934 . . . . 50.0 110.658 -179.341 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' LYS . . . . . 0.555 ' HE2' ' CZ ' ' A' ' 47' ' ' TYR . 98.9 mttt . . . . . 0 N--CA 1.491 1.59 0 O-C-N 121.294 -0.879 . . . . 50.0 110.158 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.665 HG22 ' HB2' ' A' ' 32' ' ' LEU . 85.6 m . . . . . 0 N--CA 1.491 1.61 0 CA-C-O 121.121 0.486 . . . . 50.0 110.571 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' CYS . . . . . 0.478 ' HB2' ' O ' ' A' ' 30' ' ' THR . 47.9 m 56.87 21.97 6.63 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.14 -0.975 . . . . 50.0 110.312 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.665 ' HB2' HG22 ' A' ' 30' ' ' THR . 79.2 mt -105.12 -21.05 13.33 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.193 -0.942 . . . . 50.0 110.176 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 95.2 mttt -72.58 -37.52 68.15 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.345 -0.847 . . . . 50.0 110.324 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 87.9 p -88.76 -4.04 58.61 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.292 -0.88 . . . . 50.0 110.25 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 69.42 21.38 76.01 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.195 -1.562 . . . . 50.0 109.195 -179.84 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -70.22 155.16 41.03 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.35 -1.088 . . . . 50.0 110.211 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.966 HD12 ' NE2' ' A' ' 39' ' ' HIS . 12.8 pt -104.73 151.05 7.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.21 -0.931 . . . . 50.0 110.253 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 76.2 m -105.38 139.54 39.85 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.299 -0.875 . . . . 50.0 110.031 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.966 ' NE2' HD12 ' A' ' 37' ' ' ILE . 17.3 m-70 -133.52 157.9 76.9 Favored Pre-proline 0 N--CA 1.494 1.74 0 O-C-N 121.346 -0.846 . . . . 50.0 110.192 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.466 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 45.2 Cg_endo -71.58 168.42 23.68 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 O-C-N 124.059 1.557 . . . . 50.0 110.415 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.87 HG12 ' HD2' ' A' ' 42' ' ' PHE . 10.8 t 61.84 -108.37 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.237 -0.914 . . . . 50.0 109.804 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.87 ' HD2' HG12 ' A' ' 41' ' ' VAL . 48.6 p90 -143.63 161.78 37.63 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.747 -1.221 . . . . 50.0 110.108 179.704 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' CYS . . . . . 0.462 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 70.8 m -67.33 132.43 93.24 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.222 -0.924 . . . . 50.0 110.356 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -71.29 -162.56 0.11 Allowed 'Trans proline' 0 C--N 1.306 -1.707 0 O-C-N 123.933 1.491 . . . . 50.0 110.346 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 30.2 mtt180 -78.21 -41.47 34.32 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.424 -0.798 . . . . 50.0 110.015 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 26.0 mmm180 -57.95 -27.94 63.87 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.483 -0.761 . . . . 50.0 110.21 -179.777 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' TYR . . . . . 0.535 ' CE2' ' CG ' ' A' ' 63' ' ' LYS . 21.7 m-85 -119.12 158.9 24.98 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.345 -0.847 . . . . 50.0 110.534 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -117.08 131.0 57.02 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.467 -0.77 . . . . 50.0 109.634 179.307 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.449 ' HB2' ' HB2' ' A' ' 43' ' ' CYS . 54.4 tt0 -78.14 104.14 8.53 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.276 -0.89 . . . . 50.0 111.024 -179.082 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.701 HD11 ' HD3' ' A' ' 62' ' ' LYS . 79.5 mt -68.71 -31.21 49.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.335 -0.853 . . . . 50.0 109.387 179.111 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.443 ' C ' HG23 ' A' ' 52' ' ' THR . . . 172.95 -96.67 0.11 Allowed Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.662 -1.375 . . . . 50.0 109.662 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.443 HG23 ' C ' ' A' ' 51' ' ' GLY . 68.6 p -146.7 137.2 23.8 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.207 -1.172 . . . . 50.0 110.327 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' CYS . . . . . . . . . . . . . 4.1 t -62.35 -41.43 98.58 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.263 -0.898 . . . . 50.0 110.137 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 158.93 -25.68 0.36 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 108.994 -1.642 . . . . 50.0 108.994 -179.897 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.521 ' CD1' ' HD2' ' A' ' 56' ' ' PRO . 17.4 tp -120.8 142.44 34.45 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.401 -1.059 . . . . 50.0 109.712 179.777 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.521 ' HD2' ' CD1' ' A' ' 55' ' ' LEU . 42.0 Cg_endo -67.92 -8.17 21.82 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 O-C-N 123.872 1.459 . . . . 50.0 110.442 -179.841 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -75.99 -32.09 53.88 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.062 -1.615 . . . . 50.0 109.062 179.511 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' THR . . . . . 0.464 ' HA ' ' HA ' ' A' ' 40' ' ' PRO . 4.0 m -131.28 162.12 30.75 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.262 -1.14 . . . . 50.0 110.4 179.896 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.493 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 46.5 mmtm -120.76 146.63 46.3 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.285 -0.884 . . . . 50.0 109.829 179.741 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.462 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 42.7 t -75.82 133.4 40.64 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.264 -0.898 . . . . 50.0 110.749 -179.376 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' CYS . . . . . 0.514 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 73.6 m -130.45 135.08 47.62 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.365 -0.834 . . . . 50.0 109.791 179.807 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.701 ' HD3' HD11 ' A' ' 50' ' ' ILE . 39.8 ttpt -126.51 135.15 50.95 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.09 -1.006 . . . . 50.0 110.287 -179.862 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' LYS . . . . . 0.535 ' CG ' ' CE2' ' A' ' 47' ' ' TYR . 49.5 mtmt . . . . . 0 N--CA 1.491 1.602 0 O-C-N 121.319 -0.863 . . . . 50.0 110.128 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 97.0 m . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 121.305 0.574 . . . . 50.0 110.034 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 31' ' ' CYS . . . . . 0.862 ' SG ' ' SG ' ' A' ' 53' ' ' CYS . 76.9 m -76.56 -7.15 54.62 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.274 -0.891 . . . . 50.0 110.399 -179.856 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.405 HD12 ' HA ' ' A' ' 32' ' ' LEU . 50.7 tp -65.35 -40.98 94.3 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.189 -0.945 . . . . 50.0 110.28 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -62.55 -44.19 96.94 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.321 -0.862 . . . . 50.0 110.271 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 58.1 m -66.13 -33.32 75.51 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.357 -0.839 . . . . 50.0 110.139 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 104.56 8.52 37.5 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.397 -1.481 . . . . 50.0 109.397 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' ALA . . . . . 0.669 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -96.13 123.38 39.72 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.263 -1.14 . . . . 50.0 109.95 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.457 ' O ' HG13 ' A' ' 37' ' ' ILE . 2.2 pt -71.61 151.5 8.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.155 -0.965 . . . . 50.0 110.495 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 24.5 m -91.28 154.73 19.05 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.182 -0.949 . . . . 50.0 109.871 179.645 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.545 ' O ' ' N ' ' A' ' 59' ' ' LYS . 64.7 t-80 -129.78 140.79 39.69 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.123 -0.986 . . . . 50.0 110.571 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.483 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 43.7 Cg_endo -70.4 161.83 44.6 Favored 'Trans proline' 0 C--N 1.304 -1.806 0 O-C-N 123.967 1.509 . . . . 50.0 111.091 -179.78 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.786 HG12 ' HD2' ' A' ' 42' ' ' PHE . 33.1 t 57.18 -84.23 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.536 -0.727 . . . . 50.0 110.955 179.846 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.786 ' HD2' HG12 ' A' ' 41' ' ' VAL . 14.0 p90 -155.26 157.65 37.59 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.873 -1.142 . . . . 50.0 110.457 -179.653 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' CYS . . . . . 0.422 ' SG ' ' HB3' ' A' ' 47' ' ' TYR . 0.7 OUTLIER -71.82 133.9 84.01 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 121.327 -0.858 . . . . 50.0 110.293 179.896 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.436 ' HD2' ' HB2' ' A' ' 47' ' ' TYR . 45.1 Cg_endo -70.55 -162.23 0.1 OUTLIER 'Trans proline' 0 C--N 1.306 -1.665 0 O-C-N 123.883 1.465 . . . . 50.0 110.543 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 28.7 tpt180 -81.93 -37.05 27.35 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.534 -0.729 . . . . 50.0 110.365 -179.813 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -66.39 -29.71 69.93 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.381 -0.824 . . . . 50.0 110.172 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' TYR . . . . . 0.542 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 45.8 m-85 -110.37 138.48 46.7 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.267 -0.896 . . . . 50.0 110.842 -179.597 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.452 ' O ' ' HA ' ' A' ' 61' ' ' CYS . 67.0 tttt -90.6 153.05 20.61 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.242 -0.912 . . . . 50.0 109.219 178.915 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 36.0 tt0 -102.07 98.9 9.02 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.041 -1.037 . . . . 50.0 110.302 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 97.0 mt -64.38 -28.6 45.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.46 -0.775 . . . . 50.0 109.984 179.888 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 160.5 -91.3 0.11 Allowed Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.551 -1.419 . . . . 50.0 109.551 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 67.6 p -145.29 159.28 43.27 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.283 -1.128 . . . . 50.0 110.313 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' CYS . . . . . 0.862 ' SG ' ' SG ' ' A' ' 31' ' ' CYS . 0.5 OUTLIER -104.53 -15.76 15.25 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.279 -0.888 . . . . 50.0 110.329 -179.923 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 162.34 -43.6 0.36 Allowed Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.45 -1.46 . . . . 50.0 109.45 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 87.2 mt -123.34 159.39 55.01 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.277 -1.131 . . . . 50.0 109.955 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.72 -16.99 26.37 Favored 'Trans proline' 0 C--N 1.304 -1.787 0 O-C-N 123.896 1.472 . . . . 50.0 110.383 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -68.08 -33.97 80.18 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.457 -1.457 . . . . 50.0 109.457 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' THR . . . . . 0.515 HG22 ' N ' ' A' ' 59' ' ' LYS . 34.3 m -117.24 170.14 8.92 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.262 -1.14 . . . . 50.0 110.388 179.861 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.545 ' N ' ' O ' ' A' ' 39' ' ' HIS . 73.7 mmtt -133.75 155.93 48.89 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.437 -0.789 . . . . 50.0 109.56 179.787 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 13.1 t -83.09 127.86 33.96 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.075 -1.016 . . . . 50.0 110.308 -179.586 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' CYS . . . . . 0.669 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 51.0 m -127.05 146.4 50.37 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.272 -0.892 . . . . 50.0 110.266 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 76.9 tttt -129.38 136.11 49.56 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.211 -0.931 . . . . 50.0 110.319 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' LYS . . . . . 0.542 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 97.6 mttt . . . . . 0 N--CA 1.492 1.637 0 O-C-N 121.251 -0.906 . . . . 50.0 109.968 179.805 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.458 HG22 ' HB3' ' A' ' 32' ' ' LEU . 86.1 m . . . . . 0 N--CA 1.491 1.613 0 CA-C-O 121.235 0.54 . . . . 50.0 110.012 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' CYS . . . . . 0.475 ' HB3' ' HB3' ' A' ' 36' ' ' ALA . 95.8 m -75.86 -4.55 41.41 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.35 -0.844 . . . . 50.0 110.35 -179.793 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.458 ' HB3' HG22 ' A' ' 30' ' ' THR . 49.8 tp -55.67 -49.57 72.56 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.192 -0.943 . . . . 50.0 109.996 179.764 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -59.89 -36.18 76.41 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.481 -0.762 . . . . 50.0 110.153 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 70.6 m -73.06 -27.46 61.75 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.34 -0.85 . . . . 50.0 110.235 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 95.01 -6.32 69.22 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.509 -1.436 . . . . 50.0 109.509 -179.861 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' ALA . . . . . 0.475 ' HB3' ' HB3' ' A' ' 31' ' ' CYS . . . -66.46 141.6 57.85 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.209 -1.171 . . . . 50.0 110.074 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.894 HD12 ' NE2' ' A' ' 39' ' ' HIS . 7.2 pt -86.98 150.16 3.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.203 -0.935 . . . . 50.0 110.253 -179.841 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 76.6 m -105.99 144.64 32.43 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.261 -0.9 . . . . 50.0 110.1 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.894 ' NE2' HD12 ' A' ' 37' ' ' ILE . 27.6 m-70 -135.48 158.99 73.27 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.259 -0.901 . . . . 50.0 110.315 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -70.15 172.59 12.74 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 O-C-N 124.002 1.527 . . . . 50.0 110.274 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.81 HG12 ' HD1' ' A' ' 42' ' ' PHE . 7.5 t 54.74 -115.35 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.297 -0.877 . . . . 50.0 109.788 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.81 ' HD1' HG12 ' A' ' 41' ' ' VAL . 39.4 p90 -137.88 156.31 48.04 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.774 -1.204 . . . . 50.0 109.94 179.641 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' CYS . . . . . 0.459 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 82.6 m -57.46 130.87 81.38 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.242 -0.911 . . . . 50.0 110.372 -179.737 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -71.72 -161.88 0.1 Allowed 'Trans proline' 0 C--N 1.305 -1.718 0 O-C-N 124.062 1.559 . . . . 50.0 110.73 179.777 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 19.1 ptp180 -76.35 -29.43 57.23 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.562 -0.711 . . . . 50.0 110.557 -179.584 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 62.7 mtp180 -69.88 -25.94 63.95 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.245 -0.91 . . . . 50.0 110.623 -179.544 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' TYR . . . . . 0.561 ' N ' ' CD1' ' A' ' 47' ' ' TYR . 11.6 m-85 -124.81 151.39 45.27 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.164 -0.96 . . . . 50.0 110.635 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 45.8 tttm -97.91 150.86 20.86 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.355 -0.841 . . . . 50.0 109.225 178.768 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.403 ' HA ' ' SG ' ' A' ' 43' ' ' CYS . 50.8 tt0 -93.54 95.38 9.21 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.983 -1.073 . . . . 50.0 110.42 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ILE . . . . . 0.512 HD11 ' CD ' ' A' ' 62' ' ' LYS . 97.3 mt -65.36 -31.24 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.297 -0.877 . . . . 50.0 110.068 179.807 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.498 ' C ' HG23 ' A' ' 52' ' ' THR . . . 168.77 -95.44 0.11 Allowed Glycine 0 N--CA 1.487 2.074 0 N-CA-C 109.534 -1.426 . . . . 50.0 109.534 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.498 HG23 ' C ' ' A' ' 51' ' ' GLY . 62.5 p -150.32 143.26 24.78 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.217 -1.166 . . . . 50.0 110.386 -179.824 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' CYS . . . . . 0.409 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 4.4 t -63.87 -40.95 97.76 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.237 -0.914 . . . . 50.0 109.844 179.74 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 157.84 -24.98 0.42 Allowed Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.07 -1.612 . . . . 50.0 109.07 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.514 ' CD1' ' HD2' ' A' ' 56' ' ' PRO . 16.9 tp -123.96 143.64 42.85 Favored Pre-proline 0 N--CA 1.489 1.517 0 O-C-N 121.5 -1.0 . . . . 50.0 109.596 179.773 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.514 ' HD2' ' CD1' ' A' ' 55' ' ' LEU . 39.9 Cg_endo -66.48 -5.3 12.5 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 O-C-N 123.773 1.407 . . . . 50.0 110.827 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -74.65 -33.88 54.85 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.158 -1.577 . . . . 50.0 109.158 179.378 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' THR . . . . . 0.474 HG23 ' C ' ' A' ' 39' ' ' HIS . 4.8 m -135.53 162.74 31.82 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.231 -1.158 . . . . 50.0 110.211 179.692 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.478 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 43.5 mmtm -115.49 151.82 34.1 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.346 -0.846 . . . . 50.0 109.937 179.662 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.459 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 26.6 t -81.39 133.5 35.42 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.251 -0.905 . . . . 50.0 110.656 -179.525 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' CYS . . . . . 0.516 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 72.0 m -131.12 141.22 50.1 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.371 -0.831 . . . . 50.0 109.961 179.73 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' LYS . . . . . 0.512 ' CD ' HD11 ' A' ' 50' ' ' ILE . 81.1 tttt -131.93 144.35 50.78 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.174 -0.954 . . . . 50.0 110.309 -179.737 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' LYS . . . . . 0.482 ' HE2' ' OH ' ' A' ' 47' ' ' TYR . 96.2 mttt . . . . . 0 N--CA 1.491 1.603 0 O-C-N 121.411 -0.806 . . . . 50.0 110.31 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo . . . . . 0 N--CA 1.487 1.146 0 N-CA-C 110.406 -0.652 . . . . 50.0 110.406 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.511 HG23 ' SG ' ' A' ' 31' ' ' CYS . 34.1 m -114.99 129.16 71.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.283 -0.886 . . . . 50.0 109.897 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.553 HG22 ' HB2' ' A' ' 32' ' ' LEU . 98.5 m -69.04 -19.29 64.1 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.129 -0.982 . . . . 50.0 110.566 -179.639 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' CYS . . . . . 0.511 ' SG ' HG23 ' A' ' 29' ' ' VAL . 93.3 m 56.22 22.44 6.14 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.215 -0.928 . . . . 50.0 110.311 -179.851 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.747 HD13 ' C ' ' A' ' 32' ' ' LEU . 3.4 tm? -75.35 -38.51 60.06 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.137 -0.977 . . . . 50.0 110.283 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 96.0 mttt -68.69 -41.64 78.88 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.303 -0.873 . . . . 50.0 110.209 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 94.9 p -69.77 -20.46 63.48 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.303 -0.873 . . . . 50.0 110.32 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 79.25 6.73 88.82 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.662 -1.375 . . . . 50.0 109.662 179.791 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.679 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -68.93 147.65 51.33 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.119 -1.224 . . . . 50.0 110.151 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.645 HD11 ' CE2' ' A' ' 47' ' ' TYR . 2.1 pt -93.45 151.77 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.148 -0.97 . . . . 50.0 110.063 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 86.3 m -91.27 142.57 27.57 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.244 -0.91 . . . . 50.0 110.372 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.514 ' CB ' ' SG ' ' A' ' 61' ' ' CYS . 54.4 t-80 -119.98 142.2 32.9 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.282 -0.886 . . . . 50.0 109.981 179.755 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.505 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 44.9 Cg_endo -71.52 155.85 58.87 Favored 'Trans proline' 0 C--N 1.305 -1.762 0 O-C-N 123.907 1.477 . . . . 50.0 110.857 -179.575 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.661 HG12 ' HD2' ' A' ' 42' ' ' PHE . 47.8 t 59.27 -93.87 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.449 -0.782 . . . . 50.0 110.679 179.658 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.661 ' HD2' HG12 ' A' ' 41' ' ' VAL . 21.4 p90 -139.14 161.43 37.42 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.84 -1.163 . . . . 50.0 110.62 -179.74 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' CYS . . . . . 0.51 ' CB ' ' HB2' ' A' ' 49' ' ' GLN . 0.8 OUTLIER -80.45 127.56 75.51 Favored Pre-proline 0 N--CA 1.492 1.663 0 O-C-N 121.398 -0.814 . . . . 50.0 109.958 179.822 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -72.43 -162.4 0.12 Allowed 'Trans proline' 0 C--N 1.306 -1.699 0 O-C-N 123.742 1.39 . . . . 50.0 110.445 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 6.5 mtt180 -81.25 -36.59 29.76 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.475 -0.766 . . . . 50.0 109.698 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.462 ' O ' ' HD3' ' A' ' 64' ' ' PRO . 60.0 mtp180 -58.71 -27.59 65.0 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.554 -0.716 . . . . 50.0 109.942 179.674 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.645 ' CE2' HD11 ' A' ' 37' ' ' ILE . 37.0 m-85 -120.84 138.72 53.91 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.337 -0.852 . . . . 50.0 110.294 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 88.5 mttt -95.14 124.3 39.1 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.202 -0.936 . . . . 50.0 109.837 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.51 ' HB2' ' CB ' ' A' ' 43' ' ' CYS . 41.8 tt0 -74.8 105.64 5.95 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.494 -0.754 . . . . 50.0 110.94 -179.162 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.5 mt -75.16 -28.52 20.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.198 -0.939 . . . . 50.0 109.628 179.361 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.545 ' C ' HG23 ' A' ' 52' ' ' THR . . . 176.76 -94.56 0.1 OUTLIER Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.368 -1.493 . . . . 50.0 109.368 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.545 HG23 ' C ' ' A' ' 51' ' ' GLY . 60.5 p -155.24 137.99 15.26 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.192 -1.181 . . . . 50.0 110.222 179.781 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' CYS . . . . . 0.459 ' O ' ' O ' ' A' ' 29' ' ' VAL . 18.5 t -54.12 -50.44 66.87 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.24 -0.913 . . . . 50.0 110.131 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 176.78 -45.26 0.11 Allowed Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.266 -1.534 . . . . 50.0 109.266 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.465 ' HB3' ' HD2' ' A' ' 56' ' ' PRO . 87.0 mt -110.82 164.9 13.78 Favored Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.288 -1.125 . . . . 50.0 109.973 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.465 ' HD2' ' HB3' ' A' ' 55' ' ' LEU . 45.6 Cg_endo -72.75 -3.03 12.8 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 O-C-N 123.88 1.463 . . . . 50.0 110.395 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -77.49 -43.5 15.37 Favored Glycine 0 N--CA 1.487 2.096 0 N-CA-C 109.491 -1.444 . . . . 50.0 109.491 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' THR . . . . . 0.407 HG23 ' C ' ' A' ' 39' ' ' HIS . 10.9 m -125.31 166.38 16.65 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.336 -1.097 . . . . 50.0 110.508 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.471 ' O ' ' N ' ' A' ' 39' ' ' HIS . 74.6 mmtt -123.21 148.6 45.66 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.336 -0.853 . . . . 50.0 109.902 179.857 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 13.2 t -73.52 127.93 34.08 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.145 -0.972 . . . . 50.0 110.376 -179.672 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' CYS . . . . . 0.679 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 28.3 m -128.02 154.17 45.94 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.29 -0.882 . . . . 50.0 109.994 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -132.99 138.68 46.93 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.157 -0.965 . . . . 50.0 110.249 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' LYS . . . . . 0.537 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 93.8 mttt -77.77 143.54 67.23 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.311 -0.868 . . . . 50.0 110.274 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' PRO . . . . . 0.462 ' HD3' ' O ' ' A' ' 46' ' ' ARG . 46.3 Cg_endo . . . . . 0 C--N 1.304 -1.765 0 O-C-N 124.044 1.549 . . . . 99.989999999999995 110.498 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo . . . . . 0 N--CA 1.489 1.22 0 N-CA-C 110.283 -0.699 . . . . 50.0 110.283 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.541 HG12 ' N ' ' A' ' 30' ' ' THR . 19.5 t -143.35 176.0 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.129 -0.982 . . . . 50.0 110.373 -179.881 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.541 ' N ' HG12 ' A' ' 29' ' ' VAL . 58.7 m -114.77 113.55 24.41 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.233 -0.917 . . . . 50.0 109.919 179.739 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' CYS . . . . . 0.588 ' HB3' ' HB3' ' A' ' 36' ' ' ALA . 52.8 m -75.73 -6.24 49.61 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.35 -0.843 . . . . 50.0 110.691 -179.641 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 95.3 mt -57.35 -34.73 69.09 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.032 -1.043 . . . . 50.0 110.205 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 24.8 mttp -68.03 -37.33 81.23 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.389 -0.819 . . . . 50.0 110.153 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 95.0 p -77.49 -18.25 57.26 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.474 -0.766 . . . . 50.0 110.252 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 89.81 5.71 70.86 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.503 -1.439 . . . . 50.0 109.503 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.588 ' HB3' ' HB3' ' A' ' 31' ' ' CYS . . . -77.37 147.97 35.81 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.217 -1.167 . . . . 50.0 110.284 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.472 ' O ' ' N ' ' A' ' 61' ' ' CYS . 4.0 pt -95.44 152.72 3.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.225 -0.922 . . . . 50.0 109.858 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.458 ' HA ' ' O ' ' A' ' 59' ' ' LYS . 79.0 m -100.16 139.77 35.36 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.205 -0.934 . . . . 50.0 110.143 -179.766 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.53 ' N ' ' O ' ' A' ' 59' ' ' LYS . 59.2 t-80 -117.82 136.26 23.66 Favored Pre-proline 0 N--CA 1.492 1.663 0 O-C-N 121.345 -0.847 . . . . 50.0 110.007 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.478 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 47.7 Cg_endo -72.23 164.58 35.2 Favored 'Trans proline' 0 C--N 1.303 -1.827 0 O-C-N 123.929 1.489 . . . . 50.0 110.503 -179.792 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.724 HG12 ' HD2' ' A' ' 42' ' ' PHE . 44.2 t 60.73 -82.78 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.524 -0.735 . . . . 50.0 111.171 179.538 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.724 ' HD2' HG12 ' A' ' 41' ' ' VAL . 9.7 p90 -155.7 154.29 31.28 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.957 -1.09 . . . . 50.0 110.662 -179.43 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 1.7 t -77.43 130.92 72.92 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.257 -0.902 . . . . 50.0 109.784 179.534 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -70.96 -162.29 0.1 Allowed 'Trans proline' 0 C--N 1.304 -1.803 0 O-C-N 123.88 1.463 . . . . 50.0 110.549 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 18.3 mtm180 -84.83 -40.13 17.51 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 121.475 -0.766 . . . . 50.0 109.818 -179.856 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 57.9 ttm-85 -61.73 -15.95 45.17 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.457 -0.777 . . . . 50.0 109.965 179.67 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.535 ' HB3' ' HB3' ' A' ' 61' ' ' CYS . 58.4 m-85 -123.99 134.33 53.49 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.316 -0.865 . . . . 50.0 110.507 -179.789 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -97.71 137.95 35.82 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.287 -0.883 . . . . 50.0 109.595 179.351 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.426 ' HA ' ' O ' ' A' ' 60' ' ' CYS . 36.3 tt0 -87.2 103.98 15.93 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.156 -0.965 . . . . 50.0 110.917 -179.308 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.654 HD11 ' HD2' ' A' ' 62' ' ' LYS . 96.5 mt -62.8 -29.07 46.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.301 -0.874 . . . . 50.0 109.733 179.472 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.508 ' C ' HG23 ' A' ' 52' ' ' THR . . . 171.19 -91.23 0.09 OUTLIER Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.476 -1.45 . . . . 50.0 109.476 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.508 HG23 ' C ' ' A' ' 51' ' ' GLY . 71.9 p -151.58 127.92 10.61 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.259 -1.142 . . . . 50.0 110.292 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' CYS . . . . . 0.474 ' O ' ' O ' ' A' ' 29' ' ' VAL . 15.6 t -49.82 -47.41 51.42 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.297 -0.877 . . . . 50.0 110.081 179.694 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.765 ' C ' HD12 ' A' ' 55' ' ' LEU . . . 168.77 -38.33 0.21 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 108.683 -1.767 . . . . 50.0 108.683 -179.77 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.784 ' N ' HD12 ' A' ' 55' ' ' LEU . 6.1 mp -119.79 158.1 50.64 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.475 -1.015 . . . . 50.0 109.752 179.604 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -70.8 -10.29 27.43 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 O-C-N 123.904 1.476 . . . . 50.0 110.286 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -67.87 -41.96 87.12 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.312 -1.515 . . . . 50.0 109.312 179.704 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' THR . . . . . 0.461 ' HA ' ' HA ' ' A' ' 40' ' ' PRO . 5.2 m -127.6 164.06 22.85 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.342 -1.093 . . . . 50.0 110.28 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.53 ' O ' ' N ' ' A' ' 39' ' ' HIS . 33.4 mmtp -118.75 152.6 35.88 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.318 -0.864 . . . . 50.0 109.741 179.654 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.426 ' O ' ' HA ' ' A' ' 49' ' ' GLN . 34.5 t -80.32 127.57 32.53 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.029 -1.045 . . . . 50.0 110.333 -179.793 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' CYS . . . . . 0.535 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 52.5 m -125.61 151.53 46.35 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.33 -0.856 . . . . 50.0 109.879 179.74 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.654 ' HD2' HD11 ' A' ' 50' ' ' ILE . 87.0 tttt -136.75 144.97 44.08 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.081 -1.012 . . . . 50.0 110.597 -179.775 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 50.8 mtmt -80.58 146.88 61.96 Favored Pre-proline 0 N--CA 1.493 1.685 0 O-C-N 121.289 -0.882 . . . . 50.0 110.272 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo . . . . . 0 C--N 1.307 -1.652 0 O-C-N 123.939 1.494 . . . . 99.989999999999995 110.49 179.871 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo . . . . . 0 N--CA 1.489 1.26 0 N-CA-C 110.431 -0.642 . . . . 50.0 110.431 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.497 HG23 ' SG ' ' A' ' 31' ' ' CYS . 35.7 m -126.35 133.19 69.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.3 -0.875 . . . . 50.0 109.918 179.721 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.469 ' O ' ' HB2' ' A' ' 31' ' ' CYS . 74.5 m -69.97 -15.97 63.12 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.223 -0.923 . . . . 50.0 110.392 -179.74 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' CYS . . . . . 0.497 ' SG ' HG23 ' A' ' 29' ' ' VAL . 90.4 m 56.23 27.86 12.34 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.231 -0.918 . . . . 50.0 110.586 179.773 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 67.2 tp -76.95 -43.26 35.88 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.208 -0.933 . . . . 50.0 110.08 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -67.43 -34.58 77.52 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.277 -0.889 . . . . 50.0 110.117 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 81.0 p -71.98 -24.45 61.59 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.422 -0.799 . . . . 50.0 110.259 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 75.87 10.99 84.96 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.626 -1.389 . . . . 50.0 109.626 179.829 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.597 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -77.04 156.11 32.03 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.186 -1.185 . . . . 50.0 110.257 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.494 HD11 ' CE2' ' A' ' 47' ' ' TYR . 13.8 pt -93.96 167.22 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.285 -0.885 . . . . 50.0 110.147 179.864 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 96.6 m -108.2 148.35 30.06 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.293 -0.879 . . . . 50.0 109.951 179.749 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.589 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 60.9 t-80 -138.68 145.66 47.13 Favored Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.297 -0.877 . . . . 50.0 110.435 -179.649 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.589 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 43.5 Cg_endo -69.1 160.39 50.07 Favored 'Trans proline' 0 C--N 1.305 -1.727 0 O-C-N 124.012 1.532 . . . . 50.0 110.42 179.486 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.829 HG12 ' HD2' ' A' ' 42' ' ' PHE . 15.9 t 62.3 -97.27 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.437 -0.789 . . . . 50.0 110.312 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.829 ' HD2' HG12 ' A' ' 41' ' ' VAL . 35.4 p90 -150.18 154.4 37.94 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 120.728 -1.233 . . . . 50.0 110.07 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' CYS . . . . . 0.414 ' HB2' ' HB2' ' A' ' 49' ' ' GLN . 64.6 m -61.96 133.62 93.98 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.196 -0.94 . . . . 50.0 110.581 -179.63 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.414 ' HD2' ' HB2' ' A' ' 47' ' ' TYR . 43.4 Cg_endo -68.49 -161.33 0.06 OUTLIER 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 123.959 1.505 . . . . 50.0 110.474 179.709 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 62.5 ttt180 -77.25 -44.08 31.16 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.558 -0.713 . . . . 50.0 110.664 -179.527 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.455 ' O ' ' HD3' ' A' ' 64' ' ' PRO . 51.5 mmm-85 -61.23 -31.42 71.21 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.233 -0.917 . . . . 50.0 110.422 -179.707 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.527 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 48.4 m-85 -105.73 149.38 26.47 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.273 -0.892 . . . . 50.0 110.491 -179.788 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -108.56 131.79 54.5 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.337 -0.852 . . . . 50.0 109.688 179.512 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.414 ' HB2' ' HB2' ' A' ' 43' ' ' CYS . 59.6 tt0 -82.81 101.43 10.94 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.327 -0.858 . . . . 50.0 110.702 -179.36 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.509 HD11 ' HD2' ' A' ' 62' ' ' LYS . 85.1 mt -70.36 -30.93 45.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.245 -0.909 . . . . 50.0 109.677 179.452 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 178.14 -99.05 0.12 Allowed Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.294 -1.522 . . . . 50.0 109.294 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 61.7 p -146.12 137.28 24.57 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.305 -1.115 . . . . 50.0 110.403 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' CYS . . . . . 0.446 ' HA ' ' HB2' ' A' ' 60' ' ' CYS . 17.2 t -51.95 -48.1 64.44 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.334 -0.854 . . . . 50.0 109.565 179.467 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 172.87 -30.4 0.1 Allowed Glycine 0 N--CA 1.489 2.193 0 N-CA-C 108.95 -1.66 . . . . 50.0 108.95 179.826 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 98.1 mt -124.44 159.63 56.7 Favored Pre-proline 0 N--CA 1.488 1.471 0 O-C-N 121.41 -1.053 . . . . 50.0 109.802 179.668 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -71.29 -9.81 26.03 Favored 'Trans proline' 0 C--N 1.304 -1.809 0 O-C-N 124.013 1.533 . . . . 50.0 110.537 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -73.57 -34.56 56.8 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.296 -1.521 . . . . 50.0 109.296 179.714 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' THR . . . . . 0.446 HG22 ' N ' ' A' ' 59' ' ' LYS . 25.6 m -131.6 168.42 17.73 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.302 -1.117 . . . . 50.0 109.976 179.789 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.446 ' N ' HG22 ' A' ' 58' ' ' THR . 33.6 mmtp -126.82 149.74 49.54 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.279 -0.888 . . . . 50.0 110.091 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.446 ' HB2' ' HA ' ' A' ' 53' ' ' CYS . 15.9 t -76.6 129.58 36.62 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.243 -0.911 . . . . 50.0 110.295 -179.633 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' CYS . . . . . 0.597 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 83.7 m -127.56 145.27 50.92 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.425 -0.797 . . . . 50.0 110.001 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.509 ' HD2' HD11 ' A' ' 50' ' ' ILE . 85.5 tttt -124.55 144.66 50.01 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.254 -0.904 . . . . 50.0 110.345 -179.814 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' LYS . . . . . 0.527 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 97.0 mttt -75.56 163.12 69.47 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.343 -0.848 . . . . 50.0 110.066 179.814 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' PRO . . . . . 0.455 ' HD3' ' O ' ' A' ' 46' ' ' ARG . 46.4 Cg_endo . . . . . 0 C--N 1.303 -1.832 0 O-C-N 124.031 1.543 . . . . 99.989999999999995 110.373 -179.836 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo . . . . . 0 N--CA 1.489 1.221 0 N-CA-C 110.323 -0.683 . . . . 50.0 110.323 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.533 HG12 ' N ' ' A' ' 30' ' ' THR . 27.5 t -137.17 172.32 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.172 -0.955 . . . . 50.0 110.452 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.533 ' N ' HG12 ' A' ' 29' ' ' VAL . 51.6 m -102.77 110.95 23.05 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.24 -0.912 . . . . 50.0 109.815 179.8 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 63.2 m -90.83 4.97 50.32 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.21 -0.931 . . . . 50.0 110.443 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 46.7 tp -66.68 -44.41 81.87 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.147 -0.97 . . . . 50.0 110.263 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -61.69 -39.03 90.02 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.382 -0.824 . . . . 50.0 110.384 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 87.7 p -71.32 -24.25 62.09 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.34 -0.85 . . . . 50.0 110.14 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 89.73 3.64 73.89 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.626 -1.389 . . . . 50.0 109.626 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -73.87 154.57 39.39 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.211 -1.17 . . . . 50.0 110.142 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.441 ' O ' HG13 ' A' ' 37' ' ' ILE . 3.9 pt -102.24 154.27 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.13 -0.981 . . . . 50.0 110.081 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.443 ' HA ' ' O ' ' A' ' 59' ' ' LYS . 93.0 m -98.1 138.48 35.33 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.235 -0.916 . . . . 50.0 110.208 179.873 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.49 ' N ' ' O ' ' A' ' 59' ' ' LYS . 58.6 t-80 -114.63 140.41 25.26 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.268 -0.895 . . . . 50.0 110.235 -179.8 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.5 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 44.1 Cg_endo -70.44 162.4 42.54 Favored 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 123.995 1.524 . . . . 50.0 110.272 179.84 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.779 HG12 ' HD2' ' A' ' 42' ' ' PHE . 18.3 t 62.96 -108.36 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.461 -0.775 . . . . 50.0 110.285 179.885 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.779 ' HD2' HG12 ' A' ' 41' ' ' VAL . 35.7 p90 -135.31 148.87 49.63 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.796 -1.19 . . . . 50.0 110.24 -179.842 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -68.5 131.03 91.73 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.265 -0.897 . . . . 50.0 110.204 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.432 ' HD2' ' HB2' ' A' ' 47' ' ' TYR . 46.6 Cg_endo -71.22 -163.03 0.12 Allowed 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 123.859 1.452 . . . . 50.0 110.415 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 32.3 mtt85 -80.57 -44.75 18.5 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.512 -0.743 . . . . 50.0 109.887 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 28.6 tpt180 -58.74 -24.46 61.62 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.53 -0.731 . . . . 50.0 110.152 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.533 ' HB3' ' HB3' ' A' ' 61' ' ' CYS . 42.0 m-85 -114.98 135.8 53.83 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.255 -0.903 . . . . 50.0 110.266 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 88.3 mttt -105.01 147.97 27.25 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.204 -0.935 . . . . 50.0 109.945 179.751 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.506 ' HA ' ' O ' ' A' ' 60' ' ' CYS . 15.7 tt0 -87.31 106.78 18.16 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.215 -0.928 . . . . 50.0 110.788 -179.432 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.767 HD12 ' SG ' ' A' ' 60' ' ' CYS . 67.8 mt -63.39 -24.12 35.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.289 -0.882 . . . . 50.0 109.731 179.438 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.483 ' O ' ' CB ' ' A' ' 52' ' ' THR . . . 152.5 40.18 0.03 OUTLIER Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.284 -1.527 . . . . 50.0 109.284 -179.868 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.483 ' CB ' ' O ' ' A' ' 51' ' ' GLY . 0.2 OUTLIER 69.76 151.17 0.09 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.404 -1.056 . . . . 50.0 110.435 -179.925 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 53' ' ' CYS . . . . . 0.409 ' HA ' ' HB2' ' A' ' 60' ' ' CYS . 7.3 t -71.19 -41.99 69.59 Favored 'General case' 0 N--CA 1.492 1.629 0 CA-C-O 121.763 0.792 . . . . 50.0 109.964 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.877 ' C ' HD12 ' A' ' 55' ' ' LEU . . . 154.63 -26.03 0.66 Allowed Glycine 0 N--CA 1.49 2.244 0 N-CA-C 108.438 -1.865 . . . . 50.0 108.438 -179.746 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.877 HD12 ' C ' ' A' ' 54' ' ' GLY . 5.8 mp -124.72 158.1 63.54 Favored Pre-proline 0 N--CA 1.489 1.495 0 O-C-N 121.55 -0.97 . . . . 50.0 109.465 179.611 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -71.79 -8.46 23.1 Favored 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.886 1.466 . . . . 50.0 110.432 -179.765 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -71.33 -45.83 45.5 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.545 -1.422 . . . . 50.0 109.545 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' THR . . . . . 0.407 HG23 ' C ' ' A' ' 39' ' ' HIS . 7.2 m -128.89 166.01 19.94 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.136 -1.214 . . . . 50.0 110.434 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.49 ' O ' ' N ' ' A' ' 39' ' ' HIS . 33.5 mmtp -121.16 148.49 44.16 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.415 -0.803 . . . . 50.0 109.558 179.62 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.767 ' SG ' HD12 ' A' ' 50' ' ' ILE . 35.1 t -74.82 130.54 39.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.991 -1.068 . . . . 50.0 110.117 -179.741 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' CYS . . . . . 0.533 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 59.9 m -135.32 155.11 51.15 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.274 -0.891 . . . . 50.0 110.102 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.474 ' HB3' HD11 ' A' ' 50' ' ' ILE . 34.9 pttt -146.57 166.83 25.3 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.103 -0.998 . . . . 50.0 110.299 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 52.7 mtmt -100.68 136.75 19.81 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 121.278 -0.889 . . . . 50.0 110.255 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo . . . . . 0 C--N 1.304 -1.765 0 O-C-N 124.039 1.547 . . . . 99.989999999999995 110.504 -179.981 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo . . . . . 0 N--CA 1.49 1.292 0 N-CA-C 110.551 -0.596 . . . . 50.0 110.551 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.463 HG12 ' N ' ' A' ' 30' ' ' THR . 20.9 t -141.83 170.34 12.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.209 -0.932 . . . . 50.0 110.356 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.463 ' N ' HG12 ' A' ' 29' ' ' VAL . 95.9 m -106.64 108.72 20.37 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.21 -0.931 . . . . 50.0 110.348 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 72.0 m -77.44 -12.05 59.91 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.907 . . . . 50.0 110.225 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.757 HD13 ' C ' ' A' ' 32' ' ' LEU . 3.4 tm? -57.68 -44.52 85.85 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.26 -0.9 . . . . 50.0 110.294 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -61.74 -38.01 86.36 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.312 -0.868 . . . . 50.0 110.149 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 69.5 m -72.53 -21.31 61.19 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.288 -0.882 . . . . 50.0 110.152 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 85.44 -3.18 87.57 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.633 -1.387 . . . . 50.0 109.633 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.736 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -77.47 159.49 29.35 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.14 -1.212 . . . . 50.0 110.19 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.475 ' O ' HG13 ' A' ' 37' ' ' ILE . 3.6 pt -108.22 151.15 10.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.288 -0.883 . . . . 50.0 110.118 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 85.4 m -88.78 141.29 28.63 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.198 -0.939 . . . . 50.0 109.964 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 50.5 t-80 -120.5 134.43 24.18 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.243 -0.911 . . . . 50.0 110.247 -179.77 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.494 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 44.0 Cg_endo -71.55 168.13 24.48 Favored 'Trans proline' 0 C--N 1.305 -1.724 0 O-C-N 124.001 1.527 . . . . 50.0 110.458 179.873 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.732 HG12 ' HD2' ' A' ' 42' ' ' PHE . 38.9 t 61.26 -92.51 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.383 -0.823 . . . . 50.0 110.69 179.806 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.732 ' HD2' HG12 ' A' ' 41' ' ' VAL . 16.2 p90 -148.58 148.69 30.45 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.967 -1.083 . . . . 50.0 110.379 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 1.8 t -73.47 128.74 86.76 Favored Pre-proline 0 N--CA 1.493 1.706 0 O-C-N 121.238 -0.914 . . . . 50.0 109.883 179.573 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -71.79 -162.6 0.12 Allowed 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.835 1.44 . . . . 50.0 110.568 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 6.7 ptp180 -90.51 -15.25 31.09 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.525 -0.734 . . . . 50.0 110.123 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.468 ' O ' ' HD3' ' A' ' 64' ' ' PRO . 89.6 mtm180 -73.18 -31.23 64.09 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.186 -0.946 . . . . 50.0 110.166 179.844 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.551 ' N ' ' CD1' ' A' ' 47' ' ' TYR . 6.9 m-85 -113.23 147.87 36.65 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.223 -0.923 . . . . 50.0 110.333 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 61.6 mttm -93.43 152.6 19.0 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.255 -0.903 . . . . 50.0 109.799 179.272 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 58.7 tt0 -91.59 97.47 11.06 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.068 -1.02 . . . . 50.0 110.615 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.443 HD11 ' HB2' ' A' ' 62' ' ' LYS . 86.7 mt -63.88 -32.65 57.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.312 -0.868 . . . . 50.0 109.701 179.512 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 166.17 -95.99 0.12 Allowed Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.408 -1.477 . . . . 50.0 109.408 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 21.7 p -145.24 129.07 17.32 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.329 -1.101 . . . . 50.0 110.193 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' CYS . . . . . 0.467 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 30.7 t -61.41 -47.9 83.65 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.15 -0.969 . . . . 50.0 109.654 179.577 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 129.68 1.89 5.41 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.491 -1.443 . . . . 50.0 109.491 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 92.0 mt -105.27 143.42 26.73 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.278 -1.13 . . . . 50.0 110.174 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -73.38 79.59 2.1 Favored 'Trans proline' 0 C--N 1.303 -1.821 0 O-C-N 124.062 1.559 . . . . 50.0 110.688 -179.82 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 139.17 -3.03 2.69 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.696 -1.24 . . . . 50.0 110.378 179.55 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' THR . . . . . 0.442 ' HA ' ' HA ' ' A' ' 40' ' ' PRO . 1.2 m -121.86 159.69 26.29 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.974 -1.309 . . . . 50.0 110.476 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 16.2 tppt? -129.59 123.81 32.25 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.355 -0.841 . . . . 50.0 109.895 179.584 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.467 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 34.2 t -53.92 128.99 32.4 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.177 -0.952 . . . . 50.0 110.375 -179.692 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' CYS . . . . . 0.736 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 62.3 m -128.84 146.41 50.94 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.222 -0.924 . . . . 50.0 110.076 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.482 ' O ' ' HA ' ' A' ' 47' ' ' TYR . 79.6 tttt -125.08 143.75 50.76 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.2 -0.937 . . . . 50.0 110.477 -179.678 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' LYS . . . . . 0.441 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 86.9 mttt -74.95 152.72 86.69 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.345 -0.847 . . . . 50.0 110.361 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' PRO . . . . . 0.468 ' HD3' ' O ' ' A' ' 46' ' ' ARG . 47.2 Cg_endo . . . . . 0 C--N 1.304 -1.771 0 O-C-N 124.047 1.551 . . . . 99.989999999999995 110.446 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.879 ' N ' ' HG1' ' A' ' 52' ' ' THR . 45.1 Cg_endo . . . . . 0 N--CA 1.489 1.227 0 N-CA-C 110.465 -0.629 . . . . 50.0 110.465 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.542 HG12 ' N ' ' A' ' 30' ' ' THR . 24.0 t -132.66 174.47 13.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.276 -0.89 . . . . 50.0 110.183 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.542 ' N ' HG12 ' A' ' 29' ' ' VAL . 23.7 m -75.05 -31.39 61.28 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.215 -0.928 . . . . 50.0 110.372 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' CYS . . . . . 0.478 ' HB2' ' O ' ' A' ' 30' ' ' THR . 98.7 m 58.86 19.66 7.25 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.314 -0.866 . . . . 50.0 110.538 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.516 HD12 ' CG2' ' A' ' 30' ' ' THR . 93.5 mt -111.27 -15.83 13.53 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.258 -0.901 . . . . 50.0 109.896 179.605 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 63.8 mmtt -69.26 -39.71 78.26 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.309 -0.869 . . . . 50.0 110.18 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.474 ' HB3' ' NZ ' ' A' ' 62' ' ' LYS . 66.7 m -90.27 -9.88 46.3 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.357 -0.84 . . . . 50.0 110.031 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 87.13 7.8 76.46 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.509 -1.436 . . . . 50.0 109.509 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.912 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -69.21 140.1 54.56 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.326 -1.102 . . . . 50.0 110.265 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.906 HD11 ' NE2' ' A' ' 39' ' ' HIS . 3.8 pt -100.54 155.92 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.227 -0.92 . . . . 50.0 109.871 179.821 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 83.5 m -95.46 141.0 29.52 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.152 -0.967 . . . . 50.0 110.043 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.906 ' NE2' HD11 ' A' ' 37' ' ' ILE . 38.4 m-70 -117.9 161.93 31.86 Favored Pre-proline 0 N--CA 1.497 1.889 0 O-C-N 121.33 -0.856 . . . . 50.0 110.55 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.475 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 44.0 Cg_endo -72.22 156.22 55.48 Favored 'Trans proline' 0 C--N 1.304 -1.766 0 O-C-N 124.024 1.539 . . . . 50.0 110.224 179.754 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.786 HG12 ' HD2' ' A' ' 42' ' ' PHE . 15.4 t 61.5 -108.53 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.246 -0.909 . . . . 50.0 110.064 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.786 ' HD2' HG12 ' A' ' 41' ' ' VAL . 44.0 p90 -135.16 164.79 26.88 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.685 -1.26 . . . . 50.0 110.225 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' CYS . . . . . 0.47 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 70.9 m -70.72 130.88 88.22 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.172 -0.955 . . . . 50.0 110.668 -179.547 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -71.42 -161.44 0.09 OUTLIER 'Trans proline' 0 C--N 1.305 -1.742 0 O-C-N 123.851 1.448 . . . . 50.0 110.391 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 15.3 ptm180 -81.88 -24.54 35.68 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.492 -0.755 . . . . 50.0 110.786 -179.483 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 79.5 mtp180 -71.7 -16.29 62.23 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.046 -1.034 . . . . 50.0 110.594 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.607 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 36.2 m-85 -129.81 153.06 48.63 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.088 -1.008 . . . . 50.0 110.878 -179.698 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.418 ' N ' ' O ' ' A' ' 62' ' ' LYS . 98.5 mttt -99.92 141.86 32.18 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.37 -0.831 . . . . 50.0 109.263 179.11 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 8.0 tt0 -84.44 98.82 10.29 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.162 -0.962 . . . . 50.0 110.955 -179.169 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.583 HD11 ' HB2' ' A' ' 62' ' ' LYS . 95.3 mt -62.98 -32.06 54.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.166 -0.958 . . . . 50.0 109.627 179.303 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.508 ' C ' HG23 ' A' ' 52' ' ' THR . . . 165.83 -92.09 0.1 Allowed Glycine 0 N--CA 1.487 2.044 0 N-CA-C 109.426 -1.47 . . . . 50.0 109.426 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.879 ' HG1' ' N ' ' A' ' 28' ' ' PRO . 20.9 p -152.02 134.19 15.09 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.319 -1.107 . . . . 50.0 110.152 -179.914 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' CYS . . . . . 0.546 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 5.0 t -59.14 -45.64 90.43 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.277 -0.889 . . . . 50.0 110.207 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 163.97 -41.53 0.32 Allowed Glycine 0 N--CA 1.489 2.233 0 N-CA-C 108.993 -1.643 . . . . 50.0 108.993 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 76.5 mt -118.43 158.03 47.92 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.511 -0.993 . . . . 50.0 109.928 179.747 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -71.82 -4.92 16.02 Favored 'Trans proline' 0 C--N 1.304 -1.807 0 O-C-N 123.922 1.486 . . . . 50.0 110.35 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -70.89 -30.28 68.25 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.371 -1.492 . . . . 50.0 109.371 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 5.8 m -139.11 163.56 32.08 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.284 -1.127 . . . . 50.0 110.393 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 54.8 tptt -119.31 128.18 53.88 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.405 -0.809 . . . . 50.0 109.42 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.546 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 41.1 t -63.71 131.54 48.23 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.181 -0.949 . . . . 50.0 110.431 -179.282 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' CYS . . . . . 0.912 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 74.8 m -126.2 156.81 39.61 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.467 -0.771 . . . . 50.0 110.181 -179.675 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.583 ' HB2' HD11 ' A' ' 50' ' ' ILE . 57.3 tttp -137.51 138.07 39.29 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.146 -0.971 . . . . 50.0 110.343 -179.801 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' LYS . . . . . 0.607 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 56.0 mtpt -82.26 146.15 53.9 Favored Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.122 -0.987 . . . . 50.0 110.043 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo . . . . . 0 C--N 1.306 -1.687 0 O-C-N 123.959 1.505 . . . . 99.989999999999995 110.354 179.921 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo . . . . . 0 N--CA 1.489 1.232 0 N-CA-C 110.324 -0.683 . . . . 50.0 110.324 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.761 HG23 ' O ' ' A' ' 52' ' ' THR . 14.0 m -128.31 141.25 47.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.118 -0.989 . . . . 50.0 110.438 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.459 HG22 ' HB2' ' A' ' 32' ' ' LEU . 72.9 m -107.66 110.94 22.92 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.262 -0.898 . . . . 50.0 109.899 179.748 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 52.1 m -79.4 -3.43 46.39 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.158 -0.963 . . . . 50.0 110.425 -179.856 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.459 ' HB2' HG22 ' A' ' 30' ' ' THR . 70.4 mt -56.91 -41.56 78.37 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.129 -0.982 . . . . 50.0 110.063 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 30.3 mmtp -67.52 -38.34 84.09 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.393 -0.817 . . . . 50.0 110.359 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 41.4 t -68.36 -32.64 72.87 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.29 -0.881 . . . . 50.0 110.047 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.78 -5.68 56.76 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.711 -1.356 . . . . 50.0 109.711 179.714 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.647 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -74.29 130.39 39.62 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.181 -1.188 . . . . 50.0 110.206 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 7.0 pt -73.34 162.73 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.209 -0.932 . . . . 50.0 110.22 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 71.9 m -106.44 152.29 23.82 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.273 -0.892 . . . . 50.0 110.093 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.572 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 60.4 t-80 -138.39 145.23 46.04 Favored Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.315 -0.865 . . . . 50.0 109.892 -179.734 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.572 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 41.8 Cg_endo -67.7 161.01 45.61 Favored 'Trans proline' 0 C--N 1.302 -1.912 0 O-C-N 123.898 1.473 . . . . 50.0 110.189 179.728 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.821 HG12 ' HD2' ' A' ' 42' ' ' PHE . 17.5 t 62.43 -104.59 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.42 -0.8 . . . . 50.0 110.035 -179.716 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.821 ' HD2' HG12 ' A' ' 41' ' ' VAL . 36.7 p90 -142.72 155.93 44.95 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.642 -1.286 . . . . 50.0 110.126 179.834 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' CYS . . . . . 0.448 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 75.6 m -65.06 132.45 95.44 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.286 -0.883 . . . . 50.0 110.262 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -69.1 -161.64 0.07 OUTLIER 'Trans proline' 0 C--N 1.304 -1.783 0 O-C-N 123.927 1.488 . . . . 50.0 110.802 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 14.3 mtt180 -78.46 -39.49 38.4 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.461 -0.775 . . . . 50.0 109.907 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.476 ' O ' ' HD3' ' A' ' 64' ' ' PRO . 95.4 mtt180 -60.02 -34.27 73.14 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.44 -0.787 . . . . 50.0 110.346 -179.727 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.566 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 18.7 m-85 -110.71 144.01 40.31 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.295 -0.878 . . . . 50.0 110.899 -179.558 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 64.6 mttm -98.06 138.26 35.63 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.39 -0.819 . . . . 50.0 109.183 178.899 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 39.9 tt0 -80.68 101.88 9.53 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.053 -1.029 . . . . 50.0 110.686 -179.402 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 74.4 mt -65.46 -31.26 53.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.222 -0.924 . . . . 50.0 109.618 179.366 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 165.09 -94.13 0.11 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.291 -1.523 . . . . 50.0 109.291 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.761 ' O ' HG23 ' A' ' 29' ' ' VAL . 65.3 p -143.3 136.21 27.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.311 -1.111 . . . . 50.0 110.284 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' CYS . . . . . 0.525 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 17.5 t -58.07 -49.4 77.05 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.256 -0.903 . . . . 50.0 109.793 179.67 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 176.45 -32.17 0.08 OUTLIER Glycine 0 N--CA 1.49 2.265 0 N-CA-C 108.791 -1.723 . . . . 50.0 108.791 -179.854 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 80.6 mt -127.71 160.03 63.05 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.504 -0.997 . . . . 50.0 109.545 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -72.19 -2.14 11.17 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 123.88 1.463 . . . . 50.0 110.36 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -74.75 -38.88 41.38 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.545 -1.422 . . . . 50.0 109.545 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' THR . . . . . 0.439 HG22 ' N ' ' A' ' 59' ' ' LYS . 21.2 m -126.7 168.58 14.17 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.199 -1.177 . . . . 50.0 110.367 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.439 ' N ' HG22 ' A' ' 58' ' ' THR . 14.5 tppt? -119.43 136.29 54.37 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.322 -0.861 . . . . 50.0 109.982 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.525 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 20.4 t -69.01 128.69 37.59 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.262 -0.899 . . . . 50.0 110.484 -179.739 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' CYS . . . . . 0.647 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 74.2 m -125.42 153.13 43.92 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.241 -0.912 . . . . 50.0 109.748 179.687 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.474 ' O ' ' HA ' ' A' ' 47' ' ' TYR . 83.6 tttt -130.08 144.33 51.28 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.172 -0.955 . . . . 50.0 110.487 -179.616 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' LYS . . . . . 0.566 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 97.7 mttt -79.73 154.15 75.79 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.301 -0.875 . . . . 50.0 110.047 179.718 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' PRO . . . . . 0.476 ' HD3' ' O ' ' A' ' 46' ' ' ARG . 46.6 Cg_endo . . . . . 0 C--N 1.303 -1.85 0 O-C-N 124.008 1.53 . . . . 99.989999999999995 110.388 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.502 ' HG2' ' HA2' ' A' ' 54' ' ' GLY . 46.6 Cg_endo . . . . . 0 N--CA 1.489 1.233 0 N-CA-C 110.478 -0.624 . . . . 50.0 110.478 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.568 HG12 ' N ' ' A' ' 30' ' ' THR . 40.0 t -139.11 174.18 10.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.045 -1.034 . . . . 50.0 110.336 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.568 ' N ' HG12 ' A' ' 29' ' ' VAL . 88.7 m -114.24 109.7 18.78 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.35 -0.844 . . . . 50.0 110.137 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' CYS . . . . . 0.432 ' SG ' ' HA ' ' A' ' 53' ' ' CYS . 79.3 m -77.15 -13.12 60.0 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.255 -0.903 . . . . 50.0 110.214 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 46.1 tp -57.32 -40.79 78.67 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.263 -0.898 . . . . 50.0 110.488 -179.717 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 60.3 mmtt -68.34 -41.25 81.03 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.265 -0.897 . . . . 50.0 110.297 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 56.9 m -70.86 -29.59 65.75 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.224 -0.923 . . . . 50.0 110.19 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 87.07 8.16 76.0 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.552 -1.419 . . . . 50.0 109.552 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -72.35 176.84 4.96 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.235 -1.156 . . . . 50.0 110.287 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.703 HD12 ' NE2' ' A' ' 39' ' ' HIS . 2.9 pt -115.83 153.53 17.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.316 -0.865 . . . . 50.0 109.984 179.663 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 83.0 m -112.52 153.31 27.67 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.167 -0.958 . . . . 50.0 109.969 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.703 ' NE2' HD12 ' A' ' 37' ' ' ILE . 31.6 m-70 -140.33 162.58 48.92 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 121.315 -0.865 . . . . 50.0 110.282 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -70.81 166.5 28.69 Favored 'Trans proline' 0 C--N 1.305 -1.759 0 O-C-N 124.037 1.546 . . . . 50.0 110.847 -179.659 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.793 HG12 ' HD2' ' A' ' 42' ' ' PHE . 14.4 t 54.07 -108.43 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.393 -0.817 . . . . 50.0 110.167 179.811 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.793 ' HD2' HG12 ' A' ' 41' ' ' VAL . 29.3 p90 -141.36 151.37 43.47 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.817 -1.177 . . . . 50.0 110.129 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' CYS . . . . . 0.475 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 72.5 m -50.65 130.36 27.33 Favored Pre-proline 0 N--CA 1.489 1.517 0 O-C-N 121.155 -0.965 . . . . 50.0 109.813 179.771 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.449 ' HD2' ' HB2' ' A' ' 47' ' ' TYR . 43.6 Cg_endo -70.16 -162.78 0.1 OUTLIER 'Trans proline' 0 C--N 1.304 -1.783 0 O-C-N 123.954 1.502 . . . . 50.0 110.304 179.792 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 28.8 mtp180 -74.68 -42.79 57.77 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.417 -0.802 . . . . 50.0 110.04 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 79.0 mtp180 -61.96 -14.87 39.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.486 -0.759 . . . . 50.0 110.37 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.517 ' HB3' ' HB3' ' A' ' 61' ' ' CYS . 72.6 m-85 -128.28 164.19 23.13 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.232 -0.918 . . . . 50.0 110.683 -179.68 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -127.79 154.79 45.0 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.349 -0.845 . . . . 50.0 109.958 179.787 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -87.93 115.46 25.41 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.181 -0.95 . . . . 50.0 110.06 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.436 HD13 ' HB2' ' A' ' 62' ' ' LYS . 22.6 pt -110.41 15.91 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.282 -0.886 . . . . 50.0 110.459 -179.826 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.508 ' O ' ' HB3' ' A' ' 60' ' ' CYS . . . 133.24 114.89 1.57 Allowed Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.403 -1.479 . . . . 50.0 109.403 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.476 ' OG1' ' CB ' ' A' ' 28' ' ' PRO . 75.9 p -34.65 134.05 0.24 Allowed 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.771 -0.841 . . . . 50.0 110.965 -179.841 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' CYS . . . . . 0.526 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 4.4 t -51.67 -42.03 61.84 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.452 -0.78 . . . . 50.0 110.34 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.502 ' HA2' ' HG2' ' A' ' 28' ' ' PRO . . . 163.36 -27.52 0.23 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.062 -1.615 . . . . 50.0 109.062 -179.787 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 97.0 mt -122.45 152.9 62.0 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.358 -1.084 . . . . 50.0 109.856 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.44 -16.25 27.6 Favored 'Trans proline' 0 C--N 1.303 -1.824 0 O-C-N 123.886 1.466 . . . . 50.0 110.416 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -69.02 -32.71 73.37 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.389 -1.484 . . . . 50.0 109.389 179.83 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 8.6 m -128.74 168.12 16.29 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.287 -1.125 . . . . 50.0 110.198 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.49 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 75.1 mmtt -130.91 141.96 50.33 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.365 -0.835 . . . . 50.0 109.767 179.688 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.526 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 7.4 t -73.35 139.51 46.04 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.127 -0.983 . . . . 50.0 109.98 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' CYS . . . . . 0.517 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 97.8 m -131.89 144.47 50.89 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.378 -0.826 . . . . 50.0 109.94 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.436 ' HB2' HD13 ' A' ' 50' ' ' ILE . 54.7 tttm -127.81 140.36 52.08 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.089 -1.007 . . . . 50.0 110.31 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' LYS . . . . . 0.445 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 93.3 mttt -73.0 149.19 89.68 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.219 -0.926 . . . . 50.0 110.09 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo . . . . . 0 C--N 1.305 -1.758 0 O-C-N 124.012 1.532 . . . . 99.989999999999995 110.446 -179.963 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo . . . . . 0 N--CA 1.488 1.197 0 N-CA-C 110.313 -0.687 . . . . 50.0 110.313 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.489 HG12 ' N ' ' A' ' 30' ' ' THR . 16.8 t -136.3 172.65 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.176 -0.953 . . . . 50.0 110.249 -179.877 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.489 ' N ' HG12 ' A' ' 29' ' ' VAL . 36.4 m -116.0 112.41 21.78 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.31 -0.869 . . . . 50.0 110.098 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 65.9 m -84.71 0.35 50.78 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.188 -0.945 . . . . 50.0 110.317 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.519 HD22 ' N ' ' A' ' 32' ' ' LEU . 4.2 mm? -65.82 -45.25 82.99 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.209 -0.932 . . . . 50.0 110.179 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -64.53 -36.16 83.3 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.409 -0.807 . . . . 50.0 110.181 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 95.2 p -69.48 -20.26 63.74 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.374 -0.829 . . . . 50.0 110.299 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 89.7 0.35 78.86 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.492 -1.443 . . . . 50.0 109.492 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -77.98 154.45 31.53 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.148 -1.207 . . . . 50.0 110.128 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.487 ' O ' ' O ' ' A' ' 61' ' ' CYS . 1.1 pt -99.72 157.22 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.285 -0.884 . . . . 50.0 109.875 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 70.9 m -107.06 143.7 34.79 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.012 -1.055 . . . . 50.0 110.121 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.601 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 14.8 t-80 -108.2 145.92 32.49 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.269 -0.894 . . . . 50.0 109.851 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.601 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 42.4 Cg_endo -68.03 -23.92 39.71 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 O-C-N 123.847 1.446 . . . . 50.0 110.878 -179.674 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.646 HG12 ' HD2' ' A' ' 42' ' ' PHE . 66.3 t -117.91 -88.77 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.087 -1.008 . . . . 50.0 110.527 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.646 ' HD2' HG12 ' A' ' 41' ' ' VAL . 13.4 p90 -140.02 151.31 45.35 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.111 -0.993 . . . . 50.0 110.148 -179.765 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' CYS . . . . . 0.464 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 75.8 m -61.95 123.81 79.19 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.127 -0.983 . . . . 50.0 109.937 179.782 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.479 ' HD2' ' HB2' ' A' ' 47' ' ' TYR . 45.1 Cg_endo -69.95 -163.04 0.1 Allowed 'Trans proline' 0 C--N 1.304 -1.769 0 O-C-N 123.975 1.513 . . . . 50.0 110.732 179.812 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 65.2 ttt180 -75.02 -42.29 57.66 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.475 -0.766 . . . . 50.0 110.419 -179.74 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.478 ' O ' ' HD3' ' A' ' 64' ' ' PRO . 86.4 mmt-85 -62.19 -29.07 70.11 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.366 -0.834 . . . . 50.0 110.221 -179.924 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.592 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 16.6 m-85 -113.35 159.26 19.6 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.178 -0.952 . . . . 50.0 110.717 -179.732 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 13.5 ptmm? -120.5 145.61 47.11 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.36 -0.838 . . . . 50.0 109.462 179.116 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 63.3 tt0 -90.09 103.49 16.15 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.124 -0.985 . . . . 50.0 110.714 -179.53 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.607 HD11 ' HD2' ' A' ' 62' ' ' LYS . 90.7 mt -68.17 -29.45 44.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.207 -0.933 . . . . 50.0 109.623 179.438 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 172.31 -95.31 0.11 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.217 -1.553 . . . . 50.0 109.217 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 70.7 p -144.17 134.19 24.07 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.209 -1.171 . . . . 50.0 110.309 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' CYS . . . . . 0.53 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 16.5 t -54.26 -43.79 71.28 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.134 -0.979 . . . . 50.0 109.669 179.571 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 152.65 -24.64 0.84 Allowed Glycine 0 N--CA 1.49 2.253 0 N-CA-C 108.637 -1.785 . . . . 50.0 108.637 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.465 ' CD1' ' HD2' ' A' ' 56' ' ' PRO . 16.7 tp -121.74 142.58 36.3 Favored Pre-proline 0 C--N 1.303 -1.449 0 O-C-N 121.505 -0.997 . . . . 50.0 109.374 179.594 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.465 ' HD2' ' CD1' ' A' ' 55' ' ' LEU . 41.3 Cg_endo -67.37 -5.27 13.52 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 123.794 1.418 . . . . 50.0 110.465 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -80.14 -27.63 52.01 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.333 -1.507 . . . . 50.0 109.333 179.483 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' THR . . . . . 0.479 ' CG2' ' O ' ' A' ' 39' ' ' HIS . 3.4 m -137.33 160.68 38.37 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.247 -1.149 . . . . 50.0 110.433 179.908 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.464 ' O ' ' N ' ' A' ' 39' ' ' HIS . 73.4 mmtt -113.31 155.41 25.2 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.527 -0.733 . . . . 50.0 109.538 179.425 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.53 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 37.3 t -85.8 130.88 34.43 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.185 -0.947 . . . . 50.0 110.897 -179.24 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' CYS . . . . . 0.495 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 71.3 m -134.06 128.95 35.31 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.425 -0.797 . . . . 50.0 109.301 179.542 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.607 ' HD2' HD11 ' A' ' 50' ' ' ILE . 84.8 tttt -109.48 147.74 32.38 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.003 -1.06 . . . . 50.0 111.148 -179.154 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' LYS . . . . . 0.592 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 51.3 mtmt -84.69 154.16 61.57 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.365 -0.834 . . . . 50.0 109.663 179.317 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' PRO . . . . . 0.478 ' HD3' ' O ' ' A' ' 46' ' ' ARG . 48.2 Cg_endo . . . . . 0 C--N 1.304 -1.793 0 O-C-N 123.849 1.447 . . . . 99.989999999999995 110.487 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo . . . . . 0 N--CA 1.49 1.309 0 N-CA-C 110.378 -0.662 . . . . 50.0 110.378 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.581 HG12 ' N ' ' A' ' 30' ' ' THR . 49.1 t -133.0 174.21 13.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.258 -0.901 . . . . 50.0 110.277 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.581 ' N ' HG12 ' A' ' 29' ' ' VAL . 99.8 m -115.92 104.97 12.14 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.277 -0.89 . . . . 50.0 110.345 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 65.1 m -82.1 -6.42 59.16 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.19 -0.944 . . . . 50.0 109.995 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 60.1 tp -57.99 -46.48 85.15 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.329 -0.857 . . . . 50.0 110.189 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -64.83 -34.52 78.55 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.393 -0.817 . . . . 50.0 110.21 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 65.1 m -69.67 -31.94 70.29 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.277 -0.889 . . . . 50.0 110.3 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.15 5.21 62.43 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.698 -1.361 . . . . 50.0 109.698 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.706 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -78.41 173.05 12.75 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.189 -1.183 . . . . 50.0 110.326 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.873 HD12 ' NE2' ' A' ' 39' ' ' HIS . 7.1 pt -114.73 152.25 16.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.305 -0.872 . . . . 50.0 109.925 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 77.1 m -107.18 142.76 36.38 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.326 -0.859 . . . . 50.0 110.156 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.873 ' NE2' HD12 ' A' ' 37' ' ' ILE . 23.6 m-70 -134.04 157.4 77.76 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.258 -0.901 . . . . 50.0 110.12 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.476 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 45.8 Cg_endo -72.18 165.03 33.82 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 O-C-N 124.096 1.577 . . . . 50.0 110.931 -179.42 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.835 HG12 ' HD2' ' A' ' 42' ' ' PHE . 18.6 t 61.02 -100.73 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.453 -0.78 . . . . 50.0 110.26 179.689 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.835 ' HD2' HG12 ' A' ' 41' ' ' VAL . 35.4 p90 -145.64 157.55 43.95 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.757 -1.214 . . . . 50.0 110.467 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' CYS . . . . . 0.426 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 76.5 m -68.98 131.24 90.97 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.324 -0.86 . . . . 50.0 110.089 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -69.45 -160.05 0.06 OUTLIER 'Trans proline' 0 C--N 1.305 -1.75 0 O-C-N 123.908 1.478 . . . . 50.0 110.945 -179.709 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 31.7 mtt180 -80.85 -41.22 23.54 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.537 -0.727 . . . . 50.0 109.884 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.414 ' O ' ' HD3' ' A' ' 64' ' ' PRO . 82.7 mmt-85 -55.82 -25.46 41.75 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.466 -0.771 . . . . 50.0 109.97 -179.769 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.531 ' N ' ' CD1' ' A' ' 47' ' ' TYR . 18.3 m-85 -125.82 161.61 27.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.285 -0.884 . . . . 50.0 110.399 179.722 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.421 ' N ' ' O ' ' A' ' 62' ' ' LYS . 88.8 mttt -116.43 146.12 42.76 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.443 -0.785 . . . . 50.0 109.021 178.801 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.425 ' HA ' ' O ' ' A' ' 60' ' ' CYS . 45.4 tt0 -90.23 104.02 16.64 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.96 -1.087 . . . . 50.0 111.215 -178.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.673 HD11 ' HD2' ' A' ' 62' ' ' LYS . 80.2 mt -64.81 -32.54 58.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.276 -0.89 . . . . 50.0 109.136 178.857 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 168.63 -96.07 0.12 Allowed Glycine 0 N--CA 1.488 2.108 0 N-CA-C 109.469 -1.452 . . . . 50.0 109.469 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 74.3 p -143.22 127.77 17.99 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.25 -1.147 . . . . 50.0 110.29 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' CYS . . . . . . . . . . . . . 4.4 t -50.44 -44.76 55.55 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.225 -0.922 . . . . 50.0 109.848 179.721 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 176.71 -33.23 0.08 OUTLIER Glycine 0 N--CA 1.49 2.288 0 N-CA-C 108.994 -1.642 . . . . 50.0 108.994 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 97.5 mt -127.21 161.36 54.72 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.455 -1.027 . . . . 50.0 109.77 179.651 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -72.61 -5.31 16.94 Favored 'Trans proline' 0 C--N 1.304 -1.774 0 O-C-N 123.912 1.48 . . . . 50.0 110.462 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -71.45 -34.68 63.46 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.596 -1.402 . . . . 50.0 109.596 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' THR . . . . . 0.427 HG23 ' C ' ' A' ' 39' ' ' HIS . 11.5 m -132.88 165.64 24.17 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.312 -1.111 . . . . 50.0 110.149 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.479 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 75.3 mmtt -122.31 135.46 54.73 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.38 -0.825 . . . . 50.0 109.675 179.563 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.426 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 39.4 t -68.98 133.73 48.55 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.261 -0.9 . . . . 50.0 110.426 -179.432 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' CYS . . . . . 0.706 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 71.2 m -123.13 153.58 39.79 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.355 -0.841 . . . . 50.0 110.023 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.673 ' HD2' HD11 ' A' ' 50' ' ' ILE . 65.4 tttm -139.78 147.68 41.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.068 -1.02 . . . . 50.0 110.51 -179.721 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -84.08 154.88 64.06 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.259 -0.9 . . . . 50.0 110.207 179.844 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' PRO . . . . . 0.414 ' HD3' ' O ' ' A' ' 46' ' ' ARG . 47.1 Cg_endo . . . . . 0 C--N 1.305 -1.716 0 O-C-N 124.008 1.53 . . . . 99.989999999999995 110.38 179.835 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo . . . . . 0 N--CA 1.488 1.194 0 N-CA-C 110.289 -0.696 . . . . 50.0 110.289 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.8 m -129.6 157.63 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.191 -0.943 . . . . 50.0 110.31 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.411 HG22 ' HB3' ' A' ' 32' ' ' LEU . 95.8 m -109.99 104.03 12.87 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.353 -0.842 . . . . 50.0 110.229 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' CYS . . . . . 0.463 ' SG ' ' HA ' ' A' ' 53' ' ' CYS . 72.1 m -65.67 -16.83 64.12 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.265 -0.897 . . . . 50.0 110.184 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.411 ' HB3' HG22 ' A' ' 30' ' ' THR . 9.9 tp -61.21 -45.98 92.33 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.282 -0.886 . . . . 50.0 110.082 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 67.5 mttm -63.12 -35.04 78.94 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.393 -0.817 . . . . 50.0 110.065 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 31.6 t -70.05 -24.3 63.24 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.361 -0.837 . . . . 50.0 110.204 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.03 9.9 47.33 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.604 -1.398 . . . . 50.0 109.604 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.474 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -106.78 151.45 25.15 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.196 -1.179 . . . . 50.0 110.172 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.509 HG12 ' CE2' ' A' ' 47' ' ' TYR . 6.6 pt -100.7 151.86 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.347 -0.845 . . . . 50.0 110.26 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 87.0 m -92.75 148.15 22.28 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.301 -0.874 . . . . 50.0 109.964 179.781 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.612 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 53.0 t-80 -135.42 147.05 60.29 Favored Pre-proline 0 N--CA 1.495 1.783 0 O-C-N 121.247 -0.908 . . . . 50.0 110.045 -179.488 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.612 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 43.5 Cg_endo -69.89 160.47 49.53 Favored 'Trans proline' 0 C--N 1.308 -1.597 0 O-C-N 123.773 1.407 . . . . 50.0 110.59 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.835 HG12 ' HD2' ' A' ' 42' ' ' PHE . 21.6 t 61.57 -87.54 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.427 -0.796 . . . . 50.0 110.655 179.749 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.835 ' HD2' HG12 ' A' ' 41' ' ' VAL . 25.8 p90 -155.42 164.89 38.11 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 120.845 -1.159 . . . . 50.0 110.333 179.872 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' CYS . . . . . 0.451 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 85.3 m -73.87 131.7 81.27 Favored Pre-proline 0 N--CA 1.496 1.834 0 O-C-N 121.239 -0.913 . . . . 50.0 110.601 -179.566 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -71.02 -162.18 0.1 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 O-C-N 123.9 1.474 . . . . 50.0 110.787 -179.812 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 19.4 ptp180 -80.11 -20.96 43.83 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.536 -0.727 . . . . 50.0 110.413 -179.758 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.469 ' O ' ' HD3' ' A' ' 64' ' ' PRO . 99.3 mtt180 -76.73 -26.13 54.29 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.261 -0.899 . . . . 50.0 110.013 179.821 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.513 ' N ' ' CD1' ' A' ' 47' ' ' TYR . 15.5 m-85 -124.21 158.76 31.67 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.308 -0.87 . . . . 50.0 110.6 -179.813 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.416 ' O ' ' HA ' ' A' ' 61' ' ' CYS . 54.0 tptt -111.89 156.03 22.71 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.438 -0.788 . . . . 50.0 109.151 178.849 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.472 ' HG3' ' HG3' ' A' ' 59' ' ' LYS . 32.7 tt0 -95.25 100.75 12.49 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.923 -1.11 . . . . 50.0 110.65 -179.546 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.537 HD11 ' CD ' ' A' ' 62' ' ' LYS . 66.3 mt -66.92 -31.02 51.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.284 -0.885 . . . . 50.0 109.783 179.443 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 172.67 -97.77 0.12 Allowed Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.55 -1.42 . . . . 50.0 109.55 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 64.9 p -143.36 133.15 23.91 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.205 -1.173 . . . . 50.0 110.44 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' CYS . . . . . 0.535 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 13.8 t -55.01 -45.05 75.09 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.315 -0.865 . . . . 50.0 109.67 179.57 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 167.66 -35.73 0.21 Allowed Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.383 -1.887 . . . . 50.0 108.383 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 66.4 mt -122.38 157.02 59.97 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.542 -0.975 . . . . 50.0 109.491 179.488 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -72.48 -6.5 19.17 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 123.852 1.448 . . . . 50.0 110.641 -179.79 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -71.52 -35.9 62.77 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.495 -1.442 . . . . 50.0 109.495 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 6.2 m -128.59 167.92 16.46 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.323 -1.104 . . . . 50.0 110.183 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.472 ' HG3' ' HG3' ' A' ' 49' ' ' GLN . 16.3 tppt? -124.41 133.68 53.32 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.266 -0.896 . . . . 50.0 110.173 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.535 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 35.3 t -63.06 133.83 55.13 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.29 -0.881 . . . . 50.0 110.527 -179.823 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' CYS . . . . . 0.504 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 74.7 m -133.15 138.65 46.7 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.281 -0.887 . . . . 50.0 110.084 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.537 ' CD ' HD11 ' A' ' 50' ' ' ILE . 87.5 tttt -135.65 144.45 46.05 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.199 -0.938 . . . . 50.0 110.136 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -65.63 150.04 96.6 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.124 -0.985 . . . . 50.0 109.933 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' PRO . . . . . 0.469 ' HD3' ' O ' ' A' ' 46' ' ' ARG . 45.9 Cg_endo . . . . . 0 C--N 1.305 -1.756 0 O-C-N 123.964 1.507 . . . . 99.989999999999995 110.359 -179.676 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.496 ' HB2' ' HA2' ' A' ' 54' ' ' GLY . 48.9 Cg_endo . . . . . 0 N--CA 1.489 1.246 0 N-CA-C 110.441 -0.638 . . . . 50.0 110.441 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.479 HG12 ' N ' ' A' ' 30' ' ' THR . 17.9 t -134.17 172.0 16.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.215 -0.928 . . . . 50.0 110.303 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.49 HG22 ' HB2' ' A' ' 32' ' ' LEU . 26.1 m -117.12 111.63 19.75 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.299 -0.876 . . . . 50.0 110.054 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 93.3 m -76.79 -4.54 44.02 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.264 -0.898 . . . . 50.0 110.437 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.49 ' HB2' HG22 ' A' ' 30' ' ' THR . 18.9 mt -58.91 -45.19 90.92 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.139 -0.975 . . . . 50.0 110.07 179.858 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -66.71 -34.98 79.05 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.368 -0.833 . . . . 50.0 110.223 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 46.6 t -67.58 -25.08 65.61 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.365 -0.834 . . . . 50.0 110.192 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.77 -14.22 60.46 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.707 -1.357 . . . . 50.0 109.707 179.71 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.469 ' HB2' ' HG3' ' A' ' 62' ' ' LYS . . . -70.31 170.58 11.5 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.143 -1.21 . . . . 50.0 110.255 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.787 HD12 ' NE2' ' A' ' 39' ' ' HIS . 14.7 pt -115.38 163.05 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.346 -0.846 . . . . 50.0 109.748 179.464 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 74.8 m -109.74 140.7 43.33 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.156 -0.965 . . . . 50.0 110.046 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.787 ' NE2' HD12 ' A' ' 37' ' ' ILE . 17.2 m-70 -134.34 153.92 79.6 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.198 -0.939 . . . . 50.0 110.115 179.892 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.475 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 45.1 Cg_endo -70.54 162.79 41.19 Favored 'Trans proline' 0 C--N 1.305 -1.743 0 O-C-N 124.029 1.541 . . . . 50.0 111.262 -179.178 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.764 HG12 ' HD2' ' A' ' 42' ' ' PHE . 18.9 t 62.11 -105.18 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.578 -0.701 . . . . 50.0 110.607 179.546 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.764 ' HD2' HG12 ' A' ' 41' ' ' VAL . 25.8 p90 -140.01 157.27 45.94 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.863 -1.148 . . . . 50.0 110.359 -179.688 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' CYS . . . . . 0.465 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 83.8 m -67.83 129.46 93.26 Favored Pre-proline 0 N--CA 1.492 1.626 0 O-C-N 121.181 -0.95 . . . . 50.0 109.829 179.599 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -67.6 -162.94 0.08 OUTLIER 'Trans proline' 0 C--N 1.303 -1.848 0 O-C-N 123.881 1.464 . . . . 50.0 110.846 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 16.2 ptm180 -78.33 -32.26 49.12 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.467 -0.77 . . . . 50.0 110.274 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.439 ' HG2' ' CE1' ' A' ' 47' ' ' TYR . 55.6 ttm-85 -68.3 -25.73 65.29 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.265 -0.897 . . . . 50.0 109.902 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.579 ' CE2' HD11 ' A' ' 37' ' ' ILE . 29.3 m-85 -119.84 157.4 28.75 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.258 -0.901 . . . . 50.0 110.035 179.623 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.405 ' O ' ' HA ' ' A' ' 61' ' ' CYS . 76.6 tttt -109.54 152.22 25.76 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.262 -0.899 . . . . 50.0 109.323 178.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 56.8 tp60 -95.18 101.51 13.26 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.171 -0.955 . . . . 50.0 110.24 -179.777 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 98.2 mt -72.17 -28.98 30.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.289 -0.882 . . . . 50.0 109.775 179.788 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.53 ' C ' HG23 ' A' ' 52' ' ' THR . . . 165.88 -91.87 0.1 Allowed Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.75 -1.34 . . . . 50.0 109.75 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.53 HG23 ' C ' ' A' ' 51' ' ' GLY . 76.4 p -150.52 130.91 13.75 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.188 -1.184 . . . . 50.0 110.563 -179.573 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' CYS . . . . . 0.475 ' O ' ' O ' ' A' ' 29' ' ' VAL . 8.6 t -51.2 -43.17 61.31 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.221 -0.924 . . . . 50.0 110.083 179.87 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.96 ' C ' HD22 ' A' ' 55' ' ' LEU . . . 162.91 -31.63 0.29 Allowed Glycine 0 N--CA 1.488 2.151 0 N-CA-C 109.001 -1.64 . . . . 50.0 109.001 -179.687 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.96 HD22 ' C ' ' A' ' 54' ' ' GLY . 3.2 mm? -126.43 160.9 55.6 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.442 -1.034 . . . . 50.0 109.743 179.758 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -71.45 -10.49 26.99 Favored 'Trans proline' 0 C--N 1.304 -1.799 0 O-C-N 123.801 1.421 . . . . 50.0 110.44 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -64.99 -45.03 93.59 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.595 -1.402 . . . . 50.0 109.595 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' THR . . . . . 0.41 HG22 ' N ' ' A' ' 59' ' ' LYS . 20.1 m -131.36 167.1 19.83 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.327 -1.102 . . . . 50.0 110.423 -179.873 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.492 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 47.0 mmtm -118.93 149.48 41.52 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.439 -0.788 . . . . 50.0 109.533 179.387 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.465 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 36.9 t -76.74 132.55 39.36 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.146 -0.971 . . . . 50.0 110.797 -179.093 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' CYS . . . . . 0.531 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 92.5 m -133.17 133.9 43.42 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.465 -0.772 . . . . 50.0 109.858 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.469 ' HG3' ' HB2' ' A' ' 36' ' ' ALA . 81.3 tttt -127.95 141.97 51.38 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.148 -0.97 . . . . 50.0 110.689 -179.539 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' LYS . . . . . 0.574 ' HE2' ' CZ ' ' A' ' 47' ' ' TYR . 99.4 mttt -75.94 156.69 84.21 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.36 -0.837 . . . . 50.0 110.023 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo . . . . . 0 C--N 1.304 -1.768 0 O-C-N 123.948 1.499 . . . . 99.989999999999995 110.508 179.86 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo . . . . . 0 N--CA 1.487 1.133 0 N-CA-C 110.34 -0.677 . . . . 50.0 110.34 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.463 ' O ' ' O ' ' A' ' 53' ' ' CYS . 15.5 m -107.68 134.19 50.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.305 -0.872 . . . . 50.0 110.206 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.451 ' O ' ' HB2' ' A' ' 31' ' ' CYS . 85.0 m -67.39 -11.89 58.87 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.274 -0.891 . . . . 50.0 110.314 -179.914 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' CYS . . . . . 0.451 ' HB2' ' O ' ' A' ' 30' ' ' THR . 64.1 m 57.28 19.29 4.87 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.161 -0.962 . . . . 50.0 110.399 179.813 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 33.2 tp -72.69 -32.17 65.58 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.165 -0.959 . . . . 50.0 110.633 -179.727 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -71.85 -40.18 69.2 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.103 -0.998 . . . . 50.0 110.226 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 72.3 m -71.82 -24.58 61.74 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.415 -0.803 . . . . 50.0 110.175 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 75.63 16.1 80.85 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.483 -1.447 . . . . 50.0 109.483 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.668 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -83.12 176.74 8.98 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.281 -1.129 . . . . 50.0 110.024 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.472 ' O ' HG13 ' A' ' 37' ' ' ILE . 3.7 pt -116.91 150.77 18.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.134 -0.979 . . . . 50.0 110.42 -179.901 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.446 ' HA ' ' HA ' ' A' ' 60' ' ' CYS . 61.0 m -91.26 137.3 32.47 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.173 -0.954 . . . . 50.0 109.333 179.484 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.517 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 58.3 t-80 -109.49 143.03 26.95 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.054 -1.028 . . . . 50.0 110.76 -179.157 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.517 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 47.5 Cg_endo -73.33 164.78 34.3 Favored 'Trans proline' 0 C--N 1.305 -1.713 0 O-C-N 124.19 1.626 . . . . 50.0 110.316 179.694 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.827 HG12 ' HD2' ' A' ' 42' ' ' PHE . 27.7 t 59.71 -84.02 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.298 -0.876 . . . . 50.0 110.558 179.667 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.827 ' HD2' HG12 ' A' ' 41' ' ' VAL . 16.5 p90 -158.64 161.89 37.21 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.854 -1.154 . . . . 50.0 110.389 -179.916 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' CYS . . . . . 0.434 ' SG ' ' HB3' ' A' ' 47' ' ' TYR . 0.6 OUTLIER -80.92 121.62 81.06 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.216 -0.928 . . . . 50.0 110.059 179.911 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -70.39 -162.52 0.1 OUTLIER 'Trans proline' 0 C--N 1.306 -1.677 0 O-C-N 123.908 1.478 . . . . 50.0 110.592 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 11.2 ptm180 -81.8 -29.76 32.54 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.546 -0.721 . . . . 50.0 110.369 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 45.4 mmm-85 -69.06 -16.1 63.61 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.274 -0.891 . . . . 50.0 110.163 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.568 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 72.4 m-85 -122.93 150.14 43.34 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.29 -0.881 . . . . 50.0 110.337 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 54.0 tptt -110.9 154.11 24.53 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.35 -0.844 . . . . 50.0 110.224 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.517 ' HG3' ' CE ' ' A' ' 59' ' ' LYS . 46.2 tt0 -88.48 108.91 19.63 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.23 -0.919 . . . . 50.0 110.01 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 39.4 pt -104.32 10.76 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.22 -0.925 . . . . 50.0 110.966 -179.51 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.536 ' O ' ' CB ' ' A' ' 60' ' ' CYS . . . 130.62 113.01 1.55 Allowed Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.431 -1.468 . . . . 50.0 109.431 179.927 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.493 ' C ' ' O ' ' A' ' 51' ' ' GLY . 81.9 p -29.52 140.09 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.991 -0.711 . . . . 50.0 111.633 -179.612 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' CYS . . . . . 0.463 ' O ' ' O ' ' A' ' 29' ' ' VAL . 8.3 t -59.52 -50.24 74.69 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.385 -0.822 . . . . 50.0 110.219 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -179.06 -39.85 0.07 OUTLIER Glycine 0 N--CA 1.491 2.323 0 N-CA-C 108.945 -1.662 . . . . 50.0 108.945 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.453 ' HB3' ' HD2' ' A' ' 56' ' ' PRO . 70.2 mt -126.59 164.12 36.44 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.437 -1.037 . . . . 50.0 109.836 179.664 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.453 ' HD2' ' HB3' ' A' ' 55' ' ' LEU . 45.2 Cg_endo -71.21 -7.29 21.04 Favored 'Trans proline' 0 C--N 1.305 -1.762 0 O-C-N 123.971 1.511 . . . . 50.0 110.555 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -68.98 -37.64 83.56 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.16 -1.576 . . . . 50.0 109.16 179.765 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.4 m -129.42 159.97 34.57 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.316 -1.108 . . . . 50.0 110.005 179.773 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.517 ' CE ' ' HG3' ' A' ' 49' ' ' GLN . 37.7 tptt -121.84 127.27 50.35 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.197 -0.94 . . . . 50.0 109.984 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.536 ' CB ' ' O ' ' A' ' 51' ' ' GLY . 49.8 t -57.03 134.26 55.66 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.196 -0.94 . . . . 50.0 110.073 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' CYS . . . . . 0.668 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 54.5 m -136.76 148.26 47.15 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.3 -0.875 . . . . 50.0 109.981 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 81.0 tttt -128.4 132.26 48.5 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.207 -0.933 . . . . 50.0 110.418 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' LYS . . . . . 0.568 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 49.2 mtpt -72.81 152.74 91.25 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.299 -0.875 . . . . 50.0 110.202 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo . . . . . 0 C--N 1.305 -1.758 0 O-C-N 123.983 1.517 . . . . 99.989999999999995 110.497 -179.811 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo . . . . . 0 N--CA 1.49 1.312 0 N-CA-C 110.384 -0.66 . . . . 50.0 110.384 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.528 HG12 ' N ' ' A' ' 30' ' ' THR . 38.6 t -143.29 171.37 8.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.186 -0.946 . . . . 50.0 110.53 -179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.528 ' N ' HG12 ' A' ' 29' ' ' VAL . 57.7 m -109.45 111.26 22.7 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.337 -0.852 . . . . 50.0 109.927 179.619 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 92.6 m -80.01 -8.3 59.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.252 -0.905 . . . . 50.0 110.594 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.0 mt -58.29 -33.14 69.12 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.147 -0.971 . . . . 50.0 110.38 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 95.0 mttt -67.39 -39.09 85.59 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.266 -0.896 . . . . 50.0 110.229 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 14.4 m -65.4 -31.71 72.95 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.292 -0.88 . . . . 50.0 110.154 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 106.73 15.44 16.83 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.696 -1.362 . . . . 50.0 109.696 179.865 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.875 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -120.31 126.38 50.41 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.17 -1.194 . . . . 50.0 110.152 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.74 HD11 ' NE2' ' A' ' 39' ' ' HIS . 1.1 pt -84.02 144.54 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.281 -0.887 . . . . 50.0 109.995 179.855 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.46 ' HA ' ' HA ' ' A' ' 60' ' ' CYS . 22.6 p -87.95 159.69 18.23 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.196 -0.94 . . . . 50.0 110.411 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.74 ' NE2' HD11 ' A' ' 37' ' ' ILE . 41.8 m-70 -131.02 167.88 19.66 Favored Pre-proline 0 N--CA 1.496 1.839 0 O-C-N 121.408 -0.808 . . . . 50.0 110.168 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.453 ' HD2' ' HB3' ' A' ' 39' ' ' HIS . 43.5 Cg_endo -70.16 161.17 46.97 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 O-C-N 123.711 1.374 . . . . 50.0 110.742 -179.601 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.857 HG12 ' HD2' ' A' ' 42' ' ' PHE . 9.8 t 55.82 -112.15 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.297 -0.877 . . . . 50.0 109.883 -179.682 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.857 ' HD2' HG12 ' A' ' 41' ' ' VAL . 50.2 p90 -135.2 156.27 49.27 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.676 -1.265 . . . . 50.0 109.96 179.749 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' CYS . . . . . 0.476 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 83.6 m -59.14 130.47 86.87 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.137 -0.977 . . . . 50.0 110.043 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -70.71 -162.54 0.1 Allowed 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 123.979 1.515 . . . . 50.0 110.603 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 41.5 ptt180 -78.6 -29.35 46.02 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.493 -0.754 . . . . 50.0 110.413 -179.623 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 86.5 mtm180 -72.39 -12.43 61.11 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.237 -0.914 . . . . 50.0 110.16 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.609 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 38.1 m-85 -131.36 165.66 22.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.267 -0.896 . . . . 50.0 111.084 -179.611 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.501 ' O ' ' HA ' ' A' ' 61' ' ' CYS . 33.2 mttm -117.31 142.68 46.78 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.514 -0.741 . . . . 50.0 109.295 178.865 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.497 ' HA ' ' O ' ' A' ' 60' ' ' CYS . 32.7 tt0 -88.19 110.04 20.38 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.981 -1.075 . . . . 50.0 111.188 -179.131 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.646 HD11 ' CG ' ' A' ' 62' ' ' LYS . 80.7 mt -77.21 -28.89 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.314 -0.866 . . . . 50.0 109.326 178.909 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.579 ' C ' HG23 ' A' ' 52' ' ' THR . . . 174.3 -99.54 0.14 Allowed Glycine 0 N--CA 1.488 2.166 0 N-CA-C 108.819 -1.712 . . . . 50.0 108.819 -179.836 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.579 HG23 ' C ' ' A' ' 51' ' ' GLY . 70.9 p -157.65 143.74 17.55 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.284 -1.127 . . . . 50.0 110.191 179.571 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' CYS . . . . . 0.441 ' HA ' ' SG ' ' A' ' 60' ' ' CYS . 1.8 t -58.1 -39.06 77.67 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.217 -0.927 . . . . 50.0 109.882 179.606 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.546 ' O ' HD23 ' A' ' 55' ' ' LEU . . . 165.85 -27.68 0.18 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 108.818 -1.713 . . . . 50.0 108.818 -179.936 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.546 HD23 ' O ' ' A' ' 54' ' ' GLY . 30.2 mt -127.36 166.46 22.86 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.409 -1.054 . . . . 50.0 109.816 179.748 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.488 ' HD2' ' HB3' ' A' ' 55' ' ' LEU . 45.6 Cg_endo -73.52 -4.85 16.12 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.884 1.465 . . . . 50.0 110.447 179.889 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -78.61 -32.81 40.39 Favored Glycine 0 N--CA 1.489 2.167 0 N-CA-C 109.421 -1.472 . . . . 50.0 109.421 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' THR . . . . . 0.536 HG23 ' C ' ' A' ' 39' ' ' HIS . 2.5 m -128.37 162.58 26.77 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.273 -1.134 . . . . 50.0 110.587 -179.897 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.524 ' CG ' ' O ' ' A' ' 41' ' ' VAL . 72.1 mmtt -133.38 142.96 48.63 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.536 -0.728 . . . . 50.0 109.511 179.615 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.497 ' O ' ' HA ' ' A' ' 49' ' ' GLN . 45.1 m -68.98 131.09 44.51 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.083 -1.01 . . . . 50.0 110.255 -179.861 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' CYS . . . . . 0.875 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 98.3 m -124.29 162.07 24.51 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.399 -0.813 . . . . 50.0 110.247 -179.812 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.646 ' CG ' HD11 ' A' ' 50' ' ' ILE . 46.0 mtpt -122.31 164.31 18.14 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.233 -0.917 . . . . 50.0 110.672 -179.748 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' LYS . . . . . 0.609 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 52.1 mtpt -115.19 133.87 22.63 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.364 -0.835 . . . . 50.0 110.334 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo . . . . . 0 C--N 1.307 -1.63 0 O-C-N 123.927 1.488 . . . . 99.989999999999995 110.579 179.729 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo . . . . . 0 N--CA 1.49 1.284 0 N-CA-C 110.351 -0.673 . . . . 50.0 110.351 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.3 m -135.12 145.56 31.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.208 -0.932 . . . . 50.0 110.489 -179.787 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.494 HG22 ' HB2' ' A' ' 32' ' ' LEU . 25.0 m -100.48 105.99 17.5 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.297 -0.877 . . . . 50.0 110.097 179.894 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' CYS . . . . . 0.848 ' HB3' ' HB3' ' A' ' 36' ' ' ALA . 87.2 m -77.39 -1.6 30.94 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.193 -0.942 . . . . 50.0 110.411 -179.834 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.494 ' HB2' HG22 ' A' ' 30' ' ' THR . 32.9 mt -63.35 -39.64 95.08 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.222 -0.924 . . . . 50.0 110.261 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 43.0 mmtm -66.75 -42.58 85.95 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.29 -0.882 . . . . 50.0 110.362 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 86.3 p -70.46 -14.77 62.67 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.347 -0.846 . . . . 50.0 110.143 -179.892 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 87.12 4.79 81.19 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.543 -1.423 . . . . 50.0 109.543 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.848 ' HB3' ' HB3' ' A' ' 31' ' ' CYS . . . -71.8 155.64 40.21 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.159 -1.201 . . . . 50.0 110.009 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 1.008 HD12 ' NE2' ' A' ' 39' ' ' HIS . 26.7 pt -103.89 145.0 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.185 -0.947 . . . . 50.0 110.015 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 8.7 m -101.22 125.39 47.84 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.258 -0.901 . . . . 50.0 109.936 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 1.008 ' NE2' HD12 ' A' ' 37' ' ' ILE . 12.5 m-70 -119.48 153.06 53.77 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.232 -0.917 . . . . 50.0 110.345 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.427 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 45.7 Cg_endo -71.16 169.88 19.55 Favored 'Trans proline' 0 C--N 1.305 -1.727 0 O-C-N 124.04 1.547 . . . . 50.0 110.852 -179.604 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.795 HG12 ' HD2' ' A' ' 42' ' ' PHE . 17.4 t 59.15 -109.35 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.362 -0.836 . . . . 50.0 110.186 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.795 ' HD2' HG12 ' A' ' 41' ' ' VAL . 36.8 p90 -136.24 153.64 51.15 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.827 -1.171 . . . . 50.0 110.017 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' CYS . . . . . 0.407 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 76.4 m -69.88 132.26 88.8 Favored Pre-proline 0 N--CA 1.487 1.415 0 O-C-N 121.11 -0.994 . . . . 50.0 109.911 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -68.41 -162.76 0.08 OUTLIER 'Trans proline' 0 C--N 1.305 -1.732 0 O-C-N 123.996 1.524 . . . . 50.0 111.004 -179.564 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 16.2 ptm180 -81.58 -26.37 35.01 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.558 -0.714 . . . . 50.0 110.453 -179.617 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 13.3 mmm180 -66.71 -22.22 66.07 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.148 -0.97 . . . . 50.0 110.1 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.626 ' CB ' ' HB3' ' A' ' 61' ' ' CYS . 70.8 m-85 -128.1 144.01 51.09 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.217 -0.927 . . . . 50.0 110.589 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 85.0 tttt -88.67 152.88 21.53 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.267 -0.896 . . . . 50.0 109.221 178.872 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 56.4 tt0 -93.4 96.44 9.93 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.093 -1.005 . . . . 50.0 110.562 -179.702 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 93.6 mt -69.42 -30.11 44.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.309 -0.87 . . . . 50.0 109.904 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.576 ' C ' HG23 ' A' ' 52' ' ' THR . . . 159.12 -91.86 0.12 Allowed Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.263 -1.535 . . . . 50.0 109.263 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.576 HG23 ' C ' ' A' ' 51' ' ' GLY . 63.3 p -153.92 150.58 28.5 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.26 -1.141 . . . . 50.0 109.992 179.695 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' CYS . . . . . 0.42 ' SG ' ' HB2' ' A' ' 60' ' ' CYS . 1.6 m -84.89 -27.33 26.72 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.189 -0.944 . . . . 50.0 110.694 -179.599 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 179.03 -49.5 0.09 OUTLIER Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.764 -1.334 . . . . 50.0 109.764 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 56.2 mt -119.74 161.92 35.47 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.16 -1.2 . . . . 50.0 110.419 -179.851 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -71.93 -11.4 27.42 Favored 'Trans proline' 0 C--N 1.305 -1.74 0 O-C-N 124.08 1.569 . . . . 50.0 110.292 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -68.94 -30.47 72.32 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.448 -1.461 . . . . 50.0 109.448 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -125.25 155.28 40.37 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.275 -1.132 . . . . 50.0 110.298 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.445 ' O ' ' SG ' ' A' ' 61' ' ' CYS . 14.1 tppt? -120.56 127.16 51.89 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.396 -0.815 . . . . 50.0 109.839 179.686 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.42 ' HB2' ' SG ' ' A' ' 53' ' ' CYS . 34.3 t -63.51 130.9 46.29 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.252 -0.905 . . . . 50.0 110.663 -179.604 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' CYS . . . . . 0.626 ' HB3' ' CB ' ' A' ' 47' ' ' TYR . 7.4 m -128.58 130.3 47.16 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.371 -0.831 . . . . 50.0 109.635 179.765 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 83.4 tttt -131.62 148.69 52.62 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.157 -0.964 . . . . 50.0 110.507 -179.638 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 86.0 mttt -72.76 150.36 90.77 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.281 -0.887 . . . . 50.0 110.021 179.887 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo . . . . . 0 C--N 1.306 -1.685 0 O-C-N 123.955 1.502 . . . . 99.989999999999995 110.401 179.977 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo . . . . . 0 N--CA 1.489 1.25 0 N-CA-C 110.553 -0.595 . . . . 50.0 110.553 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.47 ' O ' ' O ' ' A' ' 53' ' ' CYS . 18.2 m -125.21 125.45 69.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.311 -0.868 . . . . 50.0 110.084 179.879 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.507 HG22 ' HB2' ' A' ' 32' ' ' LEU . 85.8 m -64.7 -15.59 61.64 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.323 -0.861 . . . . 50.0 110.54 -179.789 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' CYS . . . . . 0.479 ' HB2' ' O ' ' A' ' 30' ' ' THR . 97.9 m 56.61 18.38 3.6 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.232 -0.918 . . . . 50.0 110.223 179.836 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.753 HD13 ' C ' ' A' ' 32' ' ' LEU . 3.4 tm? -76.62 -39.47 52.36 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.223 -0.923 . . . . 50.0 110.477 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 74.4 mmtt -75.13 -35.24 61.7 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.324 -0.86 . . . . 50.0 109.985 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 73.9 m -71.18 -26.72 63.09 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.374 -0.829 . . . . 50.0 110.191 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 84.98 9.0 81.54 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.493 -1.443 . . . . 50.0 109.493 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.455 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -76.66 134.37 39.29 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.232 -1.158 . . . . 50.0 110.262 -179.914 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.684 HD11 ' CE2' ' A' ' 47' ' ' TYR . 9.1 pt -83.02 148.13 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.239 -0.913 . . . . 50.0 110.028 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 96.5 m -91.79 148.79 21.98 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.075 -1.016 . . . . 50.0 109.882 179.862 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.583 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 62.6 t-80 -139.71 145.9 45.17 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 121.312 -0.868 . . . . 50.0 109.89 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.583 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 41.6 Cg_endo -66.89 159.63 50.79 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.868 1.457 . . . . 50.0 110.075 179.723 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.827 HG12 ' HD2' ' A' ' 42' ' ' PHE . 13.5 t 62.99 -105.94 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.224 -0.922 . . . . 50.0 109.913 -179.673 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.827 ' HD2' HG12 ' A' ' 41' ' ' VAL . 42.1 p90 -142.26 157.9 44.32 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.626 -1.296 . . . . 50.0 110.148 179.814 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' CYS . . . . . 0.455 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 84.4 m -65.02 132.54 95.5 Favored Pre-proline 0 N--CA 1.493 1.699 0 O-C-N 121.241 -0.912 . . . . 50.0 110.371 -179.792 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -68.71 -162.16 0.08 OUTLIER 'Trans proline' 0 C--N 1.305 -1.75 0 O-C-N 123.995 1.524 . . . . 50.0 110.839 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 27.3 tpt180 -75.61 -43.13 49.63 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.519 -0.738 . . . . 50.0 110.537 -179.681 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.454 ' HG3' ' HG3' ' A' ' 64' ' ' PRO . 45.8 ttt85 -61.45 -30.77 70.8 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.333 -0.854 . . . . 50.0 110.372 -179.723 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.684 ' CE2' HD11 ' A' ' 37' ' ' ILE . 32.2 m-85 -111.1 136.36 50.26 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.193 -0.942 . . . . 50.0 110.747 -179.85 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 24.6 tptp -87.37 157.14 19.32 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.261 -0.899 . . . . 50.0 109.387 179.034 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.416 ' HA ' ' SG ' ' A' ' 43' ' ' CYS . 53.7 tt0 -89.5 102.7 15.38 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.099 -1.001 . . . . 50.0 110.356 -179.777 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.419 ' HB ' ' SG ' ' A' ' 60' ' ' CYS . 30.6 mm -67.08 -30.66 50.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.227 -0.921 . . . . 50.0 109.555 179.552 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 153.77 -91.16 0.13 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.035 -1.626 . . . . 50.0 109.035 179.866 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 50.1 p -146.2 125.9 13.42 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.363 -1.081 . . . . 50.0 109.976 179.603 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' CYS . . . . . 0.47 ' O ' ' O ' ' A' ' 29' ' ' VAL . 19.1 t -49.85 -49.22 49.98 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.252 -0.905 . . . . 50.0 109.669 179.635 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 173.47 -30.15 0.1 OUTLIER Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.211 -1.556 . . . . 50.0 109.211 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.407 ' HA ' HD23 ' A' ' 55' ' ' LEU . 55.6 mt -124.87 160.3 54.72 Favored Pre-proline 0 N--CA 1.489 1.512 0 O-C-N 121.384 -1.068 . . . . 50.0 109.917 179.866 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -71.97 -5.8 17.83 Favored 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.928 1.488 . . . . 50.0 110.198 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -78.32 -37.12 28.83 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.469 -1.452 . . . . 50.0 109.469 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 5.1 m -130.59 162.23 29.79 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.269 -1.136 . . . . 50.0 110.268 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 66.7 mmtt -117.56 164.59 14.69 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.408 -0.808 . . . . 50.0 109.778 179.718 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.455 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 42.2 t -91.32 129.7 37.27 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.139 -0.975 . . . . 50.0 110.468 -179.78 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' CYS . . . . . 0.505 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 72.4 m -126.42 147.71 49.75 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.342 -0.849 . . . . 50.0 109.832 179.808 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 89.1 tttt -126.58 138.35 53.45 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.15 -0.969 . . . . 50.0 110.323 -179.857 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' LYS . . . . . 0.433 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 30.3 mtmm -63.07 154.69 76.43 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.333 -0.855 . . . . 50.0 110.325 179.88 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' PRO . . . . . 0.454 ' HG3' ' HG3' ' A' ' 46' ' ' ARG . 47.5 Cg_endo . . . . . 0 C--N 1.306 -1.71 0 O-C-N 124.01 1.532 . . . . 99.989999999999995 110.38 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.442 ' O ' ' HB ' ' A' ' 29' ' ' VAL . 47.1 Cg_endo . . . . . 0 N--CA 1.489 1.246 0 N-CA-C 110.399 -0.654 . . . . 50.0 110.399 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.568 HG12 ' N ' ' A' ' 30' ' ' THR . 46.9 t 56.8 172.52 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.16 -0.962 . . . . 50.0 110.102 -179.914 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.737 ' O ' HG22 ' A' ' 30' ' ' THR . 95.3 m 39.16 28.21 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.491 -0.755 . . . . 50.0 110.587 -179.812 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' CYS . . . . . 0.48 ' N ' ' O ' ' A' ' 29' ' ' VAL . 65.4 m -48.5 -22.5 0.74 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.13 -0.981 . . . . 50.0 109.721 179.682 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.7 mt -57.98 -42.76 85.76 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.249 -0.907 . . . . 50.0 110.08 179.568 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.638 ' HB2' HG22 ' A' ' 30' ' ' THR . 64.8 mmtt -68.24 -33.3 74.13 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.444 -0.785 . . . . 50.0 110.185 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 69.3 m -76.37 -17.53 59.34 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.228 -0.92 . . . . 50.0 109.942 179.837 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 91.93 -2.87 76.67 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.858 -1.297 . . . . 50.0 109.858 179.586 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.435 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -79.59 153.94 29.09 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.124 -1.221 . . . . 50.0 110.226 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.471 ' O ' ' N ' ' A' ' 61' ' ' CYS . 4.8 pt -107.79 152.88 9.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.288 -0.882 . . . . 50.0 110.052 179.826 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 71.8 m -93.32 148.98 21.57 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.202 -0.937 . . . . 50.0 110.045 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.596 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 42.0 t-80 -136.49 145.96 53.73 Favored Pre-proline 0 N--CA 1.491 1.614 0 O-C-N 121.275 -0.891 . . . . 50.0 110.16 -179.685 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.596 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 42.5 Cg_endo -68.59 153.02 74.38 Favored 'Trans proline' 0 C--N 1.307 -1.612 0 O-C-N 123.844 1.444 . . . . 50.0 110.544 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.835 HG12 ' HD2' ' A' ' 42' ' ' PHE . 18.0 t 64.24 -84.62 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.577 -0.702 . . . . 50.0 110.559 -179.784 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.835 ' HD2' HG12 ' A' ' 41' ' ' VAL . 21.6 p90 -156.56 161.96 39.94 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.714 -1.241 . . . . 50.0 110.214 179.963 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' CYS . . . . . 0.435 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 58.4 m -73.25 134.12 80.48 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.249 -0.907 . . . . 50.0 110.526 -179.665 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.454 ' O ' ' O ' ' A' ' 47' ' ' TYR . 44.3 Cg_endo -70.18 -160.63 0.07 OUTLIER 'Trans proline' 0 C--N 1.305 -1.718 0 O-C-N 123.874 1.46 . . . . 50.0 110.522 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 17.4 mmt180 -78.45 -46.58 19.41 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.493 -0.754 . . . . 50.0 109.68 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 82.1 mtm180 -54.39 -23.97 17.82 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.56 -0.713 . . . . 50.0 109.674 179.783 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.555 ' CZ ' ' HE2' ' A' ' 63' ' ' LYS . 39.4 m-85 -122.95 154.04 38.93 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.411 -0.805 . . . . 50.0 110.259 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 82.1 tttt -117.84 149.74 40.33 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.4 -0.813 . . . . 50.0 109.679 179.594 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 58.8 tt0 -88.71 94.92 10.07 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.184 -0.948 . . . . 50.0 109.892 179.638 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.463 HG13 ' N ' ' A' ' 51' ' ' GLY . 21.6 pt -71.4 -30.08 38.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.402 -0.811 . . . . 50.0 110.326 -179.821 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.504 ' C ' HG23 ' A' ' 52' ' ' THR . . . -171.52 -105.63 0.18 Allowed Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.483 -1.447 . . . . 50.0 109.483 179.76 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.504 HG23 ' C ' ' A' ' 51' ' ' GLY . 41.2 p -151.17 141.02 21.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.285 -1.127 . . . . 50.0 110.218 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' CYS . . . . . 0.577 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 10.0 t -58.49 -44.39 89.38 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.273 -0.892 . . . . 50.0 109.873 179.879 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 160.08 -36.9 0.46 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.033 -1.627 . . . . 50.0 109.033 -179.83 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 74.8 mt -113.45 155.29 44.94 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.428 -1.042 . . . . 50.0 109.924 179.669 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -71.32 -11.8 29.04 Favored 'Trans proline' 0 C--N 1.303 -1.853 0 O-C-N 123.922 1.485 . . . . 50.0 110.69 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -70.92 -41.92 61.07 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.57 -1.412 . . . . 50.0 109.57 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 14.6 m -122.79 166.86 14.27 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.337 -1.096 . . . . 50.0 110.248 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -124.7 145.66 49.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.406 -0.809 . . . . 50.0 109.87 179.806 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.577 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 45.2 t -73.47 139.36 45.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.151 -0.968 . . . . 50.0 110.431 -179.803 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' CYS . . . . . 0.494 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 74.8 m -131.49 141.65 49.81 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.389 -0.82 . . . . 50.0 109.61 179.748 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 81.8 tttt -138.65 143.52 39.26 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.205 -0.934 . . . . 50.0 110.658 -179.341 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' LYS . . . . . 0.555 ' HE2' ' CZ ' ' A' ' 47' ' ' TYR . 98.9 mttt -77.28 142.0 67.19 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.294 -0.879 . . . . 50.0 110.158 179.81 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo . . . . . 0 C--N 1.305 -1.741 0 O-C-N 123.957 1.504 . . . . 99.989999999999995 110.412 179.975 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo . . . . . 0 N--CA 1.491 1.332 0 N-CA-C 110.445 -0.637 . . . . 50.0 110.445 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.79 HG22 ' O ' ' A' ' 52' ' ' THR . 31.0 m -90.46 147.25 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.259 -0.901 . . . . 50.0 110.293 179.891 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.665 HG22 ' HB2' ' A' ' 32' ' ' LEU . 85.6 m -64.22 -40.14 95.44 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.254 -0.904 . . . . 50.0 110.571 -179.768 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' CYS . . . . . 0.758 ' SG ' HG23 ' A' ' 29' ' ' VAL . 47.9 m 56.87 21.97 6.63 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.14 -0.975 . . . . 50.0 110.312 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.665 ' HB2' HG22 ' A' ' 30' ' ' THR . 79.2 mt -105.12 -21.05 13.33 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.193 -0.942 . . . . 50.0 110.176 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 95.2 mttt -72.58 -37.52 68.15 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.345 -0.847 . . . . 50.0 110.324 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 87.9 p -88.76 -4.04 58.61 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.292 -0.88 . . . . 50.0 110.25 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 69.42 21.38 76.01 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.195 -1.562 . . . . 50.0 109.195 -179.84 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -70.22 155.16 41.03 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.35 -1.088 . . . . 50.0 110.211 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.966 HD12 ' NE2' ' A' ' 39' ' ' HIS . 12.8 pt -104.73 151.05 7.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.21 -0.931 . . . . 50.0 110.253 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 76.2 m -105.38 139.54 39.85 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.299 -0.875 . . . . 50.0 110.031 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.966 ' NE2' HD12 ' A' ' 37' ' ' ILE . 17.3 m-70 -133.52 157.9 76.9 Favored Pre-proline 0 N--CA 1.494 1.74 0 O-C-N 121.346 -0.846 . . . . 50.0 110.192 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.466 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 45.2 Cg_endo -71.58 168.42 23.68 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 O-C-N 124.059 1.557 . . . . 50.0 110.415 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.87 HG12 ' HD2' ' A' ' 42' ' ' PHE . 10.8 t 61.84 -108.37 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.237 -0.914 . . . . 50.0 109.804 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.87 ' HD2' HG12 ' A' ' 41' ' ' VAL . 48.6 p90 -143.63 161.78 37.63 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.747 -1.221 . . . . 50.0 110.108 179.704 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' CYS . . . . . 0.462 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 70.8 m -67.33 132.43 93.24 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.222 -0.924 . . . . 50.0 110.356 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -71.29 -162.56 0.11 Allowed 'Trans proline' 0 C--N 1.306 -1.707 0 O-C-N 123.933 1.491 . . . . 50.0 110.346 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 30.2 mtt180 -78.21 -41.47 34.32 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.424 -0.798 . . . . 50.0 110.015 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.466 ' O ' ' HD3' ' A' ' 64' ' ' PRO . 26.0 mmm180 -57.95 -27.94 63.87 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.483 -0.761 . . . . 50.0 110.21 -179.777 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.535 ' CE2' ' CG ' ' A' ' 63' ' ' LYS . 21.7 m-85 -119.12 158.9 24.98 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.345 -0.847 . . . . 50.0 110.534 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -117.08 131.0 57.02 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.467 -0.77 . . . . 50.0 109.634 179.307 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.449 ' HB2' ' HB2' ' A' ' 43' ' ' CYS . 54.4 tt0 -78.14 104.14 8.53 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.276 -0.89 . . . . 50.0 111.024 -179.082 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.701 HD11 ' HD3' ' A' ' 62' ' ' LYS . 79.5 mt -68.71 -31.21 49.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.335 -0.853 . . . . 50.0 109.387 179.111 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.443 ' C ' HG23 ' A' ' 52' ' ' THR . . . 172.95 -96.67 0.11 Allowed Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.662 -1.375 . . . . 50.0 109.662 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.79 ' O ' HG22 ' A' ' 29' ' ' VAL . 68.6 p -146.7 137.2 23.8 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.207 -1.172 . . . . 50.0 110.327 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' CYS . . . . . . . . . . . . . 4.1 t -62.35 -41.43 98.58 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.263 -0.898 . . . . 50.0 110.137 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 158.93 -25.68 0.36 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 108.994 -1.642 . . . . 50.0 108.994 -179.897 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.521 ' CD1' ' HD2' ' A' ' 56' ' ' PRO . 17.4 tp -120.8 142.44 34.45 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.401 -1.059 . . . . 50.0 109.712 179.777 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.521 ' HD2' ' CD1' ' A' ' 55' ' ' LEU . 42.0 Cg_endo -67.92 -8.17 21.82 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 O-C-N 123.872 1.459 . . . . 50.0 110.442 -179.841 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -75.99 -32.09 53.88 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.062 -1.615 . . . . 50.0 109.062 179.511 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' THR . . . . . 0.464 ' HA ' ' HA ' ' A' ' 40' ' ' PRO . 4.0 m -131.28 162.12 30.75 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.262 -1.14 . . . . 50.0 110.4 179.896 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.493 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 46.5 mmtm -120.76 146.63 46.3 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.285 -0.884 . . . . 50.0 109.829 179.741 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.462 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 42.7 t -75.82 133.4 40.64 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.264 -0.898 . . . . 50.0 110.749 -179.376 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' CYS . . . . . 0.514 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 73.6 m -130.45 135.08 47.62 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.365 -0.834 . . . . 50.0 109.791 179.807 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.701 ' HD3' HD11 ' A' ' 50' ' ' ILE . 39.8 ttpt -126.51 135.15 50.95 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.09 -1.006 . . . . 50.0 110.287 -179.862 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' LYS . . . . . 0.535 ' CG ' ' CE2' ' A' ' 47' ' ' TYR . 49.5 mtmt -70.97 151.83 95.01 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.319 -0.863 . . . . 50.0 110.128 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' PRO . . . . . 0.466 ' HD3' ' O ' ' A' ' 46' ' ' ARG . 45.6 Cg_endo . . . . . 0 C--N 1.304 -1.781 0 O-C-N 124.022 1.538 . . . . 99.989999999999995 110.494 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo . . . . . 0 N--CA 1.489 1.228 0 N-CA-C 110.225 -0.721 . . . . 50.0 110.225 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 5.3 m -133.44 144.36 36.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.247 -0.908 . . . . 50.0 110.373 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 97.0 m -115.72 114.24 24.56 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.337 -0.852 . . . . 50.0 110.034 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' CYS . . . . . 0.862 ' SG ' ' SG ' ' A' ' 53' ' ' CYS . 76.9 m -76.56 -7.15 54.62 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.274 -0.891 . . . . 50.0 110.399 -179.856 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.405 HD12 ' HA ' ' A' ' 32' ' ' LEU . 50.7 tp -65.35 -40.98 94.3 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.189 -0.945 . . . . 50.0 110.28 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -62.55 -44.19 96.94 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.321 -0.862 . . . . 50.0 110.271 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 58.1 m -66.13 -33.32 75.51 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.357 -0.839 . . . . 50.0 110.139 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 104.56 8.52 37.5 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.397 -1.481 . . . . 50.0 109.397 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.669 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -96.13 123.38 39.72 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.263 -1.14 . . . . 50.0 109.95 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.457 ' O ' HG13 ' A' ' 37' ' ' ILE . 2.2 pt -71.61 151.5 8.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.155 -0.965 . . . . 50.0 110.495 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 24.5 m -91.28 154.73 19.05 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.182 -0.949 . . . . 50.0 109.871 179.645 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.545 ' O ' ' N ' ' A' ' 59' ' ' LYS . 64.7 t-80 -129.78 140.79 39.69 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.123 -0.986 . . . . 50.0 110.571 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.483 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 43.7 Cg_endo -70.4 161.83 44.6 Favored 'Trans proline' 0 C--N 1.304 -1.806 0 O-C-N 123.967 1.509 . . . . 50.0 111.091 -179.78 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.786 HG12 ' HD2' ' A' ' 42' ' ' PHE . 33.1 t 57.18 -84.23 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.536 -0.727 . . . . 50.0 110.955 179.846 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.786 ' HD2' HG12 ' A' ' 41' ' ' VAL . 14.0 p90 -155.26 157.65 37.59 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.873 -1.142 . . . . 50.0 110.457 -179.653 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' CYS . . . . . 0.422 ' SG ' ' HB3' ' A' ' 47' ' ' TYR . 0.7 OUTLIER -71.82 133.9 84.01 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 121.327 -0.858 . . . . 50.0 110.293 179.896 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.436 ' HD2' ' HB2' ' A' ' 47' ' ' TYR . 45.1 Cg_endo -70.55 -162.23 0.1 OUTLIER 'Trans proline' 0 C--N 1.306 -1.665 0 O-C-N 123.883 1.465 . . . . 50.0 110.543 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 28.7 tpt180 -81.93 -37.05 27.35 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.534 -0.729 . . . . 50.0 110.365 -179.813 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -66.39 -29.71 69.93 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.381 -0.824 . . . . 50.0 110.172 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.542 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 45.8 m-85 -110.37 138.48 46.7 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.267 -0.896 . . . . 50.0 110.842 -179.597 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.452 ' O ' ' HA ' ' A' ' 61' ' ' CYS . 67.0 tttt -90.6 153.05 20.61 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.242 -0.912 . . . . 50.0 109.219 178.915 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 36.0 tt0 -102.07 98.9 9.02 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.041 -1.037 . . . . 50.0 110.302 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 97.0 mt -64.38 -28.6 45.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.46 -0.775 . . . . 50.0 109.984 179.888 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 160.5 -91.3 0.11 Allowed Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.551 -1.419 . . . . 50.0 109.551 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 67.6 p -145.29 159.28 43.27 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.283 -1.128 . . . . 50.0 110.313 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' CYS . . . . . 0.862 ' SG ' ' SG ' ' A' ' 31' ' ' CYS . 0.5 OUTLIER -104.53 -15.76 15.25 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.279 -0.888 . . . . 50.0 110.329 -179.923 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 162.34 -43.6 0.36 Allowed Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.45 -1.46 . . . . 50.0 109.45 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 87.2 mt -123.34 159.39 55.01 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.277 -1.131 . . . . 50.0 109.955 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.72 -16.99 26.37 Favored 'Trans proline' 0 C--N 1.304 -1.787 0 O-C-N 123.896 1.472 . . . . 50.0 110.383 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -68.08 -33.97 80.18 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.457 -1.457 . . . . 50.0 109.457 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' THR . . . . . 0.515 HG22 ' N ' ' A' ' 59' ' ' LYS . 34.3 m -117.24 170.14 8.92 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.262 -1.14 . . . . 50.0 110.388 179.861 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.545 ' N ' ' O ' ' A' ' 39' ' ' HIS . 73.7 mmtt -133.75 155.93 48.89 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.437 -0.789 . . . . 50.0 109.56 179.787 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 13.1 t -83.09 127.86 33.96 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.075 -1.016 . . . . 50.0 110.308 -179.586 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' CYS . . . . . 0.669 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 51.0 m -127.05 146.4 50.37 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.272 -0.892 . . . . 50.0 110.266 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 76.9 tttt -129.38 136.11 49.56 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.211 -0.931 . . . . 50.0 110.319 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' LYS . . . . . 0.542 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 97.6 mttt -79.57 143.42 59.12 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.251 -0.906 . . . . 50.0 109.968 179.805 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo . . . . . 0 C--N 1.305 -1.733 0 O-C-N 123.897 1.472 . . . . 99.989999999999995 110.394 -179.805 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.474 ' C ' HG13 ' A' ' 29' ' ' VAL . 46.4 Cg_endo . . . . . 0 N--CA 1.49 1.309 0 N-CA-C 110.478 -0.624 . . . . 50.0 110.478 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.474 HG13 ' C ' ' A' ' 28' ' ' PRO . 27.6 m -150.19 145.42 17.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.171 -0.956 . . . . 50.0 110.263 179.889 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.458 HG22 ' HB3' ' A' ' 32' ' ' LEU . 86.1 m -105.71 107.7 18.83 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.272 -0.892 . . . . 50.0 110.012 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' CYS . . . . . 0.475 ' HB3' ' HB3' ' A' ' 36' ' ' ALA . 95.8 m -75.86 -4.55 41.41 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.35 -0.844 . . . . 50.0 110.35 -179.793 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.458 ' HB3' HG22 ' A' ' 30' ' ' THR . 49.8 tp -55.67 -49.57 72.56 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.192 -0.943 . . . . 50.0 109.996 179.764 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -59.89 -36.18 76.41 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.481 -0.762 . . . . 50.0 110.153 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 70.6 m -73.06 -27.46 61.75 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.34 -0.85 . . . . 50.0 110.235 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 95.01 -6.32 69.22 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.509 -1.436 . . . . 50.0 109.509 -179.861 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.475 ' HB3' ' HB3' ' A' ' 31' ' ' CYS . . . -66.46 141.6 57.85 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.209 -1.171 . . . . 50.0 110.074 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.894 HD12 ' NE2' ' A' ' 39' ' ' HIS . 7.2 pt -86.98 150.16 3.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.203 -0.935 . . . . 50.0 110.253 -179.841 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 76.6 m -105.99 144.64 32.43 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.261 -0.9 . . . . 50.0 110.1 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.894 ' NE2' HD12 ' A' ' 37' ' ' ILE . 27.6 m-70 -135.48 158.99 73.27 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.259 -0.901 . . . . 50.0 110.315 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -70.15 172.59 12.74 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 O-C-N 124.002 1.527 . . . . 50.0 110.274 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.81 HG12 ' HD1' ' A' ' 42' ' ' PHE . 7.5 t 54.74 -115.35 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.297 -0.877 . . . . 50.0 109.788 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.81 ' HD1' HG12 ' A' ' 41' ' ' VAL . 39.4 p90 -137.88 156.31 48.04 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.774 -1.204 . . . . 50.0 109.94 179.641 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' CYS . . . . . 0.459 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 82.6 m -57.46 130.87 81.38 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.242 -0.911 . . . . 50.0 110.372 -179.737 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -71.72 -161.88 0.1 Allowed 'Trans proline' 0 C--N 1.305 -1.718 0 O-C-N 124.062 1.559 . . . . 50.0 110.73 179.777 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 19.1 ptp180 -76.35 -29.43 57.23 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.562 -0.711 . . . . 50.0 110.557 -179.584 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 62.7 mtp180 -69.88 -25.94 63.95 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.245 -0.91 . . . . 50.0 110.623 -179.544 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' TYR . . . . . 0.561 ' N ' ' CD1' ' A' ' 47' ' ' TYR . 11.6 m-85 -124.81 151.39 45.27 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.164 -0.96 . . . . 50.0 110.635 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 45.8 tttm -97.91 150.86 20.86 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.355 -0.841 . . . . 50.0 109.225 178.768 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.403 ' HA ' ' SG ' ' A' ' 43' ' ' CYS . 50.8 tt0 -93.54 95.38 9.21 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.983 -1.073 . . . . 50.0 110.42 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.512 HD11 ' CD ' ' A' ' 62' ' ' LYS . 97.3 mt -65.36 -31.24 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.297 -0.877 . . . . 50.0 110.068 179.807 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.498 ' C ' HG23 ' A' ' 52' ' ' THR . . . 168.77 -95.44 0.11 Allowed Glycine 0 N--CA 1.487 2.074 0 N-CA-C 109.534 -1.426 . . . . 50.0 109.534 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.498 HG23 ' C ' ' A' ' 51' ' ' GLY . 62.5 p -150.32 143.26 24.78 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.217 -1.166 . . . . 50.0 110.386 -179.824 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' CYS . . . . . 0.455 ' O ' ' O ' ' A' ' 29' ' ' VAL . 4.4 t -63.87 -40.95 97.76 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.237 -0.914 . . . . 50.0 109.844 179.74 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 157.84 -24.98 0.42 Allowed Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.07 -1.612 . . . . 50.0 109.07 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.514 ' CD1' ' HD2' ' A' ' 56' ' ' PRO . 16.9 tp -123.96 143.64 42.85 Favored Pre-proline 0 N--CA 1.489 1.517 0 O-C-N 121.5 -1.0 . . . . 50.0 109.596 179.773 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.514 ' HD2' ' CD1' ' A' ' 55' ' ' LEU . 39.9 Cg_endo -66.48 -5.3 12.5 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 O-C-N 123.773 1.407 . . . . 50.0 110.827 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -74.65 -33.88 54.85 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.158 -1.577 . . . . 50.0 109.158 179.378 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' THR . . . . . 0.474 HG23 ' C ' ' A' ' 39' ' ' HIS . 4.8 m -135.53 162.74 31.82 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.231 -1.158 . . . . 50.0 110.211 179.692 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.478 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 43.5 mmtm -115.49 151.82 34.1 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.346 -0.846 . . . . 50.0 109.937 179.662 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.459 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 26.6 t -81.39 133.5 35.42 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.251 -0.905 . . . . 50.0 110.656 -179.525 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' CYS . . . . . 0.516 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 72.0 m -131.12 141.22 50.1 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.371 -0.831 . . . . 50.0 109.961 179.73 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' LYS . . . . . 0.512 ' CD ' HD11 ' A' ' 50' ' ' ILE . 81.1 tttt -131.93 144.35 50.78 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.174 -0.954 . . . . 50.0 110.309 -179.737 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' LYS . . . . . 0.482 ' HE2' ' OH ' ' A' ' 47' ' ' TYR . 96.2 mttt -77.0 151.17 81.75 Favored Pre-proline 0 N--CA 1.491 1.603 0 O-C-N 121.411 -0.806 . . . . 50.0 110.31 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo . . . . . 0 C--N 1.304 -1.766 0 O-C-N 123.94 1.495 . . . . 99.989999999999995 110.435 179.967 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.553 HG22 ' HB2' ' A' ' 32' ' ' LEU . 98.5 m . . . . . 0 N--CA 1.493 1.711 0 CA-C-O 121.095 0.474 . . . . 50.0 110.566 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . 0.447 ' HB2' ' O ' ' A' ' 30' ' ' THR . 93.3 m 56.22 22.44 6.14 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.215 -0.928 . . . . 50.0 110.311 -179.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.747 HD13 ' C ' ' A' ' 32' ' ' LEU . 3.4 tm? -75.35 -38.51 60.06 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.137 -0.977 . . . . 50.0 110.283 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 96.0 mttt -68.69 -41.64 78.88 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.303 -0.873 . . . . 50.0 110.209 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 94.9 p -69.77 -20.46 63.48 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.303 -0.873 . . . . 50.0 110.32 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 79.25 6.73 88.82 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.662 -1.375 . . . . 50.0 109.662 179.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . 0.679 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -68.93 147.65 51.33 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.119 -1.224 . . . . 50.0 110.151 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.645 HD11 ' CE2' ' A' ' 47' ' ' TYR . 2.1 pt -93.45 151.77 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.148 -0.97 . . . . 50.0 110.063 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 86.3 m -91.27 142.57 27.57 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.244 -0.91 . . . . 50.0 110.372 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.514 ' CB ' ' SG ' ' A' ' 61' ' ' CYS . 54.4 t-80 -119.98 142.2 32.9 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.282 -0.886 . . . . 50.0 109.981 179.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.505 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 44.9 Cg_endo -71.52 155.85 58.87 Favored 'Trans proline' 0 C--N 1.305 -1.762 0 O-C-N 123.907 1.477 . . . . 50.0 110.857 -179.575 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.661 HG12 ' HD2' ' A' ' 42' ' ' PHE . 47.8 t 59.27 -93.87 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.449 -0.782 . . . . 50.0 110.679 179.658 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.661 ' HD2' HG12 ' A' ' 41' ' ' VAL . 21.4 p90 -139.14 161.43 37.42 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.84 -1.163 . . . . 50.0 110.62 -179.74 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . 0.51 ' CB ' ' HB2' ' A' ' 49' ' ' GLN . 0.8 OUTLIER -80.45 127.56 75.51 Favored Pre-proline 0 N--CA 1.492 1.663 0 O-C-N 121.398 -0.814 . . . . 50.0 109.958 179.822 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -72.43 -162.4 0.12 Allowed 'Trans proline' 0 C--N 1.306 -1.699 0 O-C-N 123.742 1.39 . . . . 50.0 110.445 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 6.5 mtt180 -81.25 -36.59 29.76 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.475 -0.766 . . . . 50.0 109.698 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 60.0 mtp180 -58.71 -27.59 65.0 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.554 -0.716 . . . . 50.0 109.942 179.674 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' TYR . . . . . 0.645 ' CE2' HD11 ' A' ' 37' ' ' ILE . 37.0 m-85 -120.84 138.72 53.91 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.337 -0.852 . . . . 50.0 110.294 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 88.5 mttt -95.14 124.3 39.1 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.202 -0.936 . . . . 50.0 109.837 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.51 ' HB2' ' CB ' ' A' ' 43' ' ' CYS . 41.8 tt0 -74.8 105.64 5.95 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.494 -0.754 . . . . 50.0 110.94 -179.162 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.5 mt -75.16 -28.52 20.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.198 -0.939 . . . . 50.0 109.628 179.361 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.545 ' C ' HG23 ' A' ' 52' ' ' THR . . . 176.76 -94.56 0.1 OUTLIER Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.368 -1.493 . . . . 50.0 109.368 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.545 HG23 ' C ' ' A' ' 51' ' ' GLY . 60.5 p -155.24 137.99 15.26 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.192 -1.181 . . . . 50.0 110.222 179.781 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' CYS . . . . . . . . . . . . . 18.5 t -54.12 -50.44 66.87 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.24 -0.913 . . . . 50.0 110.131 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 176.78 -45.26 0.11 Allowed Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.266 -1.534 . . . . 50.0 109.266 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.465 ' HB3' ' HD2' ' A' ' 56' ' ' PRO . 87.0 mt -110.82 164.9 13.78 Favored Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.288 -1.125 . . . . 50.0 109.973 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.465 ' HD2' ' HB3' ' A' ' 55' ' ' LEU . 45.6 Cg_endo -72.75 -3.03 12.8 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 O-C-N 123.88 1.463 . . . . 50.0 110.395 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -77.49 -43.5 15.37 Favored Glycine 0 N--CA 1.487 2.096 0 N-CA-C 109.491 -1.444 . . . . 50.0 109.491 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . 0.407 HG23 ' C ' ' A' ' 39' ' ' HIS . 10.9 m -125.31 166.38 16.65 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.336 -1.097 . . . . 50.0 110.508 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.471 ' O ' ' N ' ' A' ' 39' ' ' HIS . 74.6 mmtt -123.21 148.6 45.66 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.336 -0.853 . . . . 50.0 109.902 179.857 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 13.2 t -73.52 127.93 34.08 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.145 -0.972 . . . . 50.0 110.376 -179.672 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' CYS . . . . . 0.679 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 28.3 m -128.02 154.17 45.94 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.29 -0.882 . . . . 50.0 109.994 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -132.99 138.68 46.93 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.157 -0.965 . . . . 50.0 110.249 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . 0.537 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 93.8 mttt . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.311 -0.868 . . . . 50.0 110.274 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 58.7 m . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 121.246 0.546 . . . . 50.0 109.919 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . 0.588 ' HB3' ' HB3' ' A' ' 36' ' ' ALA . 52.8 m -75.73 -6.24 49.61 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.35 -0.843 . . . . 50.0 110.691 -179.641 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 95.3 mt -57.35 -34.73 69.09 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.032 -1.043 . . . . 50.0 110.205 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 24.8 mttp -68.03 -37.33 81.23 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.389 -0.819 . . . . 50.0 110.153 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 95.0 p -77.49 -18.25 57.26 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.474 -0.766 . . . . 50.0 110.252 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 89.81 5.71 70.86 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.503 -1.439 . . . . 50.0 109.503 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . 0.588 ' HB3' ' HB3' ' A' ' 31' ' ' CYS . . . -77.37 147.97 35.81 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.217 -1.167 . . . . 50.0 110.284 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.472 ' O ' ' N ' ' A' ' 61' ' ' CYS . 4.0 pt -95.44 152.72 3.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.225 -0.922 . . . . 50.0 109.858 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.458 ' HA ' ' O ' ' A' ' 59' ' ' LYS . 79.0 m -100.16 139.77 35.36 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.205 -0.934 . . . . 50.0 110.143 -179.766 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.53 ' N ' ' O ' ' A' ' 59' ' ' LYS . 59.2 t-80 -117.82 136.26 23.66 Favored Pre-proline 0 N--CA 1.492 1.663 0 O-C-N 121.345 -0.847 . . . . 50.0 110.007 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.478 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 47.7 Cg_endo -72.23 164.58 35.2 Favored 'Trans proline' 0 C--N 1.303 -1.827 0 O-C-N 123.929 1.489 . . . . 50.0 110.503 -179.792 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.724 HG12 ' HD2' ' A' ' 42' ' ' PHE . 44.2 t 60.73 -82.78 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.524 -0.735 . . . . 50.0 111.171 179.538 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.724 ' HD2' HG12 ' A' ' 41' ' ' VAL . 9.7 p90 -155.7 154.29 31.28 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.957 -1.09 . . . . 50.0 110.662 -179.43 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 1.7 t -77.43 130.92 72.92 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.257 -0.902 . . . . 50.0 109.784 179.534 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -70.96 -162.29 0.1 Allowed 'Trans proline' 0 C--N 1.304 -1.803 0 O-C-N 123.88 1.463 . . . . 50.0 110.549 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 18.3 mtm180 -84.83 -40.13 17.51 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 121.475 -0.766 . . . . 50.0 109.818 -179.856 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 57.9 ttm-85 -61.73 -15.95 45.17 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.457 -0.777 . . . . 50.0 109.965 179.67 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' TYR . . . . . 0.535 ' HB3' ' HB3' ' A' ' 61' ' ' CYS . 58.4 m-85 -123.99 134.33 53.49 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.316 -0.865 . . . . 50.0 110.507 -179.789 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -97.71 137.95 35.82 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.287 -0.883 . . . . 50.0 109.595 179.351 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.426 ' HA ' ' O ' ' A' ' 60' ' ' CYS . 36.3 tt0 -87.2 103.98 15.93 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.156 -0.965 . . . . 50.0 110.917 -179.308 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.654 HD11 ' HD2' ' A' ' 62' ' ' LYS . 96.5 mt -62.8 -29.07 46.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.301 -0.874 . . . . 50.0 109.733 179.472 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.508 ' C ' HG23 ' A' ' 52' ' ' THR . . . 171.19 -91.23 0.09 OUTLIER Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.476 -1.45 . . . . 50.0 109.476 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.508 HG23 ' C ' ' A' ' 51' ' ' GLY . 71.9 p -151.58 127.92 10.61 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.259 -1.142 . . . . 50.0 110.292 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' CYS . . . . . . . . . . . . . 15.6 t -49.82 -47.41 51.42 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.297 -0.877 . . . . 50.0 110.081 179.694 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.765 ' C ' HD12 ' A' ' 55' ' ' LEU . . . 168.77 -38.33 0.21 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 108.683 -1.767 . . . . 50.0 108.683 -179.77 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.784 HD12 ' N ' ' A' ' 55' ' ' LEU . 6.1 mp -119.79 158.1 50.64 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.475 -1.015 . . . . 50.0 109.752 179.604 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -70.8 -10.29 27.43 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 O-C-N 123.904 1.476 . . . . 50.0 110.286 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -67.87 -41.96 87.12 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.312 -1.515 . . . . 50.0 109.312 179.704 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . 0.461 ' HA ' ' HA ' ' A' ' 40' ' ' PRO . 5.2 m -127.6 164.06 22.85 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.342 -1.093 . . . . 50.0 110.28 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.53 ' O ' ' N ' ' A' ' 39' ' ' HIS . 33.4 mmtp -118.75 152.6 35.88 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.318 -0.864 . . . . 50.0 109.741 179.654 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.426 ' O ' ' HA ' ' A' ' 49' ' ' GLN . 34.5 t -80.32 127.57 32.53 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.029 -1.045 . . . . 50.0 110.333 -179.793 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' CYS . . . . . 0.535 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 52.5 m -125.61 151.53 46.35 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.33 -0.856 . . . . 50.0 109.879 179.74 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.654 ' HD2' HD11 ' A' ' 50' ' ' ILE . 87.0 tttt -136.75 144.97 44.08 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.081 -1.012 . . . . 50.0 110.597 -179.775 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 50.8 mtmt . . . . . 0 N--CA 1.493 1.685 0 O-C-N 121.289 -0.882 . . . . 50.0 110.272 179.879 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.469 ' O ' ' HB2' ' A' ' 31' ' ' CYS . 74.5 m . . . . . 0 N--CA 1.492 1.644 0 CA-C-O 121.213 0.53 . . . . 50.0 110.392 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . 0.469 ' HB2' ' O ' ' A' ' 30' ' ' THR . 90.4 m 56.23 27.86 12.34 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.231 -0.918 . . . . 50.0 110.586 179.773 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 67.2 tp -76.95 -43.26 35.88 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.208 -0.933 . . . . 50.0 110.08 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -67.43 -34.58 77.52 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.277 -0.889 . . . . 50.0 110.117 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 81.0 p -71.98 -24.45 61.59 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.422 -0.799 . . . . 50.0 110.259 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 75.87 10.99 84.96 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.626 -1.389 . . . . 50.0 109.626 179.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . 0.597 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -77.04 156.11 32.03 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.186 -1.185 . . . . 50.0 110.257 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.494 HD11 ' CE2' ' A' ' 47' ' ' TYR . 13.8 pt -93.96 167.22 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.285 -0.885 . . . . 50.0 110.147 179.864 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 96.6 m -108.2 148.35 30.06 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.293 -0.879 . . . . 50.0 109.951 179.749 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.589 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 60.9 t-80 -138.68 145.66 47.13 Favored Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.297 -0.877 . . . . 50.0 110.435 -179.649 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.589 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 43.5 Cg_endo -69.1 160.39 50.07 Favored 'Trans proline' 0 C--N 1.305 -1.727 0 O-C-N 124.012 1.532 . . . . 50.0 110.42 179.486 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.829 HG12 ' HD2' ' A' ' 42' ' ' PHE . 15.9 t 62.3 -97.27 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.437 -0.789 . . . . 50.0 110.312 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.829 ' HD2' HG12 ' A' ' 41' ' ' VAL . 35.4 p90 -150.18 154.4 37.94 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 120.728 -1.233 . . . . 50.0 110.07 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . 0.414 ' HB2' ' HB2' ' A' ' 49' ' ' GLN . 64.6 m -61.96 133.62 93.98 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.196 -0.94 . . . . 50.0 110.581 -179.63 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.414 ' HD2' ' HB2' ' A' ' 47' ' ' TYR . 43.4 Cg_endo -68.49 -161.33 0.06 OUTLIER 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 123.959 1.505 . . . . 50.0 110.474 179.709 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 62.5 ttt180 -77.25 -44.08 31.16 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.558 -0.713 . . . . 50.0 110.664 -179.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 51.5 mmm-85 -61.23 -31.42 71.21 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.233 -0.917 . . . . 50.0 110.422 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' TYR . . . . . 0.527 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 48.4 m-85 -105.73 149.38 26.47 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.273 -0.892 . . . . 50.0 110.491 -179.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -108.56 131.79 54.5 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.337 -0.852 . . . . 50.0 109.688 179.512 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.414 ' HB2' ' HB2' ' A' ' 43' ' ' CYS . 59.6 tt0 -82.81 101.43 10.94 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.327 -0.858 . . . . 50.0 110.702 -179.36 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.509 HD11 ' HD2' ' A' ' 62' ' ' LYS . 85.1 mt -70.36 -30.93 45.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.245 -0.909 . . . . 50.0 109.677 179.452 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 178.14 -99.05 0.12 Allowed Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.294 -1.522 . . . . 50.0 109.294 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 61.7 p -146.12 137.28 24.57 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.305 -1.115 . . . . 50.0 110.403 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' CYS . . . . . 0.446 ' HA ' ' HB2' ' A' ' 60' ' ' CYS . 17.2 t -51.95 -48.1 64.44 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.334 -0.854 . . . . 50.0 109.565 179.467 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 172.87 -30.4 0.1 Allowed Glycine 0 N--CA 1.489 2.193 0 N-CA-C 108.95 -1.66 . . . . 50.0 108.95 179.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 98.1 mt -124.44 159.63 56.7 Favored Pre-proline 0 N--CA 1.488 1.471 0 O-C-N 121.41 -1.053 . . . . 50.0 109.802 179.668 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -71.29 -9.81 26.03 Favored 'Trans proline' 0 C--N 1.304 -1.809 0 O-C-N 124.013 1.533 . . . . 50.0 110.537 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -73.57 -34.56 56.8 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.296 -1.521 . . . . 50.0 109.296 179.714 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . 0.446 HG22 ' N ' ' A' ' 59' ' ' LYS . 25.6 m -131.6 168.42 17.73 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.302 -1.117 . . . . 50.0 109.976 179.789 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.446 ' N ' HG22 ' A' ' 58' ' ' THR . 33.6 mmtp -126.82 149.74 49.54 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.279 -0.888 . . . . 50.0 110.091 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.446 ' HB2' ' HA ' ' A' ' 53' ' ' CYS . 15.9 t -76.6 129.58 36.62 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.243 -0.911 . . . . 50.0 110.295 -179.633 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' CYS . . . . . 0.597 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 83.7 m -127.56 145.27 50.92 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.425 -0.797 . . . . 50.0 110.001 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.509 ' HD2' HD11 ' A' ' 50' ' ' ILE . 85.5 tttt -124.55 144.66 50.01 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.254 -0.904 . . . . 50.0 110.345 -179.814 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . 0.527 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 97.0 mttt . . . . . 0 N--CA 1.49 1.529 0 O-C-N 121.343 -0.848 . . . . 50.0 110.066 179.814 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 51.6 m . . . . . 0 N--CA 1.49 1.528 0 CA-C-O 121.258 0.552 . . . . 50.0 109.815 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 63.2 m -90.83 4.97 50.32 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.21 -0.931 . . . . 50.0 110.443 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 46.7 tp -66.68 -44.41 81.87 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.147 -0.97 . . . . 50.0 110.263 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -61.69 -39.03 90.02 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.382 -0.824 . . . . 50.0 110.384 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 87.7 p -71.32 -24.25 62.09 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.34 -0.85 . . . . 50.0 110.14 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 89.73 3.64 73.89 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.626 -1.389 . . . . 50.0 109.626 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -73.87 154.57 39.39 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.211 -1.17 . . . . 50.0 110.142 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.441 ' O ' HG13 ' A' ' 37' ' ' ILE . 3.9 pt -102.24 154.27 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.13 -0.981 . . . . 50.0 110.081 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.443 ' HA ' ' O ' ' A' ' 59' ' ' LYS . 93.0 m -98.1 138.48 35.33 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.235 -0.916 . . . . 50.0 110.208 179.873 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.49 ' N ' ' O ' ' A' ' 59' ' ' LYS . 58.6 t-80 -114.63 140.41 25.26 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.268 -0.895 . . . . 50.0 110.235 -179.8 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.5 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 44.1 Cg_endo -70.44 162.4 42.54 Favored 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 123.995 1.524 . . . . 50.0 110.272 179.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.779 HG12 ' HD2' ' A' ' 42' ' ' PHE . 18.3 t 62.96 -108.36 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.461 -0.775 . . . . 50.0 110.285 179.885 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.779 ' HD2' HG12 ' A' ' 41' ' ' VAL . 35.7 p90 -135.31 148.87 49.63 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.796 -1.19 . . . . 50.0 110.24 -179.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -68.5 131.03 91.73 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.265 -0.897 . . . . 50.0 110.204 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.432 ' HD2' ' HB2' ' A' ' 47' ' ' TYR . 46.6 Cg_endo -71.22 -163.03 0.12 Allowed 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 123.859 1.452 . . . . 50.0 110.415 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 32.3 mtt85 -80.57 -44.75 18.5 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.512 -0.743 . . . . 50.0 109.887 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 28.6 tpt180 -58.74 -24.46 61.62 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.53 -0.731 . . . . 50.0 110.152 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' TYR . . . . . 0.533 ' HB3' ' HB3' ' A' ' 61' ' ' CYS . 42.0 m-85 -114.98 135.8 53.83 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.255 -0.903 . . . . 50.0 110.266 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 88.3 mttt -105.01 147.97 27.25 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.204 -0.935 . . . . 50.0 109.945 179.751 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.506 ' HA ' ' O ' ' A' ' 60' ' ' CYS . 52.7 tt0 -87.31 106.78 18.16 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.215 -0.928 . . . . 50.0 110.788 -179.432 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.767 HD12 ' SG ' ' A' ' 60' ' ' CYS . 67.8 mt -63.39 -24.12 35.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.289 -0.882 . . . . 50.0 109.731 179.438 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.483 ' O ' ' CB ' ' A' ' 52' ' ' THR . . . 152.5 40.18 0.03 OUTLIER Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.284 -1.527 . . . . 50.0 109.284 -179.868 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.483 ' CB ' ' O ' ' A' ' 51' ' ' GLY . 0.2 OUTLIER 69.76 151.17 0.09 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.404 -1.056 . . . . 50.0 110.435 -179.925 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' CYS . . . . . 0.409 ' HA ' ' HB2' ' A' ' 60' ' ' CYS . 7.3 t -71.19 -41.99 69.59 Favored 'General case' 0 N--CA 1.492 1.629 0 CA-C-O 121.763 0.792 . . . . 50.0 109.964 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.877 ' C ' HD12 ' A' ' 55' ' ' LEU . . . 154.63 -26.03 0.66 Allowed Glycine 0 N--CA 1.49 2.244 0 N-CA-C 108.438 -1.865 . . . . 50.0 108.438 -179.746 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.877 HD12 ' C ' ' A' ' 54' ' ' GLY . 5.8 mp -124.72 158.1 63.54 Favored Pre-proline 0 N--CA 1.489 1.495 0 O-C-N 121.55 -0.97 . . . . 50.0 109.465 179.611 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -71.79 -8.46 23.1 Favored 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.886 1.466 . . . . 50.0 110.432 -179.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -71.33 -45.83 45.5 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.545 -1.422 . . . . 50.0 109.545 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . 0.407 HG23 ' C ' ' A' ' 39' ' ' HIS . 7.2 m -128.89 166.01 19.94 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.136 -1.214 . . . . 50.0 110.434 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.49 ' O ' ' N ' ' A' ' 39' ' ' HIS . 33.5 mmtp -121.16 148.49 44.16 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.415 -0.803 . . . . 50.0 109.558 179.62 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.767 ' SG ' HD12 ' A' ' 50' ' ' ILE . 35.1 t -74.82 130.54 39.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.991 -1.068 . . . . 50.0 110.117 -179.741 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' CYS . . . . . 0.533 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 59.9 m -135.32 155.11 51.15 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.274 -0.891 . . . . 50.0 110.102 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.474 ' HB3' HD11 ' A' ' 50' ' ' ILE . 34.9 pttt -146.57 166.83 25.3 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.103 -0.998 . . . . 50.0 110.299 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 52.7 mtmt . . . . . 0 N--CA 1.492 1.643 0 O-C-N 121.278 -0.889 . . . . 50.0 110.255 -179.971 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 95.9 m . . . . . 0 N--CA 1.491 1.581 0 CA-C-O 121.23 0.538 . . . . 50.0 110.348 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 72.0 m -77.44 -12.05 59.91 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.907 . . . . 50.0 110.225 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.757 HD13 ' C ' ' A' ' 32' ' ' LEU . 3.4 tm? -57.68 -44.52 85.85 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.26 -0.9 . . . . 50.0 110.294 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -61.74 -38.01 86.36 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.312 -0.868 . . . . 50.0 110.149 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 69.5 m -72.53 -21.31 61.19 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.288 -0.882 . . . . 50.0 110.152 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 85.44 -3.18 87.57 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.633 -1.387 . . . . 50.0 109.633 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . 0.736 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -77.47 159.49 29.35 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.14 -1.212 . . . . 50.0 110.19 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.475 ' O ' HG13 ' A' ' 37' ' ' ILE . 3.6 pt -108.22 151.15 10.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.288 -0.883 . . . . 50.0 110.118 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 85.4 m -88.78 141.29 28.63 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.198 -0.939 . . . . 50.0 109.964 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 50.5 t-80 -120.5 134.43 24.18 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.243 -0.911 . . . . 50.0 110.247 -179.77 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.494 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 44.0 Cg_endo -71.55 168.13 24.48 Favored 'Trans proline' 0 C--N 1.305 -1.724 0 O-C-N 124.001 1.527 . . . . 50.0 110.458 179.873 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.732 HG12 ' HD2' ' A' ' 42' ' ' PHE . 38.9 t 61.26 -92.51 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.383 -0.823 . . . . 50.0 110.69 179.806 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.732 ' HD2' HG12 ' A' ' 41' ' ' VAL . 16.2 p90 -148.58 148.69 30.45 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.967 -1.083 . . . . 50.0 110.379 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 1.8 t -73.47 128.74 86.76 Favored Pre-proline 0 N--CA 1.493 1.706 0 O-C-N 121.238 -0.914 . . . . 50.0 109.883 179.573 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -71.79 -162.6 0.12 Allowed 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.835 1.44 . . . . 50.0 110.568 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 6.7 ptp180 -90.51 -15.25 31.09 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.525 -0.734 . . . . 50.0 110.123 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 89.6 mtm180 -73.18 -31.23 64.09 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.186 -0.946 . . . . 50.0 110.166 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' TYR . . . . . 0.551 ' N ' ' CD1' ' A' ' 47' ' ' TYR . 6.9 m-85 -113.23 147.87 36.65 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.223 -0.923 . . . . 50.0 110.333 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 61.6 mttm -93.43 152.6 19.0 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.255 -0.903 . . . . 50.0 109.799 179.272 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 58.7 tt0 -91.59 97.47 11.06 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.068 -1.02 . . . . 50.0 110.615 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.443 HD11 ' HB2' ' A' ' 62' ' ' LYS . 86.7 mt -63.88 -32.65 57.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.312 -0.868 . . . . 50.0 109.701 179.512 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 166.17 -95.99 0.12 Allowed Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.408 -1.477 . . . . 50.0 109.408 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 21.7 p -145.24 129.07 17.32 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.329 -1.101 . . . . 50.0 110.193 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' CYS . . . . . 0.467 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 30.7 t -61.41 -47.9 83.65 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.15 -0.969 . . . . 50.0 109.654 179.577 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 129.68 1.89 5.41 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.491 -1.443 . . . . 50.0 109.491 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 92.0 mt -105.27 143.42 26.73 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.278 -1.13 . . . . 50.0 110.174 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -73.38 79.59 2.1 Favored 'Trans proline' 0 C--N 1.303 -1.821 0 O-C-N 124.062 1.559 . . . . 50.0 110.688 -179.82 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 139.17 -3.03 2.69 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.696 -1.24 . . . . 50.0 110.378 179.55 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . 0.442 ' HA ' ' HA ' ' A' ' 40' ' ' PRO . 1.2 m -121.86 159.69 26.29 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.974 -1.309 . . . . 50.0 110.476 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 16.2 tppt? -129.59 123.81 32.25 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.355 -0.841 . . . . 50.0 109.895 179.584 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.467 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 34.2 t -53.92 128.99 32.4 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.177 -0.952 . . . . 50.0 110.375 -179.692 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' CYS . . . . . 0.736 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 62.3 m -128.84 146.41 50.94 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.222 -0.924 . . . . 50.0 110.076 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.482 ' O ' ' HA ' ' A' ' 47' ' ' TYR . 79.6 tttt -125.08 143.75 50.76 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.2 -0.937 . . . . 50.0 110.477 -179.678 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . 0.441 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 86.9 mttt . . . . . 0 N--CA 1.491 1.608 0 O-C-N 121.345 -0.847 . . . . 50.0 110.361 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.516 ' CG2' HD12 ' A' ' 32' ' ' LEU . 23.7 m . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 121.074 0.464 . . . . 50.0 110.372 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . 0.478 ' HB2' ' O ' ' A' ' 30' ' ' THR . 98.7 m 58.86 19.66 7.25 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.314 -0.866 . . . . 50.0 110.538 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.516 HD12 ' CG2' ' A' ' 30' ' ' THR . 93.5 mt -111.27 -15.83 13.53 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.258 -0.901 . . . . 50.0 109.896 179.605 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 63.8 mmtt -69.26 -39.71 78.26 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.309 -0.869 . . . . 50.0 110.18 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . 0.474 ' HB3' ' NZ ' ' A' ' 62' ' ' LYS . 66.7 m -90.27 -9.88 46.3 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.357 -0.84 . . . . 50.0 110.031 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 87.13 7.8 76.46 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.509 -1.436 . . . . 50.0 109.509 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . 0.912 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -69.21 140.1 54.56 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.326 -1.102 . . . . 50.0 110.265 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.906 HD11 ' NE2' ' A' ' 39' ' ' HIS . 3.8 pt -100.54 155.92 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.227 -0.92 . . . . 50.0 109.871 179.821 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 83.5 m -95.46 141.0 29.52 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.152 -0.967 . . . . 50.0 110.043 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.906 ' NE2' HD11 ' A' ' 37' ' ' ILE . 38.4 m-70 -117.9 161.93 31.86 Favored Pre-proline 0 N--CA 1.497 1.889 0 O-C-N 121.33 -0.856 . . . . 50.0 110.55 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.475 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 44.0 Cg_endo -72.22 156.22 55.48 Favored 'Trans proline' 0 C--N 1.304 -1.766 0 O-C-N 124.024 1.539 . . . . 50.0 110.224 179.754 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.786 HG12 ' HD2' ' A' ' 42' ' ' PHE . 15.4 t 61.5 -108.53 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.246 -0.909 . . . . 50.0 110.064 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.786 ' HD2' HG12 ' A' ' 41' ' ' VAL . 44.0 p90 -135.16 164.79 26.88 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.685 -1.26 . . . . 50.0 110.225 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . 0.47 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 70.9 m -70.72 130.88 88.22 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.172 -0.955 . . . . 50.0 110.668 -179.547 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -71.42 -161.44 0.09 OUTLIER 'Trans proline' 0 C--N 1.305 -1.742 0 O-C-N 123.851 1.448 . . . . 50.0 110.391 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 15.3 ptm180 -81.88 -24.54 35.68 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.492 -0.755 . . . . 50.0 110.786 -179.483 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 79.5 mtp180 -71.7 -16.29 62.23 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.046 -1.034 . . . . 50.0 110.594 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' TYR . . . . . 0.607 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 36.2 m-85 -129.81 153.06 48.63 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.088 -1.008 . . . . 50.0 110.878 -179.698 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.418 ' N ' ' O ' ' A' ' 62' ' ' LYS . 98.5 mttt -99.92 141.86 32.18 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.37 -0.831 . . . . 50.0 109.263 179.11 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.463 ' NE2' ' CE ' ' A' ' 59' ' ' LYS . 37.5 tt0 -84.44 98.82 10.29 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.162 -0.962 . . . . 50.0 110.955 -179.169 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.583 HD11 ' HB2' ' A' ' 62' ' ' LYS . 95.3 mt -62.98 -32.06 54.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.166 -0.958 . . . . 50.0 109.627 179.303 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.508 ' C ' HG23 ' A' ' 52' ' ' THR . . . 165.83 -92.09 0.1 Allowed Glycine 0 N--CA 1.487 2.044 0 N-CA-C 109.426 -1.47 . . . . 50.0 109.426 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.508 HG23 ' C ' ' A' ' 51' ' ' GLY . 20.9 p -152.02 134.19 15.09 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.319 -1.107 . . . . 50.0 110.152 -179.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' CYS . . . . . 0.546 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 5.0 t -59.14 -45.64 90.43 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.277 -0.889 . . . . 50.0 110.207 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 163.97 -41.53 0.32 Allowed Glycine 0 N--CA 1.489 2.233 0 N-CA-C 108.993 -1.643 . . . . 50.0 108.993 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 76.5 mt -118.43 158.03 47.92 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.511 -0.993 . . . . 50.0 109.928 179.747 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -71.82 -4.92 16.02 Favored 'Trans proline' 0 C--N 1.304 -1.807 0 O-C-N 123.922 1.486 . . . . 50.0 110.35 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -70.89 -30.28 68.25 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.371 -1.492 . . . . 50.0 109.371 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 5.8 m -139.11 163.56 32.08 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.284 -1.127 . . . . 50.0 110.393 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.463 ' CE ' ' NE2' ' A' ' 49' ' ' GLN . 54.8 tptt -119.31 128.18 53.88 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.405 -0.809 . . . . 50.0 109.42 179.528 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.546 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 41.1 t -63.71 131.54 48.23 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.181 -0.949 . . . . 50.0 110.431 -179.282 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' CYS . . . . . 0.912 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 74.8 m -126.2 156.81 39.61 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.467 -0.771 . . . . 50.0 110.181 -179.675 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.583 ' HB2' HD11 ' A' ' 50' ' ' ILE . 57.3 tttp -137.51 138.07 39.29 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.146 -0.971 . . . . 50.0 110.343 -179.801 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . 0.607 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 56.0 mtpt . . . . . 0 N--CA 1.491 1.625 0 O-C-N 121.122 -0.987 . . . . 50.0 110.043 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.459 HG22 ' HB2' ' A' ' 32' ' ' LEU . 72.9 m . . . . . 0 N--CA 1.492 1.65 0 CA-C-O 121.203 0.525 . . . . 50.0 109.899 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 52.1 m -79.4 -3.43 46.39 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.158 -0.963 . . . . 50.0 110.425 -179.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.459 ' HB2' HG22 ' A' ' 30' ' ' THR . 70.4 mt -56.91 -41.56 78.37 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.129 -0.982 . . . . 50.0 110.063 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 30.3 mmtp -67.52 -38.34 84.09 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.393 -0.817 . . . . 50.0 110.359 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 41.4 t -68.36 -32.64 72.87 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.29 -0.881 . . . . 50.0 110.047 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.78 -5.68 56.76 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.711 -1.356 . . . . 50.0 109.711 179.714 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . 0.647 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -74.29 130.39 39.62 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.181 -1.188 . . . . 50.0 110.206 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 7.0 pt -73.34 162.73 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.209 -0.932 . . . . 50.0 110.22 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 71.9 m -106.44 152.29 23.82 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.273 -0.892 . . . . 50.0 110.093 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.572 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 60.4 t-80 -138.39 145.23 46.04 Favored Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.315 -0.865 . . . . 50.0 109.892 -179.734 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.572 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 41.8 Cg_endo -67.7 161.01 45.61 Favored 'Trans proline' 0 C--N 1.302 -1.912 0 O-C-N 123.898 1.473 . . . . 50.0 110.189 179.728 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.821 HG12 ' HD2' ' A' ' 42' ' ' PHE . 17.5 t 62.43 -104.59 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.42 -0.8 . . . . 50.0 110.035 -179.716 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.821 ' HD2' HG12 ' A' ' 41' ' ' VAL . 36.7 p90 -142.72 155.93 44.95 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.642 -1.286 . . . . 50.0 110.126 179.834 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . 0.448 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 75.6 m -65.06 132.45 95.44 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.286 -0.883 . . . . 50.0 110.262 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -69.1 -161.64 0.07 OUTLIER 'Trans proline' 0 C--N 1.304 -1.783 0 O-C-N 123.927 1.488 . . . . 50.0 110.802 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 14.3 mtt180 -78.46 -39.49 38.4 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.461 -0.775 . . . . 50.0 109.907 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 95.4 mtt180 -60.02 -34.27 73.14 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.44 -0.787 . . . . 50.0 110.346 -179.727 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' TYR . . . . . 0.566 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 18.7 m-85 -110.71 144.01 40.31 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.295 -0.878 . . . . 50.0 110.899 -179.558 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 64.6 mttm -98.06 138.26 35.63 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.39 -0.819 . . . . 50.0 109.183 178.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 39.9 tt0 -80.68 101.88 9.53 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.053 -1.029 . . . . 50.0 110.686 -179.402 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 74.4 mt -65.46 -31.26 53.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.222 -0.924 . . . . 50.0 109.618 179.366 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 165.09 -94.13 0.11 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.291 -1.523 . . . . 50.0 109.291 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 65.3 p -143.3 136.21 27.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.311 -1.111 . . . . 50.0 110.284 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' CYS . . . . . 0.525 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 17.5 t -58.07 -49.4 77.05 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.256 -0.903 . . . . 50.0 109.793 179.67 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 176.45 -32.17 0.08 OUTLIER Glycine 0 N--CA 1.49 2.265 0 N-CA-C 108.791 -1.723 . . . . 50.0 108.791 -179.854 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 80.6 mt -127.71 160.03 63.05 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.504 -0.997 . . . . 50.0 109.545 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -72.19 -2.14 11.17 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 123.88 1.463 . . . . 50.0 110.36 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -74.75 -38.88 41.38 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.545 -1.422 . . . . 50.0 109.545 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . 0.439 HG22 ' N ' ' A' ' 59' ' ' LYS . 21.2 m -126.7 168.58 14.17 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.199 -1.177 . . . . 50.0 110.367 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.439 ' N ' HG22 ' A' ' 58' ' ' THR . 14.5 tppt? -119.43 136.29 54.37 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.322 -0.861 . . . . 50.0 109.982 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.525 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 20.4 t -69.01 128.69 37.59 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.262 -0.899 . . . . 50.0 110.484 -179.739 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' CYS . . . . . 0.647 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 74.2 m -125.42 153.13 43.92 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.241 -0.912 . . . . 50.0 109.748 179.687 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.474 ' O ' ' HA ' ' A' ' 47' ' ' TYR . 83.6 tttt -130.08 144.33 51.28 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.172 -0.955 . . . . 50.0 110.487 -179.616 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . 0.566 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 97.7 mttt . . . . . 0 N--CA 1.49 1.527 0 O-C-N 121.301 -0.875 . . . . 50.0 110.047 179.718 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 88.7 m . . . . . 0 N--CA 1.491 1.609 0 CA-C-O 121.167 0.508 . . . . 50.0 110.137 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . 0.432 ' SG ' ' HA ' ' A' ' 53' ' ' CYS . 79.3 m -77.15 -13.12 60.0 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.255 -0.903 . . . . 50.0 110.214 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 46.1 tp -57.32 -40.79 78.67 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.263 -0.898 . . . . 50.0 110.488 -179.717 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 60.3 mmtt -68.34 -41.25 81.03 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.265 -0.897 . . . . 50.0 110.297 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 56.9 m -70.86 -29.59 65.75 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.224 -0.923 . . . . 50.0 110.19 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 87.07 8.16 76.0 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.552 -1.419 . . . . 50.0 109.552 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -72.35 176.84 4.96 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.235 -1.156 . . . . 50.0 110.287 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.703 HD12 ' NE2' ' A' ' 39' ' ' HIS . 2.9 pt -115.83 153.53 17.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.316 -0.865 . . . . 50.0 109.984 179.663 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 83.0 m -112.52 153.31 27.67 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.167 -0.958 . . . . 50.0 109.969 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.703 ' NE2' HD12 ' A' ' 37' ' ' ILE . 31.6 m-70 -140.33 162.58 48.92 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 121.315 -0.865 . . . . 50.0 110.282 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -70.81 166.5 28.69 Favored 'Trans proline' 0 C--N 1.305 -1.759 0 O-C-N 124.037 1.546 . . . . 50.0 110.847 -179.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.793 HG12 ' HD2' ' A' ' 42' ' ' PHE . 14.4 t 54.07 -108.43 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.393 -0.817 . . . . 50.0 110.167 179.811 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.793 ' HD2' HG12 ' A' ' 41' ' ' VAL . 29.3 p90 -141.36 151.37 43.47 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.817 -1.177 . . . . 50.0 110.129 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . 0.475 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 72.5 m -50.65 130.36 27.33 Favored Pre-proline 0 N--CA 1.489 1.517 0 O-C-N 121.155 -0.965 . . . . 50.0 109.813 179.771 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.449 ' HD2' ' HB2' ' A' ' 47' ' ' TYR . 43.6 Cg_endo -70.16 -162.78 0.1 OUTLIER 'Trans proline' 0 C--N 1.304 -1.783 0 O-C-N 123.954 1.502 . . . . 50.0 110.304 179.792 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 28.8 mtp180 -74.68 -42.79 57.77 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.417 -0.802 . . . . 50.0 110.04 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 79.0 mtp180 -61.96 -14.87 39.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.486 -0.759 . . . . 50.0 110.37 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' TYR . . . . . 0.517 ' HB3' ' HB3' ' A' ' 61' ' ' CYS . 72.6 m-85 -128.28 164.19 23.13 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.232 -0.918 . . . . 50.0 110.683 -179.68 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -127.79 154.79 45.0 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.349 -0.845 . . . . 50.0 109.958 179.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -87.93 115.46 25.41 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.181 -0.95 . . . . 50.0 110.06 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.436 HD13 ' HB2' ' A' ' 62' ' ' LYS . 22.6 pt -110.41 15.91 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.282 -0.886 . . . . 50.0 110.459 -179.826 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.508 ' O ' ' HB3' ' A' ' 60' ' ' CYS . . . 133.24 114.89 1.57 Allowed Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.403 -1.479 . . . . 50.0 109.403 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.47 ' C ' ' O ' ' A' ' 51' ' ' GLY . 75.9 p -34.65 134.05 0.24 Allowed 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.771 -0.841 . . . . 50.0 110.965 -179.841 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' CYS . . . . . 0.526 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 4.4 t -51.67 -42.03 61.84 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.452 -0.78 . . . . 50.0 110.34 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 163.36 -27.52 0.23 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.062 -1.615 . . . . 50.0 109.062 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 97.0 mt -122.45 152.9 62.0 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.358 -1.084 . . . . 50.0 109.856 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.44 -16.25 27.6 Favored 'Trans proline' 0 C--N 1.303 -1.824 0 O-C-N 123.886 1.466 . . . . 50.0 110.416 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -69.02 -32.71 73.37 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.389 -1.484 . . . . 50.0 109.389 179.83 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 8.6 m -128.74 168.12 16.29 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.287 -1.125 . . . . 50.0 110.198 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.49 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 75.1 mmtt -130.91 141.96 50.33 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.365 -0.835 . . . . 50.0 109.767 179.688 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.526 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 7.4 t -73.35 139.51 46.04 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.127 -0.983 . . . . 50.0 109.98 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' CYS . . . . . 0.517 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 97.8 m -131.89 144.47 50.89 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.378 -0.826 . . . . 50.0 109.94 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.436 ' HB2' HD13 ' A' ' 50' ' ' ILE . 54.7 tttm -127.81 140.36 52.08 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.089 -1.007 . . . . 50.0 110.31 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . 0.445 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 93.3 mttt . . . . . 0 N--CA 1.49 1.538 0 O-C-N 121.219 -0.926 . . . . 50.0 110.09 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.444 HG22 ' HB2' ' A' ' 32' ' ' LEU . 36.4 m . . . . . 0 N--CA 1.491 1.6 0 CA-C-O 121.211 0.529 . . . . 50.0 110.098 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 65.9 m -84.71 0.35 50.78 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.188 -0.945 . . . . 50.0 110.317 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.519 HD22 ' N ' ' A' ' 32' ' ' LEU . 4.2 mm? -65.82 -45.25 82.99 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.209 -0.932 . . . . 50.0 110.179 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -64.53 -36.16 83.3 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.409 -0.807 . . . . 50.0 110.181 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 95.2 p -69.48 -20.26 63.74 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.374 -0.829 . . . . 50.0 110.299 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 89.7 0.35 78.86 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.492 -1.443 . . . . 50.0 109.492 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -77.98 154.45 31.53 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.148 -1.207 . . . . 50.0 110.128 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.487 ' O ' ' O ' ' A' ' 61' ' ' CYS . 1.1 pt -99.72 157.22 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.285 -0.884 . . . . 50.0 109.875 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 70.9 m -107.06 143.7 34.79 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.012 -1.055 . . . . 50.0 110.121 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.601 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 14.8 t-80 -108.2 145.92 32.49 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.269 -0.894 . . . . 50.0 109.851 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.601 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 42.4 Cg_endo -68.03 -23.92 39.71 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 O-C-N 123.847 1.446 . . . . 50.0 110.878 -179.674 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.646 HG12 ' HD2' ' A' ' 42' ' ' PHE . 66.3 t -117.91 -88.77 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.087 -1.008 . . . . 50.0 110.527 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.646 ' HD2' HG12 ' A' ' 41' ' ' VAL . 13.4 p90 -140.02 151.31 45.35 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.111 -0.993 . . . . 50.0 110.148 -179.765 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . 0.464 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 75.8 m -61.95 123.81 79.19 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.127 -0.983 . . . . 50.0 109.937 179.782 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.479 ' HD2' ' HB2' ' A' ' 47' ' ' TYR . 45.1 Cg_endo -69.95 -163.04 0.1 Allowed 'Trans proline' 0 C--N 1.304 -1.769 0 O-C-N 123.975 1.513 . . . . 50.0 110.732 179.812 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 65.2 ttt180 -75.02 -42.29 57.66 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.475 -0.766 . . . . 50.0 110.419 -179.74 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 86.4 mmt-85 -62.19 -29.07 70.11 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.366 -0.834 . . . . 50.0 110.221 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' TYR . . . . . 0.592 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 16.6 m-85 -113.35 159.26 19.6 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.178 -0.952 . . . . 50.0 110.717 -179.732 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 13.5 ptmm? -120.5 145.61 47.11 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.36 -0.838 . . . . 50.0 109.462 179.116 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 63.3 tt0 -90.09 103.49 16.15 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.124 -0.985 . . . . 50.0 110.714 -179.53 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.607 HD11 ' HD2' ' A' ' 62' ' ' LYS . 90.7 mt -68.17 -29.45 44.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.207 -0.933 . . . . 50.0 109.623 179.438 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 172.31 -95.31 0.11 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.217 -1.553 . . . . 50.0 109.217 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 70.7 p -144.17 134.19 24.07 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.209 -1.171 . . . . 50.0 110.309 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' CYS . . . . . 0.53 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 16.5 t -54.26 -43.79 71.28 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.134 -0.979 . . . . 50.0 109.669 179.571 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 152.65 -24.64 0.84 Allowed Glycine 0 N--CA 1.49 2.253 0 N-CA-C 108.637 -1.785 . . . . 50.0 108.637 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.465 ' CD1' ' HD2' ' A' ' 56' ' ' PRO . 16.7 tp -121.74 142.58 36.3 Favored Pre-proline 0 C--N 1.303 -1.449 0 O-C-N 121.505 -0.997 . . . . 50.0 109.374 179.594 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.465 ' HD2' ' CD1' ' A' ' 55' ' ' LEU . 41.3 Cg_endo -67.37 -5.27 13.52 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 123.794 1.418 . . . . 50.0 110.465 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -80.14 -27.63 52.01 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.333 -1.507 . . . . 50.0 109.333 179.483 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . 0.479 ' CG2' ' O ' ' A' ' 39' ' ' HIS . 3.4 m -137.33 160.68 38.37 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.247 -1.149 . . . . 50.0 110.433 179.908 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.464 ' O ' ' N ' ' A' ' 39' ' ' HIS . 73.4 mmtt -113.31 155.41 25.2 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.527 -0.733 . . . . 50.0 109.538 179.425 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.53 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 37.3 t -85.8 130.88 34.43 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.185 -0.947 . . . . 50.0 110.897 -179.24 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' CYS . . . . . 0.495 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 71.3 m -134.06 128.95 35.31 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.425 -0.797 . . . . 50.0 109.301 179.542 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.607 ' HD2' HD11 ' A' ' 50' ' ' ILE . 84.8 tttt -109.48 147.74 32.38 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.003 -1.06 . . . . 50.0 111.148 -179.154 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . 0.592 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 51.3 mtmt . . . . . 0 N--CA 1.49 1.532 0 O-C-N 121.365 -0.834 . . . . 50.0 109.663 179.317 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 99.8 m . . . . . 0 N--CA 1.492 1.653 0 CA-C-O 121.171 0.51 . . . . 50.0 110.345 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 65.1 m -82.1 -6.42 59.16 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.19 -0.944 . . . . 50.0 109.995 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 60.1 tp -57.99 -46.48 85.15 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.329 -0.857 . . . . 50.0 110.189 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -64.83 -34.52 78.55 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.393 -0.817 . . . . 50.0 110.21 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 65.1 m -69.67 -31.94 70.29 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.277 -0.889 . . . . 50.0 110.3 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.15 5.21 62.43 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.698 -1.361 . . . . 50.0 109.698 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . 0.706 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -78.41 173.05 12.75 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.189 -1.183 . . . . 50.0 110.326 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.873 HD12 ' NE2' ' A' ' 39' ' ' HIS . 7.1 pt -114.73 152.25 16.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.305 -0.872 . . . . 50.0 109.925 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 77.1 m -107.18 142.76 36.38 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.326 -0.859 . . . . 50.0 110.156 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.873 ' NE2' HD12 ' A' ' 37' ' ' ILE . 23.6 m-70 -134.04 157.4 77.76 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.258 -0.901 . . . . 50.0 110.12 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.476 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 45.8 Cg_endo -72.18 165.03 33.82 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 O-C-N 124.096 1.577 . . . . 50.0 110.931 -179.42 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.835 HG12 ' HD2' ' A' ' 42' ' ' PHE . 18.6 t 61.02 -100.73 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.453 -0.78 . . . . 50.0 110.26 179.689 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.835 ' HD2' HG12 ' A' ' 41' ' ' VAL . 35.4 p90 -145.64 157.55 43.95 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.757 -1.214 . . . . 50.0 110.467 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . 0.426 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 76.5 m -68.98 131.24 90.97 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.324 -0.86 . . . . 50.0 110.089 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -69.45 -160.05 0.06 OUTLIER 'Trans proline' 0 C--N 1.305 -1.75 0 O-C-N 123.908 1.478 . . . . 50.0 110.945 -179.709 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 31.7 mtt180 -80.85 -41.22 23.54 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.537 -0.727 . . . . 50.0 109.884 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 82.7 mmt-85 -55.82 -25.46 41.75 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.466 -0.771 . . . . 50.0 109.97 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' TYR . . . . . 0.531 ' N ' ' CD1' ' A' ' 47' ' ' TYR . 18.3 m-85 -125.82 161.61 27.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.285 -0.884 . . . . 50.0 110.399 179.722 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.421 ' N ' ' O ' ' A' ' 62' ' ' LYS . 88.8 mttt -116.43 146.12 42.76 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.443 -0.785 . . . . 50.0 109.021 178.801 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.425 ' HA ' ' O ' ' A' ' 60' ' ' CYS . 45.4 tt0 -90.23 104.02 16.64 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.96 -1.087 . . . . 50.0 111.215 -178.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.673 HD11 ' HD2' ' A' ' 62' ' ' LYS . 80.2 mt -64.81 -32.54 58.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.276 -0.89 . . . . 50.0 109.136 178.857 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 168.63 -96.07 0.12 Allowed Glycine 0 N--CA 1.488 2.108 0 N-CA-C 109.469 -1.452 . . . . 50.0 109.469 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 74.3 p -143.22 127.77 17.99 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.25 -1.147 . . . . 50.0 110.29 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' CYS . . . . . . . . . . . . . 4.4 t -50.44 -44.76 55.55 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.225 -0.922 . . . . 50.0 109.848 179.721 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 176.71 -33.23 0.08 OUTLIER Glycine 0 N--CA 1.49 2.288 0 N-CA-C 108.994 -1.642 . . . . 50.0 108.994 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 97.5 mt -127.21 161.36 54.72 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.455 -1.027 . . . . 50.0 109.77 179.651 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -72.61 -5.31 16.94 Favored 'Trans proline' 0 C--N 1.304 -1.774 0 O-C-N 123.912 1.48 . . . . 50.0 110.462 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -71.45 -34.68 63.46 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.596 -1.402 . . . . 50.0 109.596 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . 0.427 HG23 ' C ' ' A' ' 39' ' ' HIS . 11.5 m -132.88 165.64 24.17 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.312 -1.111 . . . . 50.0 110.149 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.479 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 75.3 mmtt -122.31 135.46 54.73 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.38 -0.825 . . . . 50.0 109.675 179.563 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.426 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 39.4 t -68.98 133.73 48.55 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.261 -0.9 . . . . 50.0 110.426 -179.432 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' CYS . . . . . 0.706 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 71.2 m -123.13 153.58 39.79 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.355 -0.841 . . . . 50.0 110.023 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.673 ' HD2' HD11 ' A' ' 50' ' ' ILE . 65.4 tttm -139.78 147.68 41.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.068 -1.02 . . . . 50.0 110.51 -179.721 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 97.4 mttt . . . . . 0 N--CA 1.491 1.618 0 O-C-N 121.259 -0.9 . . . . 50.0 110.207 179.844 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.411 HG22 ' HB3' ' A' ' 32' ' ' LEU . 95.8 m . . . . . 0 N--CA 1.491 1.581 0 CA-C-O 121.259 0.552 . . . . 50.0 110.229 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . 0.463 ' SG ' ' HA ' ' A' ' 53' ' ' CYS . 72.1 m -65.67 -16.83 64.12 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.265 -0.897 . . . . 50.0 110.184 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.411 ' HB3' HG22 ' A' ' 30' ' ' THR . 9.9 tp -61.21 -45.98 92.33 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.282 -0.886 . . . . 50.0 110.082 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 67.5 mttm -63.12 -35.04 78.94 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.393 -0.817 . . . . 50.0 110.065 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 31.6 t -70.05 -24.3 63.24 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.361 -0.837 . . . . 50.0 110.204 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.03 9.9 47.33 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.604 -1.398 . . . . 50.0 109.604 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . 0.474 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -106.78 151.45 25.15 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.196 -1.179 . . . . 50.0 110.172 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.509 HG12 ' CE2' ' A' ' 47' ' ' TYR . 6.6 pt -100.7 151.86 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.347 -0.845 . . . . 50.0 110.26 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 87.0 m -92.75 148.15 22.28 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.301 -0.874 . . . . 50.0 109.964 179.781 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.612 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 53.0 t-80 -135.42 147.05 60.29 Favored Pre-proline 0 N--CA 1.495 1.783 0 O-C-N 121.247 -0.908 . . . . 50.0 110.045 -179.488 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.612 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 43.5 Cg_endo -69.89 160.47 49.53 Favored 'Trans proline' 0 C--N 1.308 -1.597 0 O-C-N 123.773 1.407 . . . . 50.0 110.59 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.835 HG12 ' HD2' ' A' ' 42' ' ' PHE . 21.6 t 61.57 -87.54 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.427 -0.796 . . . . 50.0 110.655 179.749 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.835 ' HD2' HG12 ' A' ' 41' ' ' VAL . 25.8 p90 -155.42 164.89 38.11 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 120.845 -1.159 . . . . 50.0 110.333 179.872 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . 0.451 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 85.3 m -73.87 131.7 81.27 Favored Pre-proline 0 N--CA 1.496 1.834 0 O-C-N 121.239 -0.913 . . . . 50.0 110.601 -179.566 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -71.02 -162.18 0.1 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 O-C-N 123.9 1.474 . . . . 50.0 110.787 -179.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 19.4 ptp180 -80.11 -20.96 43.83 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.536 -0.727 . . . . 50.0 110.413 -179.758 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -76.73 -26.13 54.29 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.261 -0.899 . . . . 50.0 110.013 179.821 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' TYR . . . . . 0.513 ' N ' ' CD1' ' A' ' 47' ' ' TYR . 15.5 m-85 -124.21 158.76 31.67 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.308 -0.87 . . . . 50.0 110.6 -179.813 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.416 ' O ' ' HA ' ' A' ' 61' ' ' CYS . 54.0 tptt -111.89 156.03 22.71 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.438 -0.788 . . . . 50.0 109.151 178.849 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.472 ' HG3' ' HG3' ' A' ' 59' ' ' LYS . 32.7 tt0 -95.25 100.75 12.49 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.923 -1.11 . . . . 50.0 110.65 -179.546 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.537 HD11 ' CD ' ' A' ' 62' ' ' LYS . 66.3 mt -66.92 -31.02 51.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.284 -0.885 . . . . 50.0 109.783 179.443 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 172.67 -97.77 0.12 Allowed Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.55 -1.42 . . . . 50.0 109.55 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 64.9 p -143.36 133.15 23.91 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.205 -1.173 . . . . 50.0 110.44 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' CYS . . . . . 0.535 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 13.8 t -55.01 -45.05 75.09 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.315 -0.865 . . . . 50.0 109.67 179.57 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 167.66 -35.73 0.21 Allowed Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.383 -1.887 . . . . 50.0 108.383 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 66.4 mt -122.38 157.02 59.97 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.542 -0.975 . . . . 50.0 109.491 179.488 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -72.48 -6.5 19.17 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 123.852 1.448 . . . . 50.0 110.641 -179.79 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -71.52 -35.9 62.77 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.495 -1.442 . . . . 50.0 109.495 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 6.2 m -128.59 167.92 16.46 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.323 -1.104 . . . . 50.0 110.183 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.472 ' HG3' ' HG3' ' A' ' 49' ' ' GLN . 16.3 tppt? -124.41 133.68 53.32 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.266 -0.896 . . . . 50.0 110.173 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.535 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 35.3 t -63.06 133.83 55.13 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.29 -0.881 . . . . 50.0 110.527 -179.823 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' CYS . . . . . 0.504 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 74.7 m -133.15 138.65 46.7 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.281 -0.887 . . . . 50.0 110.084 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.537 ' CD ' HD11 ' A' ' 50' ' ' ILE . 87.5 tttt -135.65 144.45 46.05 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.199 -0.938 . . . . 50.0 110.136 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 97.6 mttt . . . . . 0 N--CA 1.491 1.617 0 O-C-N 121.124 -0.985 . . . . 50.0 109.933 179.965 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.49 HG22 ' HB2' ' A' ' 32' ' ' LEU . 26.1 m . . . . . 0 N--CA 1.493 1.679 0 CA-C-O 121.265 0.555 . . . . 50.0 110.054 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 93.3 m -76.79 -4.54 44.02 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.264 -0.898 . . . . 50.0 110.437 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.49 ' HB2' HG22 ' A' ' 30' ' ' THR . 18.9 mt -58.91 -45.19 90.92 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.139 -0.975 . . . . 50.0 110.07 179.858 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -66.71 -34.98 79.05 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.368 -0.833 . . . . 50.0 110.223 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 46.6 t -67.58 -25.08 65.61 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.365 -0.834 . . . . 50.0 110.192 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.77 -14.22 60.46 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.707 -1.357 . . . . 50.0 109.707 179.71 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . 0.469 ' HB2' ' HG3' ' A' ' 62' ' ' LYS . . . -70.31 170.58 11.5 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.143 -1.21 . . . . 50.0 110.255 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.787 HD12 ' NE2' ' A' ' 39' ' ' HIS . 14.7 pt -115.38 163.05 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.346 -0.846 . . . . 50.0 109.748 179.464 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 74.8 m -109.74 140.7 43.33 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.156 -0.965 . . . . 50.0 110.046 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.787 ' NE2' HD12 ' A' ' 37' ' ' ILE . 17.2 m-70 -134.34 153.92 79.6 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.198 -0.939 . . . . 50.0 110.115 179.892 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.475 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 45.1 Cg_endo -70.54 162.79 41.19 Favored 'Trans proline' 0 C--N 1.305 -1.743 0 O-C-N 124.029 1.541 . . . . 50.0 111.262 -179.178 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.764 HG12 ' HD2' ' A' ' 42' ' ' PHE . 18.9 t 62.11 -105.18 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.578 -0.701 . . . . 50.0 110.607 179.546 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.764 ' HD2' HG12 ' A' ' 41' ' ' VAL . 25.8 p90 -140.01 157.27 45.94 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.863 -1.148 . . . . 50.0 110.359 -179.688 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . 0.465 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 83.8 m -67.83 129.46 93.26 Favored Pre-proline 0 N--CA 1.492 1.626 0 O-C-N 121.181 -0.95 . . . . 50.0 109.829 179.599 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -67.6 -162.94 0.08 OUTLIER 'Trans proline' 0 C--N 1.303 -1.848 0 O-C-N 123.881 1.464 . . . . 50.0 110.846 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 16.2 ptm180 -78.33 -32.26 49.12 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.467 -0.77 . . . . 50.0 110.274 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.439 ' HG2' ' CE1' ' A' ' 47' ' ' TYR . 55.6 ttm-85 -68.3 -25.73 65.29 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.265 -0.897 . . . . 50.0 109.902 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' TYR . . . . . 0.579 ' CE2' HD11 ' A' ' 37' ' ' ILE . 29.3 m-85 -119.84 157.4 28.75 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.258 -0.901 . . . . 50.0 110.035 179.623 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.405 ' O ' ' HA ' ' A' ' 61' ' ' CYS . 76.6 tttt -109.54 152.22 25.76 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.262 -0.899 . . . . 50.0 109.323 178.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 56.8 tp60 -95.18 101.51 13.26 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.171 -0.955 . . . . 50.0 110.24 -179.777 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 98.2 mt -72.17 -28.98 30.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.289 -0.882 . . . . 50.0 109.775 179.788 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.53 ' C ' HG23 ' A' ' 52' ' ' THR . . . 165.88 -91.87 0.1 Allowed Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.75 -1.34 . . . . 50.0 109.75 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.53 HG23 ' C ' ' A' ' 51' ' ' GLY . 76.4 p -150.52 130.91 13.75 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.188 -1.184 . . . . 50.0 110.563 -179.573 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' CYS . . . . . . . . . . . . . 8.6 t -51.2 -43.17 61.31 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.221 -0.924 . . . . 50.0 110.083 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.96 ' C ' HD22 ' A' ' 55' ' ' LEU . . . 162.91 -31.63 0.29 Allowed Glycine 0 N--CA 1.488 2.151 0 N-CA-C 109.001 -1.64 . . . . 50.0 109.001 -179.687 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.96 HD22 ' C ' ' A' ' 54' ' ' GLY . 3.2 mm? -126.43 160.9 55.6 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.442 -1.034 . . . . 50.0 109.743 179.758 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -71.45 -10.49 26.99 Favored 'Trans proline' 0 C--N 1.304 -1.799 0 O-C-N 123.801 1.421 . . . . 50.0 110.44 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -64.99 -45.03 93.59 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.595 -1.402 . . . . 50.0 109.595 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . 0.41 HG22 ' N ' ' A' ' 59' ' ' LYS . 20.1 m -131.36 167.1 19.83 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.327 -1.102 . . . . 50.0 110.423 -179.873 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.492 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 47.0 mmtm -118.93 149.48 41.52 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.439 -0.788 . . . . 50.0 109.533 179.387 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.465 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 36.9 t -76.74 132.55 39.36 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.146 -0.971 . . . . 50.0 110.797 -179.093 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' CYS . . . . . 0.531 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 92.5 m -133.17 133.9 43.42 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.465 -0.772 . . . . 50.0 109.858 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.469 ' HG3' ' HB2' ' A' ' 36' ' ' ALA . 81.3 tttt -127.95 141.97 51.38 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.148 -0.97 . . . . 50.0 110.689 -179.539 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . 0.574 ' HE2' ' CZ ' ' A' ' 47' ' ' TYR . 99.4 mttt . . . . . 0 N--CA 1.491 1.595 0 O-C-N 121.36 -0.837 . . . . 50.0 110.023 179.592 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.451 ' O ' ' HB2' ' A' ' 31' ' ' CYS . 85.0 m . . . . . 0 N--CA 1.492 1.645 0 CA-C-O 121.251 0.548 . . . . 50.0 110.314 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . 0.451 ' HB2' ' O ' ' A' ' 30' ' ' THR . 64.1 m 57.28 19.29 4.87 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.161 -0.962 . . . . 50.0 110.399 179.813 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 33.2 tp -72.69 -32.17 65.58 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.165 -0.959 . . . . 50.0 110.633 -179.727 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -71.85 -40.18 69.2 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.103 -0.998 . . . . 50.0 110.226 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 72.3 m -71.82 -24.58 61.74 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.415 -0.803 . . . . 50.0 110.175 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 75.63 16.1 80.85 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.483 -1.447 . . . . 50.0 109.483 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . 0.668 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -83.12 176.74 8.98 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.281 -1.129 . . . . 50.0 110.024 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.472 ' O ' HG13 ' A' ' 37' ' ' ILE . 3.7 pt -116.91 150.77 18.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.134 -0.979 . . . . 50.0 110.42 -179.901 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.446 ' HA ' ' HA ' ' A' ' 60' ' ' CYS . 61.0 m -91.26 137.3 32.47 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.173 -0.954 . . . . 50.0 109.333 179.484 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.517 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 58.3 t-80 -109.49 143.03 26.95 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.054 -1.028 . . . . 50.0 110.76 -179.157 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.517 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 47.5 Cg_endo -73.33 164.78 34.3 Favored 'Trans proline' 0 C--N 1.305 -1.713 0 O-C-N 124.19 1.626 . . . . 50.0 110.316 179.694 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.827 HG12 ' HD2' ' A' ' 42' ' ' PHE . 27.7 t 59.71 -84.02 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.298 -0.876 . . . . 50.0 110.558 179.667 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.827 ' HD2' HG12 ' A' ' 41' ' ' VAL . 16.5 p90 -158.64 161.89 37.21 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.854 -1.154 . . . . 50.0 110.389 -179.916 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . 0.434 ' SG ' ' HB3' ' A' ' 47' ' ' TYR . 0.6 OUTLIER -80.92 121.62 81.06 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.216 -0.928 . . . . 50.0 110.059 179.911 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -70.39 -162.52 0.1 OUTLIER 'Trans proline' 0 C--N 1.306 -1.677 0 O-C-N 123.908 1.478 . . . . 50.0 110.592 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 11.2 ptm180 -81.8 -29.76 32.54 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.546 -0.721 . . . . 50.0 110.369 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 45.4 mmm-85 -69.06 -16.1 63.61 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.274 -0.891 . . . . 50.0 110.163 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' TYR . . . . . 0.568 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 72.4 m-85 -122.93 150.14 43.34 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.29 -0.881 . . . . 50.0 110.337 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 54.0 tptt -110.9 154.11 24.53 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.35 -0.844 . . . . 50.0 110.224 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.517 ' HG3' ' CE ' ' A' ' 59' ' ' LYS . 46.2 tt0 -88.48 108.91 19.63 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.23 -0.919 . . . . 50.0 110.01 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 39.4 pt -104.32 10.76 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.22 -0.925 . . . . 50.0 110.966 -179.51 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.536 ' O ' ' CB ' ' A' ' 60' ' ' CYS . . . 130.62 113.01 1.55 Allowed Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.431 -1.468 . . . . 50.0 109.431 179.927 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.493 ' C ' ' O ' ' A' ' 51' ' ' GLY . 81.9 p -29.52 140.09 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.991 -0.711 . . . . 50.0 111.633 -179.612 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' CYS . . . . . 0.403 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 8.3 t -59.52 -50.24 74.69 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.385 -0.822 . . . . 50.0 110.219 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -179.06 -39.85 0.07 OUTLIER Glycine 0 N--CA 1.491 2.323 0 N-CA-C 108.945 -1.662 . . . . 50.0 108.945 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.453 ' HB3' ' HD2' ' A' ' 56' ' ' PRO . 70.2 mt -126.59 164.12 36.44 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.437 -1.037 . . . . 50.0 109.836 179.664 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.453 ' HD2' ' HB3' ' A' ' 55' ' ' LEU . 45.2 Cg_endo -71.21 -7.29 21.04 Favored 'Trans proline' 0 C--N 1.305 -1.762 0 O-C-N 123.971 1.511 . . . . 50.0 110.555 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -68.98 -37.64 83.56 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.16 -1.576 . . . . 50.0 109.16 179.765 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.4 m -129.42 159.97 34.57 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.316 -1.108 . . . . 50.0 110.005 179.773 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.517 ' CE ' ' HG3' ' A' ' 49' ' ' GLN . 37.7 tptt -121.84 127.27 50.35 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.197 -0.94 . . . . 50.0 109.984 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.536 ' CB ' ' O ' ' A' ' 51' ' ' GLY . 49.8 t -57.03 134.26 55.66 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.196 -0.94 . . . . 50.0 110.073 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' CYS . . . . . 0.668 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 54.5 m -136.76 148.26 47.15 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.3 -0.875 . . . . 50.0 109.981 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 81.0 tttt -128.4 132.26 48.5 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.207 -0.933 . . . . 50.0 110.418 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . 0.568 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 49.2 mtpt . . . . . 0 N--CA 1.491 1.58 0 O-C-N 121.299 -0.875 . . . . 50.0 110.202 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 57.7 m . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 121.376 0.608 . . . . 50.0 109.927 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 92.6 m -80.01 -8.3 59.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.252 -0.905 . . . . 50.0 110.594 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.0 mt -58.29 -33.14 69.12 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.147 -0.971 . . . . 50.0 110.38 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 95.0 mttt -67.39 -39.09 85.59 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.266 -0.896 . . . . 50.0 110.229 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 14.4 m -65.4 -31.71 72.95 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.292 -0.88 . . . . 50.0 110.154 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 106.73 15.44 16.83 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.696 -1.362 . . . . 50.0 109.696 179.865 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . 0.875 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -120.31 126.38 50.41 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.17 -1.194 . . . . 50.0 110.152 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.74 HD11 ' NE2' ' A' ' 39' ' ' HIS . 1.1 pt -84.02 144.54 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.281 -0.887 . . . . 50.0 109.995 179.855 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.46 ' HA ' ' HA ' ' A' ' 60' ' ' CYS . 22.6 p -87.95 159.69 18.23 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.196 -0.94 . . . . 50.0 110.411 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.74 ' NE2' HD11 ' A' ' 37' ' ' ILE . 41.8 m-70 -131.02 167.88 19.66 Favored Pre-proline 0 N--CA 1.496 1.839 0 O-C-N 121.408 -0.808 . . . . 50.0 110.168 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.453 ' HD2' ' HB3' ' A' ' 39' ' ' HIS . 43.5 Cg_endo -70.16 161.17 46.97 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 O-C-N 123.711 1.374 . . . . 50.0 110.742 -179.601 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.857 HG12 ' HD2' ' A' ' 42' ' ' PHE . 9.8 t 55.82 -112.15 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.297 -0.877 . . . . 50.0 109.883 -179.682 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.857 ' HD2' HG12 ' A' ' 41' ' ' VAL . 50.2 p90 -135.2 156.27 49.27 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.676 -1.265 . . . . 50.0 109.96 179.749 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . 0.476 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 83.6 m -59.14 130.47 86.87 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.137 -0.977 . . . . 50.0 110.043 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -70.71 -162.54 0.1 Allowed 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 123.979 1.515 . . . . 50.0 110.603 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 41.5 ptt180 -78.6 -29.35 46.02 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.493 -0.754 . . . . 50.0 110.413 -179.623 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 86.5 mtm180 -72.39 -12.43 61.11 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.237 -0.914 . . . . 50.0 110.16 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' TYR . . . . . 0.609 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 38.1 m-85 -131.36 165.66 22.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.267 -0.896 . . . . 50.0 111.084 -179.611 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.501 ' O ' ' HA ' ' A' ' 61' ' ' CYS . 33.2 mttm -117.31 142.68 46.78 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.514 -0.741 . . . . 50.0 109.295 178.865 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.497 ' HA ' ' O ' ' A' ' 60' ' ' CYS . 32.7 tt0 -88.19 110.04 20.38 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.981 -1.075 . . . . 50.0 111.188 -179.131 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.646 HD11 ' CG ' ' A' ' 62' ' ' LYS . 80.7 mt -77.21 -28.89 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.314 -0.866 . . . . 50.0 109.326 178.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.579 ' C ' HG23 ' A' ' 52' ' ' THR . . . 174.3 -99.54 0.14 Allowed Glycine 0 N--CA 1.488 2.166 0 N-CA-C 108.819 -1.712 . . . . 50.0 108.819 -179.836 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.579 HG23 ' C ' ' A' ' 51' ' ' GLY . 70.9 p -157.65 143.74 17.55 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.284 -1.127 . . . . 50.0 110.191 179.571 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' CYS . . . . . 0.441 ' HA ' ' SG ' ' A' ' 60' ' ' CYS . 1.8 t -58.1 -39.06 77.67 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.217 -0.927 . . . . 50.0 109.882 179.606 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.546 ' O ' HD23 ' A' ' 55' ' ' LEU . . . 165.85 -27.68 0.18 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 108.818 -1.713 . . . . 50.0 108.818 -179.936 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.546 HD23 ' O ' ' A' ' 54' ' ' GLY . 30.2 mt -127.36 166.46 22.86 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.409 -1.054 . . . . 50.0 109.816 179.748 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.488 ' HD2' ' HB3' ' A' ' 55' ' ' LEU . 45.6 Cg_endo -73.52 -4.85 16.12 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.884 1.465 . . . . 50.0 110.447 179.889 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -78.61 -32.81 40.39 Favored Glycine 0 N--CA 1.489 2.167 0 N-CA-C 109.421 -1.472 . . . . 50.0 109.421 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . 0.536 HG23 ' C ' ' A' ' 39' ' ' HIS . 2.5 m -128.37 162.58 26.77 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.273 -1.134 . . . . 50.0 110.587 -179.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.524 ' CG ' ' O ' ' A' ' 41' ' ' VAL . 72.1 mmtt -133.38 142.96 48.63 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.536 -0.728 . . . . 50.0 109.511 179.615 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.497 ' O ' ' HA ' ' A' ' 49' ' ' GLN . 45.1 m -68.98 131.09 44.51 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.083 -1.01 . . . . 50.0 110.255 -179.861 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' CYS . . . . . 0.875 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 98.3 m -124.29 162.07 24.51 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.399 -0.813 . . . . 50.0 110.247 -179.812 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.646 ' CG ' HD11 ' A' ' 50' ' ' ILE . 46.0 mtpt -122.31 164.31 18.14 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.233 -0.917 . . . . 50.0 110.672 -179.748 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . 0.609 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 52.1 mtpt . . . . . 0 N--CA 1.492 1.638 0 O-C-N 121.364 -0.835 . . . . 50.0 110.334 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.494 HG22 ' HB2' ' A' ' 32' ' ' LEU . 25.0 m . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 121.262 0.554 . . . . 50.0 110.097 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . 0.848 ' HB3' ' HB3' ' A' ' 36' ' ' ALA . 87.2 m -77.39 -1.6 30.94 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.193 -0.942 . . . . 50.0 110.411 -179.834 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.494 ' HB2' HG22 ' A' ' 30' ' ' THR . 32.9 mt -63.35 -39.64 95.08 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.222 -0.924 . . . . 50.0 110.261 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 43.0 mmtm -66.75 -42.58 85.95 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.29 -0.882 . . . . 50.0 110.362 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 86.3 p -70.46 -14.77 62.67 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.347 -0.846 . . . . 50.0 110.143 -179.892 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 87.12 4.79 81.19 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.543 -1.423 . . . . 50.0 109.543 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . 0.848 ' HB3' ' HB3' ' A' ' 31' ' ' CYS . . . -71.8 155.64 40.21 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.159 -1.201 . . . . 50.0 110.009 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 1.008 HD12 ' NE2' ' A' ' 39' ' ' HIS . 26.7 pt -103.89 145.0 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.185 -0.947 . . . . 50.0 110.015 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 8.7 m -101.22 125.39 47.84 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.258 -0.901 . . . . 50.0 109.936 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 1.008 ' NE2' HD12 ' A' ' 37' ' ' ILE . 12.5 m-70 -119.48 153.06 53.77 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.232 -0.917 . . . . 50.0 110.345 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.427 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 45.7 Cg_endo -71.16 169.88 19.55 Favored 'Trans proline' 0 C--N 1.305 -1.727 0 O-C-N 124.04 1.547 . . . . 50.0 110.852 -179.604 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.795 HG12 ' HD2' ' A' ' 42' ' ' PHE . 17.4 t 59.15 -109.35 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.362 -0.836 . . . . 50.0 110.186 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.795 ' HD2' HG12 ' A' ' 41' ' ' VAL . 36.8 p90 -136.24 153.64 51.15 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.827 -1.171 . . . . 50.0 110.017 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . 0.407 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 76.4 m -69.88 132.26 88.8 Favored Pre-proline 0 N--CA 1.487 1.415 0 O-C-N 121.11 -0.994 . . . . 50.0 109.911 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -68.41 -162.76 0.08 OUTLIER 'Trans proline' 0 C--N 1.305 -1.732 0 O-C-N 123.996 1.524 . . . . 50.0 111.004 -179.564 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 16.2 ptm180 -81.58 -26.37 35.01 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.558 -0.714 . . . . 50.0 110.453 -179.617 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 13.3 mmm180 -66.71 -22.22 66.07 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.148 -0.97 . . . . 50.0 110.1 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' TYR . . . . . 0.626 ' CB ' ' HB3' ' A' ' 61' ' ' CYS . 70.8 m-85 -128.1 144.01 51.09 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.217 -0.927 . . . . 50.0 110.589 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 85.0 tttt -88.67 152.88 21.53 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.267 -0.896 . . . . 50.0 109.221 178.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 56.4 tt0 -93.4 96.44 9.93 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.093 -1.005 . . . . 50.0 110.562 -179.702 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 93.6 mt -69.42 -30.11 44.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.309 -0.87 . . . . 50.0 109.904 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.576 ' C ' HG23 ' A' ' 52' ' ' THR . . . 159.12 -91.86 0.12 Allowed Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.263 -1.535 . . . . 50.0 109.263 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.576 HG23 ' C ' ' A' ' 51' ' ' GLY . 63.3 p -153.92 150.58 28.5 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.26 -1.141 . . . . 50.0 109.992 179.695 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' CYS . . . . . 0.42 ' SG ' ' HB2' ' A' ' 60' ' ' CYS . 1.6 m -84.89 -27.33 26.72 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.189 -0.944 . . . . 50.0 110.694 -179.599 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 179.03 -49.5 0.09 OUTLIER Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.764 -1.334 . . . . 50.0 109.764 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 56.2 mt -119.74 161.92 35.47 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.16 -1.2 . . . . 50.0 110.419 -179.851 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -71.93 -11.4 27.42 Favored 'Trans proline' 0 C--N 1.305 -1.74 0 O-C-N 124.08 1.569 . . . . 50.0 110.292 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -68.94 -30.47 72.32 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.448 -1.461 . . . . 50.0 109.448 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -125.25 155.28 40.37 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.275 -1.132 . . . . 50.0 110.298 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.445 ' O ' ' SG ' ' A' ' 61' ' ' CYS . 14.1 tppt? -120.56 127.16 51.89 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.396 -0.815 . . . . 50.0 109.839 179.686 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.42 ' HB2' ' SG ' ' A' ' 53' ' ' CYS . 34.3 t -63.51 130.9 46.29 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.252 -0.905 . . . . 50.0 110.663 -179.604 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' CYS . . . . . 0.626 ' HB3' ' CB ' ' A' ' 47' ' ' TYR . 7.4 m -128.58 130.3 47.16 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.371 -0.831 . . . . 50.0 109.635 179.765 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 83.4 tttt -131.62 148.69 52.62 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.157 -0.964 . . . . 50.0 110.507 -179.638 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 86.0 mttt . . . . . 0 N--CA 1.49 1.575 0 O-C-N 121.281 -0.887 . . . . 50.0 110.021 179.887 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.507 HG22 ' HB2' ' A' ' 32' ' ' LEU . 85.8 m . . . . . 0 N--CA 1.492 1.666 0 CA-C-O 121.098 0.475 . . . . 50.0 110.54 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . 0.479 ' HB2' ' O ' ' A' ' 30' ' ' THR . 97.9 m 56.61 18.38 3.6 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.232 -0.918 . . . . 50.0 110.223 179.836 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.753 HD13 ' C ' ' A' ' 32' ' ' LEU . 3.4 tm? -76.62 -39.47 52.36 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.223 -0.923 . . . . 50.0 110.477 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 74.4 mmtt -75.13 -35.24 61.7 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.324 -0.86 . . . . 50.0 109.985 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 73.9 m -71.18 -26.72 63.09 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.374 -0.829 . . . . 50.0 110.191 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 84.98 9.0 81.54 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.493 -1.443 . . . . 50.0 109.493 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . 0.455 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -76.66 134.37 39.29 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.232 -1.158 . . . . 50.0 110.262 -179.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.684 HD11 ' CE2' ' A' ' 47' ' ' TYR . 9.1 pt -83.02 148.13 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.239 -0.913 . . . . 50.0 110.028 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 96.5 m -91.79 148.79 21.98 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.075 -1.016 . . . . 50.0 109.882 179.862 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.583 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 62.6 t-80 -139.71 145.9 45.17 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 121.312 -0.868 . . . . 50.0 109.89 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.583 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 41.6 Cg_endo -66.89 159.63 50.79 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.868 1.457 . . . . 50.0 110.075 179.723 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.827 HG12 ' HD2' ' A' ' 42' ' ' PHE . 13.5 t 62.99 -105.94 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.224 -0.922 . . . . 50.0 109.913 -179.673 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.827 ' HD2' HG12 ' A' ' 41' ' ' VAL . 42.1 p90 -142.26 157.9 44.32 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.626 -1.296 . . . . 50.0 110.148 179.814 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . 0.455 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 84.4 m -65.02 132.54 95.5 Favored Pre-proline 0 N--CA 1.493 1.699 0 O-C-N 121.241 -0.912 . . . . 50.0 110.371 -179.792 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -68.71 -162.16 0.08 OUTLIER 'Trans proline' 0 C--N 1.305 -1.75 0 O-C-N 123.995 1.524 . . . . 50.0 110.839 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 27.3 tpt180 -75.61 -43.13 49.63 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.519 -0.738 . . . . 50.0 110.537 -179.681 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 45.8 ttt85 -61.45 -30.77 70.8 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.333 -0.854 . . . . 50.0 110.372 -179.723 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' TYR . . . . . 0.684 ' CE2' HD11 ' A' ' 37' ' ' ILE . 32.2 m-85 -111.1 136.36 50.26 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.193 -0.942 . . . . 50.0 110.747 -179.85 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 24.6 tptp -87.37 157.14 19.32 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.261 -0.899 . . . . 50.0 109.387 179.034 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.416 ' HA ' ' SG ' ' A' ' 43' ' ' CYS . 53.7 tt0 -89.5 102.7 15.38 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.099 -1.001 . . . . 50.0 110.356 -179.777 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.419 ' HB ' ' SG ' ' A' ' 60' ' ' CYS . 30.6 mm -67.08 -30.66 50.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.227 -0.921 . . . . 50.0 109.555 179.552 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 153.77 -91.16 0.13 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.035 -1.626 . . . . 50.0 109.035 179.866 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 50.1 p -146.2 125.9 13.42 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.363 -1.081 . . . . 50.0 109.976 179.603 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' CYS . . . . . . . . . . . . . 19.1 t -49.85 -49.22 49.98 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.252 -0.905 . . . . 50.0 109.669 179.635 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 173.47 -30.15 0.1 OUTLIER Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.211 -1.556 . . . . 50.0 109.211 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.407 ' HA ' HD23 ' A' ' 55' ' ' LEU . 55.6 mt -124.87 160.3 54.72 Favored Pre-proline 0 N--CA 1.489 1.512 0 O-C-N 121.384 -1.068 . . . . 50.0 109.917 179.866 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -71.97 -5.8 17.83 Favored 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.928 1.488 . . . . 50.0 110.198 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -78.32 -37.12 28.83 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.469 -1.452 . . . . 50.0 109.469 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 5.1 m -130.59 162.23 29.79 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.269 -1.136 . . . . 50.0 110.268 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 66.7 mmtt -117.56 164.59 14.69 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.408 -0.808 . . . . 50.0 109.778 179.718 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.455 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 42.2 t -91.32 129.7 37.27 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.139 -0.975 . . . . 50.0 110.468 -179.78 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' CYS . . . . . 0.505 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 72.4 m -126.42 147.71 49.75 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.342 -0.849 . . . . 50.0 109.832 179.808 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 89.1 tttt -126.58 138.35 53.45 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.15 -0.969 . . . . 50.0 110.323 -179.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . 0.433 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 30.3 mtmm . . . . . 0 N--CA 1.491 1.598 0 O-C-N 121.333 -0.855 . . . . 50.0 110.325 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.737 ' O ' HG22 ' A' ' 30' ' ' THR . 95.3 m . . . . . 0 N--CA 1.494 1.754 0 CA-C-O 121.237 0.542 . . . . 50.0 110.587 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 65.4 m -48.5 -22.5 0.74 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.13 -0.981 . . . . 50.0 109.721 179.682 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.7 mt -57.98 -42.76 85.76 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.249 -0.907 . . . . 50.0 110.08 179.568 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.638 ' HB2' HG22 ' A' ' 30' ' ' THR . 64.8 mmtt -68.24 -33.3 74.13 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.444 -0.785 . . . . 50.0 110.185 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 69.3 m -76.37 -17.53 59.34 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.228 -0.92 . . . . 50.0 109.942 179.837 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 91.93 -2.87 76.67 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.858 -1.297 . . . . 50.0 109.858 179.586 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . 0.435 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -79.59 153.94 29.09 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.124 -1.221 . . . . 50.0 110.226 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.471 ' O ' ' N ' ' A' ' 61' ' ' CYS . 4.8 pt -107.79 152.88 9.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.288 -0.882 . . . . 50.0 110.052 179.826 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 71.8 m -93.32 148.98 21.57 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.202 -0.937 . . . . 50.0 110.045 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.596 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 42.0 t-80 -136.49 145.96 53.73 Favored Pre-proline 0 N--CA 1.491 1.614 0 O-C-N 121.275 -0.891 . . . . 50.0 110.16 -179.685 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.596 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 42.5 Cg_endo -68.59 153.02 74.38 Favored 'Trans proline' 0 C--N 1.307 -1.612 0 O-C-N 123.844 1.444 . . . . 50.0 110.544 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.835 HG12 ' HD2' ' A' ' 42' ' ' PHE . 18.0 t 64.24 -84.62 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.577 -0.702 . . . . 50.0 110.559 -179.784 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.835 ' HD2' HG12 ' A' ' 41' ' ' VAL . 21.6 p90 -156.56 161.96 39.94 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.714 -1.241 . . . . 50.0 110.214 179.963 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . 0.435 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 58.4 m -73.25 134.12 80.48 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.249 -0.907 . . . . 50.0 110.526 -179.665 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.454 ' O ' ' O ' ' A' ' 47' ' ' TYR . 44.3 Cg_endo -70.18 -160.63 0.07 OUTLIER 'Trans proline' 0 C--N 1.305 -1.718 0 O-C-N 123.874 1.46 . . . . 50.0 110.522 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 17.4 mmt180 -78.45 -46.58 19.41 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.493 -0.754 . . . . 50.0 109.68 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 82.1 mtm180 -54.39 -23.97 17.82 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.56 -0.713 . . . . 50.0 109.674 179.783 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' TYR . . . . . 0.555 ' CZ ' ' HE2' ' A' ' 63' ' ' LYS . 39.4 m-85 -122.95 154.04 38.93 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.411 -0.805 . . . . 50.0 110.259 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 82.1 tttt -117.84 149.74 40.33 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.4 -0.813 . . . . 50.0 109.679 179.594 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 58.8 tt0 -88.71 94.92 10.07 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.184 -0.948 . . . . 50.0 109.892 179.638 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.463 HG13 ' N ' ' A' ' 51' ' ' GLY . 21.6 pt -71.4 -30.08 38.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.402 -0.811 . . . . 50.0 110.326 -179.821 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.504 ' C ' HG23 ' A' ' 52' ' ' THR . . . -171.52 -105.63 0.18 Allowed Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.483 -1.447 . . . . 50.0 109.483 179.76 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.504 HG23 ' C ' ' A' ' 51' ' ' GLY . 41.2 p -151.17 141.02 21.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.285 -1.127 . . . . 50.0 110.218 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' CYS . . . . . 0.577 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 10.0 t -58.49 -44.39 89.38 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.273 -0.892 . . . . 50.0 109.873 179.879 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 160.08 -36.9 0.46 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.033 -1.627 . . . . 50.0 109.033 -179.83 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 74.8 mt -113.45 155.29 44.94 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.428 -1.042 . . . . 50.0 109.924 179.669 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -71.32 -11.8 29.04 Favored 'Trans proline' 0 C--N 1.303 -1.853 0 O-C-N 123.922 1.485 . . . . 50.0 110.69 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -70.92 -41.92 61.07 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.57 -1.412 . . . . 50.0 109.57 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 14.6 m -122.79 166.86 14.27 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.337 -1.096 . . . . 50.0 110.248 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -124.7 145.66 49.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.406 -0.809 . . . . 50.0 109.87 179.806 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.577 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 45.2 t -73.47 139.36 45.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.151 -0.968 . . . . 50.0 110.431 -179.803 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' CYS . . . . . 0.494 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 74.8 m -131.49 141.65 49.81 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.389 -0.82 . . . . 50.0 109.61 179.748 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 81.8 tttt -138.65 143.52 39.26 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.205 -0.934 . . . . 50.0 110.658 -179.341 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . 0.555 ' HE2' ' CZ ' ' A' ' 47' ' ' TYR . 98.9 mttt . . . . . 0 N--CA 1.491 1.59 0 O-C-N 121.294 -0.879 . . . . 50.0 110.158 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.665 HG22 ' HB2' ' A' ' 32' ' ' LEU . 85.6 m . . . . . 0 N--CA 1.491 1.61 0 CA-C-O 121.121 0.486 . . . . 50.0 110.571 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . 0.478 ' HB2' ' O ' ' A' ' 30' ' ' THR . 47.9 m 56.87 21.97 6.63 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.14 -0.975 . . . . 50.0 110.312 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.665 ' HB2' HG22 ' A' ' 30' ' ' THR . 79.2 mt -105.12 -21.05 13.33 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.193 -0.942 . . . . 50.0 110.176 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 95.2 mttt -72.58 -37.52 68.15 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.345 -0.847 . . . . 50.0 110.324 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 87.9 p -88.76 -4.04 58.61 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.292 -0.88 . . . . 50.0 110.25 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 69.42 21.38 76.01 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.195 -1.562 . . . . 50.0 109.195 -179.84 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -70.22 155.16 41.03 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.35 -1.088 . . . . 50.0 110.211 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.966 HD12 ' NE2' ' A' ' 39' ' ' HIS . 12.8 pt -104.73 151.05 7.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.21 -0.931 . . . . 50.0 110.253 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 76.2 m -105.38 139.54 39.85 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.299 -0.875 . . . . 50.0 110.031 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.966 ' NE2' HD12 ' A' ' 37' ' ' ILE . 17.3 m-70 -133.52 157.9 76.9 Favored Pre-proline 0 N--CA 1.494 1.74 0 O-C-N 121.346 -0.846 . . . . 50.0 110.192 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.466 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 45.2 Cg_endo -71.58 168.42 23.68 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 O-C-N 124.059 1.557 . . . . 50.0 110.415 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.87 HG12 ' HD2' ' A' ' 42' ' ' PHE . 10.8 t 61.84 -108.37 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.237 -0.914 . . . . 50.0 109.804 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.87 ' HD2' HG12 ' A' ' 41' ' ' VAL . 48.6 p90 -143.63 161.78 37.63 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.747 -1.221 . . . . 50.0 110.108 179.704 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . 0.462 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 70.8 m -67.33 132.43 93.24 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.222 -0.924 . . . . 50.0 110.356 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -71.29 -162.56 0.11 Allowed 'Trans proline' 0 C--N 1.306 -1.707 0 O-C-N 123.933 1.491 . . . . 50.0 110.346 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 30.2 mtt180 -78.21 -41.47 34.32 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.424 -0.798 . . . . 50.0 110.015 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 26.0 mmm180 -57.95 -27.94 63.87 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.483 -0.761 . . . . 50.0 110.21 -179.777 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' TYR . . . . . 0.535 ' CE2' ' CG ' ' A' ' 63' ' ' LYS . 21.7 m-85 -119.12 158.9 24.98 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.345 -0.847 . . . . 50.0 110.534 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -117.08 131.0 57.02 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.467 -0.77 . . . . 50.0 109.634 179.307 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.449 ' HB2' ' HB2' ' A' ' 43' ' ' CYS . 54.4 tt0 -78.14 104.14 8.53 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.276 -0.89 . . . . 50.0 111.024 -179.082 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.701 HD11 ' HD3' ' A' ' 62' ' ' LYS . 79.5 mt -68.71 -31.21 49.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.335 -0.853 . . . . 50.0 109.387 179.111 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.443 ' C ' HG23 ' A' ' 52' ' ' THR . . . 172.95 -96.67 0.11 Allowed Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.662 -1.375 . . . . 50.0 109.662 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.443 HG23 ' C ' ' A' ' 51' ' ' GLY . 68.6 p -146.7 137.2 23.8 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.207 -1.172 . . . . 50.0 110.327 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' CYS . . . . . . . . . . . . . 4.1 t -62.35 -41.43 98.58 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.263 -0.898 . . . . 50.0 110.137 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 158.93 -25.68 0.36 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 108.994 -1.642 . . . . 50.0 108.994 -179.897 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.521 ' CD1' ' HD2' ' A' ' 56' ' ' PRO . 17.4 tp -120.8 142.44 34.45 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.401 -1.059 . . . . 50.0 109.712 179.777 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.521 ' HD2' ' CD1' ' A' ' 55' ' ' LEU . 42.0 Cg_endo -67.92 -8.17 21.82 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 O-C-N 123.872 1.459 . . . . 50.0 110.442 -179.841 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -75.99 -32.09 53.88 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.062 -1.615 . . . . 50.0 109.062 179.511 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . 0.464 ' HA ' ' HA ' ' A' ' 40' ' ' PRO . 4.0 m -131.28 162.12 30.75 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.262 -1.14 . . . . 50.0 110.4 179.896 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.493 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 46.5 mmtm -120.76 146.63 46.3 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.285 -0.884 . . . . 50.0 109.829 179.741 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.462 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 42.7 t -75.82 133.4 40.64 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.264 -0.898 . . . . 50.0 110.749 -179.376 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' CYS . . . . . 0.514 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 73.6 m -130.45 135.08 47.62 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.365 -0.834 . . . . 50.0 109.791 179.807 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.701 ' HD3' HD11 ' A' ' 50' ' ' ILE . 39.8 ttpt -126.51 135.15 50.95 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.09 -1.006 . . . . 50.0 110.287 -179.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . 0.535 ' CG ' ' CE2' ' A' ' 47' ' ' TYR . 49.5 mtmt . . . . . 0 N--CA 1.491 1.602 0 O-C-N 121.319 -0.863 . . . . 50.0 110.128 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 97.0 m . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 121.305 0.574 . . . . 50.0 110.034 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . 0.862 ' SG ' ' SG ' ' A' ' 53' ' ' CYS . 76.9 m -76.56 -7.15 54.62 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.274 -0.891 . . . . 50.0 110.399 -179.856 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.405 HD12 ' HA ' ' A' ' 32' ' ' LEU . 50.7 tp -65.35 -40.98 94.3 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.189 -0.945 . . . . 50.0 110.28 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -62.55 -44.19 96.94 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.321 -0.862 . . . . 50.0 110.271 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 58.1 m -66.13 -33.32 75.51 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.357 -0.839 . . . . 50.0 110.139 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 104.56 8.52 37.5 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.397 -1.481 . . . . 50.0 109.397 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . 0.669 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -96.13 123.38 39.72 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.263 -1.14 . . . . 50.0 109.95 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.457 ' O ' HG13 ' A' ' 37' ' ' ILE . 2.2 pt -71.61 151.5 8.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.155 -0.965 . . . . 50.0 110.495 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 24.5 m -91.28 154.73 19.05 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.182 -0.949 . . . . 50.0 109.871 179.645 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.545 ' O ' ' N ' ' A' ' 59' ' ' LYS . 64.7 t-80 -129.78 140.79 39.69 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.123 -0.986 . . . . 50.0 110.571 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.483 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 43.7 Cg_endo -70.4 161.83 44.6 Favored 'Trans proline' 0 C--N 1.304 -1.806 0 O-C-N 123.967 1.509 . . . . 50.0 111.091 -179.78 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.786 HG12 ' HD2' ' A' ' 42' ' ' PHE . 33.1 t 57.18 -84.23 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.536 -0.727 . . . . 50.0 110.955 179.846 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.786 ' HD2' HG12 ' A' ' 41' ' ' VAL . 14.0 p90 -155.26 157.65 37.59 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.873 -1.142 . . . . 50.0 110.457 -179.653 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . 0.422 ' SG ' ' HB3' ' A' ' 47' ' ' TYR . 0.7 OUTLIER -71.82 133.9 84.01 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 121.327 -0.858 . . . . 50.0 110.293 179.896 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.436 ' HD2' ' HB2' ' A' ' 47' ' ' TYR . 45.1 Cg_endo -70.55 -162.23 0.1 OUTLIER 'Trans proline' 0 C--N 1.306 -1.665 0 O-C-N 123.883 1.465 . . . . 50.0 110.543 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 28.7 tpt180 -81.93 -37.05 27.35 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.534 -0.729 . . . . 50.0 110.365 -179.813 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -66.39 -29.71 69.93 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.381 -0.824 . . . . 50.0 110.172 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' TYR . . . . . 0.542 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 45.8 m-85 -110.37 138.48 46.7 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.267 -0.896 . . . . 50.0 110.842 -179.597 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.452 ' O ' ' HA ' ' A' ' 61' ' ' CYS . 67.0 tttt -90.6 153.05 20.61 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.242 -0.912 . . . . 50.0 109.219 178.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 36.0 tt0 -102.07 98.9 9.02 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.041 -1.037 . . . . 50.0 110.302 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 97.0 mt -64.38 -28.6 45.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.46 -0.775 . . . . 50.0 109.984 179.888 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 160.5 -91.3 0.11 Allowed Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.551 -1.419 . . . . 50.0 109.551 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 67.6 p -145.29 159.28 43.27 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.283 -1.128 . . . . 50.0 110.313 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' CYS . . . . . 0.862 ' SG ' ' SG ' ' A' ' 31' ' ' CYS . 0.5 OUTLIER -104.53 -15.76 15.25 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.279 -0.888 . . . . 50.0 110.329 -179.923 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 162.34 -43.6 0.36 Allowed Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.45 -1.46 . . . . 50.0 109.45 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 87.2 mt -123.34 159.39 55.01 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.277 -1.131 . . . . 50.0 109.955 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.72 -16.99 26.37 Favored 'Trans proline' 0 C--N 1.304 -1.787 0 O-C-N 123.896 1.472 . . . . 50.0 110.383 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -68.08 -33.97 80.18 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.457 -1.457 . . . . 50.0 109.457 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . 0.515 HG22 ' N ' ' A' ' 59' ' ' LYS . 34.3 m -117.24 170.14 8.92 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.262 -1.14 . . . . 50.0 110.388 179.861 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.545 ' N ' ' O ' ' A' ' 39' ' ' HIS . 73.7 mmtt -133.75 155.93 48.89 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.437 -0.789 . . . . 50.0 109.56 179.787 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 13.1 t -83.09 127.86 33.96 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.075 -1.016 . . . . 50.0 110.308 -179.586 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' CYS . . . . . 0.669 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 51.0 m -127.05 146.4 50.37 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.272 -0.892 . . . . 50.0 110.266 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 76.9 tttt -129.38 136.11 49.56 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.211 -0.931 . . . . 50.0 110.319 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . 0.542 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 97.6 mttt . . . . . 0 N--CA 1.492 1.637 0 O-C-N 121.251 -0.906 . . . . 50.0 109.968 179.805 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.458 HG22 ' HB3' ' A' ' 32' ' ' LEU . 86.1 m . . . . . 0 N--CA 1.491 1.613 0 CA-C-O 121.235 0.54 . . . . 50.0 110.012 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' CYS . . . . . 0.475 ' HB3' ' HB3' ' A' ' 36' ' ' ALA . 95.8 m -75.86 -4.55 41.41 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.35 -0.844 . . . . 50.0 110.35 -179.793 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.458 ' HB3' HG22 ' A' ' 30' ' ' THR . 49.8 tp -55.67 -49.57 72.56 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.192 -0.943 . . . . 50.0 109.996 179.764 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -59.89 -36.18 76.41 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.481 -0.762 . . . . 50.0 110.153 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 70.6 m -73.06 -27.46 61.75 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.34 -0.85 . . . . 50.0 110.235 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 95.01 -6.32 69.22 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.509 -1.436 . . . . 50.0 109.509 -179.861 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . 0.475 ' HB3' ' HB3' ' A' ' 31' ' ' CYS . . . -66.46 141.6 57.85 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.209 -1.171 . . . . 50.0 110.074 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.894 HD12 ' NE2' ' A' ' 39' ' ' HIS . 7.2 pt -86.98 150.16 3.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.203 -0.935 . . . . 50.0 110.253 -179.841 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 76.6 m -105.99 144.64 32.43 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.261 -0.9 . . . . 50.0 110.1 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.894 ' NE2' HD12 ' A' ' 37' ' ' ILE . 27.6 m-70 -135.48 158.99 73.27 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.259 -0.901 . . . . 50.0 110.315 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -70.15 172.59 12.74 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 O-C-N 124.002 1.527 . . . . 50.0 110.274 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.81 HG12 ' HD1' ' A' ' 42' ' ' PHE . 7.5 t 54.74 -115.35 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.297 -0.877 . . . . 50.0 109.788 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.81 ' HD1' HG12 ' A' ' 41' ' ' VAL . 39.4 p90 -137.88 156.31 48.04 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.774 -1.204 . . . . 50.0 109.94 179.641 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' CYS . . . . . 0.459 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 82.6 m -57.46 130.87 81.38 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.242 -0.911 . . . . 50.0 110.372 -179.737 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -71.72 -161.88 0.1 Allowed 'Trans proline' 0 C--N 1.305 -1.718 0 O-C-N 124.062 1.559 . . . . 50.0 110.73 179.777 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 19.1 ptp180 -76.35 -29.43 57.23 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.562 -0.711 . . . . 50.0 110.557 -179.584 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 62.7 mtp180 -69.88 -25.94 63.95 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.245 -0.91 . . . . 50.0 110.623 -179.544 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' TYR . . . . . 0.561 ' N ' ' CD1' ' A' ' 47' ' ' TYR . 11.6 m-85 -124.81 151.39 45.27 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.164 -0.96 . . . . 50.0 110.635 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 45.8 tttm -97.91 150.86 20.86 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.355 -0.841 . . . . 50.0 109.225 178.768 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.403 ' HA ' ' SG ' ' A' ' 43' ' ' CYS . 50.8 tt0 -93.54 95.38 9.21 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.983 -1.073 . . . . 50.0 110.42 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . 0.512 HD11 ' CD ' ' A' ' 62' ' ' LYS . 97.3 mt -65.36 -31.24 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.297 -0.877 . . . . 50.0 110.068 179.807 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.498 ' C ' HG23 ' A' ' 52' ' ' THR . . . 168.77 -95.44 0.11 Allowed Glycine 0 N--CA 1.487 2.074 0 N-CA-C 109.534 -1.426 . . . . 50.0 109.534 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.498 HG23 ' C ' ' A' ' 51' ' ' GLY . 62.5 p -150.32 143.26 24.78 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.217 -1.166 . . . . 50.0 110.386 -179.824 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' CYS . . . . . 0.409 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 4.4 t -63.87 -40.95 97.76 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.237 -0.914 . . . . 50.0 109.844 179.74 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 157.84 -24.98 0.42 Allowed Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.07 -1.612 . . . . 50.0 109.07 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.514 ' CD1' ' HD2' ' A' ' 56' ' ' PRO . 16.9 tp -123.96 143.64 42.85 Favored Pre-proline 0 N--CA 1.489 1.517 0 O-C-N 121.5 -1.0 . . . . 50.0 109.596 179.773 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.514 ' HD2' ' CD1' ' A' ' 55' ' ' LEU . 39.9 Cg_endo -66.48 -5.3 12.5 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 O-C-N 123.773 1.407 . . . . 50.0 110.827 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -74.65 -33.88 54.85 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.158 -1.577 . . . . 50.0 109.158 179.378 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . 0.474 HG23 ' C ' ' A' ' 39' ' ' HIS . 4.8 m -135.53 162.74 31.82 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.231 -1.158 . . . . 50.0 110.211 179.692 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.478 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 43.5 mmtm -115.49 151.82 34.1 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.346 -0.846 . . . . 50.0 109.937 179.662 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.459 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 26.6 t -81.39 133.5 35.42 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.251 -0.905 . . . . 50.0 110.656 -179.525 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' CYS . . . . . 0.516 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 72.0 m -131.12 141.22 50.1 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.371 -0.831 . . . . 50.0 109.961 179.73 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . 0.512 ' CD ' HD11 ' A' ' 50' ' ' ILE . 81.1 tttt -131.93 144.35 50.78 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.174 -0.954 . . . . 50.0 110.309 -179.737 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . 0.482 ' HE2' ' OH ' ' A' ' 47' ' ' TYR . 96.2 mttt . . . . . 0 N--CA 1.491 1.603 0 O-C-N 121.411 -0.806 . . . . 50.0 110.31 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo . . . . . 0 N--CA 1.487 1.146 0 N-CA-C 110.406 -0.652 . . . . 50.0 110.406 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.511 HG23 ' SG ' ' A' ' 31' ' ' CYS . 34.1 m -114.99 129.16 71.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.283 -0.886 . . . . 50.0 109.897 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.553 HG22 ' HB2' ' A' ' 32' ' ' LEU . 98.5 m -69.04 -19.29 64.1 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.129 -0.982 . . . . 50.0 110.566 -179.639 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . 0.511 ' SG ' HG23 ' A' ' 29' ' ' VAL . 93.3 m 56.22 22.44 6.14 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.215 -0.928 . . . . 50.0 110.311 -179.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.747 HD13 ' C ' ' A' ' 32' ' ' LEU . 3.4 tm? -75.35 -38.51 60.06 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.137 -0.977 . . . . 50.0 110.283 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 96.0 mttt -68.69 -41.64 78.88 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.303 -0.873 . . . . 50.0 110.209 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 94.9 p -69.77 -20.46 63.48 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.303 -0.873 . . . . 50.0 110.32 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 79.25 6.73 88.82 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.662 -1.375 . . . . 50.0 109.662 179.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.679 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -68.93 147.65 51.33 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.119 -1.224 . . . . 50.0 110.151 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.645 HD11 ' CE2' ' A' ' 47' ' ' TYR . 2.1 pt -93.45 151.77 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.148 -0.97 . . . . 50.0 110.063 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 86.3 m -91.27 142.57 27.57 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.244 -0.91 . . . . 50.0 110.372 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.514 ' CB ' ' SG ' ' A' ' 61' ' ' CYS . 54.4 t-80 -119.98 142.2 32.9 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.282 -0.886 . . . . 50.0 109.981 179.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.505 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 44.9 Cg_endo -71.52 155.85 58.87 Favored 'Trans proline' 0 C--N 1.305 -1.762 0 O-C-N 123.907 1.477 . . . . 50.0 110.857 -179.575 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.661 HG12 ' HD2' ' A' ' 42' ' ' PHE . 47.8 t 59.27 -93.87 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.449 -0.782 . . . . 50.0 110.679 179.658 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.661 ' HD2' HG12 ' A' ' 41' ' ' VAL . 21.4 p90 -139.14 161.43 37.42 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.84 -1.163 . . . . 50.0 110.62 -179.74 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . 0.51 ' CB ' ' HB2' ' A' ' 49' ' ' GLN . 0.8 OUTLIER -80.45 127.56 75.51 Favored Pre-proline 0 N--CA 1.492 1.663 0 O-C-N 121.398 -0.814 . . . . 50.0 109.958 179.822 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -72.43 -162.4 0.12 Allowed 'Trans proline' 0 C--N 1.306 -1.699 0 O-C-N 123.742 1.39 . . . . 50.0 110.445 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 6.5 mtt180 -81.25 -36.59 29.76 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.475 -0.766 . . . . 50.0 109.698 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.462 ' O ' ' HD3' ' A' ' 64' ' ' PRO . 60.0 mtp180 -58.71 -27.59 65.0 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.554 -0.716 . . . . 50.0 109.942 179.674 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.645 ' CE2' HD11 ' A' ' 37' ' ' ILE . 37.0 m-85 -120.84 138.72 53.91 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.337 -0.852 . . . . 50.0 110.294 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 88.5 mttt -95.14 124.3 39.1 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.202 -0.936 . . . . 50.0 109.837 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.51 ' HB2' ' CB ' ' A' ' 43' ' ' CYS . 41.8 tt0 -74.8 105.64 5.95 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.494 -0.754 . . . . 50.0 110.94 -179.162 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 96.5 mt -75.16 -28.52 20.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.198 -0.939 . . . . 50.0 109.628 179.361 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.545 ' C ' HG23 ' A' ' 52' ' ' THR . . . 176.76 -94.56 0.1 OUTLIER Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.368 -1.493 . . . . 50.0 109.368 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.545 HG23 ' C ' ' A' ' 51' ' ' GLY . 60.5 p -155.24 137.99 15.26 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.192 -1.181 . . . . 50.0 110.222 179.781 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' CYS . . . . . 0.459 ' O ' ' O ' ' A' ' 29' ' ' VAL . 18.5 t -54.12 -50.44 66.87 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.24 -0.913 . . . . 50.0 110.131 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 176.78 -45.26 0.11 Allowed Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.266 -1.534 . . . . 50.0 109.266 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.465 ' HB3' ' HD2' ' A' ' 56' ' ' PRO . 87.0 mt -110.82 164.9 13.78 Favored Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.288 -1.125 . . . . 50.0 109.973 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.465 ' HD2' ' HB3' ' A' ' 55' ' ' LEU . 45.6 Cg_endo -72.75 -3.03 12.8 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 O-C-N 123.88 1.463 . . . . 50.0 110.395 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -77.49 -43.5 15.37 Favored Glycine 0 N--CA 1.487 2.096 0 N-CA-C 109.491 -1.444 . . . . 50.0 109.491 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . 0.407 HG23 ' C ' ' A' ' 39' ' ' HIS . 10.9 m -125.31 166.38 16.65 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.336 -1.097 . . . . 50.0 110.508 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.471 ' O ' ' N ' ' A' ' 39' ' ' HIS . 74.6 mmtt -123.21 148.6 45.66 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.336 -0.853 . . . . 50.0 109.902 179.857 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 13.2 t -73.52 127.93 34.08 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.145 -0.972 . . . . 50.0 110.376 -179.672 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' CYS . . . . . 0.679 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 28.3 m -128.02 154.17 45.94 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.29 -0.882 . . . . 50.0 109.994 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -132.99 138.68 46.93 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.157 -0.965 . . . . 50.0 110.249 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . 0.537 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 93.8 mttt -77.77 143.54 67.23 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.311 -0.868 . . . . 50.0 110.274 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . 0.462 ' HD3' ' O ' ' A' ' 46' ' ' ARG . 46.3 Cg_endo . . . . . 0 C--N 1.304 -1.765 0 O-C-N 124.044 1.549 . . . . 99.989999999999995 110.498 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo . . . . . 0 N--CA 1.489 1.22 0 N-CA-C 110.283 -0.699 . . . . 50.0 110.283 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.541 HG12 ' N ' ' A' ' 30' ' ' THR . 19.5 t -143.35 176.0 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.129 -0.982 . . . . 50.0 110.373 -179.881 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.541 ' N ' HG12 ' A' ' 29' ' ' VAL . 58.7 m -114.77 113.55 24.41 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.233 -0.917 . . . . 50.0 109.919 179.739 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . 0.588 ' HB3' ' HB3' ' A' ' 36' ' ' ALA . 52.8 m -75.73 -6.24 49.61 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.35 -0.843 . . . . 50.0 110.691 -179.641 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 95.3 mt -57.35 -34.73 69.09 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.032 -1.043 . . . . 50.0 110.205 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 24.8 mttp -68.03 -37.33 81.23 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.389 -0.819 . . . . 50.0 110.153 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 95.0 p -77.49 -18.25 57.26 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.474 -0.766 . . . . 50.0 110.252 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 89.81 5.71 70.86 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.503 -1.439 . . . . 50.0 109.503 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.588 ' HB3' ' HB3' ' A' ' 31' ' ' CYS . . . -77.37 147.97 35.81 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.217 -1.167 . . . . 50.0 110.284 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.472 ' O ' ' N ' ' A' ' 61' ' ' CYS . 4.0 pt -95.44 152.72 3.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.225 -0.922 . . . . 50.0 109.858 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.458 ' HA ' ' O ' ' A' ' 59' ' ' LYS . 79.0 m -100.16 139.77 35.36 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.205 -0.934 . . . . 50.0 110.143 -179.766 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.53 ' N ' ' O ' ' A' ' 59' ' ' LYS . 59.2 t-80 -117.82 136.26 23.66 Favored Pre-proline 0 N--CA 1.492 1.663 0 O-C-N 121.345 -0.847 . . . . 50.0 110.007 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.478 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 47.7 Cg_endo -72.23 164.58 35.2 Favored 'Trans proline' 0 C--N 1.303 -1.827 0 O-C-N 123.929 1.489 . . . . 50.0 110.503 -179.792 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.724 HG12 ' HD2' ' A' ' 42' ' ' PHE . 44.2 t 60.73 -82.78 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.524 -0.735 . . . . 50.0 111.171 179.538 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.724 ' HD2' HG12 ' A' ' 41' ' ' VAL . 9.7 p90 -155.7 154.29 31.28 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.957 -1.09 . . . . 50.0 110.662 -179.43 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 1.7 t -77.43 130.92 72.92 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.257 -0.902 . . . . 50.0 109.784 179.534 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -70.96 -162.29 0.1 Allowed 'Trans proline' 0 C--N 1.304 -1.803 0 O-C-N 123.88 1.463 . . . . 50.0 110.549 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 18.3 mtm180 -84.83 -40.13 17.51 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 121.475 -0.766 . . . . 50.0 109.818 -179.856 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 57.9 ttm-85 -61.73 -15.95 45.17 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.457 -0.777 . . . . 50.0 109.965 179.67 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.535 ' HB3' ' HB3' ' A' ' 61' ' ' CYS . 58.4 m-85 -123.99 134.33 53.49 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.316 -0.865 . . . . 50.0 110.507 -179.789 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -97.71 137.95 35.82 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.287 -0.883 . . . . 50.0 109.595 179.351 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.426 ' HA ' ' O ' ' A' ' 60' ' ' CYS . 36.3 tt0 -87.2 103.98 15.93 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.156 -0.965 . . . . 50.0 110.917 -179.308 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.654 HD11 ' HD2' ' A' ' 62' ' ' LYS . 96.5 mt -62.8 -29.07 46.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.301 -0.874 . . . . 50.0 109.733 179.472 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.508 ' C ' HG23 ' A' ' 52' ' ' THR . . . 171.19 -91.23 0.09 OUTLIER Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.476 -1.45 . . . . 50.0 109.476 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.508 HG23 ' C ' ' A' ' 51' ' ' GLY . 71.9 p -151.58 127.92 10.61 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.259 -1.142 . . . . 50.0 110.292 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' CYS . . . . . 0.474 ' O ' ' O ' ' A' ' 29' ' ' VAL . 15.6 t -49.82 -47.41 51.42 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.297 -0.877 . . . . 50.0 110.081 179.694 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.765 ' C ' HD12 ' A' ' 55' ' ' LEU . . . 168.77 -38.33 0.21 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 108.683 -1.767 . . . . 50.0 108.683 -179.77 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.784 ' N ' HD12 ' A' ' 55' ' ' LEU . 6.1 mp -119.79 158.1 50.64 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.475 -1.015 . . . . 50.0 109.752 179.604 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -70.8 -10.29 27.43 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 O-C-N 123.904 1.476 . . . . 50.0 110.286 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -67.87 -41.96 87.12 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.312 -1.515 . . . . 50.0 109.312 179.704 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . 0.461 ' HA ' ' HA ' ' A' ' 40' ' ' PRO . 5.2 m -127.6 164.06 22.85 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.342 -1.093 . . . . 50.0 110.28 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.53 ' O ' ' N ' ' A' ' 39' ' ' HIS . 33.4 mmtp -118.75 152.6 35.88 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.318 -0.864 . . . . 50.0 109.741 179.654 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.426 ' O ' ' HA ' ' A' ' 49' ' ' GLN . 34.5 t -80.32 127.57 32.53 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.029 -1.045 . . . . 50.0 110.333 -179.793 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' CYS . . . . . 0.535 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 52.5 m -125.61 151.53 46.35 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.33 -0.856 . . . . 50.0 109.879 179.74 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.654 ' HD2' HD11 ' A' ' 50' ' ' ILE . 87.0 tttt -136.75 144.97 44.08 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.081 -1.012 . . . . 50.0 110.597 -179.775 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 50.8 mtmt -80.58 146.88 61.96 Favored Pre-proline 0 N--CA 1.493 1.685 0 O-C-N 121.289 -0.882 . . . . 50.0 110.272 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo . . . . . 0 C--N 1.307 -1.652 0 O-C-N 123.939 1.494 . . . . 99.989999999999995 110.49 179.871 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo . . . . . 0 N--CA 1.489 1.26 0 N-CA-C 110.431 -0.642 . . . . 50.0 110.431 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.497 HG23 ' SG ' ' A' ' 31' ' ' CYS . 35.7 m -126.35 133.19 69.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.3 -0.875 . . . . 50.0 109.918 179.721 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.469 ' O ' ' HB2' ' A' ' 31' ' ' CYS . 74.5 m -69.97 -15.97 63.12 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.223 -0.923 . . . . 50.0 110.392 -179.74 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . 0.497 ' SG ' HG23 ' A' ' 29' ' ' VAL . 90.4 m 56.23 27.86 12.34 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.231 -0.918 . . . . 50.0 110.586 179.773 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 67.2 tp -76.95 -43.26 35.88 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.208 -0.933 . . . . 50.0 110.08 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -67.43 -34.58 77.52 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.277 -0.889 . . . . 50.0 110.117 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 81.0 p -71.98 -24.45 61.59 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.422 -0.799 . . . . 50.0 110.259 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 75.87 10.99 84.96 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.626 -1.389 . . . . 50.0 109.626 179.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.597 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -77.04 156.11 32.03 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.186 -1.185 . . . . 50.0 110.257 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.494 HD11 ' CE2' ' A' ' 47' ' ' TYR . 13.8 pt -93.96 167.22 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.285 -0.885 . . . . 50.0 110.147 179.864 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 96.6 m -108.2 148.35 30.06 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.293 -0.879 . . . . 50.0 109.951 179.749 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.589 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 60.9 t-80 -138.68 145.66 47.13 Favored Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.297 -0.877 . . . . 50.0 110.435 -179.649 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.589 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 43.5 Cg_endo -69.1 160.39 50.07 Favored 'Trans proline' 0 C--N 1.305 -1.727 0 O-C-N 124.012 1.532 . . . . 50.0 110.42 179.486 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.829 HG12 ' HD2' ' A' ' 42' ' ' PHE . 15.9 t 62.3 -97.27 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.437 -0.789 . . . . 50.0 110.312 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.829 ' HD2' HG12 ' A' ' 41' ' ' VAL . 35.4 p90 -150.18 154.4 37.94 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 120.728 -1.233 . . . . 50.0 110.07 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . 0.414 ' HB2' ' HB2' ' A' ' 49' ' ' GLN . 64.6 m -61.96 133.62 93.98 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.196 -0.94 . . . . 50.0 110.581 -179.63 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.414 ' HD2' ' HB2' ' A' ' 47' ' ' TYR . 43.4 Cg_endo -68.49 -161.33 0.06 OUTLIER 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 123.959 1.505 . . . . 50.0 110.474 179.709 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 62.5 ttt180 -77.25 -44.08 31.16 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.558 -0.713 . . . . 50.0 110.664 -179.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.455 ' O ' ' HD3' ' A' ' 64' ' ' PRO . 51.5 mmm-85 -61.23 -31.42 71.21 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.233 -0.917 . . . . 50.0 110.422 -179.707 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.527 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 48.4 m-85 -105.73 149.38 26.47 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.273 -0.892 . . . . 50.0 110.491 -179.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -108.56 131.79 54.5 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.337 -0.852 . . . . 50.0 109.688 179.512 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.414 ' HB2' ' HB2' ' A' ' 43' ' ' CYS . 59.6 tt0 -82.81 101.43 10.94 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.327 -0.858 . . . . 50.0 110.702 -179.36 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.509 HD11 ' HD2' ' A' ' 62' ' ' LYS . 85.1 mt -70.36 -30.93 45.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.245 -0.909 . . . . 50.0 109.677 179.452 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 178.14 -99.05 0.12 Allowed Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.294 -1.522 . . . . 50.0 109.294 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 61.7 p -146.12 137.28 24.57 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.305 -1.115 . . . . 50.0 110.403 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' CYS . . . . . 0.446 ' HA ' ' HB2' ' A' ' 60' ' ' CYS . 17.2 t -51.95 -48.1 64.44 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.334 -0.854 . . . . 50.0 109.565 179.467 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 172.87 -30.4 0.1 Allowed Glycine 0 N--CA 1.489 2.193 0 N-CA-C 108.95 -1.66 . . . . 50.0 108.95 179.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 98.1 mt -124.44 159.63 56.7 Favored Pre-proline 0 N--CA 1.488 1.471 0 O-C-N 121.41 -1.053 . . . . 50.0 109.802 179.668 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -71.29 -9.81 26.03 Favored 'Trans proline' 0 C--N 1.304 -1.809 0 O-C-N 124.013 1.533 . . . . 50.0 110.537 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -73.57 -34.56 56.8 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.296 -1.521 . . . . 50.0 109.296 179.714 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . 0.446 HG22 ' N ' ' A' ' 59' ' ' LYS . 25.6 m -131.6 168.42 17.73 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.302 -1.117 . . . . 50.0 109.976 179.789 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.446 ' N ' HG22 ' A' ' 58' ' ' THR . 33.6 mmtp -126.82 149.74 49.54 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.279 -0.888 . . . . 50.0 110.091 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.446 ' HB2' ' HA ' ' A' ' 53' ' ' CYS . 15.9 t -76.6 129.58 36.62 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.243 -0.911 . . . . 50.0 110.295 -179.633 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' CYS . . . . . 0.597 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 83.7 m -127.56 145.27 50.92 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.425 -0.797 . . . . 50.0 110.001 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.509 ' HD2' HD11 ' A' ' 50' ' ' ILE . 85.5 tttt -124.55 144.66 50.01 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.254 -0.904 . . . . 50.0 110.345 -179.814 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . 0.527 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 97.0 mttt -75.56 163.12 69.47 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.343 -0.848 . . . . 50.0 110.066 179.814 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . 0.455 ' HD3' ' O ' ' A' ' 46' ' ' ARG . 46.4 Cg_endo . . . . . 0 C--N 1.303 -1.832 0 O-C-N 124.031 1.543 . . . . 99.989999999999995 110.373 -179.836 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo . . . . . 0 N--CA 1.489 1.221 0 N-CA-C 110.323 -0.683 . . . . 50.0 110.323 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.533 HG12 ' N ' ' A' ' 30' ' ' THR . 27.5 t -137.17 172.32 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.172 -0.955 . . . . 50.0 110.452 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.533 ' N ' HG12 ' A' ' 29' ' ' VAL . 51.6 m -102.77 110.95 23.05 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.24 -0.912 . . . . 50.0 109.815 179.8 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 63.2 m -90.83 4.97 50.32 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.21 -0.931 . . . . 50.0 110.443 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 46.7 tp -66.68 -44.41 81.87 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.147 -0.97 . . . . 50.0 110.263 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -61.69 -39.03 90.02 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.382 -0.824 . . . . 50.0 110.384 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 87.7 p -71.32 -24.25 62.09 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.34 -0.85 . . . . 50.0 110.14 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 89.73 3.64 73.89 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.626 -1.389 . . . . 50.0 109.626 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -73.87 154.57 39.39 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.211 -1.17 . . . . 50.0 110.142 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.441 ' O ' HG13 ' A' ' 37' ' ' ILE . 3.9 pt -102.24 154.27 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.13 -0.981 . . . . 50.0 110.081 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.443 ' HA ' ' O ' ' A' ' 59' ' ' LYS . 93.0 m -98.1 138.48 35.33 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.235 -0.916 . . . . 50.0 110.208 179.873 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.49 ' N ' ' O ' ' A' ' 59' ' ' LYS . 58.6 t-80 -114.63 140.41 25.26 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.268 -0.895 . . . . 50.0 110.235 -179.8 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.5 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 44.1 Cg_endo -70.44 162.4 42.54 Favored 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 123.995 1.524 . . . . 50.0 110.272 179.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.779 HG12 ' HD2' ' A' ' 42' ' ' PHE . 18.3 t 62.96 -108.36 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.461 -0.775 . . . . 50.0 110.285 179.885 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.779 ' HD2' HG12 ' A' ' 41' ' ' VAL . 35.7 p90 -135.31 148.87 49.63 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.796 -1.19 . . . . 50.0 110.24 -179.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -68.5 131.03 91.73 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.265 -0.897 . . . . 50.0 110.204 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.432 ' HD2' ' HB2' ' A' ' 47' ' ' TYR . 46.6 Cg_endo -71.22 -163.03 0.12 Allowed 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 123.859 1.452 . . . . 50.0 110.415 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 32.3 mtt85 -80.57 -44.75 18.5 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.512 -0.743 . . . . 50.0 109.887 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 28.6 tpt180 -58.74 -24.46 61.62 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.53 -0.731 . . . . 50.0 110.152 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.533 ' HB3' ' HB3' ' A' ' 61' ' ' CYS . 42.0 m-85 -114.98 135.8 53.83 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.255 -0.903 . . . . 50.0 110.266 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 88.3 mttt -105.01 147.97 27.25 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.204 -0.935 . . . . 50.0 109.945 179.751 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.506 ' HA ' ' O ' ' A' ' 60' ' ' CYS . 52.7 tt0 -87.31 106.78 18.16 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.215 -0.928 . . . . 50.0 110.788 -179.432 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.767 HD12 ' SG ' ' A' ' 60' ' ' CYS . 67.8 mt -63.39 -24.12 35.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.289 -0.882 . . . . 50.0 109.731 179.438 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.483 ' O ' ' CB ' ' A' ' 52' ' ' THR . . . 152.5 40.18 0.03 OUTLIER Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.284 -1.527 . . . . 50.0 109.284 -179.868 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.483 ' CB ' ' O ' ' A' ' 51' ' ' GLY . 0.2 OUTLIER 69.76 151.17 0.09 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.404 -1.056 . . . . 50.0 110.435 -179.925 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' CYS . . . . . 0.409 ' HA ' ' HB2' ' A' ' 60' ' ' CYS . 7.3 t -71.19 -41.99 69.59 Favored 'General case' 0 N--CA 1.492 1.629 0 CA-C-O 121.763 0.792 . . . . 50.0 109.964 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.877 ' C ' HD12 ' A' ' 55' ' ' LEU . . . 154.63 -26.03 0.66 Allowed Glycine 0 N--CA 1.49 2.244 0 N-CA-C 108.438 -1.865 . . . . 50.0 108.438 -179.746 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.877 HD12 ' C ' ' A' ' 54' ' ' GLY . 5.8 mp -124.72 158.1 63.54 Favored Pre-proline 0 N--CA 1.489 1.495 0 O-C-N 121.55 -0.97 . . . . 50.0 109.465 179.611 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -71.79 -8.46 23.1 Favored 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.886 1.466 . . . . 50.0 110.432 -179.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -71.33 -45.83 45.5 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.545 -1.422 . . . . 50.0 109.545 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . 0.407 HG23 ' C ' ' A' ' 39' ' ' HIS . 7.2 m -128.89 166.01 19.94 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.136 -1.214 . . . . 50.0 110.434 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.49 ' O ' ' N ' ' A' ' 39' ' ' HIS . 33.5 mmtp -121.16 148.49 44.16 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.415 -0.803 . . . . 50.0 109.558 179.62 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.767 ' SG ' HD12 ' A' ' 50' ' ' ILE . 35.1 t -74.82 130.54 39.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.991 -1.068 . . . . 50.0 110.117 -179.741 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' CYS . . . . . 0.533 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 59.9 m -135.32 155.11 51.15 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.274 -0.891 . . . . 50.0 110.102 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.474 ' HB3' HD11 ' A' ' 50' ' ' ILE . 34.9 pttt -146.57 166.83 25.3 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.103 -0.998 . . . . 50.0 110.299 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 52.7 mtmt -100.68 136.75 19.81 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 121.278 -0.889 . . . . 50.0 110.255 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo . . . . . 0 C--N 1.304 -1.765 0 O-C-N 124.039 1.547 . . . . 99.989999999999995 110.504 -179.981 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo . . . . . 0 N--CA 1.49 1.292 0 N-CA-C 110.551 -0.596 . . . . 50.0 110.551 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.463 HG12 ' N ' ' A' ' 30' ' ' THR . 20.9 t -141.83 170.34 12.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.209 -0.932 . . . . 50.0 110.356 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.463 ' N ' HG12 ' A' ' 29' ' ' VAL . 95.9 m -106.64 108.72 20.37 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.21 -0.931 . . . . 50.0 110.348 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 72.0 m -77.44 -12.05 59.91 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.907 . . . . 50.0 110.225 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.757 HD13 ' C ' ' A' ' 32' ' ' LEU . 3.4 tm? -57.68 -44.52 85.85 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.26 -0.9 . . . . 50.0 110.294 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -61.74 -38.01 86.36 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.312 -0.868 . . . . 50.0 110.149 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 69.5 m -72.53 -21.31 61.19 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.288 -0.882 . . . . 50.0 110.152 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 85.44 -3.18 87.57 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.633 -1.387 . . . . 50.0 109.633 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.736 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -77.47 159.49 29.35 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.14 -1.212 . . . . 50.0 110.19 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.475 ' O ' HG13 ' A' ' 37' ' ' ILE . 3.6 pt -108.22 151.15 10.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.288 -0.883 . . . . 50.0 110.118 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 85.4 m -88.78 141.29 28.63 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.198 -0.939 . . . . 50.0 109.964 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 50.5 t-80 -120.5 134.43 24.18 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.243 -0.911 . . . . 50.0 110.247 -179.77 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.494 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 44.0 Cg_endo -71.55 168.13 24.48 Favored 'Trans proline' 0 C--N 1.305 -1.724 0 O-C-N 124.001 1.527 . . . . 50.0 110.458 179.873 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.732 HG12 ' HD2' ' A' ' 42' ' ' PHE . 38.9 t 61.26 -92.51 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.383 -0.823 . . . . 50.0 110.69 179.806 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.732 ' HD2' HG12 ' A' ' 41' ' ' VAL . 16.2 p90 -148.58 148.69 30.45 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.967 -1.083 . . . . 50.0 110.379 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . . . . . . . . . 1.8 t -73.47 128.74 86.76 Favored Pre-proline 0 N--CA 1.493 1.706 0 O-C-N 121.238 -0.914 . . . . 50.0 109.883 179.573 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -71.79 -162.6 0.12 Allowed 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.835 1.44 . . . . 50.0 110.568 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 6.7 ptp180 -90.51 -15.25 31.09 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.525 -0.734 . . . . 50.0 110.123 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.468 ' O ' ' HD3' ' A' ' 64' ' ' PRO . 89.6 mtm180 -73.18 -31.23 64.09 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.186 -0.946 . . . . 50.0 110.166 179.844 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.551 ' N ' ' CD1' ' A' ' 47' ' ' TYR . 6.9 m-85 -113.23 147.87 36.65 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.223 -0.923 . . . . 50.0 110.333 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 61.6 mttm -93.43 152.6 19.0 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.255 -0.903 . . . . 50.0 109.799 179.272 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 58.7 tt0 -91.59 97.47 11.06 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.068 -1.02 . . . . 50.0 110.615 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.443 HD11 ' HB2' ' A' ' 62' ' ' LYS . 86.7 mt -63.88 -32.65 57.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.312 -0.868 . . . . 50.0 109.701 179.512 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 166.17 -95.99 0.12 Allowed Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.408 -1.477 . . . . 50.0 109.408 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 21.7 p -145.24 129.07 17.32 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.329 -1.101 . . . . 50.0 110.193 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' CYS . . . . . 0.467 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 30.7 t -61.41 -47.9 83.65 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.15 -0.969 . . . . 50.0 109.654 179.577 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 129.68 1.89 5.41 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.491 -1.443 . . . . 50.0 109.491 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 92.0 mt -105.27 143.42 26.73 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.278 -1.13 . . . . 50.0 110.174 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -73.38 79.59 2.1 Favored 'Trans proline' 0 C--N 1.303 -1.821 0 O-C-N 124.062 1.559 . . . . 50.0 110.688 -179.82 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 139.17 -3.03 2.69 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.696 -1.24 . . . . 50.0 110.378 179.55 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . 0.442 ' HA ' ' HA ' ' A' ' 40' ' ' PRO . 1.2 m -121.86 159.69 26.29 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.974 -1.309 . . . . 50.0 110.476 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 16.2 tppt? -129.59 123.81 32.25 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.355 -0.841 . . . . 50.0 109.895 179.584 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.467 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 34.2 t -53.92 128.99 32.4 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.177 -0.952 . . . . 50.0 110.375 -179.692 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' CYS . . . . . 0.736 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 62.3 m -128.84 146.41 50.94 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.222 -0.924 . . . . 50.0 110.076 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.482 ' O ' ' HA ' ' A' ' 47' ' ' TYR . 79.6 tttt -125.08 143.75 50.76 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.2 -0.937 . . . . 50.0 110.477 -179.678 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . 0.441 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 86.9 mttt -74.95 152.72 86.69 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.345 -0.847 . . . . 50.0 110.361 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . 0.468 ' HD3' ' O ' ' A' ' 46' ' ' ARG . 47.2 Cg_endo . . . . . 0 C--N 1.304 -1.771 0 O-C-N 124.047 1.551 . . . . 99.989999999999995 110.446 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.879 ' N ' ' HG1' ' A' ' 52' ' ' THR . 45.1 Cg_endo . . . . . 0 N--CA 1.489 1.227 0 N-CA-C 110.465 -0.629 . . . . 50.0 110.465 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.542 HG12 ' N ' ' A' ' 30' ' ' THR . 24.0 t -132.66 174.47 13.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.276 -0.89 . . . . 50.0 110.183 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.542 ' N ' HG12 ' A' ' 29' ' ' VAL . 23.7 m -75.05 -31.39 61.28 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.215 -0.928 . . . . 50.0 110.372 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . 0.478 ' HB2' ' O ' ' A' ' 30' ' ' THR . 98.7 m 58.86 19.66 7.25 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.314 -0.866 . . . . 50.0 110.538 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.516 HD12 ' CG2' ' A' ' 30' ' ' THR . 93.5 mt -111.27 -15.83 13.53 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.258 -0.901 . . . . 50.0 109.896 179.605 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 63.8 mmtt -69.26 -39.71 78.26 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.309 -0.869 . . . . 50.0 110.18 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.474 ' HB3' ' NZ ' ' A' ' 62' ' ' LYS . 66.7 m -90.27 -9.88 46.3 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.357 -0.84 . . . . 50.0 110.031 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 87.13 7.8 76.46 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.509 -1.436 . . . . 50.0 109.509 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.912 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -69.21 140.1 54.56 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.326 -1.102 . . . . 50.0 110.265 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.906 HD11 ' NE2' ' A' ' 39' ' ' HIS . 3.8 pt -100.54 155.92 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.227 -0.92 . . . . 50.0 109.871 179.821 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 83.5 m -95.46 141.0 29.52 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.152 -0.967 . . . . 50.0 110.043 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.906 ' NE2' HD11 ' A' ' 37' ' ' ILE . 38.4 m-70 -117.9 161.93 31.86 Favored Pre-proline 0 N--CA 1.497 1.889 0 O-C-N 121.33 -0.856 . . . . 50.0 110.55 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.475 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 44.0 Cg_endo -72.22 156.22 55.48 Favored 'Trans proline' 0 C--N 1.304 -1.766 0 O-C-N 124.024 1.539 . . . . 50.0 110.224 179.754 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.786 HG12 ' HD2' ' A' ' 42' ' ' PHE . 15.4 t 61.5 -108.53 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.246 -0.909 . . . . 50.0 110.064 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.786 ' HD2' HG12 ' A' ' 41' ' ' VAL . 44.0 p90 -135.16 164.79 26.88 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.685 -1.26 . . . . 50.0 110.225 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . 0.47 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 70.9 m -70.72 130.88 88.22 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.172 -0.955 . . . . 50.0 110.668 -179.547 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -71.42 -161.44 0.09 OUTLIER 'Trans proline' 0 C--N 1.305 -1.742 0 O-C-N 123.851 1.448 . . . . 50.0 110.391 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 15.3 ptm180 -81.88 -24.54 35.68 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.492 -0.755 . . . . 50.0 110.786 -179.483 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 79.5 mtp180 -71.7 -16.29 62.23 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.046 -1.034 . . . . 50.0 110.594 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.607 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 36.2 m-85 -129.81 153.06 48.63 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.088 -1.008 . . . . 50.0 110.878 -179.698 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.418 ' N ' ' O ' ' A' ' 62' ' ' LYS . 98.5 mttt -99.92 141.86 32.18 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.37 -0.831 . . . . 50.0 109.263 179.11 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.463 ' NE2' ' CE ' ' A' ' 59' ' ' LYS . 37.5 tt0 -84.44 98.82 10.29 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.162 -0.962 . . . . 50.0 110.955 -179.169 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.583 HD11 ' HB2' ' A' ' 62' ' ' LYS . 95.3 mt -62.98 -32.06 54.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.166 -0.958 . . . . 50.0 109.627 179.303 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.508 ' C ' HG23 ' A' ' 52' ' ' THR . . . 165.83 -92.09 0.1 Allowed Glycine 0 N--CA 1.487 2.044 0 N-CA-C 109.426 -1.47 . . . . 50.0 109.426 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.879 ' HG1' ' N ' ' A' ' 28' ' ' PRO . 20.9 p -152.02 134.19 15.09 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.319 -1.107 . . . . 50.0 110.152 -179.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' CYS . . . . . 0.546 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 5.0 t -59.14 -45.64 90.43 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.277 -0.889 . . . . 50.0 110.207 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 163.97 -41.53 0.32 Allowed Glycine 0 N--CA 1.489 2.233 0 N-CA-C 108.993 -1.643 . . . . 50.0 108.993 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 76.5 mt -118.43 158.03 47.92 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.511 -0.993 . . . . 50.0 109.928 179.747 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -71.82 -4.92 16.02 Favored 'Trans proline' 0 C--N 1.304 -1.807 0 O-C-N 123.922 1.486 . . . . 50.0 110.35 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -70.89 -30.28 68.25 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.371 -1.492 . . . . 50.0 109.371 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 5.8 m -139.11 163.56 32.08 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.284 -1.127 . . . . 50.0 110.393 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.463 ' CE ' ' NE2' ' A' ' 49' ' ' GLN . 54.8 tptt -119.31 128.18 53.88 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.405 -0.809 . . . . 50.0 109.42 179.528 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.546 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 41.1 t -63.71 131.54 48.23 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.181 -0.949 . . . . 50.0 110.431 -179.282 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' CYS . . . . . 0.912 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 74.8 m -126.2 156.81 39.61 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.467 -0.771 . . . . 50.0 110.181 -179.675 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.583 ' HB2' HD11 ' A' ' 50' ' ' ILE . 57.3 tttp -137.51 138.07 39.29 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.146 -0.971 . . . . 50.0 110.343 -179.801 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . 0.607 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 56.0 mtpt -82.26 146.15 53.9 Favored Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.122 -0.987 . . . . 50.0 110.043 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo . . . . . 0 C--N 1.306 -1.687 0 O-C-N 123.959 1.505 . . . . 99.989999999999995 110.354 179.921 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo . . . . . 0 N--CA 1.489 1.232 0 N-CA-C 110.324 -0.683 . . . . 50.0 110.324 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.761 HG23 ' O ' ' A' ' 52' ' ' THR . 14.0 m -128.31 141.25 47.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.118 -0.989 . . . . 50.0 110.438 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.459 HG22 ' HB2' ' A' ' 32' ' ' LEU . 72.9 m -107.66 110.94 22.92 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.262 -0.898 . . . . 50.0 109.899 179.748 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 52.1 m -79.4 -3.43 46.39 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.158 -0.963 . . . . 50.0 110.425 -179.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.459 ' HB2' HG22 ' A' ' 30' ' ' THR . 70.4 mt -56.91 -41.56 78.37 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.129 -0.982 . . . . 50.0 110.063 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 30.3 mmtp -67.52 -38.34 84.09 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.393 -0.817 . . . . 50.0 110.359 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 41.4 t -68.36 -32.64 72.87 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.29 -0.881 . . . . 50.0 110.047 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.78 -5.68 56.76 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.711 -1.356 . . . . 50.0 109.711 179.714 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.647 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -74.29 130.39 39.62 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.181 -1.188 . . . . 50.0 110.206 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 7.0 pt -73.34 162.73 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.209 -0.932 . . . . 50.0 110.22 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 71.9 m -106.44 152.29 23.82 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.273 -0.892 . . . . 50.0 110.093 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.572 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 60.4 t-80 -138.39 145.23 46.04 Favored Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.315 -0.865 . . . . 50.0 109.892 -179.734 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.572 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 41.8 Cg_endo -67.7 161.01 45.61 Favored 'Trans proline' 0 C--N 1.302 -1.912 0 O-C-N 123.898 1.473 . . . . 50.0 110.189 179.728 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.821 HG12 ' HD2' ' A' ' 42' ' ' PHE . 17.5 t 62.43 -104.59 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.42 -0.8 . . . . 50.0 110.035 -179.716 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.821 ' HD2' HG12 ' A' ' 41' ' ' VAL . 36.7 p90 -142.72 155.93 44.95 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.642 -1.286 . . . . 50.0 110.126 179.834 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . 0.448 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 75.6 m -65.06 132.45 95.44 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.286 -0.883 . . . . 50.0 110.262 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -69.1 -161.64 0.07 OUTLIER 'Trans proline' 0 C--N 1.304 -1.783 0 O-C-N 123.927 1.488 . . . . 50.0 110.802 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 14.3 mtt180 -78.46 -39.49 38.4 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.461 -0.775 . . . . 50.0 109.907 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.476 ' O ' ' HD3' ' A' ' 64' ' ' PRO . 95.4 mtt180 -60.02 -34.27 73.14 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.44 -0.787 . . . . 50.0 110.346 -179.727 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.566 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 18.7 m-85 -110.71 144.01 40.31 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.295 -0.878 . . . . 50.0 110.899 -179.558 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 64.6 mttm -98.06 138.26 35.63 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.39 -0.819 . . . . 50.0 109.183 178.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 39.9 tt0 -80.68 101.88 9.53 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.053 -1.029 . . . . 50.0 110.686 -179.402 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 74.4 mt -65.46 -31.26 53.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.222 -0.924 . . . . 50.0 109.618 179.366 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 165.09 -94.13 0.11 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.291 -1.523 . . . . 50.0 109.291 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.761 ' O ' HG23 ' A' ' 29' ' ' VAL . 65.3 p -143.3 136.21 27.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.311 -1.111 . . . . 50.0 110.284 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' CYS . . . . . 0.525 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 17.5 t -58.07 -49.4 77.05 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.256 -0.903 . . . . 50.0 109.793 179.67 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 176.45 -32.17 0.08 OUTLIER Glycine 0 N--CA 1.49 2.265 0 N-CA-C 108.791 -1.723 . . . . 50.0 108.791 -179.854 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 80.6 mt -127.71 160.03 63.05 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.504 -0.997 . . . . 50.0 109.545 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -72.19 -2.14 11.17 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 123.88 1.463 . . . . 50.0 110.36 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -74.75 -38.88 41.38 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.545 -1.422 . . . . 50.0 109.545 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . 0.439 HG22 ' N ' ' A' ' 59' ' ' LYS . 21.2 m -126.7 168.58 14.17 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.199 -1.177 . . . . 50.0 110.367 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.439 ' N ' HG22 ' A' ' 58' ' ' THR . 14.5 tppt? -119.43 136.29 54.37 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.322 -0.861 . . . . 50.0 109.982 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.525 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 20.4 t -69.01 128.69 37.59 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.262 -0.899 . . . . 50.0 110.484 -179.739 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' CYS . . . . . 0.647 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 74.2 m -125.42 153.13 43.92 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.241 -0.912 . . . . 50.0 109.748 179.687 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.474 ' O ' ' HA ' ' A' ' 47' ' ' TYR . 83.6 tttt -130.08 144.33 51.28 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.172 -0.955 . . . . 50.0 110.487 -179.616 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . 0.566 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 97.7 mttt -79.73 154.15 75.79 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.301 -0.875 . . . . 50.0 110.047 179.718 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . 0.476 ' HD3' ' O ' ' A' ' 46' ' ' ARG . 46.6 Cg_endo . . . . . 0 C--N 1.303 -1.85 0 O-C-N 124.008 1.53 . . . . 99.989999999999995 110.388 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.502 ' HG2' ' HA2' ' A' ' 54' ' ' GLY . 46.6 Cg_endo . . . . . 0 N--CA 1.489 1.233 0 N-CA-C 110.478 -0.624 . . . . 50.0 110.478 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.568 HG12 ' N ' ' A' ' 30' ' ' THR . 40.0 t -139.11 174.18 10.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.045 -1.034 . . . . 50.0 110.336 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.568 ' N ' HG12 ' A' ' 29' ' ' VAL . 88.7 m -114.24 109.7 18.78 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.35 -0.844 . . . . 50.0 110.137 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . 0.432 ' SG ' ' HA ' ' A' ' 53' ' ' CYS . 79.3 m -77.15 -13.12 60.0 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.255 -0.903 . . . . 50.0 110.214 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 46.1 tp -57.32 -40.79 78.67 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.263 -0.898 . . . . 50.0 110.488 -179.717 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 60.3 mmtt -68.34 -41.25 81.03 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.265 -0.897 . . . . 50.0 110.297 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 56.9 m -70.86 -29.59 65.75 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.224 -0.923 . . . . 50.0 110.19 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 87.07 8.16 76.0 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.552 -1.419 . . . . 50.0 109.552 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -72.35 176.84 4.96 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.235 -1.156 . . . . 50.0 110.287 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.703 HD12 ' NE2' ' A' ' 39' ' ' HIS . 2.9 pt -115.83 153.53 17.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.316 -0.865 . . . . 50.0 109.984 179.663 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 83.0 m -112.52 153.31 27.67 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.167 -0.958 . . . . 50.0 109.969 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.703 ' NE2' HD12 ' A' ' 37' ' ' ILE . 31.6 m-70 -140.33 162.58 48.92 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 121.315 -0.865 . . . . 50.0 110.282 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -70.81 166.5 28.69 Favored 'Trans proline' 0 C--N 1.305 -1.759 0 O-C-N 124.037 1.546 . . . . 50.0 110.847 -179.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.793 HG12 ' HD2' ' A' ' 42' ' ' PHE . 14.4 t 54.07 -108.43 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.393 -0.817 . . . . 50.0 110.167 179.811 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.793 ' HD2' HG12 ' A' ' 41' ' ' VAL . 29.3 p90 -141.36 151.37 43.47 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.817 -1.177 . . . . 50.0 110.129 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . 0.475 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 72.5 m -50.65 130.36 27.33 Favored Pre-proline 0 N--CA 1.489 1.517 0 O-C-N 121.155 -0.965 . . . . 50.0 109.813 179.771 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.449 ' HD2' ' HB2' ' A' ' 47' ' ' TYR . 43.6 Cg_endo -70.16 -162.78 0.1 OUTLIER 'Trans proline' 0 C--N 1.304 -1.783 0 O-C-N 123.954 1.502 . . . . 50.0 110.304 179.792 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 28.8 mtp180 -74.68 -42.79 57.77 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.417 -0.802 . . . . 50.0 110.04 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 79.0 mtp180 -61.96 -14.87 39.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.486 -0.759 . . . . 50.0 110.37 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.517 ' HB3' ' HB3' ' A' ' 61' ' ' CYS . 72.6 m-85 -128.28 164.19 23.13 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.232 -0.918 . . . . 50.0 110.683 -179.68 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -127.79 154.79 45.0 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.349 -0.845 . . . . 50.0 109.958 179.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -87.93 115.46 25.41 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.181 -0.95 . . . . 50.0 110.06 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.436 HD13 ' HB2' ' A' ' 62' ' ' LYS . 22.6 pt -110.41 15.91 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.282 -0.886 . . . . 50.0 110.459 -179.826 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.508 ' O ' ' HB3' ' A' ' 60' ' ' CYS . . . 133.24 114.89 1.57 Allowed Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.403 -1.479 . . . . 50.0 109.403 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.476 ' OG1' ' CB ' ' A' ' 28' ' ' PRO . 75.9 p -34.65 134.05 0.24 Allowed 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.771 -0.841 . . . . 50.0 110.965 -179.841 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' CYS . . . . . 0.526 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 4.4 t -51.67 -42.03 61.84 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.452 -0.78 . . . . 50.0 110.34 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.502 ' HA2' ' HG2' ' A' ' 28' ' ' PRO . . . 163.36 -27.52 0.23 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.062 -1.615 . . . . 50.0 109.062 -179.787 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 97.0 mt -122.45 152.9 62.0 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.358 -1.084 . . . . 50.0 109.856 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.44 -16.25 27.6 Favored 'Trans proline' 0 C--N 1.303 -1.824 0 O-C-N 123.886 1.466 . . . . 50.0 110.416 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -69.02 -32.71 73.37 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.389 -1.484 . . . . 50.0 109.389 179.83 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 8.6 m -128.74 168.12 16.29 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.287 -1.125 . . . . 50.0 110.198 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.49 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 75.1 mmtt -130.91 141.96 50.33 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.365 -0.835 . . . . 50.0 109.767 179.688 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.526 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 7.4 t -73.35 139.51 46.04 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.127 -0.983 . . . . 50.0 109.98 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' CYS . . . . . 0.517 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 97.8 m -131.89 144.47 50.89 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.378 -0.826 . . . . 50.0 109.94 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.436 ' HB2' HD13 ' A' ' 50' ' ' ILE . 54.7 tttm -127.81 140.36 52.08 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.089 -1.007 . . . . 50.0 110.31 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . 0.445 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 93.3 mttt -73.0 149.19 89.68 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.219 -0.926 . . . . 50.0 110.09 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo . . . . . 0 C--N 1.305 -1.758 0 O-C-N 124.012 1.532 . . . . 99.989999999999995 110.446 -179.963 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo . . . . . 0 N--CA 1.488 1.197 0 N-CA-C 110.313 -0.687 . . . . 50.0 110.313 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.489 HG12 ' N ' ' A' ' 30' ' ' THR . 16.8 t -136.3 172.65 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.176 -0.953 . . . . 50.0 110.249 -179.877 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.489 ' N ' HG12 ' A' ' 29' ' ' VAL . 36.4 m -116.0 112.41 21.78 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.31 -0.869 . . . . 50.0 110.098 179.78 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 65.9 m -84.71 0.35 50.78 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.188 -0.945 . . . . 50.0 110.317 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.519 HD22 ' N ' ' A' ' 32' ' ' LEU . 4.2 mm? -65.82 -45.25 82.99 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.209 -0.932 . . . . 50.0 110.179 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -64.53 -36.16 83.3 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.409 -0.807 . . . . 50.0 110.181 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 95.2 p -69.48 -20.26 63.74 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.374 -0.829 . . . . 50.0 110.299 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 89.7 0.35 78.86 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.492 -1.443 . . . . 50.0 109.492 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -77.98 154.45 31.53 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.148 -1.207 . . . . 50.0 110.128 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.487 ' O ' ' O ' ' A' ' 61' ' ' CYS . 1.1 pt -99.72 157.22 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.285 -0.884 . . . . 50.0 109.875 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 70.9 m -107.06 143.7 34.79 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.012 -1.055 . . . . 50.0 110.121 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.601 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 14.8 t-80 -108.2 145.92 32.49 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.269 -0.894 . . . . 50.0 109.851 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.601 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 42.4 Cg_endo -68.03 -23.92 39.71 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 O-C-N 123.847 1.446 . . . . 50.0 110.878 -179.674 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.646 HG12 ' HD2' ' A' ' 42' ' ' PHE . 66.3 t -117.91 -88.77 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.087 -1.008 . . . . 50.0 110.527 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.646 ' HD2' HG12 ' A' ' 41' ' ' VAL . 13.4 p90 -140.02 151.31 45.35 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.111 -0.993 . . . . 50.0 110.148 -179.765 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . 0.464 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 75.8 m -61.95 123.81 79.19 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.127 -0.983 . . . . 50.0 109.937 179.782 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.479 ' HD2' ' HB2' ' A' ' 47' ' ' TYR . 45.1 Cg_endo -69.95 -163.04 0.1 Allowed 'Trans proline' 0 C--N 1.304 -1.769 0 O-C-N 123.975 1.513 . . . . 50.0 110.732 179.812 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 65.2 ttt180 -75.02 -42.29 57.66 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.475 -0.766 . . . . 50.0 110.419 -179.74 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.478 ' O ' ' HD3' ' A' ' 64' ' ' PRO . 86.4 mmt-85 -62.19 -29.07 70.11 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.366 -0.834 . . . . 50.0 110.221 -179.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.592 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 16.6 m-85 -113.35 159.26 19.6 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.178 -0.952 . . . . 50.0 110.717 -179.732 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 13.5 ptmm? -120.5 145.61 47.11 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.36 -0.838 . . . . 50.0 109.462 179.116 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 63.3 tt0 -90.09 103.49 16.15 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.124 -0.985 . . . . 50.0 110.714 -179.53 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.607 HD11 ' HD2' ' A' ' 62' ' ' LYS . 90.7 mt -68.17 -29.45 44.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.207 -0.933 . . . . 50.0 109.623 179.438 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 172.31 -95.31 0.11 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.217 -1.553 . . . . 50.0 109.217 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 70.7 p -144.17 134.19 24.07 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.209 -1.171 . . . . 50.0 110.309 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' CYS . . . . . 0.53 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 16.5 t -54.26 -43.79 71.28 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.134 -0.979 . . . . 50.0 109.669 179.571 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 152.65 -24.64 0.84 Allowed Glycine 0 N--CA 1.49 2.253 0 N-CA-C 108.637 -1.785 . . . . 50.0 108.637 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.465 ' CD1' ' HD2' ' A' ' 56' ' ' PRO . 16.7 tp -121.74 142.58 36.3 Favored Pre-proline 0 C--N 1.303 -1.449 0 O-C-N 121.505 -0.997 . . . . 50.0 109.374 179.594 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.465 ' HD2' ' CD1' ' A' ' 55' ' ' LEU . 41.3 Cg_endo -67.37 -5.27 13.52 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 123.794 1.418 . . . . 50.0 110.465 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -80.14 -27.63 52.01 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.333 -1.507 . . . . 50.0 109.333 179.483 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . 0.479 ' CG2' ' O ' ' A' ' 39' ' ' HIS . 3.4 m -137.33 160.68 38.37 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.247 -1.149 . . . . 50.0 110.433 179.908 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.464 ' O ' ' N ' ' A' ' 39' ' ' HIS . 73.4 mmtt -113.31 155.41 25.2 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.527 -0.733 . . . . 50.0 109.538 179.425 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.53 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 37.3 t -85.8 130.88 34.43 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.185 -0.947 . . . . 50.0 110.897 -179.24 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' CYS . . . . . 0.495 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 71.3 m -134.06 128.95 35.31 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.425 -0.797 . . . . 50.0 109.301 179.542 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.607 ' HD2' HD11 ' A' ' 50' ' ' ILE . 84.8 tttt -109.48 147.74 32.38 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.003 -1.06 . . . . 50.0 111.148 -179.154 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . 0.592 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 51.3 mtmt -84.69 154.16 61.57 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.365 -0.834 . . . . 50.0 109.663 179.317 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . 0.478 ' HD3' ' O ' ' A' ' 46' ' ' ARG . 48.2 Cg_endo . . . . . 0 C--N 1.304 -1.793 0 O-C-N 123.849 1.447 . . . . 99.989999999999995 110.487 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo . . . . . 0 N--CA 1.49 1.309 0 N-CA-C 110.378 -0.662 . . . . 50.0 110.378 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.581 HG12 ' N ' ' A' ' 30' ' ' THR . 49.1 t -133.0 174.21 13.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.258 -0.901 . . . . 50.0 110.277 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.581 ' N ' HG12 ' A' ' 29' ' ' VAL . 99.8 m -115.92 104.97 12.14 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.277 -0.89 . . . . 50.0 110.345 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 65.1 m -82.1 -6.42 59.16 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.19 -0.944 . . . . 50.0 109.995 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 60.1 tp -57.99 -46.48 85.15 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.329 -0.857 . . . . 50.0 110.189 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -64.83 -34.52 78.55 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.393 -0.817 . . . . 50.0 110.21 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 65.1 m -69.67 -31.94 70.29 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.277 -0.889 . . . . 50.0 110.3 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.15 5.21 62.43 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.698 -1.361 . . . . 50.0 109.698 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.706 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -78.41 173.05 12.75 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.189 -1.183 . . . . 50.0 110.326 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.873 HD12 ' NE2' ' A' ' 39' ' ' HIS . 7.1 pt -114.73 152.25 16.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.305 -0.872 . . . . 50.0 109.925 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 77.1 m -107.18 142.76 36.38 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.326 -0.859 . . . . 50.0 110.156 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.873 ' NE2' HD12 ' A' ' 37' ' ' ILE . 23.6 m-70 -134.04 157.4 77.76 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.258 -0.901 . . . . 50.0 110.12 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.476 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 45.8 Cg_endo -72.18 165.03 33.82 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 O-C-N 124.096 1.577 . . . . 50.0 110.931 -179.42 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.835 HG12 ' HD2' ' A' ' 42' ' ' PHE . 18.6 t 61.02 -100.73 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.453 -0.78 . . . . 50.0 110.26 179.689 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.835 ' HD2' HG12 ' A' ' 41' ' ' VAL . 35.4 p90 -145.64 157.55 43.95 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.757 -1.214 . . . . 50.0 110.467 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . 0.426 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 76.5 m -68.98 131.24 90.97 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.324 -0.86 . . . . 50.0 110.089 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -69.45 -160.05 0.06 OUTLIER 'Trans proline' 0 C--N 1.305 -1.75 0 O-C-N 123.908 1.478 . . . . 50.0 110.945 -179.709 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 31.7 mtt180 -80.85 -41.22 23.54 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.537 -0.727 . . . . 50.0 109.884 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.414 ' O ' ' HD3' ' A' ' 64' ' ' PRO . 82.7 mmt-85 -55.82 -25.46 41.75 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.466 -0.771 . . . . 50.0 109.97 -179.769 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.531 ' N ' ' CD1' ' A' ' 47' ' ' TYR . 18.3 m-85 -125.82 161.61 27.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.285 -0.884 . . . . 50.0 110.399 179.722 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.421 ' N ' ' O ' ' A' ' 62' ' ' LYS . 88.8 mttt -116.43 146.12 42.76 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.443 -0.785 . . . . 50.0 109.021 178.801 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.425 ' HA ' ' O ' ' A' ' 60' ' ' CYS . 45.4 tt0 -90.23 104.02 16.64 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.96 -1.087 . . . . 50.0 111.215 -178.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.673 HD11 ' HD2' ' A' ' 62' ' ' LYS . 80.2 mt -64.81 -32.54 58.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.276 -0.89 . . . . 50.0 109.136 178.857 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 168.63 -96.07 0.12 Allowed Glycine 0 N--CA 1.488 2.108 0 N-CA-C 109.469 -1.452 . . . . 50.0 109.469 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 74.3 p -143.22 127.77 17.99 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.25 -1.147 . . . . 50.0 110.29 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' CYS . . . . . . . . . . . . . 4.4 t -50.44 -44.76 55.55 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.225 -0.922 . . . . 50.0 109.848 179.721 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 176.71 -33.23 0.08 OUTLIER Glycine 0 N--CA 1.49 2.288 0 N-CA-C 108.994 -1.642 . . . . 50.0 108.994 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 97.5 mt -127.21 161.36 54.72 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.455 -1.027 . . . . 50.0 109.77 179.651 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -72.61 -5.31 16.94 Favored 'Trans proline' 0 C--N 1.304 -1.774 0 O-C-N 123.912 1.48 . . . . 50.0 110.462 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -71.45 -34.68 63.46 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.596 -1.402 . . . . 50.0 109.596 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . 0.427 HG23 ' C ' ' A' ' 39' ' ' HIS . 11.5 m -132.88 165.64 24.17 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.312 -1.111 . . . . 50.0 110.149 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.479 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 75.3 mmtt -122.31 135.46 54.73 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.38 -0.825 . . . . 50.0 109.675 179.563 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.426 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 39.4 t -68.98 133.73 48.55 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.261 -0.9 . . . . 50.0 110.426 -179.432 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' CYS . . . . . 0.706 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 71.2 m -123.13 153.58 39.79 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.355 -0.841 . . . . 50.0 110.023 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.673 ' HD2' HD11 ' A' ' 50' ' ' ILE . 65.4 tttm -139.78 147.68 41.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.068 -1.02 . . . . 50.0 110.51 -179.721 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -84.08 154.88 64.06 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.259 -0.9 . . . . 50.0 110.207 179.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . 0.414 ' HD3' ' O ' ' A' ' 46' ' ' ARG . 47.1 Cg_endo . . . . . 0 C--N 1.305 -1.716 0 O-C-N 124.008 1.53 . . . . 99.989999999999995 110.38 179.835 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo . . . . . 0 N--CA 1.488 1.194 0 N-CA-C 110.289 -0.696 . . . . 50.0 110.289 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.8 m -129.6 157.63 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.191 -0.943 . . . . 50.0 110.31 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.411 HG22 ' HB3' ' A' ' 32' ' ' LEU . 95.8 m -109.99 104.03 12.87 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.353 -0.842 . . . . 50.0 110.229 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . 0.463 ' SG ' ' HA ' ' A' ' 53' ' ' CYS . 72.1 m -65.67 -16.83 64.12 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.265 -0.897 . . . . 50.0 110.184 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.411 ' HB3' HG22 ' A' ' 30' ' ' THR . 9.9 tp -61.21 -45.98 92.33 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.282 -0.886 . . . . 50.0 110.082 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 67.5 mttm -63.12 -35.04 78.94 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.393 -0.817 . . . . 50.0 110.065 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 31.6 t -70.05 -24.3 63.24 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.361 -0.837 . . . . 50.0 110.204 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.03 9.9 47.33 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.604 -1.398 . . . . 50.0 109.604 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.474 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -106.78 151.45 25.15 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.196 -1.179 . . . . 50.0 110.172 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.509 HG12 ' CE2' ' A' ' 47' ' ' TYR . 6.6 pt -100.7 151.86 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.347 -0.845 . . . . 50.0 110.26 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 87.0 m -92.75 148.15 22.28 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.301 -0.874 . . . . 50.0 109.964 179.781 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.612 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 53.0 t-80 -135.42 147.05 60.29 Favored Pre-proline 0 N--CA 1.495 1.783 0 O-C-N 121.247 -0.908 . . . . 50.0 110.045 -179.488 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.612 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 43.5 Cg_endo -69.89 160.47 49.53 Favored 'Trans proline' 0 C--N 1.308 -1.597 0 O-C-N 123.773 1.407 . . . . 50.0 110.59 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.835 HG12 ' HD2' ' A' ' 42' ' ' PHE . 21.6 t 61.57 -87.54 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.427 -0.796 . . . . 50.0 110.655 179.749 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.835 ' HD2' HG12 ' A' ' 41' ' ' VAL . 25.8 p90 -155.42 164.89 38.11 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 120.845 -1.159 . . . . 50.0 110.333 179.872 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . 0.451 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 85.3 m -73.87 131.7 81.27 Favored Pre-proline 0 N--CA 1.496 1.834 0 O-C-N 121.239 -0.913 . . . . 50.0 110.601 -179.566 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -71.02 -162.18 0.1 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 O-C-N 123.9 1.474 . . . . 50.0 110.787 -179.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 19.4 ptp180 -80.11 -20.96 43.83 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.536 -0.727 . . . . 50.0 110.413 -179.758 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.469 ' O ' ' HD3' ' A' ' 64' ' ' PRO . 99.3 mtt180 -76.73 -26.13 54.29 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.261 -0.899 . . . . 50.0 110.013 179.821 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.513 ' N ' ' CD1' ' A' ' 47' ' ' TYR . 15.5 m-85 -124.21 158.76 31.67 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.308 -0.87 . . . . 50.0 110.6 -179.813 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.416 ' O ' ' HA ' ' A' ' 61' ' ' CYS . 54.0 tptt -111.89 156.03 22.71 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.438 -0.788 . . . . 50.0 109.151 178.849 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.472 ' HG3' ' HG3' ' A' ' 59' ' ' LYS . 32.7 tt0 -95.25 100.75 12.49 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.923 -1.11 . . . . 50.0 110.65 -179.546 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.537 HD11 ' CD ' ' A' ' 62' ' ' LYS . 66.3 mt -66.92 -31.02 51.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.284 -0.885 . . . . 50.0 109.783 179.443 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 172.67 -97.77 0.12 Allowed Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.55 -1.42 . . . . 50.0 109.55 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 64.9 p -143.36 133.15 23.91 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.205 -1.173 . . . . 50.0 110.44 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' CYS . . . . . 0.535 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 13.8 t -55.01 -45.05 75.09 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.315 -0.865 . . . . 50.0 109.67 179.57 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 167.66 -35.73 0.21 Allowed Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.383 -1.887 . . . . 50.0 108.383 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 66.4 mt -122.38 157.02 59.97 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.542 -0.975 . . . . 50.0 109.491 179.488 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -72.48 -6.5 19.17 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 123.852 1.448 . . . . 50.0 110.641 -179.79 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -71.52 -35.9 62.77 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.495 -1.442 . . . . 50.0 109.495 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 6.2 m -128.59 167.92 16.46 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.323 -1.104 . . . . 50.0 110.183 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.472 ' HG3' ' HG3' ' A' ' 49' ' ' GLN . 16.3 tppt? -124.41 133.68 53.32 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.266 -0.896 . . . . 50.0 110.173 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.535 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 35.3 t -63.06 133.83 55.13 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.29 -0.881 . . . . 50.0 110.527 -179.823 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' CYS . . . . . 0.504 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 74.7 m -133.15 138.65 46.7 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.281 -0.887 . . . . 50.0 110.084 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.537 ' CD ' HD11 ' A' ' 50' ' ' ILE . 87.5 tttt -135.65 144.45 46.05 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.199 -0.938 . . . . 50.0 110.136 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -65.63 150.04 96.6 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.124 -0.985 . . . . 50.0 109.933 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . 0.469 ' HD3' ' O ' ' A' ' 46' ' ' ARG . 45.9 Cg_endo . . . . . 0 C--N 1.305 -1.756 0 O-C-N 123.964 1.507 . . . . 99.989999999999995 110.359 -179.676 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.496 ' HB2' ' HA2' ' A' ' 54' ' ' GLY . 48.9 Cg_endo . . . . . 0 N--CA 1.489 1.246 0 N-CA-C 110.441 -0.638 . . . . 50.0 110.441 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.479 HG12 ' N ' ' A' ' 30' ' ' THR . 17.9 t -134.17 172.0 16.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.215 -0.928 . . . . 50.0 110.303 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.49 HG22 ' HB2' ' A' ' 32' ' ' LEU . 26.1 m -117.12 111.63 19.75 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.299 -0.876 . . . . 50.0 110.054 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 93.3 m -76.79 -4.54 44.02 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.264 -0.898 . . . . 50.0 110.437 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.49 ' HB2' HG22 ' A' ' 30' ' ' THR . 18.9 mt -58.91 -45.19 90.92 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.139 -0.975 . . . . 50.0 110.07 179.858 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -66.71 -34.98 79.05 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.368 -0.833 . . . . 50.0 110.223 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 46.6 t -67.58 -25.08 65.61 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.365 -0.834 . . . . 50.0 110.192 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.77 -14.22 60.46 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.707 -1.357 . . . . 50.0 109.707 179.71 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.469 ' HB2' ' HG3' ' A' ' 62' ' ' LYS . . . -70.31 170.58 11.5 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.143 -1.21 . . . . 50.0 110.255 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.787 HD12 ' NE2' ' A' ' 39' ' ' HIS . 14.7 pt -115.38 163.05 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.346 -0.846 . . . . 50.0 109.748 179.464 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 74.8 m -109.74 140.7 43.33 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.156 -0.965 . . . . 50.0 110.046 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.787 ' NE2' HD12 ' A' ' 37' ' ' ILE . 17.2 m-70 -134.34 153.92 79.6 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.198 -0.939 . . . . 50.0 110.115 179.892 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.475 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 45.1 Cg_endo -70.54 162.79 41.19 Favored 'Trans proline' 0 C--N 1.305 -1.743 0 O-C-N 124.029 1.541 . . . . 50.0 111.262 -179.178 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.764 HG12 ' HD2' ' A' ' 42' ' ' PHE . 18.9 t 62.11 -105.18 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.578 -0.701 . . . . 50.0 110.607 179.546 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.764 ' HD2' HG12 ' A' ' 41' ' ' VAL . 25.8 p90 -140.01 157.27 45.94 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.863 -1.148 . . . . 50.0 110.359 -179.688 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . 0.465 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 83.8 m -67.83 129.46 93.26 Favored Pre-proline 0 N--CA 1.492 1.626 0 O-C-N 121.181 -0.95 . . . . 50.0 109.829 179.599 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -67.6 -162.94 0.08 OUTLIER 'Trans proline' 0 C--N 1.303 -1.848 0 O-C-N 123.881 1.464 . . . . 50.0 110.846 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 16.2 ptm180 -78.33 -32.26 49.12 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.467 -0.77 . . . . 50.0 110.274 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.439 ' HG2' ' CE1' ' A' ' 47' ' ' TYR . 55.6 ttm-85 -68.3 -25.73 65.29 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.265 -0.897 . . . . 50.0 109.902 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.579 ' CE2' HD11 ' A' ' 37' ' ' ILE . 29.3 m-85 -119.84 157.4 28.75 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.258 -0.901 . . . . 50.0 110.035 179.623 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.405 ' O ' ' HA ' ' A' ' 61' ' ' CYS . 76.6 tttt -109.54 152.22 25.76 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.262 -0.899 . . . . 50.0 109.323 178.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 56.8 tp60 -95.18 101.51 13.26 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.171 -0.955 . . . . 50.0 110.24 -179.777 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 98.2 mt -72.17 -28.98 30.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.289 -0.882 . . . . 50.0 109.775 179.788 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.53 ' C ' HG23 ' A' ' 52' ' ' THR . . . 165.88 -91.87 0.1 Allowed Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.75 -1.34 . . . . 50.0 109.75 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.53 HG23 ' C ' ' A' ' 51' ' ' GLY . 76.4 p -150.52 130.91 13.75 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.188 -1.184 . . . . 50.0 110.563 -179.573 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' CYS . . . . . 0.475 ' O ' ' O ' ' A' ' 29' ' ' VAL . 8.6 t -51.2 -43.17 61.31 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.221 -0.924 . . . . 50.0 110.083 179.87 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.96 ' C ' HD22 ' A' ' 55' ' ' LEU . . . 162.91 -31.63 0.29 Allowed Glycine 0 N--CA 1.488 2.151 0 N-CA-C 109.001 -1.64 . . . . 50.0 109.001 -179.687 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.96 HD22 ' C ' ' A' ' 54' ' ' GLY . 3.2 mm? -126.43 160.9 55.6 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.442 -1.034 . . . . 50.0 109.743 179.758 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -71.45 -10.49 26.99 Favored 'Trans proline' 0 C--N 1.304 -1.799 0 O-C-N 123.801 1.421 . . . . 50.0 110.44 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -64.99 -45.03 93.59 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.595 -1.402 . . . . 50.0 109.595 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . 0.41 HG22 ' N ' ' A' ' 59' ' ' LYS . 20.1 m -131.36 167.1 19.83 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.327 -1.102 . . . . 50.0 110.423 -179.873 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.492 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 47.0 mmtm -118.93 149.48 41.52 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.439 -0.788 . . . . 50.0 109.533 179.387 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.465 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 36.9 t -76.74 132.55 39.36 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.146 -0.971 . . . . 50.0 110.797 -179.093 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' CYS . . . . . 0.531 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 92.5 m -133.17 133.9 43.42 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.465 -0.772 . . . . 50.0 109.858 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.469 ' HG3' ' HB2' ' A' ' 36' ' ' ALA . 81.3 tttt -127.95 141.97 51.38 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.148 -0.97 . . . . 50.0 110.689 -179.539 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . 0.574 ' HE2' ' CZ ' ' A' ' 47' ' ' TYR . 99.4 mttt -75.94 156.69 84.21 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.36 -0.837 . . . . 50.0 110.023 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo . . . . . 0 C--N 1.304 -1.768 0 O-C-N 123.948 1.499 . . . . 99.989999999999995 110.508 179.86 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo . . . . . 0 N--CA 1.487 1.133 0 N-CA-C 110.34 -0.677 . . . . 50.0 110.34 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.463 ' O ' ' O ' ' A' ' 53' ' ' CYS . 15.5 m -107.68 134.19 50.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.305 -0.872 . . . . 50.0 110.206 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.451 ' O ' ' HB2' ' A' ' 31' ' ' CYS . 85.0 m -67.39 -11.89 58.87 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.274 -0.891 . . . . 50.0 110.314 -179.914 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . 0.451 ' HB2' ' O ' ' A' ' 30' ' ' THR . 64.1 m 57.28 19.29 4.87 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.161 -0.962 . . . . 50.0 110.399 179.813 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 33.2 tp -72.69 -32.17 65.58 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.165 -0.959 . . . . 50.0 110.633 -179.727 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -71.85 -40.18 69.2 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.103 -0.998 . . . . 50.0 110.226 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 72.3 m -71.82 -24.58 61.74 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.415 -0.803 . . . . 50.0 110.175 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 75.63 16.1 80.85 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.483 -1.447 . . . . 50.0 109.483 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.668 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -83.12 176.74 8.98 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.281 -1.129 . . . . 50.0 110.024 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.472 ' O ' HG13 ' A' ' 37' ' ' ILE . 3.7 pt -116.91 150.77 18.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.134 -0.979 . . . . 50.0 110.42 -179.901 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.446 ' HA ' ' HA ' ' A' ' 60' ' ' CYS . 61.0 m -91.26 137.3 32.47 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.173 -0.954 . . . . 50.0 109.333 179.484 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.517 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 58.3 t-80 -109.49 143.03 26.95 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.054 -1.028 . . . . 50.0 110.76 -179.157 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.517 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 47.5 Cg_endo -73.33 164.78 34.3 Favored 'Trans proline' 0 C--N 1.305 -1.713 0 O-C-N 124.19 1.626 . . . . 50.0 110.316 179.694 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.827 HG12 ' HD2' ' A' ' 42' ' ' PHE . 27.7 t 59.71 -84.02 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.298 -0.876 . . . . 50.0 110.558 179.667 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.827 ' HD2' HG12 ' A' ' 41' ' ' VAL . 16.5 p90 -158.64 161.89 37.21 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.854 -1.154 . . . . 50.0 110.389 -179.916 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . 0.434 ' SG ' ' HB3' ' A' ' 47' ' ' TYR . 0.6 OUTLIER -80.92 121.62 81.06 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.216 -0.928 . . . . 50.0 110.059 179.911 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -70.39 -162.52 0.1 OUTLIER 'Trans proline' 0 C--N 1.306 -1.677 0 O-C-N 123.908 1.478 . . . . 50.0 110.592 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 11.2 ptm180 -81.8 -29.76 32.54 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.546 -0.721 . . . . 50.0 110.369 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 45.4 mmm-85 -69.06 -16.1 63.61 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.274 -0.891 . . . . 50.0 110.163 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.568 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 72.4 m-85 -122.93 150.14 43.34 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.29 -0.881 . . . . 50.0 110.337 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 54.0 tptt -110.9 154.11 24.53 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.35 -0.844 . . . . 50.0 110.224 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.517 ' HG3' ' CE ' ' A' ' 59' ' ' LYS . 46.2 tt0 -88.48 108.91 19.63 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.23 -0.919 . . . . 50.0 110.01 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 39.4 pt -104.32 10.76 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.22 -0.925 . . . . 50.0 110.966 -179.51 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.536 ' O ' ' CB ' ' A' ' 60' ' ' CYS . . . 130.62 113.01 1.55 Allowed Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.431 -1.468 . . . . 50.0 109.431 179.927 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.493 ' C ' ' O ' ' A' ' 51' ' ' GLY . 81.9 p -29.52 140.09 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.991 -0.711 . . . . 50.0 111.633 -179.612 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' CYS . . . . . 0.463 ' O ' ' O ' ' A' ' 29' ' ' VAL . 8.3 t -59.52 -50.24 74.69 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.385 -0.822 . . . . 50.0 110.219 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -179.06 -39.85 0.07 OUTLIER Glycine 0 N--CA 1.491 2.323 0 N-CA-C 108.945 -1.662 . . . . 50.0 108.945 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.453 ' HB3' ' HD2' ' A' ' 56' ' ' PRO . 70.2 mt -126.59 164.12 36.44 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.437 -1.037 . . . . 50.0 109.836 179.664 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.453 ' HD2' ' HB3' ' A' ' 55' ' ' LEU . 45.2 Cg_endo -71.21 -7.29 21.04 Favored 'Trans proline' 0 C--N 1.305 -1.762 0 O-C-N 123.971 1.511 . . . . 50.0 110.555 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -68.98 -37.64 83.56 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.16 -1.576 . . . . 50.0 109.16 179.765 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 1.4 m -129.42 159.97 34.57 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.316 -1.108 . . . . 50.0 110.005 179.773 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.517 ' CE ' ' HG3' ' A' ' 49' ' ' GLN . 37.7 tptt -121.84 127.27 50.35 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.197 -0.94 . . . . 50.0 109.984 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.536 ' CB ' ' O ' ' A' ' 51' ' ' GLY . 49.8 t -57.03 134.26 55.66 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.196 -0.94 . . . . 50.0 110.073 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' CYS . . . . . 0.668 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 54.5 m -136.76 148.26 47.15 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.3 -0.875 . . . . 50.0 109.981 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 81.0 tttt -128.4 132.26 48.5 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.207 -0.933 . . . . 50.0 110.418 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . 0.568 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 49.2 mtpt -72.81 152.74 91.25 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.299 -0.875 . . . . 50.0 110.202 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo . . . . . 0 C--N 1.305 -1.758 0 O-C-N 123.983 1.517 . . . . 99.989999999999995 110.497 -179.811 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo . . . . . 0 N--CA 1.49 1.312 0 N-CA-C 110.384 -0.66 . . . . 50.0 110.384 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.528 HG12 ' N ' ' A' ' 30' ' ' THR . 38.6 t -143.29 171.37 8.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.186 -0.946 . . . . 50.0 110.53 -179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.528 ' N ' HG12 ' A' ' 29' ' ' VAL . 57.7 m -109.45 111.26 22.7 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.337 -0.852 . . . . 50.0 109.927 179.619 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . . . . . . . . . 92.6 m -80.01 -8.3 59.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.252 -0.905 . . . . 50.0 110.594 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.0 mt -58.29 -33.14 69.12 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.147 -0.971 . . . . 50.0 110.38 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 95.0 mttt -67.39 -39.09 85.59 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.266 -0.896 . . . . 50.0 110.229 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 14.4 m -65.4 -31.71 72.95 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.292 -0.88 . . . . 50.0 110.154 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 106.73 15.44 16.83 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.696 -1.362 . . . . 50.0 109.696 179.865 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.875 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -120.31 126.38 50.41 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.17 -1.194 . . . . 50.0 110.152 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.74 HD11 ' NE2' ' A' ' 39' ' ' HIS . 1.1 pt -84.02 144.54 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.281 -0.887 . . . . 50.0 109.995 179.855 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.46 ' HA ' ' HA ' ' A' ' 60' ' ' CYS . 22.6 p -87.95 159.69 18.23 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.196 -0.94 . . . . 50.0 110.411 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.74 ' NE2' HD11 ' A' ' 37' ' ' ILE . 41.8 m-70 -131.02 167.88 19.66 Favored Pre-proline 0 N--CA 1.496 1.839 0 O-C-N 121.408 -0.808 . . . . 50.0 110.168 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.453 ' HD2' ' HB3' ' A' ' 39' ' ' HIS . 43.5 Cg_endo -70.16 161.17 46.97 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 O-C-N 123.711 1.374 . . . . 50.0 110.742 -179.601 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.857 HG12 ' HD2' ' A' ' 42' ' ' PHE . 9.8 t 55.82 -112.15 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.297 -0.877 . . . . 50.0 109.883 -179.682 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.857 ' HD2' HG12 ' A' ' 41' ' ' VAL . 50.2 p90 -135.2 156.27 49.27 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.676 -1.265 . . . . 50.0 109.96 179.749 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . 0.476 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 83.6 m -59.14 130.47 86.87 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.137 -0.977 . . . . 50.0 110.043 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -70.71 -162.54 0.1 Allowed 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 123.979 1.515 . . . . 50.0 110.603 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 41.5 ptt180 -78.6 -29.35 46.02 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.493 -0.754 . . . . 50.0 110.413 -179.623 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 86.5 mtm180 -72.39 -12.43 61.11 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.237 -0.914 . . . . 50.0 110.16 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.609 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 38.1 m-85 -131.36 165.66 22.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.267 -0.896 . . . . 50.0 111.084 -179.611 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.501 ' O ' ' HA ' ' A' ' 61' ' ' CYS . 33.2 mttm -117.31 142.68 46.78 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.514 -0.741 . . . . 50.0 109.295 178.865 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.497 ' HA ' ' O ' ' A' ' 60' ' ' CYS . 32.7 tt0 -88.19 110.04 20.38 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.981 -1.075 . . . . 50.0 111.188 -179.131 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.646 HD11 ' CG ' ' A' ' 62' ' ' LYS . 80.7 mt -77.21 -28.89 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.314 -0.866 . . . . 50.0 109.326 178.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.579 ' C ' HG23 ' A' ' 52' ' ' THR . . . 174.3 -99.54 0.14 Allowed Glycine 0 N--CA 1.488 2.166 0 N-CA-C 108.819 -1.712 . . . . 50.0 108.819 -179.836 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.579 HG23 ' C ' ' A' ' 51' ' ' GLY . 70.9 p -157.65 143.74 17.55 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.284 -1.127 . . . . 50.0 110.191 179.571 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' CYS . . . . . 0.441 ' HA ' ' SG ' ' A' ' 60' ' ' CYS . 1.8 t -58.1 -39.06 77.67 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.217 -0.927 . . . . 50.0 109.882 179.606 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.546 ' O ' HD23 ' A' ' 55' ' ' LEU . . . 165.85 -27.68 0.18 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 108.818 -1.713 . . . . 50.0 108.818 -179.936 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.546 HD23 ' O ' ' A' ' 54' ' ' GLY . 30.2 mt -127.36 166.46 22.86 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.409 -1.054 . . . . 50.0 109.816 179.748 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.488 ' HD2' ' HB3' ' A' ' 55' ' ' LEU . 45.6 Cg_endo -73.52 -4.85 16.12 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.884 1.465 . . . . 50.0 110.447 179.889 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -78.61 -32.81 40.39 Favored Glycine 0 N--CA 1.489 2.167 0 N-CA-C 109.421 -1.472 . . . . 50.0 109.421 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . 0.536 HG23 ' C ' ' A' ' 39' ' ' HIS . 2.5 m -128.37 162.58 26.77 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.273 -1.134 . . . . 50.0 110.587 -179.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.524 ' CG ' ' O ' ' A' ' 41' ' ' VAL . 72.1 mmtt -133.38 142.96 48.63 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.536 -0.728 . . . . 50.0 109.511 179.615 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.497 ' O ' ' HA ' ' A' ' 49' ' ' GLN . 45.1 m -68.98 131.09 44.51 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.083 -1.01 . . . . 50.0 110.255 -179.861 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' CYS . . . . . 0.875 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 98.3 m -124.29 162.07 24.51 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.399 -0.813 . . . . 50.0 110.247 -179.812 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.646 ' CG ' HD11 ' A' ' 50' ' ' ILE . 46.0 mtpt -122.31 164.31 18.14 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.233 -0.917 . . . . 50.0 110.672 -179.748 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . 0.609 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 52.1 mtpt -115.19 133.87 22.63 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.364 -0.835 . . . . 50.0 110.334 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo . . . . . 0 C--N 1.307 -1.63 0 O-C-N 123.927 1.488 . . . . 99.989999999999995 110.579 179.729 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo . . . . . 0 N--CA 1.49 1.284 0 N-CA-C 110.351 -0.673 . . . . 50.0 110.351 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.3 m -135.12 145.56 31.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.208 -0.932 . . . . 50.0 110.489 -179.787 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.494 HG22 ' HB2' ' A' ' 32' ' ' LEU . 25.0 m -100.48 105.99 17.5 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.297 -0.877 . . . . 50.0 110.097 179.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . 0.848 ' HB3' ' HB3' ' A' ' 36' ' ' ALA . 87.2 m -77.39 -1.6 30.94 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.193 -0.942 . . . . 50.0 110.411 -179.834 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.494 ' HB2' HG22 ' A' ' 30' ' ' THR . 32.9 mt -63.35 -39.64 95.08 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.222 -0.924 . . . . 50.0 110.261 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 43.0 mmtm -66.75 -42.58 85.95 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.29 -0.882 . . . . 50.0 110.362 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 86.3 p -70.46 -14.77 62.67 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.347 -0.846 . . . . 50.0 110.143 -179.892 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 87.12 4.79 81.19 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.543 -1.423 . . . . 50.0 109.543 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.848 ' HB3' ' HB3' ' A' ' 31' ' ' CYS . . . -71.8 155.64 40.21 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.159 -1.201 . . . . 50.0 110.009 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 1.008 HD12 ' NE2' ' A' ' 39' ' ' HIS . 26.7 pt -103.89 145.0 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.185 -0.947 . . . . 50.0 110.015 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 8.7 m -101.22 125.39 47.84 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.258 -0.901 . . . . 50.0 109.936 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 1.008 ' NE2' HD12 ' A' ' 37' ' ' ILE . 12.5 m-70 -119.48 153.06 53.77 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.232 -0.917 . . . . 50.0 110.345 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.427 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 45.7 Cg_endo -71.16 169.88 19.55 Favored 'Trans proline' 0 C--N 1.305 -1.727 0 O-C-N 124.04 1.547 . . . . 50.0 110.852 -179.604 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.795 HG12 ' HD2' ' A' ' 42' ' ' PHE . 17.4 t 59.15 -109.35 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.362 -0.836 . . . . 50.0 110.186 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.795 ' HD2' HG12 ' A' ' 41' ' ' VAL . 36.8 p90 -136.24 153.64 51.15 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.827 -1.171 . . . . 50.0 110.017 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . 0.407 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 76.4 m -69.88 132.26 88.8 Favored Pre-proline 0 N--CA 1.487 1.415 0 O-C-N 121.11 -0.994 . . . . 50.0 109.911 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -68.41 -162.76 0.08 OUTLIER 'Trans proline' 0 C--N 1.305 -1.732 0 O-C-N 123.996 1.524 . . . . 50.0 111.004 -179.564 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 16.2 ptm180 -81.58 -26.37 35.01 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.558 -0.714 . . . . 50.0 110.453 -179.617 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 13.3 mmm180 -66.71 -22.22 66.07 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.148 -0.97 . . . . 50.0 110.1 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.626 ' CB ' ' HB3' ' A' ' 61' ' ' CYS . 70.8 m-85 -128.1 144.01 51.09 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.217 -0.927 . . . . 50.0 110.589 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 85.0 tttt -88.67 152.88 21.53 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.267 -0.896 . . . . 50.0 109.221 178.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 56.4 tt0 -93.4 96.44 9.93 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.093 -1.005 . . . . 50.0 110.562 -179.702 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 93.6 mt -69.42 -30.11 44.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.309 -0.87 . . . . 50.0 109.904 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.576 ' C ' HG23 ' A' ' 52' ' ' THR . . . 159.12 -91.86 0.12 Allowed Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.263 -1.535 . . . . 50.0 109.263 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.576 HG23 ' C ' ' A' ' 51' ' ' GLY . 63.3 p -153.92 150.58 28.5 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.26 -1.141 . . . . 50.0 109.992 179.695 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' CYS . . . . . 0.42 ' SG ' ' HB2' ' A' ' 60' ' ' CYS . 1.6 m -84.89 -27.33 26.72 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.189 -0.944 . . . . 50.0 110.694 -179.599 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 179.03 -49.5 0.09 OUTLIER Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.764 -1.334 . . . . 50.0 109.764 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 56.2 mt -119.74 161.92 35.47 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.16 -1.2 . . . . 50.0 110.419 -179.851 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -71.93 -11.4 27.42 Favored 'Trans proline' 0 C--N 1.305 -1.74 0 O-C-N 124.08 1.569 . . . . 50.0 110.292 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -68.94 -30.47 72.32 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.448 -1.461 . . . . 50.0 109.448 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -125.25 155.28 40.37 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.275 -1.132 . . . . 50.0 110.298 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.445 ' O ' ' SG ' ' A' ' 61' ' ' CYS . 14.1 tppt? -120.56 127.16 51.89 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.396 -0.815 . . . . 50.0 109.839 179.686 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.42 ' HB2' ' SG ' ' A' ' 53' ' ' CYS . 34.3 t -63.51 130.9 46.29 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.252 -0.905 . . . . 50.0 110.663 -179.604 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' CYS . . . . . 0.626 ' HB3' ' CB ' ' A' ' 47' ' ' TYR . 7.4 m -128.58 130.3 47.16 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.371 -0.831 . . . . 50.0 109.635 179.765 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 83.4 tttt -131.62 148.69 52.62 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.157 -0.964 . . . . 50.0 110.507 -179.638 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 86.0 mttt -72.76 150.36 90.77 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.281 -0.887 . . . . 50.0 110.021 179.887 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo . . . . . 0 C--N 1.306 -1.685 0 O-C-N 123.955 1.502 . . . . 99.989999999999995 110.401 179.977 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo . . . . . 0 N--CA 1.489 1.25 0 N-CA-C 110.553 -0.595 . . . . 50.0 110.553 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.47 ' O ' ' O ' ' A' ' 53' ' ' CYS . 18.2 m -125.21 125.45 69.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.311 -0.868 . . . . 50.0 110.084 179.879 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.507 HG22 ' HB2' ' A' ' 32' ' ' LEU . 85.8 m -64.7 -15.59 61.64 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.323 -0.861 . . . . 50.0 110.54 -179.789 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . 0.479 ' HB2' ' O ' ' A' ' 30' ' ' THR . 97.9 m 56.61 18.38 3.6 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.232 -0.918 . . . . 50.0 110.223 179.836 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.753 HD13 ' C ' ' A' ' 32' ' ' LEU . 3.4 tm? -76.62 -39.47 52.36 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.223 -0.923 . . . . 50.0 110.477 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 74.4 mmtt -75.13 -35.24 61.7 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.324 -0.86 . . . . 50.0 109.985 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 73.9 m -71.18 -26.72 63.09 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.374 -0.829 . . . . 50.0 110.191 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 84.98 9.0 81.54 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.493 -1.443 . . . . 50.0 109.493 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.455 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -76.66 134.37 39.29 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.232 -1.158 . . . . 50.0 110.262 -179.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.684 HD11 ' CE2' ' A' ' 47' ' ' TYR . 9.1 pt -83.02 148.13 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.239 -0.913 . . . . 50.0 110.028 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 96.5 m -91.79 148.79 21.98 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.075 -1.016 . . . . 50.0 109.882 179.862 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.583 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 62.6 t-80 -139.71 145.9 45.17 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 121.312 -0.868 . . . . 50.0 109.89 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.583 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 41.6 Cg_endo -66.89 159.63 50.79 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.868 1.457 . . . . 50.0 110.075 179.723 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.827 HG12 ' HD2' ' A' ' 42' ' ' PHE . 13.5 t 62.99 -105.94 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.224 -0.922 . . . . 50.0 109.913 -179.673 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.827 ' HD2' HG12 ' A' ' 41' ' ' VAL . 42.1 p90 -142.26 157.9 44.32 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.626 -1.296 . . . . 50.0 110.148 179.814 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . 0.455 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 84.4 m -65.02 132.54 95.5 Favored Pre-proline 0 N--CA 1.493 1.699 0 O-C-N 121.241 -0.912 . . . . 50.0 110.371 -179.792 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -68.71 -162.16 0.08 OUTLIER 'Trans proline' 0 C--N 1.305 -1.75 0 O-C-N 123.995 1.524 . . . . 50.0 110.839 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 27.3 tpt180 -75.61 -43.13 49.63 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.519 -0.738 . . . . 50.0 110.537 -179.681 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.454 ' HG3' ' HG3' ' A' ' 64' ' ' PRO . 45.8 ttt85 -61.45 -30.77 70.8 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.333 -0.854 . . . . 50.0 110.372 -179.723 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.684 ' CE2' HD11 ' A' ' 37' ' ' ILE . 32.2 m-85 -111.1 136.36 50.26 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.193 -0.942 . . . . 50.0 110.747 -179.85 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 24.6 tptp -87.37 157.14 19.32 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.261 -0.899 . . . . 50.0 109.387 179.034 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.416 ' HA ' ' SG ' ' A' ' 43' ' ' CYS . 53.7 tt0 -89.5 102.7 15.38 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.099 -1.001 . . . . 50.0 110.356 -179.777 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.419 ' HB ' ' SG ' ' A' ' 60' ' ' CYS . 30.6 mm -67.08 -30.66 50.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.227 -0.921 . . . . 50.0 109.555 179.552 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 153.77 -91.16 0.13 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.035 -1.626 . . . . 50.0 109.035 179.866 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 50.1 p -146.2 125.9 13.42 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.363 -1.081 . . . . 50.0 109.976 179.603 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' CYS . . . . . 0.47 ' O ' ' O ' ' A' ' 29' ' ' VAL . 19.1 t -49.85 -49.22 49.98 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.252 -0.905 . . . . 50.0 109.669 179.635 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 173.47 -30.15 0.1 OUTLIER Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.211 -1.556 . . . . 50.0 109.211 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.407 ' HA ' HD23 ' A' ' 55' ' ' LEU . 55.6 mt -124.87 160.3 54.72 Favored Pre-proline 0 N--CA 1.489 1.512 0 O-C-N 121.384 -1.068 . . . . 50.0 109.917 179.866 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -71.97 -5.8 17.83 Favored 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.928 1.488 . . . . 50.0 110.198 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -78.32 -37.12 28.83 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.469 -1.452 . . . . 50.0 109.469 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 5.1 m -130.59 162.23 29.79 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.269 -1.136 . . . . 50.0 110.268 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 66.7 mmtt -117.56 164.59 14.69 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.408 -0.808 . . . . 50.0 109.778 179.718 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.455 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 42.2 t -91.32 129.7 37.27 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.139 -0.975 . . . . 50.0 110.468 -179.78 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' CYS . . . . . 0.505 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 72.4 m -126.42 147.71 49.75 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.342 -0.849 . . . . 50.0 109.832 179.808 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 89.1 tttt -126.58 138.35 53.45 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.15 -0.969 . . . . 50.0 110.323 -179.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . 0.433 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 30.3 mtmm -63.07 154.69 76.43 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.333 -0.855 . . . . 50.0 110.325 179.88 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . 0.454 ' HG3' ' HG3' ' A' ' 46' ' ' ARG . 47.5 Cg_endo . . . . . 0 C--N 1.306 -1.71 0 O-C-N 124.01 1.532 . . . . 99.989999999999995 110.38 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.442 ' O ' ' HB ' ' A' ' 29' ' ' VAL . 47.1 Cg_endo . . . . . 0 N--CA 1.489 1.246 0 N-CA-C 110.399 -0.654 . . . . 50.0 110.399 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.568 HG12 ' N ' ' A' ' 30' ' ' THR . 46.9 t 56.8 172.52 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.16 -0.962 . . . . 50.0 110.102 -179.914 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.737 ' O ' HG22 ' A' ' 30' ' ' THR . 95.3 m 39.16 28.21 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.491 -0.755 . . . . 50.0 110.587 -179.812 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . 0.48 ' N ' ' O ' ' A' ' 29' ' ' VAL . 65.4 m -48.5 -22.5 0.74 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.13 -0.981 . . . . 50.0 109.721 179.682 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.7 mt -57.98 -42.76 85.76 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.249 -0.907 . . . . 50.0 110.08 179.568 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.638 ' HB2' HG22 ' A' ' 30' ' ' THR . 64.8 mmtt -68.24 -33.3 74.13 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.444 -0.785 . . . . 50.0 110.185 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 69.3 m -76.37 -17.53 59.34 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.228 -0.92 . . . . 50.0 109.942 179.837 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 91.93 -2.87 76.67 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.858 -1.297 . . . . 50.0 109.858 179.586 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.435 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -79.59 153.94 29.09 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.124 -1.221 . . . . 50.0 110.226 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.471 ' O ' ' N ' ' A' ' 61' ' ' CYS . 4.8 pt -107.79 152.88 9.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.288 -0.882 . . . . 50.0 110.052 179.826 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 71.8 m -93.32 148.98 21.57 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.202 -0.937 . . . . 50.0 110.045 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.596 ' CG ' ' HD2' ' A' ' 40' ' ' PRO . 42.0 t-80 -136.49 145.96 53.73 Favored Pre-proline 0 N--CA 1.491 1.614 0 O-C-N 121.275 -0.891 . . . . 50.0 110.16 -179.685 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.596 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 42.5 Cg_endo -68.59 153.02 74.38 Favored 'Trans proline' 0 C--N 1.307 -1.612 0 O-C-N 123.844 1.444 . . . . 50.0 110.544 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.835 HG12 ' HD2' ' A' ' 42' ' ' PHE . 18.0 t 64.24 -84.62 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.577 -0.702 . . . . 50.0 110.559 -179.784 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.835 ' HD2' HG12 ' A' ' 41' ' ' VAL . 21.6 p90 -156.56 161.96 39.94 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.714 -1.241 . . . . 50.0 110.214 179.963 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . 0.435 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 58.4 m -73.25 134.12 80.48 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.249 -0.907 . . . . 50.0 110.526 -179.665 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.454 ' O ' ' O ' ' A' ' 47' ' ' TYR . 44.3 Cg_endo -70.18 -160.63 0.07 OUTLIER 'Trans proline' 0 C--N 1.305 -1.718 0 O-C-N 123.874 1.46 . . . . 50.0 110.522 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 17.4 mmt180 -78.45 -46.58 19.41 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.493 -0.754 . . . . 50.0 109.68 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 82.1 mtm180 -54.39 -23.97 17.82 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.56 -0.713 . . . . 50.0 109.674 179.783 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.555 ' CZ ' ' HE2' ' A' ' 63' ' ' LYS . 39.4 m-85 -122.95 154.04 38.93 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.411 -0.805 . . . . 50.0 110.259 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 82.1 tttt -117.84 149.74 40.33 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.4 -0.813 . . . . 50.0 109.679 179.594 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 58.8 tt0 -88.71 94.92 10.07 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.184 -0.948 . . . . 50.0 109.892 179.638 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.463 HG13 ' N ' ' A' ' 51' ' ' GLY . 21.6 pt -71.4 -30.08 38.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.402 -0.811 . . . . 50.0 110.326 -179.821 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.504 ' C ' HG23 ' A' ' 52' ' ' THR . . . -171.52 -105.63 0.18 Allowed Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.483 -1.447 . . . . 50.0 109.483 179.76 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.504 HG23 ' C ' ' A' ' 51' ' ' GLY . 41.2 p -151.17 141.02 21.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.285 -1.127 . . . . 50.0 110.218 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' CYS . . . . . 0.577 ' N ' ' HB2' ' A' ' 60' ' ' CYS . 10.0 t -58.49 -44.39 89.38 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.273 -0.892 . . . . 50.0 109.873 179.879 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 160.08 -36.9 0.46 Allowed Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.033 -1.627 . . . . 50.0 109.033 -179.83 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 74.8 mt -113.45 155.29 44.94 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.428 -1.042 . . . . 50.0 109.924 179.669 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -71.32 -11.8 29.04 Favored 'Trans proline' 0 C--N 1.303 -1.853 0 O-C-N 123.922 1.485 . . . . 50.0 110.69 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -70.92 -41.92 61.07 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.57 -1.412 . . . . 50.0 109.57 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 14.6 m -122.79 166.86 14.27 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.337 -1.096 . . . . 50.0 110.248 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -124.7 145.66 49.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.406 -0.809 . . . . 50.0 109.87 179.806 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.577 ' HB2' ' N ' ' A' ' 53' ' ' CYS . 45.2 t -73.47 139.36 45.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.151 -0.968 . . . . 50.0 110.431 -179.803 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' CYS . . . . . 0.494 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 74.8 m -131.49 141.65 49.81 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.389 -0.82 . . . . 50.0 109.61 179.748 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 81.8 tttt -138.65 143.52 39.26 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.205 -0.934 . . . . 50.0 110.658 -179.341 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . 0.555 ' HE2' ' CZ ' ' A' ' 47' ' ' TYR . 98.9 mttt -77.28 142.0 67.19 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.294 -0.879 . . . . 50.0 110.158 179.81 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo . . . . . 0 C--N 1.305 -1.741 0 O-C-N 123.957 1.504 . . . . 99.989999999999995 110.412 179.975 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo . . . . . 0 N--CA 1.491 1.332 0 N-CA-C 110.445 -0.637 . . . . 50.0 110.445 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.79 HG22 ' O ' ' A' ' 52' ' ' THR . 31.0 m -90.46 147.25 5.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.259 -0.901 . . . . 50.0 110.293 179.891 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.665 HG22 ' HB2' ' A' ' 32' ' ' LEU . 85.6 m -64.22 -40.14 95.44 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.254 -0.904 . . . . 50.0 110.571 -179.768 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . 0.758 ' SG ' HG23 ' A' ' 29' ' ' VAL . 47.9 m 56.87 21.97 6.63 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.14 -0.975 . . . . 50.0 110.312 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.665 ' HB2' HG22 ' A' ' 30' ' ' THR . 79.2 mt -105.12 -21.05 13.33 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.193 -0.942 . . . . 50.0 110.176 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 95.2 mttt -72.58 -37.52 68.15 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.345 -0.847 . . . . 50.0 110.324 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 87.9 p -88.76 -4.04 58.61 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.292 -0.88 . . . . 50.0 110.25 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 69.42 21.38 76.01 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.195 -1.562 . . . . 50.0 109.195 -179.84 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -70.22 155.16 41.03 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.35 -1.088 . . . . 50.0 110.211 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.966 HD12 ' NE2' ' A' ' 39' ' ' HIS . 12.8 pt -104.73 151.05 7.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.21 -0.931 . . . . 50.0 110.253 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 76.2 m -105.38 139.54 39.85 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.299 -0.875 . . . . 50.0 110.031 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.966 ' NE2' HD12 ' A' ' 37' ' ' ILE . 17.3 m-70 -133.52 157.9 76.9 Favored Pre-proline 0 N--CA 1.494 1.74 0 O-C-N 121.346 -0.846 . . . . 50.0 110.192 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.466 ' O ' ' HB ' ' A' ' 41' ' ' VAL . 45.2 Cg_endo -71.58 168.42 23.68 Favored 'Trans proline' 0 C--N 1.306 -1.666 0 O-C-N 124.059 1.557 . . . . 50.0 110.415 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.87 HG12 ' HD2' ' A' ' 42' ' ' PHE . 10.8 t 61.84 -108.37 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.237 -0.914 . . . . 50.0 109.804 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.87 ' HD2' HG12 ' A' ' 41' ' ' VAL . 48.6 p90 -143.63 161.78 37.63 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.747 -1.221 . . . . 50.0 110.108 179.704 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . 0.462 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 70.8 m -67.33 132.43 93.24 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.222 -0.924 . . . . 50.0 110.356 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -71.29 -162.56 0.11 Allowed 'Trans proline' 0 C--N 1.306 -1.707 0 O-C-N 123.933 1.491 . . . . 50.0 110.346 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 30.2 mtt180 -78.21 -41.47 34.32 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.424 -0.798 . . . . 50.0 110.015 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.466 ' O ' ' HD3' ' A' ' 64' ' ' PRO . 26.0 mmm180 -57.95 -27.94 63.87 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.483 -0.761 . . . . 50.0 110.21 -179.777 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.535 ' CE2' ' CG ' ' A' ' 63' ' ' LYS . 21.7 m-85 -119.12 158.9 24.98 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.345 -0.847 . . . . 50.0 110.534 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -117.08 131.0 57.02 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.467 -0.77 . . . . 50.0 109.634 179.307 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.449 ' HB2' ' HB2' ' A' ' 43' ' ' CYS . 54.4 tt0 -78.14 104.14 8.53 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.276 -0.89 . . . . 50.0 111.024 -179.082 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.701 HD11 ' HD3' ' A' ' 62' ' ' LYS . 79.5 mt -68.71 -31.21 49.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.335 -0.853 . . . . 50.0 109.387 179.111 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.443 ' C ' HG23 ' A' ' 52' ' ' THR . . . 172.95 -96.67 0.11 Allowed Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.662 -1.375 . . . . 50.0 109.662 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.79 ' O ' HG22 ' A' ' 29' ' ' VAL . 68.6 p -146.7 137.2 23.8 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.207 -1.172 . . . . 50.0 110.327 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' CYS . . . . . . . . . . . . . 4.1 t -62.35 -41.43 98.58 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.263 -0.898 . . . . 50.0 110.137 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 158.93 -25.68 0.36 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 108.994 -1.642 . . . . 50.0 108.994 -179.897 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.521 ' CD1' ' HD2' ' A' ' 56' ' ' PRO . 17.4 tp -120.8 142.44 34.45 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.401 -1.059 . . . . 50.0 109.712 179.777 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.521 ' HD2' ' CD1' ' A' ' 55' ' ' LEU . 42.0 Cg_endo -67.92 -8.17 21.82 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 O-C-N 123.872 1.459 . . . . 50.0 110.442 -179.841 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -75.99 -32.09 53.88 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.062 -1.615 . . . . 50.0 109.062 179.511 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . 0.464 ' HA ' ' HA ' ' A' ' 40' ' ' PRO . 4.0 m -131.28 162.12 30.75 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.262 -1.14 . . . . 50.0 110.4 179.896 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.493 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 46.5 mmtm -120.76 146.63 46.3 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.285 -0.884 . . . . 50.0 109.829 179.741 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.462 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 42.7 t -75.82 133.4 40.64 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.264 -0.898 . . . . 50.0 110.749 -179.376 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' CYS . . . . . 0.514 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 73.6 m -130.45 135.08 47.62 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.365 -0.834 . . . . 50.0 109.791 179.807 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.701 ' HD3' HD11 ' A' ' 50' ' ' ILE . 39.8 ttpt -126.51 135.15 50.95 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.09 -1.006 . . . . 50.0 110.287 -179.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . 0.535 ' CG ' ' CE2' ' A' ' 47' ' ' TYR . 49.5 mtmt -70.97 151.83 95.01 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.319 -0.863 . . . . 50.0 110.128 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . 0.466 ' HD3' ' O ' ' A' ' 46' ' ' ARG . 45.6 Cg_endo . . . . . 0 C--N 1.304 -1.781 0 O-C-N 124.022 1.538 . . . . 99.989999999999995 110.494 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo . . . . . 0 N--CA 1.489 1.228 0 N-CA-C 110.225 -0.721 . . . . 50.0 110.225 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 5.3 m -133.44 144.36 36.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.247 -0.908 . . . . 50.0 110.373 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 97.0 m -115.72 114.24 24.56 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.337 -0.852 . . . . 50.0 110.034 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . 0.862 ' SG ' ' SG ' ' A' ' 53' ' ' CYS . 76.9 m -76.56 -7.15 54.62 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.274 -0.891 . . . . 50.0 110.399 -179.856 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.405 HD12 ' HA ' ' A' ' 32' ' ' LEU . 50.7 tp -65.35 -40.98 94.3 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.189 -0.945 . . . . 50.0 110.28 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -62.55 -44.19 96.94 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.321 -0.862 . . . . 50.0 110.271 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 58.1 m -66.13 -33.32 75.51 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.357 -0.839 . . . . 50.0 110.139 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 104.56 8.52 37.5 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.397 -1.481 . . . . 50.0 109.397 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.669 ' HB1' ' O ' ' A' ' 61' ' ' CYS . . . -96.13 123.38 39.72 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.263 -1.14 . . . . 50.0 109.95 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.457 ' O ' HG13 ' A' ' 37' ' ' ILE . 2.2 pt -71.61 151.5 8.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.155 -0.965 . . . . 50.0 110.495 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 24.5 m -91.28 154.73 19.05 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.182 -0.949 . . . . 50.0 109.871 179.645 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.545 ' O ' ' N ' ' A' ' 59' ' ' LYS . 64.7 t-80 -129.78 140.79 39.69 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.123 -0.986 . . . . 50.0 110.571 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.483 ' HD2' ' CG ' ' A' ' 39' ' ' HIS . 43.7 Cg_endo -70.4 161.83 44.6 Favored 'Trans proline' 0 C--N 1.304 -1.806 0 O-C-N 123.967 1.509 . . . . 50.0 111.091 -179.78 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.786 HG12 ' HD2' ' A' ' 42' ' ' PHE . 33.1 t 57.18 -84.23 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.536 -0.727 . . . . 50.0 110.955 179.846 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.786 ' HD2' HG12 ' A' ' 41' ' ' VAL . 14.0 p90 -155.26 157.65 37.59 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.873 -1.142 . . . . 50.0 110.457 -179.653 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . 0.422 ' SG ' ' HB3' ' A' ' 47' ' ' TYR . 0.7 OUTLIER -71.82 133.9 84.01 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 121.327 -0.858 . . . . 50.0 110.293 179.896 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.436 ' HD2' ' HB2' ' A' ' 47' ' ' TYR . 45.1 Cg_endo -70.55 -162.23 0.1 OUTLIER 'Trans proline' 0 C--N 1.306 -1.665 0 O-C-N 123.883 1.465 . . . . 50.0 110.543 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 28.7 tpt180 -81.93 -37.05 27.35 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.534 -0.729 . . . . 50.0 110.365 -179.813 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -66.39 -29.71 69.93 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.381 -0.824 . . . . 50.0 110.172 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.542 ' CE2' ' HG2' ' A' ' 63' ' ' LYS . 45.8 m-85 -110.37 138.48 46.7 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.267 -0.896 . . . . 50.0 110.842 -179.597 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.452 ' O ' ' HA ' ' A' ' 61' ' ' CYS . 67.0 tttt -90.6 153.05 20.61 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.242 -0.912 . . . . 50.0 109.219 178.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 36.0 tt0 -102.07 98.9 9.02 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.041 -1.037 . . . . 50.0 110.302 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 97.0 mt -64.38 -28.6 45.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.46 -0.775 . . . . 50.0 109.984 179.888 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 160.5 -91.3 0.11 Allowed Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.551 -1.419 . . . . 50.0 109.551 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 67.6 p -145.29 159.28 43.27 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.283 -1.128 . . . . 50.0 110.313 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' CYS . . . . . 0.862 ' SG ' ' SG ' ' A' ' 31' ' ' CYS . 0.5 OUTLIER -104.53 -15.76 15.25 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.279 -0.888 . . . . 50.0 110.329 -179.923 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 162.34 -43.6 0.36 Allowed Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.45 -1.46 . . . . 50.0 109.45 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 87.2 mt -123.34 159.39 55.01 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.277 -1.131 . . . . 50.0 109.955 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.72 -16.99 26.37 Favored 'Trans proline' 0 C--N 1.304 -1.787 0 O-C-N 123.896 1.472 . . . . 50.0 110.383 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -68.08 -33.97 80.18 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.457 -1.457 . . . . 50.0 109.457 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . 0.515 HG22 ' N ' ' A' ' 59' ' ' LYS . 34.3 m -117.24 170.14 8.92 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.262 -1.14 . . . . 50.0 110.388 179.861 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.545 ' N ' ' O ' ' A' ' 39' ' ' HIS . 73.7 mmtt -133.75 155.93 48.89 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.437 -0.789 . . . . 50.0 109.56 179.787 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 13.1 t -83.09 127.86 33.96 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.075 -1.016 . . . . 50.0 110.308 -179.586 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' CYS . . . . . 0.669 ' O ' ' HB1' ' A' ' 36' ' ' ALA . 51.0 m -127.05 146.4 50.37 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.272 -0.892 . . . . 50.0 110.266 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 76.9 tttt -129.38 136.11 49.56 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.211 -0.931 . . . . 50.0 110.319 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . 0.542 ' HG2' ' CE2' ' A' ' 47' ' ' TYR . 97.6 mttt -79.57 143.42 59.12 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.251 -0.906 . . . . 50.0 109.968 179.805 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo . . . . . 0 C--N 1.305 -1.733 0 O-C-N 123.897 1.472 . . . . 99.989999999999995 110.394 -179.805 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.474 ' C ' HG13 ' A' ' 29' ' ' VAL . 46.4 Cg_endo . . . . . 0 N--CA 1.49 1.309 0 N-CA-C 110.478 -0.624 . . . . 50.0 110.478 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.474 HG13 ' C ' ' A' ' 28' ' ' PRO . 27.6 m -150.19 145.42 17.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.171 -0.956 . . . . 50.0 110.263 179.889 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.458 HG22 ' HB3' ' A' ' 32' ' ' LEU . 86.1 m -105.71 107.7 18.83 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.272 -0.892 . . . . 50.0 110.012 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' CYS . . . . . 0.475 ' HB3' ' HB3' ' A' ' 36' ' ' ALA . 95.8 m -75.86 -4.55 41.41 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.35 -0.844 . . . . 50.0 110.35 -179.793 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.458 ' HB3' HG22 ' A' ' 30' ' ' THR . 49.8 tp -55.67 -49.57 72.56 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.192 -0.943 . . . . 50.0 109.996 179.764 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -59.89 -36.18 76.41 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.481 -0.762 . . . . 50.0 110.153 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 70.6 m -73.06 -27.46 61.75 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.34 -0.85 . . . . 50.0 110.235 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 95.01 -6.32 69.22 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.509 -1.436 . . . . 50.0 109.509 -179.861 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.475 ' HB3' ' HB3' ' A' ' 31' ' ' CYS . . . -66.46 141.6 57.85 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.209 -1.171 . . . . 50.0 110.074 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.894 HD12 ' NE2' ' A' ' 39' ' ' HIS . 7.2 pt -86.98 150.16 3.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.203 -0.935 . . . . 50.0 110.253 -179.841 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 76.6 m -105.99 144.64 32.43 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.261 -0.9 . . . . 50.0 110.1 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.894 ' NE2' HD12 ' A' ' 37' ' ' ILE . 27.6 m-70 -135.48 158.99 73.27 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.259 -0.901 . . . . 50.0 110.315 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -70.15 172.59 12.74 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 O-C-N 124.002 1.527 . . . . 50.0 110.274 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.81 HG12 ' HD1' ' A' ' 42' ' ' PHE . 7.5 t 54.74 -115.35 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.297 -0.877 . . . . 50.0 109.788 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.81 ' HD1' HG12 ' A' ' 41' ' ' VAL . 39.4 p90 -137.88 156.31 48.04 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.774 -1.204 . . . . 50.0 109.94 179.641 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' CYS . . . . . 0.459 ' SG ' ' O ' ' A' ' 60' ' ' CYS . 82.6 m -57.46 130.87 81.38 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.242 -0.911 . . . . 50.0 110.372 -179.737 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -71.72 -161.88 0.1 Allowed 'Trans proline' 0 C--N 1.305 -1.718 0 O-C-N 124.062 1.559 . . . . 50.0 110.73 179.777 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 19.1 ptp180 -76.35 -29.43 57.23 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.562 -0.711 . . . . 50.0 110.557 -179.584 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 62.7 mtp180 -69.88 -25.94 63.95 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.245 -0.91 . . . . 50.0 110.623 -179.544 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' TYR . . . . . 0.561 ' N ' ' CD1' ' A' ' 47' ' ' TYR . 11.6 m-85 -124.81 151.39 45.27 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.164 -0.96 . . . . 50.0 110.635 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 45.8 tttm -97.91 150.86 20.86 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.355 -0.841 . . . . 50.0 109.225 178.768 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.403 ' HA ' ' SG ' ' A' ' 43' ' ' CYS . 50.8 tt0 -93.54 95.38 9.21 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.983 -1.073 . . . . 50.0 110.42 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.512 HD11 ' CD ' ' A' ' 62' ' ' LYS . 97.3 mt -65.36 -31.24 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.297 -0.877 . . . . 50.0 110.068 179.807 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.498 ' C ' HG23 ' A' ' 52' ' ' THR . . . 168.77 -95.44 0.11 Allowed Glycine 0 N--CA 1.487 2.074 0 N-CA-C 109.534 -1.426 . . . . 50.0 109.534 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.498 HG23 ' C ' ' A' ' 51' ' ' GLY . 62.5 p -150.32 143.26 24.78 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.217 -1.166 . . . . 50.0 110.386 -179.824 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' CYS . . . . . 0.455 ' O ' ' O ' ' A' ' 29' ' ' VAL . 4.4 t -63.87 -40.95 97.76 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.237 -0.914 . . . . 50.0 109.844 179.74 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 157.84 -24.98 0.42 Allowed Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.07 -1.612 . . . . 50.0 109.07 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.514 ' CD1' ' HD2' ' A' ' 56' ' ' PRO . 16.9 tp -123.96 143.64 42.85 Favored Pre-proline 0 N--CA 1.489 1.517 0 O-C-N 121.5 -1.0 . . . . 50.0 109.596 179.773 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.514 ' HD2' ' CD1' ' A' ' 55' ' ' LEU . 39.9 Cg_endo -66.48 -5.3 12.5 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 O-C-N 123.773 1.407 . . . . 50.0 110.827 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -74.65 -33.88 54.85 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.158 -1.577 . . . . 50.0 109.158 179.378 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . 0.474 HG23 ' C ' ' A' ' 39' ' ' HIS . 4.8 m -135.53 162.74 31.82 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.231 -1.158 . . . . 50.0 110.211 179.692 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.478 ' HG3' ' O ' ' A' ' 41' ' ' VAL . 43.5 mmtm -115.49 151.82 34.1 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.346 -0.846 . . . . 50.0 109.937 179.662 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.459 ' O ' ' SG ' ' A' ' 43' ' ' CYS . 26.6 t -81.39 133.5 35.42 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.251 -0.905 . . . . 50.0 110.656 -179.525 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' CYS . . . . . 0.516 ' HB3' ' HB3' ' A' ' 47' ' ' TYR . 72.0 m -131.12 141.22 50.1 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.371 -0.831 . . . . 50.0 109.961 179.73 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . 0.512 ' CD ' HD11 ' A' ' 50' ' ' ILE . 81.1 tttt -131.93 144.35 50.78 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.174 -0.954 . . . . 50.0 110.309 -179.737 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . 0.482 ' HE2' ' OH ' ' A' ' 47' ' ' TYR . 96.2 mttt -77.0 151.17 81.75 Favored Pre-proline 0 N--CA 1.491 1.603 0 O-C-N 121.411 -0.806 . . . . 50.0 110.31 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo . . . . . 0 C--N 1.304 -1.766 0 O-C-N 123.94 1.495 . . . . 99.989999999999995 110.435 179.967 . . . . . . . . 0 0 . 1 stop_ save_